Citric Acid and Certain Citrate Salts from Canada and China
Investigation Nos. 701-TA-456 and 731-TA-1151-1152 (Final)
Citric Acid and Certain Citrate Salts from Canada and China
Investigation Nos. 701-TA-456 and 731-TA-1151-1152 (Final)
# CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Determinations</td>
<td>1</td>
</tr>
<tr>
<td>Views of the Commission</td>
<td>3</td>
</tr>
<tr>
<td>Dissenting views of Chairman Shara L. Aranoff, Vice Chairman Daniel R. Pearson, and Commissioner Deanna Tanner Okun</td>
<td>39</td>
</tr>
</tbody>
</table>

### Part I: Introduction
- Background
- Statutory criteria and organization of the report
- Statutory criteria
- Organization of the report
- U.S. market summary
- Summary data and data sources
- Previous and related investigations
- Nature and extent of sales at LTFV
- Nature of countervailable subsidies

### Part II: Conditions of competition in the U.S. market
- U.S. market segments
- Channels of distribution
- Supply and demand considerations
- U.S. supply
- U.S. demand
- Substitutability issues
- Lead times
- Response if subject imports were no longer available
- Factors affecting purchasing decisions
- Comparisons of domestic products and subject imports

### Part III: U.S. producers’ production, shipments, and employment
- U.S. producers
- U.S. capacity, production, and capacity utilization
- U.S. producers’ U.S. shipments and export shipments
- U.S. producers’ imports and purchases of imports
- U.S. producers’ inventories
- U.S. employment, wages, and productivity
# CONTENTS

**Part IV: U.S. imports, apparent consumption, and market shares**
- U.S. importers ................................................................ IV-1
- U.S. imports ................................................................ IV-1
- Cumulation considerations ........................................ IV-3
  - Fungibility ............................................................... IV-3
  - Geographical markets ............................................. IV-5
  - Simultaneous presence in the market ......................... IV-5
- Negligibility ............................................................... IV-6
- Apparent U.S. consumption ......................................... IV-6
- U.S. market shares ..................................................... IV-8
- Ratio of imports to U.S. production .............................. IV-8

**Part V: Pricing and related information**
- Factors affecting prices ........................................... V-1
  - Raw material costs ................................................... V-1
  - Transportation costs to the U.S. market ...................... V-2
  - U.S. inland transportation costs .................................. V-2
  - Exchange rates ........................................................ V-2
- Pricing practices ....................................................... V-4
  - Pricing methods ....................................................... V-4
  - Sales terms and discounts ......................................... V-10
- Price data ............................................................... V-10
  - Price trends and comparisons .................................. V-11
  - Lost sales and lost revenues ..................................... V-19

**Part VI: Financial experience of U.S. producers**
- Background ................................................................ VI-1
- Operations on citric acid and certain citrate salts .......... VI-1
- Capital expenditures and research and development expenses ................................................................ VI-8
- Assets and return on investment .................................. VI-8
- Capital and investment ................................................ VI-9

**Part VII: Threat considerations and information on producers in nonsubject countries**
- The industry in Canada ............................................ VII-2
- The industry in China ................................................ VII-3
- Combined industry data for both subject countries ....... VII-6
- U.S. importers’ inventories ....................................... VII-6
- U.S. importers’ current orders ...................................... VII-8
- Antidumping and countervailing duty orders in third-country markets ........................................................... VII-8
- Information on producers in nonsubject countries ......... VII-8
## CONTENTS

### Appendixes

<table>
<thead>
<tr>
<th>Appendix</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.</td>
<td><em>Federal Register</em> notices</td>
<td>A-1</td>
</tr>
<tr>
<td>B.</td>
<td>Hearing witnesses</td>
<td>B-1</td>
</tr>
<tr>
<td>C.</td>
<td>Summary data</td>
<td>C-1</td>
</tr>
<tr>
<td>D.</td>
<td>Largest purchasers’ data on bids and prices</td>
<td>D-1</td>
</tr>
</tbody>
</table>

Note.—Information that would reveal confidential operations of individual concerns may not be published and therefore has been deleted from this report. Such deletions are indicated by asterisks.
On the basis of the record developed in the subject investigations, the United States International Trade Commission (Commission) determines, pursuant to sections 705(b) and 735(b) of the Tariff Act of 1930 (19 U.S.C. §§ 1671d(b) and 1673d(b)) (the Act), that an industry in the United States is materially injured by reason of imports from Canada and China of citric acid and certain citrate salts, provided for in subheadings 2918.14.00, 2918.15.10, and 2918.15.50 of the Harmonized Tariff Schedule of the United States, that have been found by the Department of Commerce (Commerce) to be subsidized by the Government of China and to be sold in the United States at less than fair value (LTFV).

BACKGROUND

The Commission instituted these investigations effective April 14, 2008, following receipt of a petition filed with the Commission and Commerce by Archer Daniels Midland Co., Decatur, IL; Cargill, Inc., Wayzata, MN; and Tate & Lyle Americas, Inc., Decatur, IL. The final phase of the investigations was scheduled by the Commission following notification of preliminary determinations by Commerce that imports of citric acid and certain citrate salts from China were being subsidized within the meaning of section 703(b) of the Act (19 U.S.C. § 1671b(b)) and that imports of citric acid and certain citrate salts from Canada and China were being sold at LTFV within the meaning of section 733(b) of the Act (19 U.S.C. § 1673b(b)). Notice of the scheduling of the final phase of the Commission’s investigations and of a public hearing to be held in connection therewith was given by posting copies of the notice in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notice in the Federal Register of December 4, 2008 (73 FR 73955). The hearing was held in Washington, DC, on April 7, 2009, and all persons who requested the opportunity were permitted to appear in person or by counsel.

1 The record is defined in sec. 207.2(f) of the Commission’s Rules of Practice and Procedure (19 CFR § 207.2(f)).
2 Chairman Shara L. Aranoff, Vice Chairman Daniel R. Pearson, and Commissioner Deanna Tanner Okun determined that an industry in the United States is not materially injured or threatened with material injury by reason of imports from Canada and China of citric acid and certain citrate salts.
Chairman Aranoff, Vice Chairman Pearson, and Commissioner Okun find that an industry in the United States is neither materially injured nor threatened with material injury by reason of imports of citric acid and certain citrate salts from Canada and China that Commerce found were sold at less than fair value and imports from China that Commerce found to be subsidized by the Government of China.1

I. BACKGROUND

The petitions in these investigations were filed by the three known U.S. producers of citric acid and certain citrate salts: Archer Daniels Midland Company (“ADM”) of Decatur, IL; Cargill, Inc. (“Cargill”) of Wayzata, MN; and Tate & Lyle Americas, Inc. (“Tate & Lyle”) of Decatur, IL.2 Representatives from each petitioning company participated in the preliminary staff conference and in the Commission’s hearing accompanied by counsel. They filed joint postconference, prehearing and posthearing briefs and final comments. In addition to petitioners, several respondents also participated in the staff conference and hearing and submitted post-conference, prehearing and posthearing briefs, and final comments. These include the following: Jungbunzlauer Technology GmbH & Co. KG (“JBL Canada”), the only known producer of subject merchandise in Canada; a number of Chinese producers/exporters;3 and Procter & Gamble Co. (“P&G”), a U.S. purchaser and industrial user of citric acid ***. Representatives from and counsel for U.S. purchaser PepsiCo participated in the Commission’s hearing and submitted prehearing and

---

1 Chairman Aranoff, Vice Chairman Pearson, and Commissioner Okun find that an industry in the United States is neither materially injured nor threatened with material injury by reason of imports of citric acid and certain citrate salts from Canada and China that Commerce found were sold at less than fair value and imports from China that Commerce found were subsidized by the Government of China. Except as otherwise noted, they join the discussion and analysis in sections I to V.B of this opinion and provide the remainder of their analysis in separate views. See Separate and Dissenting Views of Chairman Shara L. Aranoff, Vice Chairman Daniel R. Pearson, and Commissioner Deanna Tanner Okun.

2 ADM’s production facility is in Southport, North Carolina whereas Cargill’s production facility is in Eddyville, Iowa, and Tate & Lyle’s production facility is in Dayton, Ohio. See, e.g., Confidential Staff Report, Mem. INV-GG-036 at I-1, Table III-1 (Apr. 27, 2009), as amended by Mem. INV-GG-038 (May 7, 2009) (“CR”); Citric Acid and Certain Citrate Salts from Canada and China, Invs. Nos. 701-TA-456 and 731-TA-1151 to 1152 (Final), USITC Pub. 4076 at I-1, Table III-1 (May 2009) (“PR”).

In December 1999, the same petitioners sought antidumping duty relief against imports of citric acid and sodium citrate from China. The Commission made a negative preliminary determination. At that time, the Commission found that imports from China were largely confined to the industrial segment and would not qualify for two to three years to supply the food and beverage segment, a segment that accounted for two-thirds of the U.S. market. The Commission also found that fairly traded non-subject imports (primarily from Israel and Austria) accounted for a majority of imports into the United States, had a significant and growing presence in the U.S. market, and were of equal quality to domestically produced products. See, e.g., Citric Acid and Sodium Citrate from China, Inv. No. 731-TA-863 (Prelim.), USITC Pub. 3277 (Feb. 2000).


---
A representative of United Food Corporation, a distributor of various food products in the United States that imports subject merchandise from China and purchases from the domestic industry, appeared at the staff conference in the preliminary phase of these investigations. See, e.g., Transcript of May 7, 2008, Preliminary Staff Conference (“Confer. Tr.”) at 108 (Hsu for United Food Corporation).

See, e.g., CR at I-4.

See, e.g., CR at I-4.

See, e.g., CR at I-4.

See, e.g., CR at I-4.


See, e.g., Cleo, Inc. v. United States, 501 F.3d 1291, 1299 (Fed. Cir. 2007); NEC Corp. v. Department of Commerce, 36 F. Supp. 2d 380, 383 (Ct. Int’l Trade 1998); Nippon Steel Corp. v. United States, 19 CIT 450, 455 (1995); Torrington Co. v. United States, 747 F. Supp. 744, 749 n.3 (Ct. Int’l Trade 1990), aff’d, 938 F.2d 1278 (Fed. Cir. 1991) (“every like product determination ‘must be made on the particular record at issue’ and the ‘unique facts of each case’”). The Commission generally considers a number of factors, including the following: (1) physical characteristics and uses; (2) interchangeability; (3) channels of distribution; (4) customer and producer perceptions of the products; (5) common manufacturing facilities, production processes, and production employees; and, where appropriate, (6) price. See Nippon, 19 CIT at 455 n.4; Timken Co. v. United States, 913 F. Supp. 580, 584 (Ct. Int’l Trade 1996).
may consider other factors it deems relevant based on the facts of a particular investigation.\textsuperscript{13} The Commission looks for clear dividing lines among possible like products and disregards minor variations.\textsuperscript{14} Although the Commission must accept Commerce’s determination as to the scope of the imported merchandise that is subsidized or sold at less than fair value,\textsuperscript{15} the Commission determines what domestic product is like the imported articles Commerce has identified.\textsuperscript{16}

B. Product Description

Commerce defined the imported merchandise within the scope of these investigations as follows:

all grades and granulation sizes of citric acid, sodium citrate, and potassium citrate in their unblended forms, whether dry or in solution, and regardless of packaging type. The scope also includes blends of citric acid, sodium citrate, and potassium citrate; as well as blends with other ingredients, such as sugar, where the unblended form(s) of citric acid, sodium citrate, and potassium citrate constitute 40 percent or more, by weight, of the blend. The scope of the investigation also includes all forms of crude calcium citrate, including dicalcium citrate monohydrate, and tricalcium citrate tetrahydrate, which are intermediate products in the production of citric acid, sodium citrate, and potassium citrate. The scope of this investigation does not include calcium citrate that satisfies the standards set forth in the United States Pharmacopeia and has been mixed with a functional excipient, such as dextrose or starch, where the excipient constitutes at least 2 percent, by weight, of the product. The scope of this investigation includes the hydrous and anhydrous forms of citric acid, the dihydrate and anhydrous forms of sodium citrate, otherwise known as citric acid sodium salt, and the monohydrate and monopotassium forms of potassium citrate. Sodium citrate also includes both trisodium citrate and monosodium citrate, which are also known as citric acid trisodium salt and citric acid monosodium salt, respectively.\textsuperscript{17}
In the United States, citric acid, sodium citrate, and potassium citrate are produced at overlapping manufacturing facilities by the same employees, at least for the early production stages.\(^{18}\) At the first manufacturing stage, domestic producers ferment a substrate (a starch or other sugary base such as corn starch, molasses, dextrose, and/or high fructose corn syrup) into crude citric acid using a fermenting organism (normally a specific mold or yeast) in a deep tank.\(^{19}\) At the second stage, domestic producers recover the crude citric acid produced by fermentation and refine it by one of three processes: (i) the lime sulfuric acid method; (ii) the solvent-extraction method; or (iii) the ion-exchange method.\(^{20}\) All three methods yield citric acid dissolved in water, and manufacturers produce hydrous or anhydrous citric acid by adjusting the temperature of the crystallization process, using the same or separate equipment to do so.\(^{21}\) Citric acid can be sold as is or converted into “salts” such as sodium citrate or potassium citrate.\(^{22}\)

Whereas, of the products covered by the scope of these investigations, Tate & Lyle only produces citric acid, both ADM and Cargill produce citric acid, sodium citrate, and potassium citrate.\(^{23}\) ADM and Cargill produce sodium citrate and potassium citrate at the same plants used to produce citric acid. To produce sodium citrate, they divert a stream of crude citric acid slurry to a reactor for reaction with sodium hydroxide or sodium carbonate and then crystallization. Alternatively, the slurry is converted into potassium citrate when reacted with potassium hydroxide or potassium carbonate.\(^{24}\) The same equipment is used to produce both sodium citrate and potassium citrate, and petitioners report that only minimal costs and a few hours are needed to switch the equipment from producing sodium to potassium citrate or vice versa. The capital equipment used to convert citric acid into sodium or potassium citrate is relatively inexpensive. Independent converters can and do produce these citrates using finished citric acid as the input.\(^{25}\)

\(^{17}\) (...continued)

Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the merchandise is dispositive.” \(^{18}\) See, e.g., CR at I-9.

The Commission’s negative preliminary opinion in the 1999/2000 investigation defined the domestic like product as citric acid and sodium citrate, as requested in that petition. \(^{19}\) See, e.g., USITC Pub. 3277 at 3-7. Unlike the previous investigation, the scope of the instant investigations includes crude calcium citrate, an intermediate product resulting when one of three particular processes is used to produce citric acid. \(^{20}\) See, e.g., CR at I-15. In other parts of the world, crude calcium citrate is shipped elsewhere for conversion into its only possible use, citric acid. For that reason, petitioners included crude calcium citrate in the scope, although they are unaware of any crude calcium citrate imports into the U.S. market at this time. \(^{21}\) See, e.g., Petitions, Vol. I at 8-9; Confer. Tr. at 58-59 (Ellis for Petitioners), 86-87 (Oakley for ADM). The scope also includes certain blends, although petitioners are unaware of any domestic production or imports of these blends. \(^{22}\) See, e.g., Confer. Tr. at 61-63 (Ellis for Petitioners). Potassium citrate also was not included in the scope of the previous investigation, although the staff report corresponding to that investigation did include some information about potassium citrate. \(^{23}\) See, e.g., USITC Pub. 3277 at I-2 to I-4, III-1, Table C-6.

\(^{18}\) See, e.g., CR at I-13 to I-16.

\(^{19}\) See, e.g., CR at I-13 to I-15, V-1; Petitioners’ Posthearing Br. at Exh. 2 at 4.

\(^{20}\) See, e.g., CR at I-13, I-14. During the lime sulfuric acid refining process ***, crude calcium citrate is produced, but this product’s sole purpose is to be converted into citric acid. \(^{21}\) See, e.g., CR at I-11, I-15.

\(^{21}\) See, e.g., CR at I-16.

\(^{22}\) See, e.g., CR at I-16.

\(^{23}\) See, e.g., CR at III-2 at n.6.

\(^{24}\) See, e.g., CR at I-16.

\(^{25}\) See, e.g., Confer. Tr. at 23 (Oakley for ADM), 85 (Staloch for Cargill); CR at I-16, III-1 at n.1.
C. Analysis

Crude calcium citrate is an intermediate product in the production of citric acid, and citric acid is used to make both sodium citrate and potassium citrate. Thus, in the preliminary phase of these investigations, the Commission considered whether there are clear lines dividing crude calcium citrate, citric acid, sodium citrate, and potassium citrate and/or dividing different grades and/or chemical or physical forms of these products such that there are two or more domestic like products corresponding to the scope of these investigations.26 In its preliminary determinations, the Commission defined a single domestic like product that included crude calcium citrate, citric acid, potassium citrate, and sodium citrate.27 In the final phase of these investigations, no party advocated a different domestic like product.28

Based on the record evidence, we find no clear dividing lines among domestically produced products corresponding to the scope of these investigations based on chemical or physical form, grade, or product type.29 Whether in an intermediate form as crude calcium citrate, as citric acid, or transformed into sodium citrate or potassium citrate, citric acid and its citrate salts come in a variety of chemical

26 See, e.g., Liquid Sulfur Dioxide from Canada, Inv. No. 731-TA-1098 (Prelim.), USITC Pub. 3826 at 6 (Dec. 2005) quoting Bulk Acetylsalicylic Acid (Aspirin) from China, Inv. No. 731-TA-828 (Final), USITC Pub. 3314 at 5-6 (June 2000); Sulfanilic Acid from Hungary and Portugal, Invs. Nos. 701-TA-426 and 731-TA-984 to 985 (Final), USITC Pub. 3554 at 7 n.34 (Nov. 2002); Barium Carbonate from China, Inv. No. 731-TA-1020 (Prelim.), USITC Pub. 3561 at 7 n.28 (Nov. 2002).


28 See, e.g., Petitioners’ Prehearing Br. at 6.

29 See, e.g., Softwood Lumber from Canada, Invs. Nos. 701-TA-404 and 731-TA-928 (Final), USITC Pub. 3509 at 6-15 (May 2002); Professional Electric Cutting and Sanding/Grinding Tools from Japan, Inv. No. 731-TA-571 (Final), USITC Pub. 2658 at 8-10, 49-51 (Jul. 1993) (Commission found two like products based on operating element – cutting tool and sanding/grinding tool – refusing to further subdivide more narrowly into 28 families of tools); Polyethylene Terephthalate Film, Sheet, and Strip from Japan and the Republic of Korea (“PET Film”), Invs. Nos. 731-TA-458 to 459 (Final), USITC Pub. 2383 at 8, 10 (May 1991) (“a continuum product without clear dividing lines between the multiple like products ... {a}lthough there are many distinct end uses for different types of PET film ... essential characteristics are common to all PET Film”).
forms, physical forms, and grades. Physical appearance varies accordingly but all have similar chemical composition.

Crude calcium citrate is used only to produce citric acid, and some citric acid is used to produce sodium citrate or potassium citrate. Although citric acid, sodium citrate, and potassium citrate are not substitutable in all applications, they are used in an overlapping manner in some of the same types of end-use products as buffers, acidulants, and preservatives. There are some limitations in interchangeability among grades (such as for use in food, beverage, or pharmaceutical applications) and chemical or physical forms.

Most domestically produced citric acid, sodium citrate, and potassium citrate is sold to end users, although crude calcium citrate is solely consumed in the process of making citric acid. As for domestic producer and customer perceptions, all domestic producers assert that citric acid, sodium citrate, potassium citrate, and crude calcium citrate are part of the same domestic like product. Citric acid, sodium citrate, and potassium citrate are treated as part of a single industry in studies such as the August 2006 Chemical Economics Handbook Marketing Research Report on Citric Acid conducted by SRI Consulting. Some customers purchase more than one chemical or physical form, and others have

---

30 Citric acid may be produced as citric acid anhydrous (C\(_6\)H\(_8\)O\(_7\)) or as citric acid monohydrate (C\(_6\)H\(_8\)O\(_7\)·H\(_2\)O). Sodium citrate may be produced in an anhydrous or trisodium anhydrous form (Na\(_3\)C\(_6\)H\(_5\)O\(_7\)), in a dihydrate or trisodium dihydrate form (Na\(_3\)C\(_6\)H\(_5\)O\(_7\)·2H\(_2\)O), and as a monosodium (NaH\(_2\)(C\(_3\)H\(_5\)O(COO))\(_3\)). Potassium citrate may be produced as potassium citrate monohydrate or tripotassium citrate monohydrate (K\(_3\)C\(_6\)H\(_5\)O\(_7\)·H\(_2\)O) and monopotassium citrate (KH\(_2\)C\(_6\)H\(_5\)O\(_7\)). Crude calcium citrate may be produced as tricalcium citrate (Ca\(_3\)(C\(_6\)H\(_5\)O\(_7\))\(_2\)), dicalcium citrate (Ca\(_2\)H\(_2\)(C\(_3\)H\(_5\)O)(COO)\(_3\)·H\(_2\)O), and tricalcium citrate tetrahydrate (Ca\(_3\)(C\(_6\)H\(_5\)O\(_7\))\(_2\)(COO)\(_3\)·4H\(_2\)O). See, e.g., Petitions, Vol. I at 6.

31 In their dry form as odorless, translucent crystals, citric acid, sodium citrate, and potassium citrate are sold as granular or fine granular products, with only a very small amount sold as powder. See, e.g., Confer. Tr. at 17 (Oakley for ADM). A water solution of citric acid (normally a 50-percent citric acid solution) is produced and sold in the United States, and the solution can be reversed to a dry form. See, e.g., Petitions, Vol. I at 6; CR at V-5.

32 In the United States, citric acid, sodium citrate, and potassium citrate must meet Food Chemical Codex (“FCC”) standards for use in beverage and food products and U.S. Pharmacopoeia (“USP”) standards for use in pharmaceutical products. See, e.g., CR at I-12. Non-conforming products, however, may be used in industrial applications. See, e.g., CR at II-1.


34 See, e.g., CR at I-11, I-16.

35 See, e.g., CR at I-12, II-1, II-15.

36 See, e.g., CR at I-12 to I-13, II-1, II-27, II-28.

37 Particular end users prefer citric acid in anhydrous or monohydrate form, others prefer citric acid in solution form due to limitations in their production processes, while other purchasers such as P&G purchase citric acid in monohydrate, anhydrous, and solution forms but can only use particular forms for particular plants, and others have specific granulation requirements. See, e.g., CR at II-26 to II-30, IV-8; CR/PR at Table II-3 (summarizing questionnaire responses regarding interchangeability among forms); Confer. Tr. at 103, 105, 141-45 (Smith for P&G).

38 See, e.g., CR at I-11, II-4; CR/PR at Table II-1.

39 See, e.g., Petitioners’ Prehearing Br. at 6.

handling requirements developed over time but could switch between chemical or physical forms or grades in some situations. 41

In the United States, citric acid, sodium citrate, and potassium citrate are produced at overlapping manufacturing facilities by the same employees, at least for the early production stages. 42 There are differences in how the dry and solution forms are packaged. 43 There are also some differences in price based on the chemical and physical form and grade. 44

In light of these facts and in the absence of any contrary arguments, for purposes of the final phase of these investigations, we define one domestic like product consisting of citric acid (whether in crude form as crude calcium citrate or in finished form), sodium citrate, and potassium citrate in all chemical and physical forms and grades. 45

III. DOMESTIC INDUSTRY

The domestic industry is defined as the domestic “producers as a whole of a domestic like product, or those producers whose collective output of a domestic like product constitutes a major proportion of the total domestic production of the product.” 46 In defining the domestic industry, the Commission’s general practice has been to include in the industry all producers of the domestic like product, whether toll-produced, captive consumed, or sold in the domestic merchant market.

Consistent with our definition of the domestic like product, we define the domestic industry as consisting of all domestic producers of citric acid and citrate salts (i.e., ADM, Cargill, and Tate & Lyle). 47

41 See, e.g., CR at II-26 to II-30, IV-8; CR/PR at Table II-3 (summarizing questionnaire responses regarding interchangeability among forms), Table II-5 (summarizing importance of various purchase factors); Confer. Tr. at 103, 105, 141-45 (Smith for P&G).

42 See, e.g., CR at I-13 to I-16.

43 Dry forms are typically packaged in 50-pound or 25-kilogram polyethylene lined bags or in super sack bags typically containing 500 to 2,000 pounds. Citric acid sold in solution form is not packaged, but is instead shipped in 200- to 275-pound drums, or in rail cars or tank trucks. See, e.g., CR at I-16.

44 Fine granular citric acid is priced somewhat higher than granular citric acid, and citric acid is somewhat higher priced than sodium citrate but somewhat lower priced than potassium citrate. See, e.g., Confidential Staff Report from Preliminary Phase, Mem. INV-FF-060 at Table V-1 (granular), Table V-2 (fine granular) (May 22, 2008); USITC Pub. 4008 at Table V-1 (granular), Table V-2 (fine granular); CR/PR at Table III-1. CR/PR at Tables V-4 to V-8. Citric acid sold in an industrial-grade solution that is 50 percent citric acid and 50 percent water is usually priced at about 50 percent of the equivalent dry price. See, e.g., CR at V-5. Anyhydrous citric acid costs about nine percent more than the monohydrate form due to the presence of nine percent water in the monohydrate version. See, e.g., CR at V-5.

45 For convenience, we use the term “citric acid and certain citrate salts” hereinafter to refer to the collective grouping of citric acid (crude and finished), sodium citrate, and potassium citrate.


47 See, e.g., CR at III-1. Although no party made any related party arguments in the preliminary or final phase of these investigations, the record indicates that domestic producer *** imported subject merchandise from ***. See, e.g., CR/PR at Table III-4. As such, *** is a related party. We do not, however, find appropriate circumstances exist to exclude *** from the domestic industry. The company imported *** dry pounds of subject merchandise from ***. See, e.g., CR at III-6 n.8; CR/PR at Table III-4. In the preliminary phase of these investigations, *** reported that it ***. See, e.g., Mem. INV-FF-060 at Table III-4 n.1; USITC Pub. 4008 at Table III-4 n.1. *** imports from *** were relatively small, equivalent to *** percent of the subject merchandise imported from *** or *** percent of *** U.S. production ***. See, e.g., CR/PR at Table III-4, Table C-1. Its imports of subject merchandise were ***. See, e.g., CR/PR at Table III-4. For all of these reasons, we do not find appropriate (continued...)
IV. CUMULATION

A. Legal Framework

For purposes of evaluating the volume and price effects for a determination of material injury by reason of the subject imports, section 771(7)(G)(I) of the Act requires the Commission to cumulate subject imports from all countries as to which petitions were filed and/or investigations self-initiated by Commerce on the same day, if such imports compete with each other and the domestic like product in the U.S. market. In assessing whether subject imports compete with each other and with the domestic like product, the Commission has generally considered four factors, including the following:

1. the degree of fungibility between the subject imports from different countries and between imports and the domestic like product, including consideration of specific customer requirements and other quality-related questions;

47 (continued)

circumstances exist to exclude *** from the domestic industry as a related party.

48 Before reaching the issue of whether subject imports from Canada and China are negligible, the Commission must first decide which data to use to measure subject and non-subject imports into the U.S. market.

In the preliminary phase of these investigations, the Commission measured the volume of subject imports from Canada using importer questionnaire responses in response to respondents’ concern that official Census data on imports of citric acid in solution form from Canada reflected the weight of citric acid in solution rather than the anhydrous equivalent weight reported in the questionnaires. See, e.g., USITC Pub. 4008 at 14. In the final phase of these investigations, absent contrary party arguments, we again measure imports from Canada using importer questionnaire responses. See, e.g., CR at I-4.

With respect to imports from China, in the preliminary phase of these investigations, respondents reported that at least some of the imports from China consisted of product in monohydrate form, and they were uncertain whether the Census data reflected the monohydrate dry form or the anhydrous equivalent weight. See, e.g., Confer. Tr. at 128-31 (Lafave for P&G, Porter for Chinese Respondents). Petitioners argued that any imports of monohydrate form from China were limited and asked the Commission to measure imports from China using Census data rather than importer questionnaire responses that they contended under-reported imports from China. See, e.g., Petitioners’ Postconf. Br. at 23-24, Exh. 1 at 4-5. The questionnaire data appear to understate subject imports from China, but any overstatement of subject imports from China by official import statistics appears to be limited due to the minimal portion of imports from China consisting of monohydrate form. See, e.g., CR at VII-5 at n.5; CR/PR at Table IV-1, Table VII-2, Table C-1. Thus, absent contrary party arguments, in the final phase of these investigations we again measure imports from China using official import statistics. See, e.g., CR at I-4, IV-1 at n.4.

Similarly, importer questionnaire responses appear to understate imports from non-subject countries compared to official import statistics. We again measure imports from non-subject countries using official import statistics and note that any overstatement due to imports of monohydrate form appears to be minimal, since questionnaire respondents reported only limited imports of monohydrate form from non-subject countries. See, e.g., CR/PR at Table IV-1 (questionnaire data on non-subject imports), Table C-1 (official statistics on non-subject imports); CR at IV-1 at n.4.

Based on these data, subject imports are not “negligible” within the meaning of 19 U.S.C. § 1677(24). Subject imports from Canada and China were well above three percent of total imports for the most recent 12-month period preceding the April 14, 2008, filing of the petitions for which data are available (January through December 2007). Subject imports from Canada accounted for *** percent, and subject imports from China accounted for *** percent, of total imports of citric acid and certain citrate salts in that period. See, e.g., CR at IV-12.


50 Commissioner Lane notes that, with respect to fungibility, her analysis does not require such similarity of products that a perfectly symmetrical fungibility is required, and she notes that this factor would be better described (continued...)
(2) the presence of sales or offers to sell in the same geographic markets of subject imports from different countries and the domestic like product;
(3) the existence of common or similar channels of distribution for subject imports from different countries and the domestic like product; and
(4) whether the subject imports are simultaneously present in the market.51

While no single factor is necessarily determinative, and the list of factors is not exclusive, these factors are intended to provide the Commission with a framework for determining whether the subject imports compete with each other and with the domestic like product.52 Only a “reasonable overlap” of competition is required.53 Subject imports from Canada and China are eligible for cumulation because the petitions concerning these subject countries were filed on the same day and none of the statutory exceptions to cumulation applies.

B. Analysis

We now examine whether there is a reasonable overlap of competition among the domestic like product, subject imports from Canada, and subject imports from China.54 55

---

50 (...continued)
as an analysis of whether subject imports from each country and the domestic like product could be substituted for each other. See Separate Views of Commissioner Charlotte R. Lane, Certain Lightweight Thermal Paper from China, Germany, and Korea, Invs. Nos. 701-TA-451 and 731-TA-1126 to 1128 (Prelim.), USITC Pub. 3964 (Nov. 2007).


53 The SAA states that “the new section will not affect current Commission practice under which the statutory requirement is satisfied if there is a reasonable overlap of competition.” SAA at 848 (citing Fundicao Tupy, S.A. v. United States, 678 F. Supp. 898, 902 (Ct. Int’l Trade 1988), aff’d, 859 F.2d 915 (Fed. Cir. 1988)); see also, e.g., Goss Graphic Sys., Inc. v. United States, 33 F. Supp. 2d 1082, 1087 (Ct. Int’l Trade 1998) (“cumulation does not require two products to be highly fungible”); Wieland Werke, AG, 718 F. Supp. at 52 (“Completely overlapping markets are not required.”).

54 Petitioners argue that the Commission should cumulate subject imports from Canada and China because there is a reasonable overlap of competition among these imports and the domestic like product. See, e.g., Petitioners’ Postconf. Br. at 2-3, 6-15; Petitioners’ Prehearing Br. at 6-10, 40-44; Petitioners’ Posthearing Br. at Exh. 1 at 19-29, Exh. 2 at 13-15, Exh. 3 at 40-42. JBL Canada and purchaser P&G argue that the Commission should not cumulate subject imports from Canada and China based on what they assert are differences in fungibility, channels of distribution, simultaneous presence, and other differences that limit competition. See, e.g., P&G’s Postconf. Br. at 4, 25-30; P&G’s Prehearing Br. at 64-70; JBL’s Postconf. Br. at 2, 9, 10; Confer. Tr. at 12 (Waite for JBL), 162-64, 166-67 (Waite); JBL’s Prehearing Br. at 20-29. Chinese Respondents argued against cumulation in the preliminary phase of these investigations; in the final phase, they contend that they have no basis to argue against cumulation for purposes of the Commission’s present material injury or threat of material injury determinations. See, e.g., Confer. Tr. at 14-15 (Porter), 152-53; Chinese Respondents’ Postconf. Br. at 2, 6-13; Hearing Tr. at 256 (Cameron); Chinese Respondents’ Posthearing Br. at Exh. A at 24-25.

55 We note that JBL Canada also asserts that differences in *** are another reason not to cumulate subject imports from Canada and China. While data obtained in investigating *** relates to causation issues more than the cumulation issue of whether there is a “reasonable overlap of competition.” See Fundicao Tupy, 678 F. Supp. at 902 (“the operation of the cumulation provision does not involve a specific causation finding with respect to each (continued...)
1. **Fungibility**

There is considerable overlap in the chemical forms supplied to the U.S. market by the domestic industry and producers in the subject countries, despite some differences. The domestic industry and subject producers in both Canada and China supplied large quantities of citric acid to the U.S. market throughout the period of investigation. Citric acid accounts for the vast majority of sales of citric acid and certain citrate salts whereas sodium citrate and potassium citrate account for a small share of the U.S. market. With respect to the sales of the more limited quantities of sodium citrate and potassium citrate, overlap was more limited. Although there are some applications or end uses where sodium citrate or potassium citrate are preferred, there are a number of applications and end uses where citric acid could be used instead of sodium citrate or potassium citrate.

In terms of physical form, the domestic industry, the subject producer in Canada, and subject producers in China all at least predominantly supplied anhydrous citric acid to the U.S. market during the period of investigation. Direct overlap for sales of citric acid in monohydrate and solution forms was more limited. Unlike producers in Canada and the United States, Chinese producers supply limited quantities of citric acid in monohydrate form to the U.S. market, and do not supply citric acid in solution

---

55 (...continued)

56 See, e.g., CR/PR at Table V-4 to Table V-6, Table C-2.

57 Compare, e.g., CR/PR at Table C-2 (citric acid) with, e.g., CR/PR at Table C-1 (citric acid and certain citrate salts).

58 JBL Canada does not produce sodium citrate or potassium citrate, but the domestic industry and Chinese producers both sold sodium citrate and potassium citrate in the U.S. market. See, e.g., CR at VII-2; CR/PR at Table V-7 (sodium citrate), Table V-8 (potassium citrate).

59 See, e.g., CR at I-12, II-1, II-15.

60 See, e.g., CR at IV-7 & n.12 (indicating that *** percent of JBL Canada’s U.S. shipments in 2008 were in anhydrous form compared to *** percent for ADM, *** percent for Cargill, and *** percent for Tate & Lyle); CR at IV-1 at n.4 (imports in anhydrous form account for approximately *** percent of subject imports from China according to questionnaire responses).

61 The relatively limited volume of subject imports of citric acid in monohydrate form from China competes in a more limited fashion with subject imports from Canada and the domestic like product. Imports of citric acid in monohydrate form accounted for a small percentage (*** percent of subject imports from China. See, e.g., CR at IV-1 at n.4. The domestic industry and the Canadian producer do not supply citric acid in monohydrate form, although the domestic industry says it could supply monohydrate form to the few customers that want it. See, e.g., CR at IV-7; Confer. Tr. at 67 (Christiansen for Cargill), 89-90 (Oakley for ADM, Staloch for Cargill, Ellis for Petitioners), 103-05 (Smith for P&G), 116 (Waite for JBL); JBL’s Postconf. Br. at 11 n.42; Petitioners’ Posthearing Br. at Exh. 6. Petitioners also caution that it would be easy to use citric acid in monohydrate form for a wide range of applications, so the limited current use of monohydrate does not mean that it could not be substituted in a far greater amount in applications and end uses currently using citric acid in anhydrous or solution form. See, e.g., Confer. Tr. at 90 (Anderson for Petitioners); Petitioners’ Posthearing Br. at Exh. 6 at 1-3; CR at I-16 at n.61.
due to the transportation costs associated with ocean shipment.62 Due to its geographical proximity to U.S. customers, JBL Canada does supply citric acid in solution form to the U.S. market in rail cars and thus competes with the domestic industry in that respect.63 Although some end users prefer to use citric acid in monohydrate, anhydrous, or in solution form due to constraints in their production facilities and/or production processes, they may be able to convert the dry forms into solution, or have third parties do the conversion for them.64

We also considered quality and other non-price differences among the three sources. Producers in the United States, Canada, and China manufacture citric acid and certain citrate salts that meet quality requirements for sale as FCC/USP products.65 Although questionnaire respondents reported some non-price differences such as product quality among sources,66 the vast majority reported that subject imports from Canada and China are at least frequently if not always interchangeable with one another and with the domestic like product.67 Although caking was reported more frequently as a problem for subject imports from China,68 Chinese product was nevertheless sold in substantial quantities even to the highly demanding soft drink sector, as discussed below.69

We also examined whether products produced in the United States, Canada, and China were sold for overlapping end-use applications. The largest end-use segment of the U.S. market is food and beverage applications (particularly for soft drink beverages), followed by industrial applications (particularly for household detergents and cleaners) and pharmaceutical applications (including for beauty and oral hygiene/cosmetics).70 The record in the final phase of these investigations shows that U.S.,
Canadian, and Chinese products were sold for overlapping end uses.\textsuperscript{71} The only area with no reported overlap was for sales in a *** end-use category that accounted for about *** percent of total reported U.S. shipments in 2008 (**), where there were sales of products from ***.\textsuperscript{72} Indeed, products produced in the United States, Canada, and China were sold to some of the same customers during the period of investigation.\textsuperscript{73} In short, although there are some differences in terms of the chemical and physical forms and grades sold by domestic, Canadian, and Chinese producers in the U.S. market, there is also considerable overlap, particularly for anhydrous citric acid. Moreover, all three sources competed for sales of food, beverage, pharmaceutical, and industrial-grade products, including for soft-drink applications, and even to some of the same customers. Thus, the record in the final phase of these investigations supports a finding that U.S., Canadian, and Chinese products are fungible with one another.

\section*{2. Overlapping Geographical Markets}

Petitioners sell citric acid and certain citrate salt products nationwide.\textsuperscript{74} Imports of subject merchandise from China entered multiple U.S. ports of entry and dispersed across the nation.\textsuperscript{75} Although Canadian-produced citric acid is imported primarily through Buffalo and Detroit due to the location of JBL Canada’s production facility, it is transported by truck or rail and competes nationwide with products produced in the United States and China.\textsuperscript{76} Thus, we find that the U.S., Canadian, and Chinese products are sold in overlapping geographical markets.

\textsuperscript{71} See, \textit{e.g.}, CR/PR at Table IV-3, reflecting the following overlap: \textit{Food and beverage} – *** percent of the domestic industry’s U.S. shipments in 2008 were to the food and beverage market segment (***) percent for soft drinks and (***) percent for food) as compared to (***) percent of U.S. shipments of subject imports from Canada (***) percent for soft drinks and (***) percent for food) and (***) percent of reported U.S. shipments of subject imports from China (***) percent for soft drinks and (***) percent for food); \textit{Industrial} – (***) percent of the domestic industry’s U.S. shipments in 2008 (***) percent for household detergents and cleaners), as compared to (***) percent of U.S. shipments of subject imports from Canada (***) percent for household detergents and cleaners), and (***) percent of reported U.S. shipments of subject imports from China (***) percent for household detergents and cleaners); \textit{Pharmaceutical} – (***) percent of the domestic industry’s U.S. shipments in 2008 as compared to (***) percent of U.S. shipments of subject imports from Canada and (***) percent of reported U.S. shipments of subject imports from China. Petitioners note that (**). \textit{See, e.g.},Petitioners’ Prehearing Br. at 35; Petitioners’ Posthearing Br. at Exh. 1 at 20-21, Exh. 2 at 13-14, Exh. 4 at 19.

\textsuperscript{72} See, \textit{e.g.}, CR/PR at Table IV-3.

\textsuperscript{73} See, \textit{e.g.}, CR/PR at Table II-2 (reporting, \textit{inter alia}, that during the period of investigation (***) purchased products made in the United States, Canada, and China, as did (***)). The top purchasers of citric acid and certain citrate salts during the period of investigation were (**), each of which reported purchasing more than (***) pounds during that period. \textit{See, e.g.}, CR at II-3 to II-5; \textit{see also, e.g.}, Petitioners’ Prehearing Br. at Exh. 8; Petitioners’ Posthearing Br. at Exh. 21 (showing sales of domestically produced products to purchasers of a wide range of sizes). Thus, the record refutes Chinese Respondents’ argument in the preliminary phase of these investigations that subject imports from China predominantly served the smaller “mom and pop” establishments in the United States that domestic producers do not bother or declined to serve. \textit{See, e.g.}, Confer. Tr. at 112-14 (Hsu for United Food Corp.); Chinese Respondents’ Postconf. Br. at 3, 10-13.

\textsuperscript{74} See, \textit{e.g.}, CR at II-2.

\textsuperscript{75} See, \textit{e.g.}, CR at II-2, IV-11.

\textsuperscript{76} See, \textit{e.g.}, CR at IV-11; JBL’s Postconf. Br. at 11.
3. **Channels of Distribution**

Citic acid products manufactured in the United States, Canada, and China were sold predominantly to end users but also to distributors. Because products produced in the United States, Canada, and China are sold to end users and distributors and, as noted above, even to some of the same end users and distributors, we find an overlap in the channels of distribution for subject imports from Canada and China and the domestic like product.

4. **Simultaneous Presence**

U.S., Canadian, and Chinese products were each present in the U.S. market in every month of the period of investigation. Thus, we find that this criterion is also met.

C. **Conclusion**

For the reasons discussed above, we conclude that there is a reasonable overlap of competition between subject imports from Canada and China and between subject imports and the domestic like product. We therefore cumulatively assess the volume and effects of subject imports from Canada and China for our analysis of present material injury by reason of subject imports.

V. **MATERIAL INJURY BY REASON OF CUMULATED SUBJECT IMPORTS**

A. **Legal Standards**

In the final phase of antidumping and countervailing duty investigations, the Commission determines whether an industry in the United States is materially injured or threatened with material injury by reason of the imports under investigation. In making this determination, the Commission must consider the volume of subject imports, their effect on prices for the domestic like product, and their impact on domestic producers of the domestic like product, but only in the context of U.S. production
operations. The statute defines “material injury” as “harm which is not inconsequential, immaterial, or unimportant.” In assessing whether the domestic industry is materially injured by reason of subject imports, we consider all relevant economic factors that bear on the state of the industry in the United States. No single factor is dispositive, and all relevant factors are considered “within the context of the business cycle and conditions of competition that are distinctive to the affected industry.”

Although the statute requires the Commission to determine whether the domestic industry is “materially injured by reason of” unfairly traded imports, it does not define the phrase “by reason of,” indicating that this aspect of the injury analysis is left to the Commission’s reasonable exercise of its discretion. In identifying a causal link, if any, between subject imports and material injury to the domestic industry, the Commission examines the facts of record that relate to the significance of the volume and price effects of the subject imports and any impact of those imports on the condition of the domestic industry. This evaluation under the “by reason of” standard must ensure that subject imports are more than a minimal or tangential cause of injury and that there is a sufficient causal, not merely a temporal, nexus between subject imports and material injury.

In many investigations, there are other economic factors at work, some or all of which may also be having adverse effects on the domestic industry. Such economic factors might include non-subject imports; changes in technology, demand, or consumer tastes; competition among domestic producers; or management decisions by domestic producers. The legislative history explains that the Commission must examine factors other than subject imports to ensure that it is not attributing injury from other factors to the subject imports, thereby inflating an otherwise tangential cause of injury into one that satisfies the statutory material injury threshold. In performing its examination, however, the Commission need not

---

81 19 U.S.C. § 1677(7)(B)(i). The Commission “may consider such other economic factors as are relevant to the determination” but shall “identify each {such} factor ... and explain in full its relevance to the determination.” 19 U.S.C. § 1677(7)(B).


85 19 U.S.C. §§ 1671d(a), 1673d(a).

86 Angus Chemical Co. v. United States, 140 F.3d 1478, 1484-85 (Fed. Cir. 1998) (“{T}he statute does not ‘compel the commissioners’ to employ {a particular methodology}.’”), aff’g 944 F. Supp. 943, 951 (Ct. Int’l Trade 1996).

87 The Federal Circuit, in addressing the causation standard of the statute, observed that “{a}s long as its effects are not merely incidental, tangential, or trivial, the foreign product sold at less than fair value meets the causation requirement.” Nippon Steel Corp. v. USITC, 345 F.3d 1379, 1384 (Fed. Cir. 2003). This was further ratified in Mittal Steel Point Lisas Ltd. v. United States, 542 F.3d 867, 873 (Fed. Cir. 2008), where the Federal Circuit, quoting Gerald Metals, Inc. v. United States, 132 F.3d 716, 722 (Fed. Cir. 1997), stated that “this court requires evidence in the record ‘to show that the harm occurred “by reason of” the LTFV imports, not by reason of a minimal or tangential contribution to material harm caused by LTFV goods.’”. See also Nippon Steel Corp. v. United States, 458 F.3d 1345, 1357 (Fed. Cir. 2006); Taiwan Semiconductor Industry Ass’n v. USITC, 266 F.3d 1339, 1345 (Fed. Cir. 2001).

88 Statement of Administrative Action (“SAA”) on Uruguay Round Agreements Act (“URAA”), H.R. Rep. 103-316, Vol. I at 851-52 (1994) (“{T}he Commission must examine other factors to ensure that it is not attributing injury from other sources to the subject imports.”); S. Rep. 96-249 at 75 (1979) (the Commission “will consider information which indicates that harm is caused by factors other than less-than-fair-value imports.”); H.R. Rep. 96-317 at 47 (1979) (“in examining the overall injury being experienced by a domestic industry, the ITC will take into account evidence presented to it which demonstrates that the harm attributed by the petitioner to the subsidized or dumped imports is attributable to such other factors;” those factors include “the volume and prices of nonsubsidized (continued...)
isolate the injury caused by other factors from injury caused by unfairly traded imports. 89 Nor does the “by reason of” standard require that unfairly traded imports be the “principal” cause of injury or contemplate that injury from unfairly traded imports be weighed against other factors, such as non-subject imports, which may be contributing to overall injury to an industry. 90 It is clear that the existence of injury caused by other factors does not compel a negative determination. 91

Assessment of whether material injury to the domestic industry is “by reason of” subject imports “does not require the Commission to address the causation issue in any particular way” as long as “the injury to the domestic industry can reasonably be attributed to the subject imports” and the Commission “ensure[s] that it is not attributing injury from other sources to the subject imports.” 92 93 Indeed, the

88 (continued)

imports or imports sold at fair value, contraction in demand or changes in patterns of consumption, trade restrictive practices of and competition between the foreign and domestic producers, developments in technology and the export performance and productivity of the domestic industry); accord Mittal Steel, 542 F.3d at 877.

89 SAA at 851-52 (“{T}he Commission need not isolate the injury caused by other factors from injury caused by unfair imports.”); Taiwan Semiconductor Industry Ass’n v. USITC, 266 F.3d 1339, 1345 (Fed. Cir. 2001) (“{T}he Commission need not isolate the injury caused by other factors from injury caused by unfair imports .... Rather, the Commission must examine other factors to ensure that it is not attributing injury from other sources to the subject imports.” (emphasis in original)); Asociacion de Productores de Salmon y Trucha de Chile AG v. United States, 180 F. Supp. 2d 1360, 1375 (Ct. Int’l Trade 2002) (“{t}he Commission is not required to isolate the effects of subject imports from other factors contributing to injury” or make “bright-line distinctions” between the effects of subject imports and other causes.); see also Softwood Lumber from Canada, Invs. Nos. 701-TA-414 and 731-TA-928 (Remand), USITC Pub. 3658 at 100-01 (Dec. 2003) (Commission recognized that “‘if an alleged other factor is found not to have or threaten to have injurious effects to the domestic industry, i.e., it is not an ‘other causal factor,’ then there is nothing to further examine regarding attribution to injury”), citing Gerald Metals, Inc. v. United States, 132 F.3d 716, 722 (Fed. Cir. 1997) (the statute “does not suggest that an importer of LTFV goods can escape countervailing duties by finding some tangential or minor cause unrelated to the LTFV goods that contributed to the harmful effects on domestic market prices.”).

90 S. Rep. 96-249 at 74-75; H.R. Rep. 96-317 at 47.

91 See Nippon Steel Corp., 345 F.3d at 1381 (“an affirmative material-injury determination under the statute requires no more than a substantial-factor showing. That is, the ‘dumping’ need not be the sole or principal cause of injury.”).

92 Mittal Steel, 542 F.3d at 877-78; see also id. at 873 (“While the Commission may not enter an affirmative determination unless it finds that a domestic industry is materially injured ‘by reason of’ subject imports, the Commission is not required to follow a single methodology for making that determination ... {and has} broad discretion with respect to its choice of methodology.”) citing United States Steel Group v. United States, 96 F.3d 1352, 1362 (Fed. Cir. 1997) and S. Rep. 96-249 at 75.

93 Commissioner Pinkert does not join this paragraph or the following four paragraphs. He points out that the Federal Circuit, in Bratsk, 444 F.3d 1369, and Mittal, held that the Commission is required, in certain circumstances, to undertake a particular kind of analysis of non-subject imports. Mittal explains as follows:

What Bratsk held is that “where commodity products are at issue and fairly traded, price-competitive, non-subject imports are in the market,” the Commission would not fulfill its obligation to consider an important aspect of the problem if it failed to consider whether non-subject or non-LTFV imports would have replaced LTFV subject imports during the period of investigation without a continuing benefit to the domestic industry. 444 F.3d at 1369. Under those circumstances, Bratsk requires the Commission to consider whether replacement of the LTFV subject imports might have occurred during the period of investigation, and it requires the Commission to provide an explanation of its conclusion with respect to that factor.

542 F.3d at 878.
Federal Circuit has examined and affirmed various Commission methodologies and has disavowed “rigid adherence to a specific formula.”94

The Federal Circuit’s decisions in Gerald Metals, Bratsk, and Mittal Steel all involved cases where the relevant “other factor” was the presence in the market of significant volumes of price-competitive non-subject imports. The Commission interpreted the Federal Circuit’s guidance in Bratsk as requiring it to apply a particular additional methodology following its finding of material injury in cases involving commodity products and a significant market presence of price-competitive non-subject imports.95 The additional “replacement/benefit” test looked at whether non-subject imports might have replaced subject imports without any benefit to the U.S. industry. The Commission applied that specific additional test in subsequent cases, including the Carbon and Certain Alloy Steel Wire Rod from Trinidad and Tobago determination that underlies the Mittal Steel litigation.

Mittal Steel clarifies that the Commission’s interpretation of Bratsk was too rigid and makes clear that the Federal Circuit does not require the Commission to apply an additional test nor any one specific methodology; instead, the court requires the Commission to have “evidence in the record” to “show that the harm occurred ‘by reason of’ the LTFV imports,” and requires that the Commission not attribute injury from non-subject imports or other factors to subject imports.96 Accordingly, we do not consider ourselves required to apply the replacement/benefit test that was included in Commission opinions subsequent to Bratsk.

The progression of Gerald Metals, Bratsk, and Mittal Steel clarifies that, in cases involving commodity products where price-competitive non-subject imports are a significant factor in the U.S. market, the Court will require the Commission to give full consideration, with adequate explanation, to non-attribution issues when it performs its causation analysis.97 98

The question of whether the material injury threshold for subject imports is satisfied notwithstanding any injury from other factors is factual, subject to review under the substantial evidence standard.99 Congress has delegated this factual finding to the Commission because of the agency’s institutional expertise in resolving injury issues.100

94  Nucor Corp. v. United States, 414 F.3d 1331, 1336, 1341 (Fed. Cir. 2005); see also Mittal Steel, 542 F.3d at 879 (“Bratsk did not read into the antidumping statute a Procrustean formula for determining whether a domestic injury was ‘by reason of’ subject imports.”).

95  Mittal Steel, 542 F.3d at 875-79.

96  Mittal Steel, 542 F.3d at 873 (quoting from Gerald Metals, 132 F.3d at 722), 875-79 & n.2 (recognizing the Commission’s alternative interpretation of Bratsk as a reminder to conduct a non-attribution analysis).

97  Commissioner Lane also refers to her dissenting views in Polyethylene Terephthalate Film, Sheet, and Strip from Brazil, China, Thailand, and the United Arab Emirates, Invs. Nos. 731-TA-1131 to 1134 (Final), USITC Pub. 4040 (Oct. 2008), for further discussion of Mittal Steel.

98  To that end, after the Federal Circuit issued its decision in Bratsk, the Commission began to present published information or send out information requests in final phase investigations to producers in non-subject countries that accounted for substantial shares of U.S. imports of subject merchandise (if, in fact, there were large non-subject import suppliers). In order to provide a more complete record for the Commission’s causation analysis, these requests typically seek information on capacity, production, and shipments of the product under investigation in the major source countries that export to the United States. The Commission plans to continue utilizing published or requested information in final phase investigations in which there are substantial levels of non-subject imports.

99  We provide in our respective discussions of volume, price effects, and impact a full analysis of other factors alleged to have caused any material injury experienced by the domestic industry.

100  Mittal Steel, 542 F.3d at 873; Nippon Steel Corp., 458 F.3d at 1350, citing U.S. Steel Group, 96 F.3d at 1357; S. Rep. 96-249 at 75 (“The determination of the ITC with respect to causation is ... complex and difficult, and is a matter for the judgment of the ITC.”).
B. **Conditions of Competition and the Business Cycle**

The following conditions of competition inform our analysis of whether there is material injury or threat of material injury by reason of subject imports from Canada and China.

1. **Demand Conditions**

Demand for citric acid and certain citrate salts is derived from the demand for the products in which they are ultimately incorporated. As discussed above, the largest end-use segment of the U.S. market is food and beverage applications (particularly for soft drink beverages), followed by industrial applications (particularly for household detergents and cleaners) and pharmaceutical applications (including for beauty and oral hygiene/cosmetics). Citric acid and certain citrate salts account for a relatively low share of the cost of the products in which they are used. There are relatively few substitutes for citric acid and certain citrate salts.

The demand for citric acid and certain citrate salts in the United States was strong and grew by approximately *** percent between 2006 and 2008. During the period of investigation, demand, as measured by total apparent U.S. consumption (the sum of the domestic industry’s U.S. shipments and imports from subject and non-subject countries of citric acid and certain citrate salts) increased from *** dry pounds in 2006 to *** dry pounds in 2007 and *** dry pounds in 2008.

Questionnaire respondents generally agreed that demand for citric acid and certain citrate salts increased during the period of investigation. Reasons for the increased demand included economic growth; citric acid’s relatively low cost; reformulation of downstream products to increase use of citric acid; increased use in detergents; sodium-reduction initiatives; new products; and increased demand for the end-use products in which citric acid and certain citrate salts are used.

Products manufactured in the United States and imported from Canada and China were all sold more frequently to end users than to distributors, although domestic producers shipped a somewhat higher share of their products to end users than did importers. Nonetheless, some of the largest distributors of domestically produced products are also importers of Chinese products.
The parties agree that purchasers of citric acid and certain citrate salts number in the hundreds but that the top purchasers account for a substantial portion of total purchases. The five largest purchasers that provided questionnaire responses accounted for 48.3 percent of apparent U.S. consumption between 2006 and 2008.  The 12 largest purchasers accounted for 98.7 percent of purchases reported by purchasers in these investigations and 66.9 percent of apparent U.S. consumption between 2006 and 2008.  The top purchasers based on quantities purchased are ***, each of which reported purchasing more than *** pounds during the period of investigation.  *** dry pounds, respectively.  All other purchasers reported purchasing less than *** pounds of citric acid and citrate salts during the three-year period from 2006 to 2008.

Demand by beverage manufacturers peaks between April and August of each year.  Sales to beverage manufacturers accounted for over one-quarter of combined U.S. shipments of products produced in the United States, Canada, and China.  Respondents and some responding purchasers asserted that due to limitations in their manufacturing equipment, beverage manufacturers, particularly soft-drink manufacturers, required anhydrous citric acid that did not “cake” or clog their machinery.

Domestic producers report contracting for a large portion of their sales in the final quarter of each year for shipments the following year; Cargill estimated that domestic producers contract for approximately 80 percent of their output in November and December each year to a few very large purchasers.  Responding purchasers generally agreed that long-term contracts, which are typically 12 months in duration in this industry, are common.  Although there were differences in the percentage of sales made under long-term contracts, a large portion of sales by the domestic industry, JBL Canada, and importers of Chinese product were made through long-term contracts.
Short-term contracts ranged in duration from 1 to 9 months. The food and beverage industries were the most commonly reported end users purchasing using short-term contracts. Purchasers typically reported entering into these contracts on an as-needed or quarterly basis. *** U.S. producers, 15 importers, and 20 purchasers reported using short-term contracts for citric acid and certain citrate salts. JBL Canada reported selling *** percent of the Canadian product using short-term contracts. Although 47 of the 65 responding purchasers reported spot purchases between 2006 and 2008, the largest end users were less likely to purchase citric acid and certain citrate salts on a spot basis.

2. **Supply Conditions**

There are three sources of supply in the U.S. market: domestic production, imports of subject merchandise from Canada and China, and imports from non-subject countries. During the period of investigation, the domestic industry held the largest share of the market followed by cumulated subject imports from Canada and China and then imports from non-subject countries. The domestic industry’s share of the U.S. market, by quantity, fluctuated from year to year and declined from *** percent in 2006 to *** percent in 2008. Cumulated subject imports’ share of the U.S. market, by quantity, increased from *** percent in 2006 to *** percent in 2008. During the period of investigation, non-subject imports’ share of the U.S. market, by quantity, decreased from *** percent in 2006 to *** percent in 2008.

a. **Domestic Production**

As previously stated, whereas, of the products covered by the scope of these investigations, Tate & Lyle produces only citric acid, both ADM and Cargill produce citric acid, sodium citrate, and potassium citrate. All three U.S. producers are global companies that produce and sell agricultural-

---

122 See, e.g., CR at V-12.
123 See, e.g., CR at V-12.
124 See, e.g., CR at V-12.
125 See, e.g., CR at V-12.
126 See, e.g., CR at V-12. Eleven importers of Chinese products reported using short-term contracts, with three of these reporting that 60 to 100 percent of their sales were made using short-term contracts and eight firms reporting that 10 to 40 percent of their sales were made using short-term contracts. The duration for short-term contracts ranged from 1 to 9 months. See, e.g., CR at V-12.
127 See, e.g., CR at V-13. Between 2006 and 2008, the percentages of spot sales made by ADM, Cargill, and Tate & Lyle were ***, ***, and *** percent, respectively. See, e.g., CR at V-13. JBL Canada reported selling *** percent of the Canadian product on a spot basis. Six of the 16 importers of Chinese product reported selling all citric acid and certain citrate salts on a spot basis, four reported that spot sales accounted for 10 to 40 percent of sales, five reported these were 60 to 80 percent of sales, and one indicated that spot sales accounted for 85 percent of its total sales. See, e.g., CR at V-13.
128 See, e.g., CR/PR at Table C-1.
129 See, e.g., CR/PR at Table C-1.
130 See, e.g., CR/PR at Table C-1.
131 See, e.g., Petitions, Vol. I at 2; CR at III-4 at n.6. Petitioners ADM, Cargill, and Tate & Lyle each submitted producer questionnaire responses, so domestic industry data reflect 100 percent of the domestic industry’s production. See, e.g., CR at III-1.
based products in many different countries around the world. ADM entered the citric acid business in 1990 when it purchased the business from Pfizer. In addition to its Dayton, Ohio facility, Tate & Lyle also produces citric acid in Brazil and Colombia. Cargill **. The three domestic producers have production capacity, with **. We find that this high fixed cost, capital-intensive industry is dependent on continuous production of an organic product in a tightly controlled and sanitary fermentation process that cannot easily be slowed or stopped. Slowdowns affect yields and shutdowns engender lengthy flushing and sterilization operations prior to resumption of production. Furthermore, the physical design of a modern citric acid production facility makes it difficult to engage in incremental capacity expansion. Back-end (refining and recovery) capacity increases cannot be done in small increments whereas any increase in the front end (fermentation) must be accompanied by increases on the back end.

b. Imports of Subject Merchandise from Canada and China

Canada: Only one producer, JBL Canada, produces subject merchandise in Canada. JBL Canada is wholly owned by the Swiss firm Jungbunzlauer AG. Jungbunzlauer AG has been selling citric acid in the U.S. market since the 1970s when it supplied the market from its plant in Vienna, Austria. In 1999, it built a plant in Canada in order to supply its customers in the United States and Western Hemisphere from a facility located closer to those markets. After the Canadian facility became operational in 2002, JBL ceased shipping citric acid to the U.S. market from Austria and replaced those shipments with Canadian products. JBL Canada produces only food-grade citric acid at its facility in Canada (no citrate salts).

China: The Chinese citric acid industry is the largest in the world. The five largest reporting Chinese producers, ***, accounted for the vast majority of reported 2008 production. 

---

132 See, e.g., Hearing Tr. at 33-34 (Poulos).
133 See, e.g., Hearing Tr. at 22 (Baroni). ADM acquired a plant in Ireland as part of that transaction, but asserts that it had to close that facility due to competition with Chinese imports into the E.U. market. See, e.g., id.
134 See, e.g., Hearing Tr. at 33-34 (Poulos). Tate & Lyle previously operated citric acid plants in Selby, England and Cuernavaca, Mexico, but contended that it was forced to close the U.K. plant due to competition from unfairly traded Chinese citric acid imports into the E.U. market. See, e.g., id.
135 See, e.g., CR/PR at Table III-1 at n.2.
136 See, e.g., CR/PR at Table III-2.
137 See, e.g., Petitioners’ Prehearing Br. at 18-19, 79-81; CR at II-7, VI-9 at n.15.
138 See, e.g., CR at VII-2.
139 See, e.g., CR at VII-2.
140 See, e.g., Confer. Tr. at 116 (Waite for JBL); JBL’s Postconf. Br. at 1-2; CR at VII-3.
141 See, e.g., Confer. Tr. at 117-18 (Waite for JBL); Hearing Tr. at 167-68 (Rainville for JBL); JBL’s Posthearing Br. at Exh. 5 at 1-2; CR at VII-3.
142 See, e.g., CR at VII-2.
143 See, e.g., CR/PR at Table VII-7.
144 See, e.g., CR at VII-5. Data regarding the Chinese industry are based on questionnaire responses from 14 foreign producers that are believed to account for approximately 90 percent of Chinese export shipments to the United States in 2008. See, e.g., CR at VII-5. Sixteen foreign producers/exporters of subject merchandise in China submitted questionnaire responses. Two reported that they did not export subject merchandise to the United States (continued...)
c. **Non-Subject Imports**

Non-subject imports represent a declining share of the U.S. market and a declining share of total imports. As a share of total imports into the U.S. market, non-subject imports declined from *** percent in 2006 to *** percent in 2007 and *** percent in 2008. In descending order of import volume in 2008, non-subject sources included Israel, Colombia, Germany, Thailand, Austria, and Belgium.

3. **Raw Material Costs**

The principal raw materials used to produce citric acid and certain citrate salts consist of the substrate (such as corn starch, molasses, dextrose and/or high fructose corn syrup) and chemicals (including calcium carbonate and sulfuric acid). Energy, including electricity and the cost of producing steam, are other significant components of the cost of producing citric acid. U.S. and Canadian producers use corn (and sometimes other feedstocks such as molasses) as the substrate. Chinese producers, on the other hand, use a variety of substrates including sweet potato powder, tapioca, wheat, and corn. The costs of both substrates and energy generally rose since January 2006 but declined since mid-2008. The prices of electric-power generation, transmission, and distribution rose by 10.6 percent from January 2006 to December 2008.

C. **Volume of the Cumulated Subject Imports**

In evaluating the volume of subject imports, section 771(7)(C)(i) of the Tariff Act provides that the “Commission shall consider whether the volume of imports of the merchandise, or any increase in that volume, either in absolute terms or relative to production or consumption in the United States, is significant.”

Subject imports had a large and growing presence in the U.S. market during the period of investigation. In absolute terms, the volume of cumulated subject imports from Canada and China during the period of investigation, ***. See, e.g., CR at VII-5 & n.4. Chinese Respondents argue that the Government of China’s recent environmental protection policies caused rapid consolidation of producers of citric acid and citrate salts in China, with the number of producers falling from over 100 to below 20. See, e.g., Confer. Tr. at 131 (Porter for Chinese Respondents); Chinese Respondents’ Postconf. Br. at 1; CR at VII-5 & n.6. According to ***. See, e.g., CR at VII-7 at n.7.

---

144 (...continued) See, e.g., CR at VII-5 & n.4. Chinese Respondents argue that the Government of China’s recent environmental protection policies caused rapid consolidation of producers of citric acid and citrate salts in China, with the number of producers falling from over 100 to below 20. See, e.g., Confer. Tr. at 131 (Porter for Chinese Respondents); Chinese Respondents’ Postconf. Br. at 1; CR at VII-5 & n.6. According to ***. See, e.g., CR at VII-7 at n.7.

145 See, e.g., CR/PR at Table IV-2.

146 See, e.g., CR at IV-4.

147 See, e.g., CR at I-13 to I-15, V-1; Petitioners’ Posthearing Br. at Exh. 2 at 4.

148 See, e.g., CR at I-13 to I-15, V-1; Petitioners’ Posthearing Br. at Exh. 2 at 4.

149 See, e.g., CR at V-1.

150 See, e.g., CR at V-1; CR/PR at Figure V-1.

151 See, e.g., CR at V-1.

152 Chairman Aranoff, Vice Chairman Pearson, and Commissioner Okun do not join the remainder of this opinion. See Separate and Dissenting Views of Chairman Shara L. Aranoff, Vice Chairman Daniel R. Pearson, and Commissioner Deanna Tanner Okun.

increased from *** dry pounds in 2006 to *** dry pounds in 2007 and *** dry pounds in 2008.\textsuperscript{154} In contrast, imports from non-subject countries had a smaller and declining presence in the U.S. market. The volume of imports from non-subject countries declined in absolute terms from 68.6 million dry pounds in 2006 to 65.6 million dry pounds in 2007 and 55.6 million dry pounds in 2008.\textsuperscript{155} The domestic industry’s U.S. shipments of citric acid and certain citrate salts increased from 369.5 million dry pounds in 2006 to 399.6 million dry pounds in 2007 and 402.5 million dry pounds in 2008.\textsuperscript{156}

As discussed earlier, apparent U.S. consumption was strong and increasing throughout the period of investigation, increasing by *** percent between 2006 and 2007 and by *** percent between 2007 and 2008, for an overall increase of *** percent during the period of investigation.\textsuperscript{157}

Cumulated subject imports grew at a faster pace than demand, increasing by *** percent between 2006 and 2007 and by *** percent between 2007 and 2008, for an overall increase of *** percent.\textsuperscript{158} As a result, cumulated subject imports captured an increasing share of the U.S. market, first at the expense of non-subject imports and by 2008 at the expense of the U.S. industry. Cumulated subject imports increased their share of the U.S. market, by quantity, from *** percent in 2006 to *** percent in 2007 and *** percent in 2008.\textsuperscript{159} Non-subject imports’ share of the U.S. market declined progressively from *** percent in 2006 to *** percent in 2007 and *** percent in 2008.\textsuperscript{160} The domestic industry’s market share increased marginally from *** percent in 2006 to *** percent in 2007 and then decreased to *** percent in 2008.\textsuperscript{161} Thus, despite strong and increasing apparent U.S. consumption, the domestic industry’s U.S. shipments grew at a much slower rate than U.S. consumption between 2006 and 2008, as the domestic industry’s U.S. shipments increased by 9.0 percent while apparent U.S. consumption increased by *** percent.\textsuperscript{162}

The domestic industry’s production increased from 475.4 million dry pounds in 2006 to 488.4 million dry pounds in 2007 and 507.9 million dry pounds in 2008.\textsuperscript{163} Despite this growth in domestic production, the ratio of cumulated subject imports from Canada and China to domestic production increased from *** percent in 2006 to *** percent in 2007 and *** percent in 2008.\textsuperscript{164}

In summary, subject imports held between one-third and one-half of the domestic market throughout the period of investigation. Their quantity and market share grew steadily. The domestic industry’s shipments and production rose at a pace well below the rate at which consumption increased; thus, the domestic industry was unable to take full advantage of exceptionally strong demand conditions. As discussed below in Section V.D (Price Effects), the large and growing subject import volume stifled the domestic producers’ ability to obtain price increases necessary to compensate for increased production costs.

\textsuperscript{154} See, e.g., CR/PR at Table C-1.
\textsuperscript{155} See, e.g., CR/PR at Table C-1.
\textsuperscript{156} See, e.g., CR/PR at Table C-1.
\textsuperscript{157} See, e.g., CR/PR at Table C-1.
\textsuperscript{158} See, e.g., CR/PR at Table C-1.
\textsuperscript{159} See, e.g., CR/PR at Table C-1.
\textsuperscript{160} See, e.g., CR/PR at Table C-1.
\textsuperscript{161} See, e.g., CR/PR at Table C-1; see also, e.g., CR/PR at Tables V-4 to V-6 (showing ***); Petitioners’ Prehearing Br. at Exh. 8 (showing ***).
\textsuperscript{162} See, e.g., CR/PR at Table C-1.
\textsuperscript{163} See, e.g., CR/PR at Table C-1.
\textsuperscript{164} See, e.g., CR/PR at Table IV-6.
On this basis, we find that the volume of cumulated subject imports is significant, both absolutely and relative to consumption and production in the United States. Moreover, we find that, during the period of investigation, the *** percent increase in the volume of subject imports is significant relative to the *** percent increase in apparent U.S. consumption.

D. Price Effects of the Cumulated Subject Imports

In evaluating the price effects of the subject imports, section 771(7)(C)(ii) of the Tariff Act provides that the Commission shall consider whether –

(I) there has been significant price underselling by the imported merchandise as compared with the price of domestic like products of the United States, and

(II) the effect of imports of such merchandise otherwise depresses prices to a significant degree or prevents price increases, which otherwise would have occurred, to a significant degree.\textsuperscript{165}

The record indicates that citric acid and certain citrate salts are commodities.\textsuperscript{166} Although these products account for a small portion of the total cost of the products in which they are used,\textsuperscript{167} price is an important consideration to purchasers, who also reported quality and availability to be important considerations.\textsuperscript{168}

In evaluating price effects, we considered quality and other non-price differences among the domestic like product and subject imports from Canada and China. As discussed above, there was considerable overlap in the chemical and physical forms of products supplied to the U.S. market by the domestic industry and producers in the subject countries, and all three sources sold large quantities of anhydrous citric acid.\textsuperscript{169} Although caking was reported more frequently as a problem for subject imports from China,\textsuperscript{170} Chinese product was nevertheless sold in substantial quantities for the same end-use applications, to many of the same purchasers, and even to the highly demanding soft drink sector, as discussed above.\textsuperscript{171} Producers in the United States, Canada, and China manufacture products that meet quality requirements for sale as FCC/USP products.\textsuperscript{172} Despite some non-price differences among


\textsuperscript{166} See, e.g., Petitioners’ Prehearing Br. at 11-12; Petitioners’ Posthearing Br. at 8; Hearing Tr. at 22 (Baroni), 34 (Poulos); Chinese Respondents’ Postconf. Br. at 38; Hearing Tr. at 17-18, 20, 287 (Cameron).

\textsuperscript{167} See, e.g., CR at II-22. There are relatively few substitutes for citric acid and certain citrate salts, and questionnaire respondents reported that the prices of these substitutes did not affect the price of citric acid and certain citrate salts. See, e.g., CR at II-21 to II-22.

\textsuperscript{168} See, e.g., CR/PR at Table II-4.

\textsuperscript{169} See, e.g., CR/PR at Table V-4 to V-6, Table V-2. Citric acid in solution form *** imported from China, although U.S. and Canadian producers sold citric acid in solution form to the U.S. market. Nevertheless, the record reflects that end users can convert dry forms into solution or have third parties perform that function for them, as discussed above.

\textsuperscript{170} See, e.g., CR at II-28 to II-30; PepsiCo’s Prehearing Br. at 12-13.

\textsuperscript{171} See, e.g., Petitioners’ Posthearing Br. at Exh. 3 at I-2; CR/PR at Table II-2, Table IV-3.

\textsuperscript{172} See, e.g., Petitioners’ Posthearing Br. at 8; CR at II-1, II-11, II-27, II-32 to II-37; CR/PR at Table II-2, Table II-8, Table IV-3.
sources,173 products manufactured in the United States, Canada, and China are generally of similar quality.174 Questionnaire respondents generally reported that subject imports from Canada and China are substitutable for one another and for the domestic like product.175 Because producers in the United States, Canada, and China supply a product of acceptable quality and all sold large quantities to the U.S. market, we find that they competed primarily on price.

In the final phase of these investigations, the Commission tailored its collection of pricing data to reflect more precisely the conditions of competition in this industry as revealed during the preliminary phase. Specifically, the Commission requested that importers and domestic producers report sales prices as follows: on a delivered basis to control for differences in transportation costs; to end users and distributors separately; for citric acid sold in solution form; and for spot and contract sales separately for three citric acid pricing products that accounted for a large portion of the U.S. market.176 In the final-phase questionnaires, the Commission also asked a number of questions, particularly of purchasers, about how the U.S. market works, the negotiation process, and the role of the various players in the market.177 In addition to collecting traditional pricing data and narrative data from purchasers,178 the Commission also requested pricing data and bid data on the largest annual bids from those purchasers that purchased more than 20 million pounds of citric acid and certain citrate salts in 2006, 2007, or 2008.179 As discussed below, we find that these more comprehensive data portray a very different picture than the more limited data from the preliminary phase.

The Commission obtained usable quarterly delivered pricing data for five products sold to unrelated customers from three domestic producers, *** of subject merchandise from Canada, and 21 importers of subject merchandise from China.180 Pricing data reported in the final phase of these investigations by these firms accounted for approximately 56.3 percent of the domestic industry’s U.S. shipments of citric acid and certain citrate salts, *** percent of U.S. shipments of subject imports from Canada, and 60.0 percent of U.S. shipments of subject imports from China in 2008.181 Taken as a whole, these pricing data show mixed under- and over-selling, with underselling occurring in *** percent of all observations.182 183 Because the domestic industry’s sales were highly

---

173 See, e.g., CR at II-25 to II-37.
174 See, e.g., CR/PR at Table II-8.
175 See, e.g., CR/PR at Table II-6, Table II-7, Table II-8.
176 See, e.g., CR at V-17; CR/PR at Tables V-4 to V-8, Table C-1.
177 See, e.g., CR at II-14 to II-37, V-1 to V-2, V-5 to V-16; CR/PR at Tables II-2 to II-8, Table IV-3, Table V-2, Table V-3.
178 See, e.g., CR/PR at Tables V-4 to V-10 (traditional pricing data); CR at II-14 to II-37, V-1 to V-2, V-5 to V-16; CR/PR at Tables II-2 to II-8, Table IV-3, Table V-2, Table V-3 (narrative data from purchasers).
179 See, e.g., CR at II-5 at n.14; CR/PR at D-3 to D-10 and Table D-1 (bid data); CR/PR at Tables D-2 to D-4 (purchaser pricing data).
180 These products are as follows: (1) citric acid, granular, in dry form in 25 kilogram and 50 pound bags, excluding all product packaged and sold as fine granular product; (2) citric acid, granular, in dry form packed in bulk sacks (“supersacks”), excluding all product packaged and sold as fine granular product; (3) citric acid, in 48 to 52 percent solution form; (4) sodium citrate, granular, in dry form in 25-kilogram and 50-pound bags; and (5) potassium citrate, granular, in dry form in 25-kilogram and 50-pound bags. See, e.g., CR at V-17.
181 See, e.g., CR at V-17.
182 The data show 139 instances of underselling at margins that ranged from less than 0.5 percent to 31.7 percent and averaged 12.7 percent, compared to 92 instances of overselling at margins that ranged from 0.4 percent to 55.7 percent and averaged 15.0 percent. See, e.g., CR/PR at Table V-10. We note that higher margins of overselling (continued...)
concentrated in contract transactions, we have paid particular attention to those data. Like the data as a whole, those data show a mixed picture of underselling and overselling, with 31 instances of underselling and 51 instances of overselling. Most of the volume of reported import and domestic contract sales was associated with overselling comparisons.

In addition, the record indicates that the filing of the petitions in April 2008 affected prices in the U.S. market; subject import prices, even for contract sales (particularly for China), rose substantially over the course of 2008. We note that the relative instances of overselling and underselling changed after the filing of the petitions in the first quarter of 2008, and that underselling was much more prevalent prior to that time. Again paying particular attention to the contract transactions, breaking down the above-cited 31 instances of underselling and 51 instances of overselling, the data reveals that through the first quarter of 2008, the contract transactions reflected 28 instances of underselling and 35 instances of overselling, which is more balanced. In the last three quarters of 2008, contract transactions reflected only 3 instances of underselling and 16 instances of overselling. Moreover, the margins of overselling, which had been fairly small through the first quarter of 2008 and, as we explain below, had been acting as a cap or ceiling on domestic prices, tended to widen during the last three quarters of 2008. This widening of margins or raising of the ceiling on domestic prices after the filing of the petitions did not benefit the domestic industry in 2008 as much as might be expected, due to the portion of the domestic industry’s

---

182 (...continued)

183 Commissioner Lane and Commissioner Pinkert note that, in the preliminary phase of these investigations the more limited pricing data collected indicated that: “subject imports were consistently priced higher than the domestic like product in the U.S. market, at substantial margins .” USITC Pub. 4008 at 35. In the preliminary phase, there was underselling in only 12 of 104 price comparisons, accompanied by considerable overselling margins (as high as 120.6 percent, and at least ten percent in 32 quarters for subject imports from China). USITC Pub. 4008 at 35. In stark contrast to the limited pricing data in the preliminary phase, the additional and more detailed pricing data in the final phase of these investigations show underselling in 139 of 231 comparisons, with much smaller margins of overselling, particularly in the contracts categories and for prices through the first quarter of 2008. See, e.g., CR/PR at Tables V-4 to V-6.

184 (derived from CR/PR at Table V-4 to Table V-6).

185 (derived from CR/PR at Table V-4 to Table V-6) (indicating that 77.7 percent of the domestic industry’s sales of pricing products 1 to 3, by quantity, were oversold by subject imports from either China or Canada and that 58.9 percent of sales of pricing products 1 to 3 imported from Canada oversold the domestic like product compared to 58.4 percent of sales of pricing products 1 to 3 imported from China).

186 See, e.g., CR/PR at Tables V-4 to V-6 showing the following price increases:

* * * * * * * * *

See also, e.g., Hearing Tr. at 15 (Ellis), 55 (Lorusso), 114 (Szmosszegi), 139, 158 (Anderson).

187 Overall, the data show underselling in 44 percent of comparisons, representing 45 percent of subject import quantities and 30 percent of the domestic industry’s quantities for contract sales of pricing products 1 to 3. For subject imports from China alone, underselling occurred in 64 percent of comparisons, representing 58 percent of subject import quantities from China and 53 percent of the domestic industry’s quantities for contract sales of pricing products 1 to 3 where there were comparisons. (derived from CR/PR at Tables V-4 to V-6).

188 19 U.S.C. § 1677(I). Although we have separately analyzed the pricing data from before and following the filing of the petitions, we do not discount the data beginning in late 2007, as requested by petitioners.

189 See, e.g., CR/PR at Tables V-4 to V-6.
sales that were under annual contracts. Finally, we observe that most purchasers considered subject imports to be lower-priced than the domestic like product.

Overall, we find that the pricing data present a varied picture that is consistent with a finding of significant underselling, particularly for a commodity-type product for which large price differences would not be expected. Moreover, as is evident from Figures V-3 through V-5 of the Staff Report, subject import prices and domestic prices for contract sales to end users, which accounted for a majority of the domestic and import volume, were nearly the same and tracked closely. As discussed below, the import prices were sufficiently low to prevent price increases needed by the domestic industry to compensate for increased costs. Subject import pricing acted essentially as a cap or ceiling on the price levels that could be obtained by domestic producers. The underselling that occurred was significant because it established the cap or ceiling at low levels.

Prices of the domestic like product and subject merchandise from Canada and China were generally stable in the earlier portion of the period of investigation and were higher at the end of the period of investigation. Accordingly, we do not find that cumulated subject imports from Canada and China significantly depressed prices of the domestic like product in the U.S. market.

We have also considered whether cumulated subject imports from Canada and China suppressed prices of the domestic like product to a significant degree. Consistent with increasing substrate and energy costs, the domestic industry’s average unit cost of goods sold (“COGS”) increased from $0.44 per dry pound in 2006 to $0.46 per dry pound in 2007 and $0.52 per dry pound in 2008. During this time, the domestic industry’s average unit sales value was only slightly, if at all, higher than its unit COGS, not even factoring in selling, general, and administrative costs. Although market demand was strong and increasing, the domestic industry was not able to increase its prices to levels that were sufficient to cover the increase in its costs. Consequently, the domestic industry experienced a cost-price

---

190 We note that prices for the domestic like product increased by much less than prices of subject imports in 2008 because most domestic sales are subject to annual fixed-price contracts whose prices are set in the final quarter of the preceding year whereas a larger proportion of sales of subject imports are made pursuant to short-term contracts, long-term contracts set at less regular intervals, and spot sales. See, e.g., CR at V-11 to V-13. Moreover, some purchasers indicated that Chinese suppliers are less likely to adhere to contract price terms. See, e.g., CR at V-6. As a result, the prices of subject imports reacted sooner to the April 2008 filing of the petitions in these investigations than prices of the domestic like product.

191 See, e.g., CR/PR at Table II-8 (for those purchasers reporting subject imports to be higher or lower-priced than the domestic like product, more (33 purchasers) reported subject imports to be lower priced than reported domestically produced products to be lower priced (14 purchasers)).

192 We have also examined data submitted by purchasers (predominantly large purchasers) on the prices they paid for citric acid products produced in the United States and imported from the subject countries. See, e.g., CR/PR at Table D-2 to D-4. These data show mostly underselling by the subject imports and thus, if anything, further support a finding of significant underselling. We recognize that the purchaser pricing data must be taken into account carefully, because the purchaser pricing data on subject imports is not precisely comparable to the purchaser pricing data on the domestic like product.

We have also examined data submitted by purchasers on their largest annual bids during the period of investigation. See, e.g., CR/PR at Table D-1; CR at D-9 to D-10. These data are consistent with our analysis to the extent that they also show that subject imports from Canada and China were priced at similar levels to, and competed for, sales to large purchasers against domestically produced citric acid and certain citrate salt products. See, e.g., id.

193 See, e.g., CR/PR at Tables V-4 to V-8.

194 See, e.g., CR at V-1.

195 See, e.g., CR/PR at Table C-1.

196 The domestic industry’s average unit net sales value was $0.44 in 2006, $0.44 in 2007, and $0.53 in 2008 compared to average unit COGS of $0.44 in 2006, $0.46 in 2007, and $0.52 in 2008. See, e.g., CR/PR at Table C-1.
squeeze, as its unit COGS as a share of unit net sales was very high throughout the period of investigation and increased from 98.6 percent in 2006 to 103.6 percent in 2007 before declining to 97.9 percent in 2008.\(^{197}\)\(^{198}\)

We next examined the extent to which subject imports played a role in the cost-price squeeze experienced by the industry. In particular, we considered price and market developments that contributed to the industry’s contract price levels for 2007 and 2008, the most recent contract years within the period of investigation. As described above, in the fourth quarter of each year the domestic industry negotiates annual fixed-price contracts for nearly all of its sales volumes for the upcoming year.

The domestic industry’s contract prices for 2007 were relatively unchanged from 2006.\(^ {199}\) The flat price levels occurred despite the fact that the price of corn, which represents the industry’s largest single cost item, increased by more than 50 percent from September 2006 to November 2006.\(^ {200}\) The flat industry prices were a key reason for the spike in the COGS/net sales ratio experienced by the domestic industry in 2007.

We find that the domestic industry’s inability to obtain higher prices in 2007, despite the large increase in corn prices and growing demand for citric acid, was due in significant part to the large and growing presence of relatively low-priced subject imports. Subject imports had increased in market share by *** percentage points from 2005 to 2006.\(^ {201}\) Subject import prices in late 2006 for contract sales, and even certain spot sales, were frequently near, at, or below the low levels that domestic producers obtained for their 2007 contracts.\(^ {202}\) The increased presence of low-priced subject imports left the domestic industry in no position to demand 2007 prices sufficient to offset surging corn costs. Had the domestic industry insisted on higher prices reflective of its increasing raw materials costs, its prices would have exceeded the prices of subject imports. Even though many of the resulting subject import prices for the 2007 contracts were at, or somewhat above, domestic prices, the pricing pressure from the large and increasing volume of cumulated subject imports made it impracticable for the domestic industry to increase its prices to the degree that would have been required to recover its increasing production costs.\(^ {203}\)

We do not agree with respondent’s position that the domestic industry was unable to recover its increasing raw material costs in 2007 because of contracts negotiated near the end of 2006 that did not

---

\(^{197}\) See, e.g., CR/PR at Table C-1.

\(^{198}\) Commissioner Lane notes that, in the preliminary phase of these investigations, COGS as a share of net sales was 96.3 percent in 2005 and 101.1 percent in 2007, but improved significantly to 92.8 percent in the first quarter of 2008. Based on that information, Commissioner Lane found that there was only “some indication of price suppression.” USITC Pub. 4008 at 36. The complete record for the final phase of these investigations, however, shows COGS as a share of net sales was 98.6 percent in 2006, 103.6 percent in 2007, and 97.9 percent in 2008. Thus, it is now clear that the domestic industry experienced a significant cost-price squeeze from 2006 to 2007 and was not able to raise prices in 2008 to sufficiently cover costs such that it could operate at a reasonable level of profitability.

\(^{199}\) See, e.g., CR/PR at Table V-4 to V-8.

\(^{200}\) See, e.g., CR/PR at Figure V-1.

\(^{201}\) Compare, e.g., Mem. INV-FF-060 at Table C-1 with, e.g., CR/PR at Table C-1.


\(^{203}\) See, e.g., CR/PR at Table C-1 (showing ratio of COGS to net sales of *** percent in 2007).
account for an unexpected and significant increase in corn prices in 2007. In fact, corn prices rose substantially in the latter part of 2006. Although corn prices remained relatively flat and low during the first nine months of 2006, prices increased by 28 percent between September 2006 and October 2006, and another 21 percent in November 2006. The October 2006 spot price for Central Illinois yellow corn was 33 percent higher than the average price over the first nine months of 2006. By November 2006 the spot price was a startling 61 percent higher than the average price over the first nine months of 2006. Thus, the prospects for increases in corn prices above the average 2006 levels were not unknown to the domestic citric acid industry in the last quarter of 2006 when it was negotiating its 2007 contracts. Yet the domestic industry was unable to secure adequate price increases to recover the 2007 increase in raw material costs.

With regard to the 2008 contracts, after an extended period of high corn prices in 2007 and deeper operating losses, the domestic industry was able to secure meaningful but inadequate price increases from its customers. We find that subject imports, whose volume continued to grow sharply in 2008 (by *** percent) and to take more market share (*** percentage points), played a large role in keeping U.S. producers from obtaining sufficient price increases both to recover the cost increases of 2007/2008 and to increase net operating income to more reasonable levels. Although certain subject import prices were rising toward the end of 2007, the prices generally remained at or near domestic prices and were low in comparison with the domestic industry’s negotiated contract prices for 2008. The increases that the domestic industry was able to negotiate for 2008 mirrored, to a significant degree, contemporaneous increases in prices for subject imports. Thus, for the 2008 contract year, it appears that subject imports continued to establish prices that had a suppressing effect on the ability of the domestic industry to obtain reasonable profits. At these prices, the domestic industry continued to have high COGS to net sales ratios and to experience significant losses, as discussed below. Remarkably, the domestic industry’s high COGS to net sales ratios occurred in a time of strong and increasing demand.

Our finding of significant price suppression is buttressed by the fact that the domestic industry obtained significantly higher prices for its 2009 contracts negotiated in the final quarter of 2008. These negotiations took place after the filing of the petitions and after Commerce had issued its affirmative preliminary antidumping and countervailing duty determinations. The domestic price increases that

---

204 See, e.g., Chinese Respondents’ Prehearing Br. at 44; P&G’s Prehearing Br. at 42-43.
205 See, e.g., CR/PR at Figure V-1.
206 See, e.g., CR/PR at Figure I-1, Tables V-4 to V-8, Tables D-1 to D-4.
208 See, e.g., CR/PR at Tables V-4 to V-6. Per-pound prices for contracts to end users from fourth quarter 2007 to first quarter 2008: pricing product 1 – U.S. $*** to $***; Canada $*** to $***; China $*** to $0.57; pricing product 2 – U.S. $0.47 to $0.52, Canada $*** to $***, China $*** to $***; pricing product 3 – U.S. $0.44 to $0.51, Canada $*** to $***.
209 See, e.g., CR/PR at Table C-1.
210 See, e.g., CR/PR at Table C-1.
211 See, e.g., Petitioners’ Prehearing Br. at 67-68; Petitioners’ Posthearing Br. at 4-5.
followed the retreat of subject imports from the market confirm the dampening effects of the imports on domestic prices in 2006, 2007, and 2008.212 213

We have considered respondents’ contention that low prices obtained by the domestic industry were due to intra-industry competition among the three domestic producers. The record does reflect that ***, which ***. Moreover, purchasers indicated that some lost sales and revenues allegations actually reflected competition among domestic producers. Thus we find that intra-industry competition played a role in the inadequate price levels obtained by domestic producers. This does not call into question the record evidence showing significant pricing pressure from cumulated subject imports from Canada and China, as described above.215 The share of purchasers reporting that the market presence of subject imports tended to reduce contract prices was much larger than the share reporting that the

---

212 See, e.g. EDIS Doc No. 402203. Purchaser input, overall, tends to confirm the price-dampening effects of subject imports, particularly imports from China. Most purchasers reported that the availability of Chinese product tended to reduce contract prices. See, e.g., CR at V-8 to V-10; CR/PR at Table V-1, Table V-2. In conversations with staff regarding lost sales and lost revenue allegations, purchasers also reported price-based competition from subject imports from Canada and China and that the domestic industry lost sales and/or revenues to price-competitive subject imports from Canada and China, although there were relatively few fully confirmed lost sales and lost revenue allegations. See, e.g., CR at V-38 to V-52; CR/PR at Table V-11, Table V-12.

213 Commissioners Lane and Pinkert add their finding that, under the specific conditions of competition for this industry (whereby a large percentage of the domestic industry’s sales occur pursuant to annual contracts that are entered into well in advance), the existence and availability of significant subject producer capacity, production, and inventories enhanced the price-dampening effects of subject imports in the U.S. market. CR/PR at Table VII-4. They note in this regard that there was extensive testimony at the hearing as to the leverage enjoyed by purchasers during contract negotiations as a result of the overhang of subject producer capacity. Hearing Tr. at 44 (Christiansen), 77-78, 108-09 (Baroni), 314 (Ellis).

Commissioners Lane and Pinkert find further that the record of the final phase investigations reflects significantly increased interest in 2008 on the part of Chinese producers in the U.S. market (relative to the interest that was evident during the preliminary investigation). Although the record of the preliminary investigation indicated a steady decrease in exports from China to the United States as a share of the Chinese industry’s total shipments (as well as projections of a further year-over-year decrease from 9.3 percent in 2007 to 7.3 percent for 2008), the final-phase record shows exports from China to the United States increasing as a share of total shipments from 9.4 percent in 2007 to 10.0 percent in 2008. CR/PR at Table VII-3.

Similarly, during the preliminary phase of these investigations, subject producer end-of-period inventories (which were primarily from China) were projected to be *** million pounds for 2008, but the record in the final phase shows that subject end-of-period inventories turned out to be *** million pounds for 2008. Compare, e.g., Mem. INV-FF-060 at Tables VII-1 and VII-2 with, e.g., CR/PR at Tables VII-1, VII-3 and VII-4. Although it is not necessary for them to determine whether the domestic industry is imminently threatened with material injury, Commissioners Lane and Pinkert note that the increase in the immediate availability of subject imports is indicative of such threat.

214 (derived from domestic producers’ questionnaire responses).

215 Commissioner Lane and Commissioner Pinkert note that the evidence on the record of the preliminary investigations did not support a finding of a reasonable indication of significant pricing pressure from subject imports because the pricing data showed overwhelming overselling at large margins as well as significant cost-price gains in the first quarter of 2008. However, the evidence on the record of the final investigations, in stark contrast to the preliminary record, shows significant underselling of substantial volumes of the domestic like product, a meaningful but inadequate cost-price gain in full-year 2008, and a causal nexus between subject imports and the domestic industry’s poor performance, as discussed below in section V.E (Impact). Thus, it is clear that subject imports exerted significant pricing pressure on the domestic industry throughout the period of investigation.
presence of competing U.S. products tended to reduce such prices. Moreover, the competition between the three domestic producers continued in 2008 (as 2009 contracts were being negotiated) and did not prevent the industry from obtaining significant price increases as the presence of subject imports in the U.S. market diminished.

For all of these reasons, we find that the large and increasing volume of subject imports have had significant adverse effects on prices of the domestic like product.

E. Impact of the Cumulated Subject Imports on the Domestic Industry

In examining the impact of subject imports, section 771(7)(C)(iii) of the Tariff Act provides that the Commission “shall evaluate all relevant economic factors which have a bearing on the state of the industry.” These factors include output, sales, inventories, ability to raise capital, research and development, and factors affecting domestic prices. No single factor is dispositive and all relevant factors are considered “within the context of the business cycle and conditions of competition that are distinctive to the affected industry.”

We have examined the performance indicia for the domestic industry producing citric acid and certain citrate salts. Overall, the record in the final phase of these investigations indicates that a number of the domestic industry’s performance indicators improved between 2006 and 2007 but slowed or declined between 2007 and 2008 notwithstanding strong and increasing demand in the U.S. market throughout the three-year period between 2006 and 2008. Moreover, improvements in output or sales volumes are of limited benefit to the domestic industry if it is unable to raise prices sufficiently to produce a reasonable positive operating income, net income, and cash flow. The domestic industry was

---

216 According to purchasers, subject imports, in particular those from China, tended to bring prices down in negotiations, whereas the presence of competing U.S. products had a more mixed effect on negotiations, sometimes causing prices to decrease and sometimes to increase. Purchasers were asked whether the presence of U.S., Canadian, or Chinese sellers in contract negotiations increased prices, reduced prices, or had no impact on price at all. Most purchasers, 76.9 percent, reported that the presence of Chinese products reduced the price, as compared to 42.6 percent for U.S. products and 38.1 percent for Canadian products. A significant share of purchasers, 22.2 percent, also reported that the presence of U.S. sellers tends to raise prices, as compared to 9.5 percent for Canada and zero for China. These data further support our conclusion that subject imports put downward pricing pressure on domestic prices in contract negotiations. (derived from CR/PR at Table V-2).

217 In its final determinations, Commerce calculated a 23.21 percent weighted-average ad valorem dumping margin for Canadian producer JBL and all other Canadian producers. Commerce calculated the following margins for Chinese producers: 94.61 percent (Yixing Union Biochemical Co., Ltd.); 129.08 percent (Shandong TTCA Biochemistry Co., Ltd.); and 111.85 (various named exporter/producer combinations); and 156.87 percent (all others). See, e.g., CR at I-6 and I-7. Commerce also made affirmative countervailing duty determinations regarding subject imports from China. It assigned the following ad valorem margins: 3.60 percent (Yixing Union Biochemical Co., Ltd. and Yixing Union Cogeneration Co., Ltd.); 12.68 percent (Shandong TTCA Biochemistry Co., Ltd.); 118.95 percent (Anhui BBCA Biochemical Co., Ltd.); and 8.14 percent (all others). See, e.g., CR at I-7 to I-8.

218 19 U.S.C. § 1677(7)(C)(iii); see also SAA at 851 and 885 (“In material injury determinations, the Commission considers, in addition to imports, other factors that may be contributing to overall injury. While these factors, in some cases, may account for the injury to the domestic industry, they also may demonstrate that an industry is facing difficulties from a variety of sources and is vulnerable to dumped or subsidized imports.”).


220 As noted above, apparent U.S. consumption increased from *** dry pounds in 2006 to *** dry pounds in 2007 and *** dry pounds in 2008. See, e.g., CR/PR at Table C-1.
unable to do this, as evidenced by the fact that it had substantial operating losses, negative net income, and negative cash flow throughout the period of investigation.\(^\text{221}\)

We find that the domestic industry benefitted from purchasers’ preference for a U.S. supplier\(^\text{222}\) to the extent that many of its production indicators remained positive, but the large and increasing presence of cumulated subject imports put pressure on the prices that the domestic industry received for its sales. Despite strong and increasing demand, it was unable to raise prices adequately to improve its operating income while meeting rising costs for raw materials and energy, and its financial performance continued to suffer. By the end of the period of investigation, cumulated subject imports, which had previously gained market share at the expense of non-subject imports, began taking market share from the domestic industry, as discussed above, with significant adverse effects on the domestic industry’s performance.

As previously stated, the domestic industry’s output rose from 2006 through 2008. The domestic industry’s 6.8 percent increase in production quantity, however, did not match the much greater increase in apparent U.S. consumption of *** percent. The domestic industry’s production capacity increased from 475.4 million dry pounds in 2006 to 488.4 million dry pounds in 2007 and 507.9 million dry pounds in 2008.\(^\text{223}\) The domestic industry’s average production capacity remained stable at 553.9 million dry pounds between 2006 and 2008.\(^\text{224}\) The domestic industry’s capacity-utilization levels improved over the period of investigation.\(^\text{225}\)

Industry productivity increased by 11.8 percent between 2006 and 2008 and per-unit labor costs dropped by 10.1 percent. Although these labor-related production indicators should have improved the domestic industry’s bottom line, such improvements were not sufficient to allow the domestic industry to

\(^{221}\) The domestic industry’s operating income was negative $10.7 million in 2006, negative $21.6 million in 2007, and negative $7.5 million in 2008. Its net income was negative $18.6 million in 2006, negative $26.1 million in 2007, and negative $53.2 million in 2008. Its cash flow was negative $3.1 million in 2006, negative $11.9 million in 2007, and negative $41.7 million in 2008. See, e.g., CR/PR at Table VI-1. We note that the net loss for 2008 was impacted by large non-operating expenses representing ***. See, e.g., CR at VI-3 at nn.7-8. These items represent application of proper accounting principles for determining net income, but may not represent current cash outflow. However, even without these non-operating expense items, in addition to negative operating income, the domestic industry would have had negative net income and negative cash flow in 2008.

\(^{222}\) See, e.g., Hearing Tr. at 18 (Cameron), 193 (Hoffman), 204 (Bloom), 228 (Cameron), 265-66 (Cameron).

\(^{223}\) See, e.g., CR/PR at Table C-1.

\(^{224}\) See, e.g., CR/PR at Table C-1.

\(^{225}\) U.S. export shipments of citric acid and certain citrate salts increased from 96.7 million dry pounds in 2006 to 114.3 million dry pounds in 2007 but then decreased to 113.0 million dry pounds in 2008. See, e.g., CR/PR at Table C-1. These shipments accounted for a fairly stable percentage of total industry shipments, of between 21 and 22 percent. (derived from CR/PR at Table C-1).

\(^{226}\) See, e.g., CR/PR at Table C-1.

\(^{227}\) See, e.g., CR/PR at Table C-1.

\(^{228}\) The domestic industry’s capacity utilization levels increased from 85.8 percent in 2006 to 88.2 percent in 2007 and 91.7 percent in 2008. See, e.g., CR/PR at Table C-1.
produce reasonable positive financial results. In addition, the domestic industry testified that the increased productivity was not necessarily, in and of itself, a positive for the industry as it was partially accomplished by foregoing plant maintenance.\textsuperscript{229} Moreover, the improvements came at the expense of the employees in the industry. From 2006 to 2008, the number of production-related jobs fell by 4.6 percent and hours worked fell by 4.5 percent. Overall, wage expenses fell by 4.0 percent as the average hourly wages increased by only 0.5 percent.\textsuperscript{230}

The domestic industry’s net sales increased by 10.6 percent from 2006 to 2008, when measured by quantity, and increased by 32.0 percent over the same period, when measured by value.\textsuperscript{231} Although the domestic industry’s net sales and production volumes increased, they did not increase proportionally to demand, so the domestic industry’s market share fell. The domestic industry’s share of the U.S. market, by quantity, increased from *** percent in 2006 to *** percent in 2007 but then decreased to *** percent in 2008.\textsuperscript{232}

The domestic industry’s average unit COGS increased from $0.44 per dry pound in 2006 to $0.46 per dry pound in 2007 and $0.52 per dry pounds in 2008.\textsuperscript{233} During this time, the domestic industry’s average unit COGS was equal to or within pennies of its average unit net sales value.\textsuperscript{234} Despite strong and growing demand, the domestic industry’s price increases were not always sufficient to cover increases in its cost of production and were not sufficient to avert operating losses. Consequently, the domestic industry experienced a cost-price squeeze to the extent that its COGS as a share of net sales was very high throughout the period of investigation and increased from 98.6 percent in 2006 to 103.6 percent in 2007 before declining to 97.9 percent in 2008.\textsuperscript{235}

The domestic industry posted operating losses in each full year from 2006 to 2008. The domestic industry’s $10.7 million operating loss in 2006 deteriorated to a $21.6 million operating loss in 2007 before improving somewhat, but still remaining significant, as the industry posted a $7.5 million operating loss in 2008.\textsuperscript{236} The domestic industry’s operating income margin declined from negative 5.2 percent in 2006 to negative 9.5 percent in 2007 before improving somewhat to negative 2.8 percent in 2008.\textsuperscript{237} Capital expenditures were low and less than depreciation in every period, an indication that the domestic industry was not expanding or improving its productive facilities, but at best maintaining them.\textsuperscript{238} The overall level of research and development expenditures was also low.\textsuperscript{239}

\begin{itemize}
\item \textsuperscript{229} See, e.g., Hearing Tr. at 29 (Warner for ADM), 99 (Baroni for ADM).
\item \textsuperscript{230} See, e.g., CR/PR at Table C-1.
\item \textsuperscript{231} See, e.g., CR/PR at Table C-1. Net sales, by quantity, increased from 466.1 million dry pounds in 2006 to 513.9 million dry pounds in 2007 and 515.5 million dry pounds in 2008. Id.
\item \textsuperscript{232} See, e.g., CR/PR at Table C-1. Commissioner Lane and Commissioner Pinkert note that, in the preliminary phase of these investigations, data through first quarter 2008 showed that the domestic industry’s market share had improved to *** percent, up from 2007; however, in the final phase of these investigations, the data for full-year 2008 indicate the opposite (i.e., the domestic industry’s market share declined from *** percent in 2007 to *** percent in 2008). Compare, e.g., Mem. INV-FF-060 at Table C-1 with, e.g., CR/PR at Table C-1.
\item \textsuperscript{233} See, e.g., CR/PR at Table C-1.
\item \textsuperscript{234} The domestic industry’s average unit net sales value was $0.44 in 2006, $0.44 in 2007, and $0.53 in 2008 compared to average unit COGS of $0.44 in 2006, $0.46 in 2007, and $0.52 in 2008. See, e.g., CR/PR at Table C-1.
\item \textsuperscript{235} See, e.g., CR/PR at Table C-1.
\item \textsuperscript{236} See, e.g., CR/PR at Table C-1.
\item \textsuperscript{237} See, e.g., CR/PR at Table C-1.
\item \textsuperscript{238} See, e.g., CR at VI-12, VI-14 to VI-15; CR/PR at Table VI-5.
\item \textsuperscript{239} See, e.g., CR at VI-12; CR/PR at Table VI-5.
\end{itemize}
We conclude that cumulated subject imports had a material adverse impact on the condition of the domestic industry. We find that there is a sufficient causal nexus between the subject imports and the domestic industry’s poor performance during the period of investigation to attribute significant adverse effects on the domestic industry to subject imports. Specifically, we find that the volume of cumulated subject imports from Canada and China was significant both absolutely and relative to production and consumption and increased significantly relative to consumption. Cumulated subject imports, which were already large, increased faster than demand, first taking market share from non-subject imports and then the domestic industry. As the domestic industry’s costs increased, the significant and increasing volume of cumulated subject imports put downward pressure on prices, precluding the domestic industry from reaping the price benefits of the increasing demand. The large and growing volume of subject imports that suppressed prices of the domestic like product to a significant degree caused poor financial operating performance by the domestic industry during the period of investigation.

We have considered whether there are other factors that have had an impact on the domestic industry. Non-subject imports were a small and declining portion of the U.S. market during the period of investigation. The presence of non-subject imports does not undermine our finding of significant adverse effects due to cumulated subject imports because non-subject imports were priced higher and were not taking sales from the domestic industry.240

Respondents contend that the domestic industry had inadequate capacity to supply the entire U.S. market, and they claim that purchasers needed additional sources due to concerns about the domestic industry’s reliability. They assert that larger purchasers needed to multi-source because the magnitude of their demand was greater than any individual supplier could reliably supply.241 Contrary to the implication of respondents’ argument, the fact that the domestic industry may not be able to supply all of demand does not mean that the domestic industry cannot be materially injured or threatened with material injury by reason of subject imports.242 Moreover, we find that respondents’ claims concerning the reliability of the domestic industry are exaggerated. Although there is some evidence that shipments from the domestic industry were delayed or that domestic producers were unable to meet certain customers’ requests for products or supplemental quantities,243 ***.244 Finally, respondents’ arguments fail to take

240 With respect to the analysis required by the Federal Circuit in Bratsk, Commissioner Pinkert finds that the first triggering factor is satisfied, as citric acid is a commodity product for these purposes, but that the second trigger factor is not satisfied, because price-competitive non-subject imports are not a significant factor in the U.S. market. Non-subject imports decreased over the period of investigation, and, at their highest level, only accounted for *** percent of the U.S. market. CR/PR at Table IV-5.

241 See, e.g., Chinese Respondents’ Prehearing Br. at 12-24, 32; PepsiCo’s Prehearing Br. at 1-6; ; JBL’s Prehearing Br. at 12-13; P&G’s Prehearing Br. at 16-28; JBL’s Posthearing Br. at 1-4; Hearing Tr. at 75-76 (Hodges), 183-84 (Smith), 189-90 (Taylor), 193-94 (Hofmann), 199-200 (Pensak), 203-04 (Bloom); Chinese Respondents’ Posthearing Br. at Exh. A at 46-51; PepsiCo’s Posthearing Br. at 3-5.


243 See, e.g., CR at II-8 to II-10, II-21.

244 See, e.g., CR at III-2 (indicating that ***).
into consideration that purchasers seeking multiple sources have three domestic producers from which to choose, provided that they are willing to pay domestic prices.\textsuperscript{245}

We have addressed above in our price effects analysis respondents’ arguments concerning the domestic industry’s practice of entering into fixed-price contracts for a large portion of its sales as well as rising corn costs during the period of investigation. Although corn prices did rise during the period of investigation, they began rising in 2006, well before the domestic industry’s average COGS exceeded its average net sales value in 2007. The domestic industry was unable to secure adequate price increases for its 2007 contracts in the final quarter of 2006 due to pricing pressure from the large and increasing volume of subject imports from Canada and China.\textsuperscript{246}

Respondents claim that the industry’s poor aggregate financial performance resulted to a significant degree from ***.\textsuperscript{247} We reject this argument for several reasons. First, although ***.\textsuperscript{248} Second, as directed by the statute, the Commission focuses on the domestic industry “as a whole,” not on individual firms in the industry; there will inevitably be differences between members of the domestic industry in regard to cost structure and profits. Third, we do not find the hedging practices of *** or any other domestic producer to be inadequate. At the Commission’s request, domestic producers provided detailed information on their costs and hedging practices.\textsuperscript{249} All domestic producers hedged their corn prices to some degree.\textsuperscript{250} The Commission also verified the data reported by ***.\textsuperscript{251} Contrary to respondents’ contention, ***.\textsuperscript{252}

Finally, we also reject respondents’ contention that any problems the domestic industry has experienced are due to competition among the three domestic producers. As discussed in detail above in section V.D (Price Effects), record evidence shows significant pricing pressure from cumulated subject imports from Canada and China. Despite intra-industry competition among the three domestic producers, the domestic industry was able to negotiate significant price increases for 2009 contracts after the discipline of Commerce’s preliminary margins diminished the subject imports’ pricing pressure. Thus, we have not attributed injury from intra-industry competition to the subject imports.

\textsuperscript{245} We note that the domestic industry’s exports, some of which are to affiliated companies, fell in 2009 as domestic producers were able to divert some of these sales back to the U.S. market once prices began to improve. See, e.g., Petitioners’ Posthearing Br. at Exh. 2 at 17, Exh. 3 at 6-7; 19 U.S.C. § 1677(I). Furthermore, many of the purchaser complaints about lack of supply pertain to 2008 and 2009, after our period of investigation and/or after imposition of the requirement for antidumping and countervailing duty deposits on subject imports. See, e.g., Hearing Tr. at 45-46 (Christiansen), 60-61 (Anderson), 193-95 (Hofmann), 199-201 (Pensak), 315 (Ellis); CR at II-9. It is not surprising that the market would experience a period of adjustment when the supply of subject imports has fallen off substantially. See, e.g., EDIS Doc No. 402203; EDIS Doc. No. 402231; Petitioners’ Posthearing Br. at Exh. 33.

\textsuperscript{246} See, e.g., CR at VI-10; CR/PR at Table VI-4 (indicating that a variance analysis illustrates that from 2006 to 2008, the decrease in the domestic industry’s losses resulted from a positive price variance ($44.1 million; unit revenues increased), in spite of a negative cost/expense variance (negative $39.8 million; unit total costs increased)).

\textsuperscript{247} See, e.g., Chinese Respondents’ Prehearing Br. at 54-64; P&G’s Prehearing Br. at 34-39; Chinese Respondents’ Posthearing Br. at Exh. A at 6-10.

\textsuperscript{248} Moreover, ***. See, e.g., CR at VI-13 at n.18.

\textsuperscript{249} See, e.g., Petitioners’ Posthearing Br. at 6-8, Exhs. 1 to 4, Exh. 20 (as revised).

\textsuperscript{250} See, e.g., CR at V-1, VI-8.

\textsuperscript{251} See, e.g., CR at VI-1 to VI-2.

\textsuperscript{252} Derived from domestic producer supplemental questionnaire responses. Moreover, even if they could successfully hedge against significant adverse price movements in the cost of raw materials by locking in future raw material prices, such hedging could not protect the domestic producers against operating losses if they were unable to reflect current raw material costs.
Consequently, the record in these investigations indicates a sufficient causal nexus between the subject imports and the condition of the domestic industry and thus demonstrates material injury by reason of subject imports. We therefore conclude that subject imports have had a significant adverse impact on the domestic industry.

**CONCLUSION**

For the reasons stated above, we find that an industry in the United States is materially injured by reason of imports of citric acid and certain citrate salts from Canada and China that Commerce found to be sold at less than fair value and imports from China that Commerce found to be subsidized by the Government of China.
SEPARATE AND DISSENTING VIEWS OF CHAIRMAN SHARA L. ARANOFF, VICE CHAIRMAN DANIEL R. PEARSON, AND COMMISSIONER DEANNA TANNER OKUN

Based on the record in these final phase investigations, we find that an industry in the United States is not materially injured or threatened with material injury by reason of imports of citric acid and certain citrate salts from Canada and China that have been found to be sold in the United States at less than fair value (“LTFV”) and imports of citric acid and certain citrate salts from China that have been found to be subsidized by the Government of China.

I. NO MATERIAL INJURY BY REASON OF THE SUBJECT IMPORTS FROM CANADA AND CHINA

A. Additional Conditions of Competition

The U.S. market. The U.S. market for citric acid is relatively concentrated and dominated by end users. The five largest responding purchasers *** accounted for 48.3 percent, and the 17 largest purchasers accounted for 66.9 percent, of apparent U.S. consumption between 2006 and 2008. Four of the top five, and eight of the top ten, leading purchasers were end users rather than distributors. Food and beverage producers dominate the ranks of the high-volume end user purchasers. Nearly 95 percent of the domestic industry’s sales were made to end users, virtually all by long-term contract, with the remaining five percent sold to distributors generally under contract. While the majority of subject import sales by volume also were made to end users, a significant volume of subject imports from China were sold to end users on the spot market compared with either the sales for the domestic product or subject imports from Canada. Only nonsubject imports were more likely to be sold to distributors and to be sold on the spot market as well.

Domestic sales of citric acid by the domestic industry were overwhelmingly made by long-term contracts, typically 12 months in duration coinciding with the calendar year. For the U.S. industry as a whole, long-term contract sales accounted for approximately 99 percent of the quantity of citric acid pricing products 1, 2, and 3 sold over the period of investigation. While the majority of subject imports were sold by contract – *** percent for subject imports from Canada, and 60 percent for imports from China – the terms of these contracts were both short-term (reportedly 1 to 9 months) and long-term (12 months or longer).

Negotiations for the high-volume long-term contracts typically occur in the last quarter of the previous year. Domestic producers prefer to book as much of their productive capacity into these

---

1 We join the Commission’s Views with respect to domestic like product, domestic industry, negligibility, cumulation for purposes of the Commission’s material injury analysis, and conditions of competition.

2 CR at II-2, PR at II-2.

3 CR/PR at Table II-2.

4 For subject imports from Canada, *** percent were sold to end users under contract, as were 60.4 percent of subjects from China. CR at V-7, PR at V-5.

5 CR at V-7, PR at V-5.

6 CR at V-7, PR at V-5. Among industry participants, the share of total sales made by long-term contract varied somewhat. Cargill reported selling *** percent of its citric acid by long-term contract, Tate & Lyle reported *** percent, and ADM *** percent. Id.

7 CR at V-7, PR at V-5.
contracts as possible, and domestic producers regard these high-volume customers as having “tremendous negotiating leverage.”\(^8\) The members of the domestic industry compete fiercely for these contracts.\(^9\)

The high-volume end users generally prefer buying from domestic producers but all divide their purchases among multiple sources.\(^10\) These high-volume end user purchasers also exhibit marked preferences for buying product under contracts of a year or more. ***.\(^11\)

\textit{Citric acid supply.} Over the last several years the worldwide citric acid industry has gone through some fairly significant changes. The vast majority of the world’s citric acid productive capacity is in China, the European Union (EU), and the United States.\(^12\) While the total capacity in China increased significantly over the period of investigation, the Chinese industry has been substantially consolidated since 2002, with the number of firms allegedly falling from over 100 to 20.\(^13\) Nonetheless, Chinese capacity utilization remained at relatively high levels over the period of investigation and reportedly was 88.3 percent in 2008.\(^14\) In the EU, Tate & Lyle closed a citric acid facility in the United Kingdom in 2007, and ADM closed a facility in Ireland in 2005.\(^15\) All of the citric acid capacity in Central and South America is controlled by the petitioners.\(^16\) Finally, the industry in Japan is now ***.\(^17\)

Citric acid rarely accounts for a significant portion of the finished products in which it’s used, but it is a vital component, and end users cannot afford significant interruptions in supply. While the parties are divided, the record suggests that the citric acid market experienced tightness of supply during the period of investigation, particularly in 2008.\(^18\) Domestic producers claim that there was no shortness of supply apart from disruptions caused by reactions to the antidumping duty investigation filed in the EU in 2007 and by reactions to this action. Respondents argue that the global market for citric acid has been tight regardless of any of these investigations.

\section*{B. Volume of the Subject Imports}

Section 771(7)(C)(i) of the Act provides that the “Commission shall consider whether the volume of imports of the merchandise, or any increase in that volume, either in absolute terms or relative to production or consumption in the United States, is significant.”\(^19\)

We concur with the Commission majority that the absolute volume of cumulated subject imports is significant. Subject imports were in the U.S. market in substantial volumes throughout the period of investigation, never accounting for less than *** of the market. While the increase in the volume of

\begin{footnotesize}
\begin{enumerate}
\item CR at V-11, \textit{citing} Tr. at 28-29, PR at V-7.
\item CR at V-11, PR at V-7.
\item CR at II-20 and II-21, PR at II-1; \textit{see also} CR/PR at Table D-1 (Major U.S. Purchasers’ Bid Information which provides information on multiple sourcing and domestic competition for large contracts).
\item JBL prehearing brief at 31-32.
\item CR/PR at Table VII-7.
\item CR at VII-5, n. 6 and Table VII-7. Respondents argue that the Government of China’s recent environmental protection policies caused rapid consolidation of producers of citric acid and citrate salts in China. \textit{See, e.g.}, Conf. Tr. at 131; Chinese Respondents’ Postconference Br. at 1.
\item CR/PR at Table VII-7.
\item CR at VII-14, PR at VII-9.
\item CR at VII-14, PR at VII-9.
\item CR at VII-15, PR at VII-9.
\item CR at II-8-II-10, V-43 ***, V-45 ***, V-47-V-49 ***, PR at II-4-II-5, V-19; \textit{see also} Domestic producers’ posthearing brief at Exh. 3, pp. 29-31.
\end{enumerate}
\end{footnotesize}
subject imports was at a rate higher than the increase in apparent U.S. consumption, market share gained by subject imports came largely at the expense of nonsubject imports rather than the domestic product. Subject imports’ market share increased from *** percent in 2006 to *** percent in 2008 while the domestic industry’s market share declined only from *** percent in 2006 to *** percent in 2008. The increase in subject import volume, therefore, occurred at a time when demand was increasing and the domestic industry was itself increasing both production and shipments, and substantially reducing its end-of-period inventories in absolute terms and as a share of shipments. By 2008, the domestic industry was operating at 91.7 percent capacity utilization. The record suggests that the industry was operating close to its practical capacity in 2008, and apparently suffering some capacity constraints, as customers began to experience delays and the domestic industry declined to take on additional business.

The record also suggests some separation in the markets served by the domestic industry and the subject imports. The domestic industry focused its marketing efforts on securing high-volume contracts with the largest end user purchasers in order to fill its capacity with as few customers as possible. This strategy meant that the domestic industry devoted very little of its production to distributor sales, a niche filled by subject and nonsubject imports. For these reasons, we find that the volume of subject imports is significant both in absolute terms and relative to consumption and production in the United States.

C. Price Effects of the Subject Imports

Section 771(C)(ii) of the Act provides that, in evaluating the price effects of subject imports, the Commission shall consider whether – (I) there has been significant price underselling by the imported merchandise as compared with the price of domestic like products of the United States, and (II) the effect of imports of such merchandise otherwise depresses prices to a significant degree or prevents price increases, which otherwise would have occurred, to a significant degree.

Producers and importers gave mixed responses as to the importance of price in purchasing decisions. All three domestic producers responded that factors other than price were never a significant factor in their sales of subject product. However, a majority of responding importers and purchasers indicated that non-price differences were always or frequently significant when comparing the domestic like product to subject imports from China or subject imports from Canada to subject imports from China.

---

20 CR/PR at Table C-1.
21 CR/PR at Table C-1.
22 CR/PR at Table C-1.
23 CR at V-7, PR at V-5. Only five percent of domestic industry sales were to distributors whereas *** percent of total sales of subject imports from Canada and 14.0 percent of total sales of subject imports from China were to distributors. Id.
25 CR/PR at Table II-7.
26 CR/PR at Table II-7. Less than half of responding importers thought that non-price factors were never significant, and a majority of those responding indicated that non-price differences were always or frequently significant when comparing the domestic like product to subject imports from China or subject imports from Canada to subject imports from China. Purchasers were also far less likely than domestic producers to report non-price differences as being never important. Purchasers, like importers, were more likely to find non-price differences always or frequently important when comparing the domestic like product to subject imports from China and when (continued...)

41
The product-specific pricing data gathered in the final phase of these investigations show more individual instances of underselling by subject imports than did the preliminary data. The data, however, also reveal that most underselling by subject imports occurred in segments where domestic sales volumes were generally modest.

In the final phase of these investigations, staff gathered quarterly pricing data on five products. For products 1-3, the pricing data were gathered by spot sales to end users, contract sales to end users, spot sales to distributors, and contract sales to distributors. For products 4 and 5, data were gathered by sales to end users and sales to distributors. As in the preliminary phase, these surveyed products accounted for a significant share of shipments. These five products accounted for approximately 56.3 percent of domestic shipments, *** percent of U.S. shipments of subject imports from Canada, and 60.0 percent of U.S. shipments of subject imports from China.

Aggregating the pricing data for these products yielded 231 quarterly comparisons, with subject imports underselling in 139, or 60 percent, of those comparisons. But aggregating the quarterly comparison results obscures some significant differences in volume and underselling. Splitting pricing data for products 1-3 into four categories yielded far more quarterly comparisons and also more underselling. Subject imports were significantly more likely to undersell the domestic like product in spot sales than in contract sales. For product 1 spot sales to end users, subject imports undersold the domestic like product in 18 of 24 quarterly comparisons. But for sales of product 1 made under contract to end users, subject imports undersold the domestic like product in only four of 24 quarterly comparisons. Similar disparities were present when comparing spot and contract sales to distributors as well.

More striking, however, were the differences in the volumes in the different channels of distribution. Subject imports consistently undersold the domestic like product in product 1 sales on the spot market to end users and consistently oversold the domestic like product in contract sales to end users. But the volume of sales in these markets was quite disparate, particularly for the domestic like product. The domestic industry reported pricing information for *** pounds of product sold to end users over the period of investigation. The vast majority of product 1 end user sales reported by the domestic industry,
*** percent, were sold under contract, a market segment wherein subject imports were priced above the domestic product in 20 of 24 comparisons. For end user sales on the spot market, reported domestic sales were only *** pounds, *** percent of reported product 1 sales to end users. This market segment, accounting for such a minuscule share of product 1 domestic shipments, much less total reported product-specific shipments, nonetheless accounted for a significant portion of underselling instances, with underselling by subject imports in 18 of 24 quarters.  

Similar patterns and disparities can be seen in other product/channel segments as well. For product 1 sales to distributors, reported shipments by the domestic industry were heavily concentrated by contract (***), but most of the reported underselling by subject imports occurred in sales on the spot market (23 of 24 quarters). For products 2 and 3 as well, instances of underselling by subject imports occurred most frequently in the spot market, but domestic sales volumes were concentrated in the contract sales market. Product-specific pricing data for products 4 and 5 were not reported by contract and spot, but domestic shipments were concentrated in the end user segment while most underselling occurred in the distributor segment.  

Domestic producers have put forward several arguments as to why the significant overselling by subject imports in the contract sales segment should be ignored. Domestic producers point out that the average volume sold by the domestic industry to the largest producers was *** pounds, while the average volume sold by importers to the largest producers was ***, and even this figure overstates the average volume of imports sold to the largest customers, which is actually closer to ***. As discussed above, domestic producers prefer these high-volume contracts to end users but they also indicate that these purchasers have “tremendous negotiating leverage” and that the domestic producers compete fiercely for these contracts. The larger volumes sold in these contracts may affect the price and thus skew this pricing data reducing the U.S. prices relative to that of imports. The smaller volumes of subject imports in these segments and the frequency of lower prices by the domestic industry suggest that purchasers in these market segments prefer domestic product and that much of the competition in these segments is between the domestic producers.  

Domestic producers have also argued that most underselling by subject imports occurred in 2008, and that underselling margins prior to 2008 were too small to draw conclusions. In a market as described by domestic producers, however, where citric acid is largely a commodity product with intense price competition, we would be hesitant to entirely dismiss even modest margins. Here, however, the average underselling margin by subject imports was 12.7 percent, while the average overselling margin

---

32 Calculated from CR/PR at Table V-4.
33 Calculated from CR/PR at Table V-4. There was also a significant difference in concentration in this segment. Sales on the spot market to distributors accounted for only *** percent of domestically produced product 1 sold to distributors, while spot sales to distributors accounted for *** percent of reported sales of subject imported product 1 from Canada and *** percent of subject imported product 1 from China. Id.
34 Calculated from CR/PR at Tables V-5 and V-6.
35 Calculated from CR/PR at Tables V-7 and V-8.
36 Domestic producers’ posthearing brief at Exh. 1, pp. 5-6.
37 CR at V-11 and Table D-1, PR at V-7 and Table D-1.
38 Domestic producers’ posthearing brief at Exh. 1, pp. 5-6.
39 Domestic producers’ volume arguments could be extended to explain underselling in the spot market, where subject import volumes sometimes exceeded the volume of domestic sales. For example, for sales of product 1 to end users on the spot market, total reported domestic sales were *** pounds over the period of investigation, versus *** million pounds of subject imports. Calculated from CR/PR at Table V-4.
40 Domestic producers’ posthearing brief at Exh. 1, p.5.
was 15.0 percent. Moreover, in the segments of the market with the highest volumes, such as product 1 contract sales to end users, overselling by subject imports tended to be spread out throughout the period of investigation and not concentrated in the later quarters of the period of investigation. Based on the record evidence in the final phase investigation, we find that there has not been significant underselling of the domestic like product by subject imports.

We do not see evidence of price depression. All parties agree that prices for both the domestic like product and subject imports rose significantly in 2008. Domestic producers argue that the 2008 price increases should be discounted, in part because of the pendency of these investigations and because the antidumping duty investigation in the EU inflated U.S. prices. Although the statute permits us to discount the significance of post-petition data, given the facts of record, we decline to attribute the 2008 price increases to the pendency of these investigations. These petitions were filed in April 2008. Given that the significant majority of all domestic sales are made under long-term contract with prices negotiated in the fourth quarter of the preceding year, these investigations were not pending at the time that 2008 prices received by the domestic industry were largely determined. Nor is there evidence on the record that the possibility of these petitions being filed was known or discussed within the industry.

Domestic producers have also argued that price increases reflect the filing of an EU antidumping duty investigation in 2007, and should be discounted. But product-specific data show price increases in 2007, and, because of the preponderance of long-term contracts in the market, most of these 2007 price increases would have been negotiated in 2006, well before the EU action began. Furthermore, we see little evidence that the EU investigation significantly affected the volume or pricing of imports into the United States, particularly since volume and pricing for subject imports from Canada, exempt from the EU investigation and not likely to replace Chinese imports in the EU market, followed trends similar to subject imports from China.

41 CR/PR at Table V-10.
42 Domestic producers have argued that the pricing data for 2005, gathered during the preliminary phase of these investigations, ought to be considered as well. We decline to do so, as the data were not gathered for the same products at the same level of detail.

43 Commission staff also gathered product-specific pricing data from purchasers, CR/PR at Tables D-2-D-4, as well as information on specific bids and awards, CR/PR at Table D-1. The purchaser pricing data suggest more frequent underselling, even in contract sales, than is apparent in the producer/importer pricing data. We have reviewed these data and found them useful. However, we do not rely on the purchasing pricing data in drawing conclusions about underselling or overselling. Here, we have good coverage of the market through our producer/importer pricing data, and better coverage than is available in the purchaser pricing data. The producer/importer pricing dataset has also benefitted from careful review and revision by Commission staff and the parties to ensure that only appropriate sales were included in the dataset; time and resources preclude such review to ensure that only the appropriate products at the appropriate level of trade were included in the purchaser pricing data.

44 Domestic producers’ posthearing brief at Exh. 1, pp. 5-6.
45 We note that the product-specific pricing data for domestic sales to end users show very little movement in price within a given calendar year. See CR/PR at Tables V-4-V-8.

46 Domestic producers have conjectured that the pendency of the EU petition prompted concerns that similar actions would be filed in the United States. However, there is no evidence on the record that such concerns changed behavior on the part of importers or purchasers. Import volume increases in 2008 were similar to volume import increases in 2007 and there is no other record evidence that volumes [or prices] were reacting to the EU petition.

47 CR/PR at Table C-1 (AUVs for subject imports) and Tables V-4, V-5, and V-7.
48 In 2008, *** percent of Canada’s total shipments of citric acid were exported to the United States, *** percent of its shipments were to its home market, and *** percent of its shipments were exported to other countries, principally to ***. CR/PR at Table VII-1.
We find that while there is evidence of price suppression, the record does not indicate that subject imports were the reason for the industry’s inability to raise prices more rapidly.\textsuperscript{40} The industry’s unit cost of goods sold jumped by 5.1 percent between 2006 and 2007, unit sales values were flat, and the industry’s COGS/sales ratio went from 98.6 percent in 2006 to 103.6 percent in 2007. The industry was able to raise prices in 2008, but its COGS/sales ratio remained at an anemic rate of 97.9 percent.\textsuperscript{50} As noted above, prices for a significant portion of the domestic industry’s sales are set as much as a quarter before the beginning of the calendar year, and prices for those contract sales show very little movement during the calendar year. The record suggests that the rapid increase in raw materials costs was not adequately anticipated or prepared for at the time 2007 contracts were negotiated.\textsuperscript{51} By the time 2008 contracts were negotiated, the run-up in corn prices was widely known and domestic producers changed their contracts to incorporate price escalation clauses.\textsuperscript{52} For 2008 calendar year sales, before these petitions were filed, the domestic industry was able to gain significant price increases despite the presence of increased volumes of subject imports in the U.S. market, and prices for subject imports rose as well.\textsuperscript{53}

In considering price suppression, we have also considered the effect of intra-industry competition in preventing price increases.\textsuperscript{54}

Commission staff were able to gather data on specific bids and awards for citric acid from some of the U.S. market’s.\textsuperscript{55} The bidding data indicate that large purchasers sought bids from multiple sources on these contracts and not infrequently sought additional rounds of bidding. But the bidding data also show that the lowest bidder rarely secured the total volume of a contract.\textsuperscript{54} split each of its three largest purchases between two suppliers,\textsuperscript{54} split its largest purchase between two sources,\textsuperscript{54} and split its largest purchase among four suppliers. The general practice among these high-volume purchasers was to divide up the contract purchases relatively evenly, rather than awarding a significant majority to the lowest bidder. The contract data also show that domestic producers were participants in most of the bidding processes, that they competed strongly for these contracts, and underbid both each other and subject imports.

\textsuperscript{40} Compare Domestic prehearing brief at 55.
\textsuperscript{50} CR/PR at Table C-1.
\textsuperscript{51} Domestic producers’ posthearing brief at Exh. 7, pp. 1-2, and Exh. 20.
\textsuperscript{52} CR/PR at V-1 and V-2. Petitioners reported that their contracts did not include price escalation clauses during the 2006 to 2008 period and that until 2007, when raw material costs increased dramatically, the lack of escalations had not been a problem.\textsuperscript{50} Id.
\textsuperscript{53} Domestic producers have argued that substantial price increases gained for 2009 contracts indicate that subject imports have suppressed prices and that only the pendency of these investigations allowed the industry to win such substantial price increases. We are hesitant to draw significant conclusions on the basis of pricing data alone, but we also note that we found price increases occurring over most of the period of investigation, though, because of the market’s own contract cycle, at a lag from price increases. We view the 2009 price increases as consistent with the pattern that emerged in 2007 and 2008.

We also note that the domestic industry has continued to devote a significant portion of its shipments to export markets. AUVs for its exports increased over the period of investigation at essentially the same rate as AUVs for its domestic shipments, and the industry apparently expects continued increases in this market. This pattern indicates that the domestic industry finds increased citric acid prices to be a market-wide phenomenon rather than one local to the U.S. market and caused largely by these investigations.

\textsuperscript{54} ***.
\textsuperscript{55} CR/PR at Table D-1.
We have also considered the allegations of lost sales and lost revenues.\textsuperscript{56} Purchaser responses to these allegations were generally not supportive.\textsuperscript{57} Some purchasers did indicate that imports were low-priced players in the U.S. market or that they switched to imports for price-based reasons.\textsuperscript{58} But other responses also indicated that purchasers had in fact switched from one domestic producer to another or had struggled with domestic availability, particularly in 2008.

The record indicates that overselling by subject imports, not underselling, was the norm in the market segments most important to the domestic industry; that prices began to rise even before any unfair trade investigations were begun either in the United States or in the EU; that the industry’s apparent price-cost squeeze was not well correlated with trends in import volumes, pricing, or underselling; that competition is intense among the domestic industry for high-volume contracts to end users and shifts by these purchasers from one domestic producer to another were not uncommon during the period of investigation.\textsuperscript{59} For these reasons, we do not find that subject imports had significant adverse effects on domestic prices.

D. Impact of the Subject Imports\textsuperscript{60}

Section 771(7)(C)(iii) provides that the Commission, in examining the impact of the subject imports on the domestic industry, “shall evaluate all relevant economic factors which have a bearing on the state of the industry.”\textsuperscript{61} These factors include output, sales, inventories, capacity utilization, market share, employment, wages, productivity, profits, cash flow, return on investment, ability to raise capital, research and development, and factors affecting domestic prices. No single factor is dispositive and all relevant factors are considered “within the context of the business cycle and conditions of competition that are distinctive to the affected industry.”\textsuperscript{62}

The domestic industry saw improvement in several key metrics over the period of investigation. Production increased by 6.8 percent between 2006 and 2008; capacity utilization rose from 85.8 percent to 91.7 percent over the same period; U.S. shipments increased by 9.0 percent and export shipments by 16.8 percent. Inventories at the end of 2008 were down 42.5 percent from the end of 2006. The number of production and related workers declined by 4.6 percent, but productivity rose by 11.8 percent. Gross profit in 2008 was nearly double that in 2006.\textsuperscript{63}

Despite these improvements, the industry’s financial position was weak over the period of investigation. The industry recorded losses at the operating level in each of the three years, though losses

\textsuperscript{56} CR/PR at Tables V-11 and V-12.
\textsuperscript{57} See, e.g., CR at V-45 and V-46 (**).  
\textsuperscript{58} See, e.g., CR at V-43 (**), V-44 (**), V-47 (**) and V-48 (**).
\textsuperscript{59} CR/PR at Table D-1.
\textsuperscript{60} Commerce estimated a dumping margin of 23.21 percent for Canadian respondent JBL and all others, and margins ranging from 94.61 percent to 129.08 percent for named China respondents, as well as a margin of 156.87 for all others. CR at I-6-I-7, PR at I-4-I-5.
\textsuperscript{61} 19 U.S.C. § 1677(7)(C)(iii); see also SAA at 851 and 885 (“In material injury determinations, the Commission considers, in addition to imports, other factors that may be contributing to overall injury. While these factors, in some cases, may account for the injury to the domestic industry, they also may demonstrate that an industry is facing difficulties from a variety of sources and is vulnerable to dumped or subsidized imports.”) SAA at 885.
\textsuperscript{63} CR/PR at Table C-1.
in 2008 were significantly smaller.\textsuperscript{64} The industry’s capital expenditures in 2008 were lower than in 2006 or 2007, and it has consistently had negative returns on its assets.\textsuperscript{65} Moreover, we recognize that these losses have occurred at a time when import volume increased.

Nevertheless, we do not find a sufficient causal link between the presence and behavior of subject imports in the market and the current condition of the domestic industry. As an initial matter, we note that, according to information submitted by domestic producers, this is an industry that has been marked by falling prices and returns for at least a decade, well before significant volumes of subject imports entered the U.S. market.\textsuperscript{66} Focusing on the period of investigation, we do not find clear correlations between trends in subject import volumes and prices and the performance of the domestic industry. As demand increased over the period of investigation, subject import volume increased as did the domestic industry’s shipments and production. Increases in subject imports’ market share were largely at the expense of nonsubject imports.\textsuperscript{67} Moreover, by 2008, the domestic industry was operating at *** percent capacity utilization, with evidence that it was experiencing some capacity constraints (e.g., delays in shipments and declining to take on additional business).

We recognize that subject import volume and market share rose from 2006 to 2007 (*** percent and *** percentage points, respectively), when the domestic industry suffered its worst losses of the period of investigation.\textsuperscript{68} However, subject import volume and market share increased again from 2007 to 2008 (*** percent and *** percentage points, respectively), as the domestic industry recorded increased production, capacity utilization, sales, and prices and its best financial performance of the period of investigation.

We have also noted some differences in market concentrations and the general trend of subject imports overselling, not underselling, the domestic like product in the domestic industry’s preferred market segments. Prices for the domestic like product rose in tandem with rising import volumes. The record suggests that the domestic industry might have suffered a cost-price squeeze in 2007, but the industry’s situation improved in 2008 even as import volume rose.

As discussed above, the record indicates that all three domestic producers are concentrated in the same portion of the market: high-volume sales by contract to major end users. While we consider the industry as a whole, variations in individual market participants’ sales and performance demonstrate that the overall industry’s performance was affected by intra-industry competition. Domestic producers rationally seek to fill as much as their productive capacity as possible through as few contracts as possible with high volume purchasers with fairly predictable needs. ***.\textsuperscript{69} ***.

\textsuperscript{69} ***.

The record suggests that concentration by the domestic industry in end user contract sales, the contract cycle particular to this industry, and price leverage on the part of high-volume end user purchasers made it difficult for the domestic industry to raise prices quickly enough to keep pace with the significant increase in raw material costs. Moreover, these increases in raw material costs were unanticipated and not prepared for during 2007 contract negotiations which did not contain price

\textsuperscript{64} CR/PR at Table C-1.
\textsuperscript{65} CR/PR at Tables VI-5 and VI-6.
\textsuperscript{66} Domestic producers’ posthearing brief at Exh. 7.
\textsuperscript{67} Subject imports gained *** percentage points of U.S. market share from 2006 to 2008 whereas the domestic industry lost *** percentage points and non-subject imports lost *** percentage points of U.S. market share for the same period. CR/PR at Table C-1.
\textsuperscript{68} CR/PR at Table C-1.
\textsuperscript{69} CR/PR at Table VI-2.
\textsuperscript{70} Calculated from CR/PR at Table VI-2.
\textsuperscript{71} Calculated from CR/PR at Table VI-2.
escalation clauses. The industry’s general difficulties were compounded by ***. But the record also indicates that the industry was able to begin recouping its higher costs. By the start of the 2008 contract cycle, before these petitions had been filed and while subject import volumes were still rising, the domestic industry had won significant price increases along with increases in shipment volumes that represented a peak for this investigation period and significantly decreased inventory levels.

We find that the record does not indicate a causal nexus between subject import trends and the domestic industry’s performance. Therefore, we do not find that the domestic industry is materially injured by reason of subject imports.

II. NO THREAT OF MATERIAL INJURY BY REASON OF SUBJECT IMPORTS FROM CANADA AND CHINA

A. Legal Standards

Section 771(7)(F) of the Act directs the Commission to determine whether the U.S. industry is threatened with material injury by reason of the subject imports by analyzing whether “further dumped or subsidized imports are imminent and whether material injury by reason of imports would occur unless an order is issued or a suspension agreement is accepted.”72 The Commission may not make such a determination “on the basis of mere conjecture or supposition,” and considers the threat factors “as a whole” in making its determination whether dumped or subsidized imports are imminent and whether material injury by reason of subject imports would occur unless an order is issued.73 In making our determination, we consider all statutory threat factors that are relevant to this investigation.74

B. Cumulation

For purposes of determining if a threat of material injury exists, cumulation is discretionary. Under section 771(7)(H) of the Act, the Commission may cumulatively assess the volume and price effects of subject imports from all countries as to which petitions were filed on the same day if the requirements for cumulation for material injury analysis are satisfied.75

As we have already found in our material injury cumulation analysis, in which we joined the Commission’s Majority Views, none of the cumulation exceptions apply to these investigations, and there is a reasonable overlap of competition among subject imports from Canada and China and the domestic like product.

In addition to that analysis, for purposes of assessing whether we should cumulate subject imports from Canada and China for purposes of our threat of material injury analysis, we have considered the volume and pricing trends exhibited by the subject imports. We find sufficient similarities in those trends. Subject imports from both Canada and China increased over the period of investigation and gained market share. As for pricing trends, AUVs for imports from both countries increased over the period of investigation, and product-specific pricing data showed increases across most products over the period of investigation. We exercise our discretion to cumulate subject imports from Canada and China for purposes of our threat of material injury analysis.

74 19 U.S.C. §1677(7)(F)(ii). Statutory threat factors (VII) is inapplicable, as no imports of agricultural factors are involved. Id.
C. Analysis of Statutory Threat Factors

We have found the volume of subject imports in the U.S. market to be significant absolutely, but we do not find a substantial increase in subject imports in the imminent future likely. Subject import volume increased at a time when overall demand was increasing, and the domestic industry’s U.S. market share remained large and only slightly changed over the period of investigation.

Moreover, we do not find that the capacity and export trends of the industries in the subject countries suggest a significant increase in subject import volume in the imminent future. The industry in Canada reported ** increase in capacity over the period of investigation and **. The industry operated ** increasing capacity utilization rates throughout the period of investigation and **, **. The U.S. market has been the primary focus of the industry in Canada and **. Moreover, the share of shipments exported to the United States has been ** over the period of investigation. Inventories were ** higher at the end of 2008, but the increase in inventories was ** to overall shipments.

While the industry in China experienced significant increases in capacity over the period of investigation, more modest increases are projected for the near future. Furthermore, Chinese capacity utilization rates were relatively high over the period of investigation, at a reported 88.3 percent in 2008. Inventories have grown significantly over the period of investigation and, at the end of 2008, were higher than total shipments to the United States that year. The industry in China differs from the industry in Canada in that the United States is not, and never has been, its primary market. The citric acid producers in China serve a significant domestic market, where by 2008, shipments to the home market exceeded shipments to the United States by a nearly 3-to-1 margin. This market is expected to continue to grow at a high rate in the near future. Even with a strong home market, the industry in China exports significant portions of its production. The EU has long been the industry’s primary export market. The recent EU investigation limited access to this important market throughout the latter portion of the period of investigation. However, recent data suggest that producers in China have been able to export to the EU and obtain prices above those specified in the price undertaking. Unlike producers in the United States and Canada, the industry in China does not use genetically modified organisms in its citric acid production, and as such it has an advantage in shipping to the EU, where citric acid capacity remains well short of demand.

We recognize that combined, these two industries have available capacity and inventories relatively significant to total shipments to the United States. Production capacity in the U.S. market is well short of demand, and imports will continue to be necessary to meet or fill that demand. Imports from Canada and China have long been part of the U.S. market and at significant volumes.

The conditions of competition in this market also suggest that it would be difficult for subject imports to gain significant additional volume in the U.S. market that would bring significant competition with the domestic industry. As noted, the high-volume, end user contract sales are set in a relatively narrow time frame, and this is the portion of the market where the domestic industry concentrates most of its energy. The domestic industry already devotes virtually all of its domestic shipments to this share of the market. Given current high levels of production, the domestic industry has little available additional

---

76 CR/PR at Table VII-1.
77 CR/PR at Table VII-1. Exports to the U.S. market as a share of total Canadian shipments were ** 2009 and 2010.
78 CR/PR at Table VII-3. Chinese industry data are based on usable foreign producer questionnaire responses of 14 companies that reported collectively accounting for approximately 90 percent of Chinese exports to the United States during the period of investigation. CR at I-4.
79 CR/PR at Table VII-3. Chinese shipments to its home market as a share of its total shipments were 27.8 percent in 2008 whereas Chinese exports to the U.S. market as a share of China’s total shipments were 10.0 percent in 2008. Id.
capacity for new customers and little motivation to increase its penetration of the markets that subject imports currently dominate, namely spot sales and distributor sales.

We have already found that subject imports have not significantly impacted domestic prices. Subject imports generally oversold the domestic like product in the market segments dominated by the domestic industry. Prices for subject imports rose along with raw material prices, as did prices for the domestic like product. Prices for the domestic like product did not initially rise quickly enough to keep up with significant raw material cost increases, leaving the industry in a cost-price squeeze in 2007, but the record indicates that prices rose significantly in 2008, despite the presence of an increased volume of subject imports. Intra-industry competition also has affected prices in the U.S. market. Pricing data from 2007 and 2008 indicate that the market has been adjusting to increased raw material costs and an apparent tightness in supply, and the pricing adjustments have occurred despite increases in import volume and apparent available capacity and inventories in the subject countries.

Accordingly, based on the record, we determine that the domestic industry producing citric acid and certain citrate salts is not threatened with material injury by reason of subject imports from Canada and China.

III. CONCLUSION

For the reasons stated above, we find that the domestic industry producing citric acid and certain citrate salts is not materially injured or threatened with material injury by reason of subject imports from Canada and China sold at LTFV and subject imports from China subsidized by the Government of China.
PART I: INTRODUCTION

BACKGROUND

These investigations result from a petition filed on April 14, 2008, by Archer Daniels Midland Co. of Decatur, IL (“ADM”); Cargill, Inc. of Wayzata, MN (“Cargill”); and Tate & Lyle Americas, Inc. of Decatur, IL (“Tate & Lyle”), alleging that an industry in the United States is materially injured and is threatened with material injury by reason of imports from Canada and China of citric acid and certain citrate salts\(^1\) that are allegedly sold in the United States at less than fair value (“LTFV”) and subsidized by the government of China. Information relating to the background of these investigations is provided below.\(^2\)

<table>
<thead>
<tr>
<th>Effective date</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>April 14, 2008</td>
<td>Petition filed with Commerce and the Commission; Commission institutes investigations (73 FR 21650, April 22, 2008)</td>
</tr>
<tr>
<td>May 13, 2008</td>
<td>Commerce’s notice of initiation (73 FR 27492)</td>
</tr>
<tr>
<td>May 28, 2008</td>
<td>Commission’s preliminary determinations (73 FR 33115, June 11, 2008)</td>
</tr>
<tr>
<td>September 19, 2008</td>
<td>Commerce’s preliminary countervailing duty determination (73 FR 54367)</td>
</tr>
<tr>
<td>November 20, 2008</td>
<td>Commerce’s preliminary antidumping duty determinations (73 FR 70324)(Canada) and (73 FR 70328)(China)</td>
</tr>
<tr>
<td>November 20, 2008</td>
<td>Commission’s scheduling of its final phase investigations (73 FR 73955, December 4, 2008)</td>
</tr>
<tr>
<td>April 13, 2009</td>
<td>Commerce’s final antidumping and countervailing duty determinations (74 FR 16836, 16838, and 16843)</td>
</tr>
<tr>
<td>April 7, 2009</td>
<td>Commission’s hearing(^1)</td>
</tr>
<tr>
<td>May 8, 2009</td>
<td>Commission’s vote</td>
</tr>
<tr>
<td>May 22, 2009</td>
<td>Commission’s determinations and views transmitted to Commerce</td>
</tr>
</tbody>
</table>

\(^1\) A list of witnesses that appeared at the hearing is in app. B.

\(^2\) Federal Register notices cited in the tabulation after the Commission’s scheduling of its final investigations are presented in app. A.

---

\(^1\) A complete description of the imported product subject to these investigations is presented in the section entitled The Subject Merchandise located in Part I of this report.

\(^2\) Federal Register notices cited in the tabulation after the Commission’s scheduling of its final investigations are presented in app. A.
STATUTORY CRITERIA AND ORGANIZATION OF THE REPORT

Statutory Criteria

Section 771(7)(B) of the Tariff Act of 1930 (the “Act”) (19 U.S.C. § 1677(7)(B)) provides that in making its determinations of injury to an industry in the United States, the Commission--

shall consider (I) the volume of imports of the subject merchandise, (II) the effect of imports of that merchandise on prices in the United States for domestic like products, and (III) the impact of imports of such merchandise on domestic producers of domestic like products, but only in the context of production operations within the United States; and . . . may consider such other economic factors as are relevant to the determination regarding whether there is material injury by reason of imports.

Section 771(7)(C) of the Act (19 U.S.C. § 1677(7)(C)) further provides that--

In evaluating the volume of imports of merchandise, the Commission shall consider whether the volume of imports of the merchandise, or any increase in that volume, either in absolute terms or relative to production or consumption in the United States is significant.

. . .

In evaluating the effect of imports of such merchandise on prices, the Commission shall consider whether . . . (I) there has been significant price underselling by the imported merchandise as compared with the price of domestic like products of the United States, and (II) the effect of imports of such merchandise otherwise depletes prices to a significant degree or prevents price increases, which otherwise would have occurred, to a significant degree.

. . .

In examining the impact required to be considered under subparagraph (B)(i)(III), the Commission shall evaluate (within the context of the business cycle and conditions of competition that are distinctive to the affected industry) all relevant economic factors which have a bearing on the state of the industry in the United States, including, but not limited to . . .

(I) actual and potential declines in output, sales, market share, profits, productivity, return on investments, and utilization of capacity, (II) factors affecting domestic prices, (III) actual and potential negative effects on cash flow, inventories, employment, wages, growth, ability to raise capital, and investment, (IV) actual and potential negative effects on the existing development and production efforts of the domestic industry, including efforts to develop a derivative or more advanced version of the domestic
like product, and (V) in {an antidumping investigation}, the magnitude of the margin of dumping.

Organization of the Report

Information on the subject merchandise, margins of dumping and subsidies, and domestic like product is presented in Part I. Information on conditions of competition and other relevant economic factors is presented in Part II. Part III presents information on the condition of the U.S. industry, including data on capacity, production, shipments, inventories, and employment. The volume and pricing of imports of the subject merchandise are presented in Parts IV and V, respectively. Part VI presents information on the financial experience of U.S. producers. Information obtained for use in the Commission’s consideration of the question of threat of material injury is presented in Part VII.

U.S. MARKET SUMMARY

The U.S. market for citric acid and certain citrate salts totaled *** dry pounds and approximately *** in 2008. Currently, three firms produce citric acid and certain citrate salts in the United States. These firms are the petitioners, ADM, Cargill, and Tate & Lyle. ***, Jungbunzlauer Technology GmbH & Co. (“JBL”) *** imported citric acid from Canada in 2008. At least 31 firms have reported importing citric acid and/or certain citrate salts from China since 2006.

U.S. producers’ U.S. shipments of citric acid and certain citrate salts totaled 403 million dry pounds valued at $215 million in 2008, and accounted for *** percent of apparent U.S. consumption by quantity (*** percent by value). U.S. imports from Canada totaled *** dry pounds valued at *** in 2008, and accounted for *** percent of apparent U.S. consumption by quantity (*** percent by value). U.S. imports from China totaled 194 million dry pounds valued at $118.3 million in 2008, and accounted for *** percent of apparent U.S. consumption by quantity (*** percent by value). U.S. imports from all other sources combined totaled 55.6 million dry pounds valued at $41.1 million in 2008, and accounted for *** percent of apparent U.S. consumption by quantity (*** percent by value). Citric acid and certain citrate salts are generally used as an acidulant, preservative, and flavor enhancer in food and beverage end uses as well as an ingredient in many household and industrial detergents and cleaners.

SUMMARY DATA AND DATA SOURCES

A summary of data collected in these investigations is presented in appendix C, table C-1. U.S. industry data are based on the questionnaire responses of the three petitioning firms that accounted for all U.S. production of citric acid and certain citrate salts in 2008. Data for U.S. imports from Canada are compiled using the reported U.S. imports of JBL, the U.S. importer of Canadian product which accounted for *** U.S. imports from Canada. Data for U.S. imports from China and nonsubject countries are compiled using official Commerce statistics. Data regarding the Canadian industry are based on the foreign producer questionnaire response of Jungbunzlauer Technology GmbH & Co. (“JBL Canada”), which accounted for all Canadian export shipments to the United States in 2008. Data regarding the Chinese industry are based on 14 foreign producer questionnaires. The responding foreign producers

---

3 ***. JBL Canada, the sole Canadian producer, did not produce sodium citrate or potassium citrate during the period of investigation.

4 Appendix C, table C-2 displays data compiled regarding the U.S. citric acid market, table C-3 displays data regarding the U.S. sodium citrate market, and table C-4 displays data regarding the U.S. potassium citrate market.

5 ***.
estimate that they collectively accounted for approximately 90 percent of Chinese export shipments to the United States during the period for which data were collected in the investigations.

PREVIOUS AND RELATED INVESTIGATIONS

Citric acid and certain citrate salts have been the subject of a previous Commission investigation.\textsuperscript{6} In 2000, in investigation No. 731-TA-863 (Preliminary), the Commission determined that there was no reasonable indication that an industry in the United States was materially injured or threatened with material injury by reason of imports from China that were allegedly sold at LTFV.\textsuperscript{7} The Commission determined that the volume of U.S. imports from China was not significant, stating that “Chinese imports have not made significant inroads into sales made by the domestic industry to U.S. food and beverage manufacturers {by far the largest market segment in the United States at the time}. Rather, the large majority of subject imports compete with the domestic product only in the industrial use market, where the subject imports have already increased their market share without a significant adverse impact on the industry.”\textsuperscript{8} Further, the Commission determined that the record did not indicate price depression or suppression and that the U.S. industry was not adversely impacted by reason of U.S. imports from China.\textsuperscript{9} Finally, the Commission determined that there was no reasonable indication that the U.S. industry was threatened with material injury by reason of the subject imports, noting that “Chinese producers of citric acid and sodium citrate are currently operating at a high capacity utilization level” and that “Chinese home market and third country market shipments have risen each year since 1996.”\textsuperscript{10,11}

NATURE AND EXTENT OF SALES AT LTFV

On April 13, 2009, Commerce published notices in the Federal Register setting forth its final determinations with regard to its antidumping investigations on citric acid and certain citrate salts from Canada\textsuperscript{12} and China.\textsuperscript{13} The estimated weighted-average dumping margins (in percent ad valorem), as reported by Commerce are summarized in the tabulation below:

---

\textsuperscript{6} The scope of the 2000 investigation consisted of citric acid and sodium citrate. The current investigations’ broader scope consists of those products, potassium citrate, and crude calcium citrate.

\textsuperscript{7} Citric Acid and Sodium Citrate From China, Inv. No. 731-TA-863 (Preliminary), USITC Publication 3277, February 2000, p. 1.

\textsuperscript{8} Ibid., at p. 12.

\textsuperscript{9} Ibid., pp. 14-15.

\textsuperscript{10} Ibid., pp. 16-17.

\textsuperscript{11} Also mentioned in the Commission’s prior investigation was a price-fixing conspiracy in the citric acid industry that took place in the 1990s. ADM and Haarmann & Reimer pled guilty in October 1996 and January 1997, respectively, to participation, along with two European producers, in a price-fixing conspiracy which the U.S. Justice Department found to be in place as early as 1991. The guilty plea resulted in total fines of $100 million for the four firms. **. Also, several U.S. civil class action law suits were filed in 1996 and 1997 in which ADM agreed to pay $85 million and Haarmann & Reimer agreed to pay $46 million to bottlers and food processors. In all, fines paid out on the cases totaled over $200 million. In 1998, Haarmann & Reimer sold its entire worldwide citric acid business to Tate & Lyle. Ibid., p. III-1, fn. 3. The Commission explicitly stated that it gave the price fixing “little weight” in its determination “as it may have affected prices only for the early part of the investigation.” Ibid., p. 13, fn. 88.

\textsuperscript{12} Notice of Final Determination of Sales at Less Than Fair Value: Citric Acid and Certain Citrate Salts from Canada: 74 FR 16843, April 13, 2009.

\textsuperscript{13} Citric Acid and Certain Citrate Salts from the People’s Republic of China: Final Determination of Sales at Less Than Fair Value: 74 FR 16838, April 13, 2009.

I-4
<table>
<thead>
<tr>
<th>Exporter</th>
<th>Producer</th>
<th>Margin (percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Canada</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jungbunzlauer Technology GmbH &amp; Co. KG</td>
<td></td>
<td>23.21</td>
</tr>
<tr>
<td>All others</td>
<td></td>
<td>23.21</td>
</tr>
<tr>
<td><strong>China</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TTCA Co., Ltd. (a.k.a. Shandong TTCA Biochemistry Co., Ltd.)</td>
<td>TTCA Co., Ltd. (a.k.a. Shandong TTCA Biochemistry Co., Ltd.)</td>
<td>129.08</td>
</tr>
<tr>
<td>Yixing Union Biochemical Co., Ltd.</td>
<td>Yixing Union Biochemical Co., Ltd.</td>
<td>94.61</td>
</tr>
<tr>
<td>Anhui BBCA Biochemical Co., Ltd.</td>
<td>Anhui BBCA Biochemical Co., Ltd.</td>
<td>111.85</td>
</tr>
<tr>
<td>Anhui BBCA Biochemical Co., Ltd.</td>
<td>China BBCA Maanshan Biochemical Corp.</td>
<td>111.85</td>
</tr>
<tr>
<td>A.H.A. International Co., Ltd.</td>
<td>Yixing Union Biochemical Co., Ltd.</td>
<td>111.85</td>
</tr>
<tr>
<td>A.H.A. International Co., Ltd.</td>
<td>Nantong Feiyu Fine Chemical Co., Ltd.</td>
<td>111.85</td>
</tr>
<tr>
<td>High Hope International Group Jiangsu Native Produce IMP &amp; EXP Co., Ltd.</td>
<td>Yixing Union Biochemical Co., Ltd.</td>
<td>111.85</td>
</tr>
<tr>
<td>Huangshi Xinghua Biochemical Co., Ltd.</td>
<td>Huangshi Xinghua Biochemical Co., Ltd.</td>
<td>111.85</td>
</tr>
<tr>
<td>Lianyungang JF International Trade Co., Ltd.</td>
<td>TTCA Co., Ltd. (a.k.a. Shandong TTCA Biochemistry Co., Ltd.)</td>
<td>111.85</td>
</tr>
<tr>
<td>Laiwu Taihe Biochemistry Co., Ltd.</td>
<td>Laiwu Taihe Biochemistry Co., Ltd.</td>
<td>111.85</td>
</tr>
<tr>
<td>Lianyungang Shure N Science Import &amp; Export Co., Ltd.</td>
<td>Lianyungang Great Chemical Industry Co., Ltd.</td>
<td>111.85</td>
</tr>
<tr>
<td>RZBC Imp &amp; Exp. Co., Ltd./ RZBC Co., Ltd./ RZBC (Juxian) Co., Ltd.</td>
<td>RZBC Co., Ltd.</td>
<td>111.85</td>
</tr>
<tr>
<td>RZBC Imp &amp; Exp. Co., Ltd./ RZBC Co., Ltd./ RZBC (Juxian) Co., Ltd.</td>
<td>RZBC (Juxian) Co., Ltd.</td>
<td>111.85</td>
</tr>
<tr>
<td>RZBC Imp &amp; Exp. Co., Ltd./ RZBC Co., Ltd./ RZBC (Juxian) Co., Ltd.</td>
<td>Lianyungang Great Chemical Industry Co., Ltd.</td>
<td>111.85</td>
</tr>
<tr>
<td>Shihezi City Changyun Biochemical Co., Ltd.</td>
<td>Shihezi City Changyun Biochemical Co., Ltd.</td>
<td>111.85</td>
</tr>
<tr>
<td>Weifang Ensign Industry Co., Ltd.</td>
<td>Weifang Ensign Industry Co., Ltd.</td>
<td>111.85</td>
</tr>
<tr>
<td>All others</td>
<td></td>
<td>156.87</td>
</tr>
</tbody>
</table>
NATURE OF COUNTERVAILABLE SUBSIDIES

On April 13, 2009, Commerce published a notice in the Federal Register setting forth its final determination with regard to its countervailing duty investigation on citric acid and certain citrate salts from China. Commerce determined that the government of China is providing countervailable subsidies to Chinese producers. The countervailable subsidy rates (in percent *ad valorem*), as reported by Commerce, are presented in the following tabulation.

<table>
<thead>
<tr>
<th>Exporter/producer</th>
<th>Margin (percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>China</td>
<td></td>
</tr>
<tr>
<td>TTCA Co., Ltd. (a.k.a. Shandong TTCA Biochemistry Co., Ltd.)</td>
<td>12.68</td>
</tr>
<tr>
<td>Yixing Union Biochemical Co., Ltd. and Yixing Union Cogeneration Co., Ltd.</td>
<td>3.60</td>
</tr>
<tr>
<td>Anhui BBCA Biochemical Co., Ltd.</td>
<td>118.95</td>
</tr>
<tr>
<td>All others</td>
<td>8.14</td>
</tr>
</tbody>
</table>

Commerce made the following final determinations regarding specific programs of the government of China found to have provided countervailable subsidies to producers of citric acid and certain citrate salts in China:

A. Government Policy Lending
B. “Famous Brands” Program–Yixing City
C. Reduced Income Tax Rates to FIEs Based on Location
D. “Two Free, Three Half” Program
E. Reduced Income Tax Rate for Technology or Knowledge Intensive FIEs
F. Income Tax Credits on Purchases of Domestically Produced Equipment
G. VAT Rebate on Purchases by FIEs of Domestically Produced Equipment
H. VAT and Duty Exemptions on Imported Equipment
I. Local Income Tax Exemption and Reduction Program for “Productive” FIEs
J. Energy and Water Savings Grant
K. Provision of Land in the AEDZ for LTAR
L. Land Use Rights Extension in Yixing City

---

14 Commerce has determined that the current nature of the economy in China does not create obstacles to apply the necessary criteria in the countervailing duty law and initiated a countervailing duty investigation against China. See Coated Free Sheet Paper from the People’s Republic of China: Amended Preliminary Affirmative Countervailing Duty Determination, 72 FR 17484, 17486 (April 9, 2007).


16 In addition, Commerce listed the following alleged programs for which it deferred investigation to any future administrative review: (A) Provision of TTCA’s Plant and Equipment for LTAR and (B) Provision of Land in Zhuqiao Key Open Park for LTAR.
THE SUBJECT MERCHANDISE

Commerce’s Scope

Commerce has defined the scope of these investigations as follows:

All grades and granulation sizes of citric acid, sodium citrate, and potassium citrate in their unblended forms, whether dry or in solution, and regardless of packaging type. The scope also includes blends of citric acid, sodium citrate, and potassium citrate; as well as blends with other ingredients, such as sugar, where the unblended form(s) of citric acid, sodium citrate, and potassium citrate constitute 40 percent or more, by weight, of the blend.

The scope of these investigations also includes all forms of crude calcium citrate, including dicalcium citrate monohydrate, and tricalcium citrate tetrahydrate, which are intermediate products in the production of citric acid, sodium citrate, and potassium citrate.

The scope of these investigations does not include calcium citrate that satisfies the standards set forth in the United States Pharmacopeia and has been mixed with a functional excipient, such as dextrose or starch, where the excipient constitutes at least 2 percent, by weight, of the product.

The scope of these investigations includes the hydrous and anhydrous forms of citric acid, the dihydrate and anhydrous forms of sodium citrate, otherwise known as citric acid sodium salt, and the monohydrate and monopotassium forms of potassium citrate. Sodium citrate also includes both trisodium citrate and monosodium citrate, which are also known as citric acid trisodium salt and citric acid monosodium salt, respectively.

Citric acid and sodium citrate are classifiable under 2918.14.0000 and 2918.15.1000 of the Harmonized Tariff Schedule of the United States (“HTSUS”), respectively. Potassium citrate and crude calcium citrate are classifiable under 2918.15.5000 and 3824.90.9290 of the HTSUS, respectively. Blends that include citric acid, sodium citrate, and potassium citrate are classifiable under 3824.90.9290 of the HTSUS. Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the merchandise is dispositive.

Tariff Treatment

During the period of investigation, citric acid has been classifiable in the Harmonized Tariff Schedule of the United States (“HTS”) under subheading 2918.14.00, sodium citrate under HTS
subheading 2918.15.10, and potassium citrate under HTS subheading 2918.15.50. Table I-1 depicts the HTS subheadings under which citric acid and certain citrate salts are classified and their tariff treatment.

**Table I-1**  
Citric acid and certain citrate salts: Tariff treatment, 2009

<table>
<thead>
<tr>
<th>HTS provision</th>
<th>Article description</th>
<th>General</th>
<th>Special</th>
<th>Column 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>2918</td>
<td>Carboxylic acids with additional oxygen function and their anhydrides, halides, peroxides and peroxyacids; their halogenated, sulfonated, nitrated or nitrosated derivatives:</td>
<td>6.0</td>
<td>Free</td>
<td>39.5</td>
</tr>
<tr>
<td>2918.14.00</td>
<td>Citric acid..........</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2918.15</td>
<td>Salts and esters of citric acid:</td>
<td>6.5</td>
<td>Free</td>
<td>42.0</td>
</tr>
<tr>
<td>2918.15.10</td>
<td>Sodium citrate.......</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2918.15.50</td>
<td>Other..................</td>
<td>3.7</td>
<td>Free</td>
<td>25.0</td>
</tr>
</tbody>
</table>

1 Normal trade relations, formerly known as the most-favored-nation duty rate, applicable to China.  
2 Special rates are applicable to originating goods of Canada under the NAFTA. Other special rates apply to nonsubject countries. China is not eligible for the special rates.  
3 Applies to imports from a small number of countries that do not enjoy normal trade relations duty status.  

The imported products subject to these investigations are citric acid and certain citrate salts, specifically sodium citrate, potassium citrate, and crude calcium citrate (“CCC”).

Citric acid, sodium citrate, and potassium citrate are all available as odorless, translucent crystals. These crystals are normally sold in three granulations: granular, fine granular, and powder.

---

17 Although HTS subheading 2918.15.50 is a residual or “basket” subheading covering salts and esters of citric acid other than sodium citrate, during the preliminary phase of these investigations, petitioners contended that the vast majority of U.S. imports entering under it are potassium citrate. In the event that crude calcium citrate were imported into the United States, it may be classified under this subheading. However, the parties to these investigations are unaware of any U.S. imports of crude calcium citrate. Conference transcript, p. 54 (Ellis).

18 The scope of these investigations also included blends of citric acid and certain citrate salts classifiable in HTS subheading 3824.90.92. This is a residual subheading for the heading “Prepared binders for foundry molds or cores; chemical products and preparations of the chemical or allied industries, not elsewhere specified or included.” During the preliminary phase of these investigations, petitioners reported that they were unaware of any product within the scope of these investigations imported under this subheading, but included it in the scope language in order to prevent circumvention. See Citric Acid and Certain Citrate Salts from Canada and China, Inv. Nos. 701-TA-456 and 731-TA-1151-1152 (Preliminary), USITC Publication 4008, June 2008, p. 13, fn. 79.

19 During the preliminary phase of these investigations, crude calcium citrate was referred to as “unrefined calcium citrate.” An interested party requested that Commerce clarify the definition and rename this product “crude calcium citrate” in its scope language. See Citric Acid and Certain Citrate Salts from the People’s Republic of China: Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Countervailing Duty Determination with Final Antidumping Duty Determination; 73 FR 54367, September 19, 2008.

20 Petition, pp. 5-6.

21 Petition, p. 6.
Citric acid is also available in solution.\textsuperscript{22} Purchasers can buy the dry product and put it into solution or have an independent converter do it.\textsuperscript{23} Petitioners argue that the products have only minor molecular differences which do not significantly alter their essential characteristics or uses.\textsuperscript{24} CCC is an intermediate form in the production of citric acid via the lime/sulfuric acid process.\textsuperscript{25} CCC can be shipped to another facility for further processing into refined citric acid.\textsuperscript{26} Citric acid is produced and sold in the U.S. market in both its dry and solution forms, and can be easily and reversibly converted between these two forms. Whether dry or dissolved in water, the product’s chemical properties are the same.\textsuperscript{27} The petitioners stated that the bulk of their shipments are in the dry form, but they do ship as much as 25 percent in solution.\textsuperscript{28} Sodium citrate and potassium citrate are sold in dry forms.\textsuperscript{29} According to the petitioners, the three products are used basically for the same purposes, sold in the same markets, and produced in the same production facilities.\textsuperscript{30} Citric acid is produced as a white granular or crystalline powder with a strong acidic taste. It is produced by the fermentation of glucose from a substrate such as corn, molasses, sweet potato, tapioca, or wheat.\textsuperscript{31} Citric acid is produced both in anhydrous form and as a monohydrate. Both forms are isolated and purified through successive recrystallizations.

Sodium citrate is a white, granular crystalline powder with a pleasant acidic taste. Sodium citrate is produced by mixing citric acid slurry with sodium hydroxide (or sodium carbonate) and then crystallizing the resulting sodium citrate.\textsuperscript{32} Potassium citrate is produced by reacting citric acid slurry with potassium hydroxide (or potassium carbonate).\textsuperscript{33} Citric acid, sodium citrate, and potassium citrate are chemical products used in the production and formulation of a wide variety of foods, beverages, pharmaceuticals, and cosmetics as well as commercial and household products including detergents and metal cleaners, and in textile finishing treatments and other industrial applications. Citric acid is used in the food and beverage industry as an acidulant, preservative, and flavor enhancer because of its tart flavor, high solubility, acidity, and buffering capabilities.\textsuperscript{34} It is commonly used in carbonated and non-carbonated drinks, dry powdered beverages, wines and wine coolers, jams, jellies, preserves, gelatin desserts, candies, frozen foods, and canned fruits and vegetables.\textsuperscript{35} The use of citric acid in laundry detergents has increased because it has replaced phosphate-based formulations and because more concentrated liquid detergents, which are increasing in popularity, require more citric acid than do powdered detergents.\textsuperscript{36}

\begin{itemize}
\item \textsuperscript{22} Petition, p. 6.
\item \textsuperscript{23} Petition, p. 6.
\item \textsuperscript{24} Petition, p. 6.
\item \textsuperscript{25} Petition, p. 8.
\item \textsuperscript{26} Petition, pp. 8-9.
\item \textsuperscript{27} Petition, p. 6.
\item \textsuperscript{28} Conference transcript, p. 65 (Poulos and Christiansen).
\item \textsuperscript{29} Petition, p. 6.
\item \textsuperscript{30} Conference transcript, p. 60 (Anderson).
\item \textsuperscript{31} Petition, p. 9.
\item \textsuperscript{32} Petition, p. 12.
\item \textsuperscript{33} Petition, p. 12.
\item \textsuperscript{34} Petition, p. 7.
\item \textsuperscript{35} Conference transcript, p. 18 (Oakley).
\item \textsuperscript{36} Petition, p. 8.
\end{itemize
Sodium citrate, in addition to similar applications as citric acid, is used in cheese and dairy products to improve emulsifying properties, texture, and melting properties and to act as a preservative and aging agent.\textsuperscript{37} It also has pharmaceutical applications such as a diuretic and an expectorant in cough syrup.\textsuperscript{38}

Potassium citrate is used as an antacid, a diuretic, an expectorant, and as a systemic and urinary alkalizer. In industrial applications, potassium citrate can be used in electropolishing and as a buffering agent. In food and beverage applications, potassium citrate has been replacing sodium citrate as a means of reducing sodium content in low- or no-salt products.\textsuperscript{39}

Both petitioners and respondents state that citric acid and certain citrate salts are produced to meet very high purity U.S. Pharmacopoeia (“USP”) or Food Chemical Codex (“FCC”) standards. The Canadian and Chinese producers sometimes certify their products as complying with the British Pharmacopoeia (“BP”) standards, which are very similar to those of the USP.\textsuperscript{40} The products must meet these standards to be used in food and beverage or pharmaceutical applications. Both petitioners and respondents stated that most of the world-class producers try to produce the highest quality product so that it will pass USP or FCC standards since some of the largest customers are in the food and beverage business. A respondent stated that in addition to high purity standards, other quality factors in the product such as color, acidity level, consistency of pH level, and granulation or clumping play an important role in the sale of the product. According to this witness, these factors, in addition to the FCC and USP standards, determine in what market segment the subject product will be used.\textsuperscript{41} At the staff conference, both petitioners and respondents referred to quality tiers in end-use markets for citric acid and certain citrate salts. End uses in foods, beverages, and pharmaceuticals constitute an upper tier, while detergent formulation and industrial uses make up a lower tier.

JBL Canada, the sole Canadian producer, manufactures only citric acid at its plant in Canada. It does not produce any of the salts. It ships citric acid in both dry and solution forms.

The Chinese producers manufacture primarily citric acid. A witness at the conference stated that China’s limited resources of the sodium and potassium compounds used to make the subject salts render Chinese-produced salts less competitive in the U.S. market.\textsuperscript{42}

Manufacturing Processes

Citric acid is produced in a two-stage process. In the first stage, sugars are fermented using a fermenting organism such as molds or yeasts. In the second stage, the crude citric acid is recovered and refined. Sodium citrate and potassium citrate are produced by reacting citric acid slurry with a solution containing certain sodium or potassium compounds (e.g., sodium hydrosxide or potassium hydroxide).\textsuperscript{43} The domestic producers stated during the conference that they produce sodium citrate and potassium citrate using some of the same equipment and workers that are used for citric acid.\textsuperscript{44}

\begin{footnotesize}
\begin{enumerate}
\item[37] Petition, p. 8.
\item[38] Petition, p. 8.
\item[39] Petition, p. 8.
\item[40] Petition, p. 7.
\item[41] Conference transcript, p. 161 (Hsu).
\item[42] Conference transcript, p. 171 (Hsu).
\item[43] Petition, p. 12.
\item[44] Conference transcript, pp. 84-85 (Oakley and Staloch).
\end{enumerate}
\end{footnotesize}
Modern, large-scale production of citric acid is achieved through fermentation. The fermentation process involves the action of specific strains of organisms such as the *Aspergillus niger* mold or the *Candida lipolytica* or *Candida guilliermondii* yeast upon a substrate. Once the substrate is turned into glucose, it is fermented into crude citric acid by the organism. The yield of citric acid can be optimized through the careful control of fermentation conditions, such as temperature, acidity or alkalinity, dissolved air or oxygen, and the rate of stirring of the mixture. Each fermentation reaction is done in batch in large tanks which hold several thousand gallons and takes approximately *** percent to achieve a citric acid yield of *** percent, based on the weight of the sugar.

Producers ferment the substrate by one of three different methods: “shallow pan,” “deep tank,” or solid-state. Citric acid was originally produced using a shallow pan or liquid surface culture technology, where microbial fermentation occurred on the surface of the liquid. Some smaller, older Chinese plants may still use this technology. Most modern production of citric acid uses a deep tank or a submerged culture process, where the reaction is constantly agitated or stirred with air in order to allow the organism to grow throughout the mixture. The petitioners use only the deep tank method ***. The submerged culture process is favored due to the economics of increased yields, although reaction conditions must be more tightly controlled. According to petitioners, solid-state fermentation is used only in Japan.

Corn starch is the principal substrate in the United States, Canada, and China. U.S. producers also use molasses. Some Chinese producers also use cassava, sweet potato, or wheat.

The second stage of production, recovery and refining, is normally performed by one of three common processes: the lime/sulfuric acid method, the solvent extraction method, or the ion exchange method. All three of these processes are compatible with either the shallow pan or deep tank fermentation processes.

In the lime/sulfuric acid refining process, calcium hydroxide (lime) is added to the fermentation broth to precipitate out calcium citrate slurry, the CCC that is also part of the scope. After the calcium citrate is separated by filtration, it is washed to remove soluble impurities. The citrate is then mixed with sulfuric acid to produce a citric acid/charcoal slurry and gypsum (calcium sulfate). The citric acid is then purified through evaporation, crystallization, centrifugation, and drying. This process is used by *** most Chinese producers.

The second common refining method, used by ***, is the solvent extraction process. This process does not involve the production of calcium citrate or gypsum. Instead, solvents separate the citric
acid slurry from spent biomass. The subsequent processes of evaporation, crystallization, centrifugation, and drying are similar to those used in the lime/sulfuric acid process.

The third refining method, ion exchange, is a recent development. In this method, the slurry is passed through a bed of polymer-based resin. Ionic mineral elements such as calcium and magnesium adhere to the resin, thus removing them from the citric acid slurry. The subsequent steps are similar to the other two processes. **58** *** use the ion exchange method. ***59

All three refining methods produce citric acid that is dissolved in water. The temperature used for the crystallization process determines whether the anhydrous or hydrous form is produced.60

Producers can either sell the citric acid or convert it into salts. Petitioners produce dihydrate sodium citrate and anhydrous sodium citrate by diverting some of the citric acid slurry to a line dedicated to citric salt production, where the slurry is reacted with sodium hydroxide or sodium carbonate.61 Similarly, potassium citrate is produced by reacting citric acid slurry with potassium hydroxide or potassium carbonate.62

The dry forms of the subject merchandise are packaged in polyethylene-lined paper bags, typically holding 50 pounds or 25 kilograms. “Super sacks” containing 500 to 2,000 pounds are also used. When preferred in solution form, the subject product is shipped in drums, railcars, or tank trucks. Drums are usually 200 to 275 pounds.63

Sodium citrate and potassium citrate can also be produced by some distributors that are known as “converters.” Converters can provide either citric acid as purchased from the manufacturer, or have the equipment on hand to blend sodium hydroxide or potassium hydroxide with citric acid, thus producing sodium citrate or potassium citrate, respectively.64

**INTERMEDIATE PRODUCT**

Crude calcium citrate (“CCC”)65 is an intermediate product of producers that use the lime/sulfuric acid refining method.66 During the preliminary phase of these investigations, petitioners asserted that CCC has only one function - to be converted into citric acid.67 Respondents did not contradict this assertion. Petitioners stated that there is not a separate CCC market in the United States or anywhere else

---

58 Petition, p. 11; Petitioners’ posthearing brief, exh. 2, p. 9.
59 Staff telephone interview with ***. E-mail from ***.
60 Petition, p. 11.
61 During the preliminary phase of these investigations, at least one purchaser claimed that monosodium citrate is not made by the U.S. producers and questioned why it is covered in the scope of these investigations. Petitioners acknowledged that they do not produce monosodium citrate, but stated that they are able to do so. They also stated that monosodium citrate can substitute for citric acid and trisodium citrate, and that the conversion from monosodium citrate to either citric acid or trisodium citrate involves a relatively simple and inexpensive process. Petitioners’ posthearing brief, exh. 6, pp. 1-3.
62 Petition, p. 12.
63 Petition, p. 13.
64 Conference transcript, pp. 23-24 (Oakley).
65 During the preliminary phase of these investigations, crude calcium citrate was referred to as “unrefined calcium citrate.” An interested party requested that Commerce clarify the definition and rename this product “crude calcium citrate” in its scope language. See Citric Acid and Certain Citrate Salts from the People’s Republic of China: Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Countervailing Duty Determination with Final Antidumping Duty Determination; 73 FR 54367, September 19, 2008.
66 Conference transcript, p. 19 (Oakley).
67 Conference transcript, p. 19 (Oakley) and p. 87 (Ellis).
around the globe, but they have been aware of instances when CCC was shipped from one country to another for further processing. Although there are no known imports of CCC, petitioners said that they included it in the scope of the subject product to avoid circumvention. The parties have not raised issues with regard to CCC during the final phase of these investigations.

**DOMESTIC LIKE PRODUCT ISSUES**

During the preliminary phase of these investigations, the petitioners contended that the Commission should find one domestic like product that is co-extensive with the scope of merchandise subject to the investigations as identified by Commerce. They claim that potassium citrate, much like sodium citrate, has many of the same end uses as citric acid, is derived from the citric molecule, produced in the same production facilities, and sold in the same markets. During the preliminary phase, respondents agreed with petitioners’ proposed definition of the domestic like product.

The Commission preliminarily determined that the domestic like product should be defined in the same manner as the scope defined by Commerce. Based on the preliminary record, the Commission stated that “there is a continuum of domestically produced products corresponding to the scope of these investigations, and no clear dividing lines based on chemical or physical form, grade, or product type. Whether in an intermediate form as unrefined calcium citrate, as citric acid, or transformed into sodium citrate or potassium citrate, citric acid and its citrate salts come in a variety of chemical and physical forms and grades for a variety of end uses, and physical appearance varies accordingly. All have similar chemical composition.”

In the final phase of these investigations, petitioners urge the Commission to continue to hold the position they took in the preliminary phase, calling for a single domestic like product coextensive with the scope as determined by Commerce. No respondent has raised an issue with regard to the domestic like product in the final phase of these investigations.

---

68 Conference transcript, pp. 19 and 87 (Oakley).

69 Conference transcript, p. 54 (Ellis).

70 Conference transcript, p. 59 (Ellis).

71 Petitioners’ postconference brief, p. 4.

72 Ibid., exh. 1, p. 2.

73 E.g., Chinese respondents’ postconference brief, p. 6; conference transcript, p. 137 (Porter, Waite).

74 *Citric Acid and Certain Citrate Salts from Canada and China, Inv. Nos. 701-TA-456 and 731-TA-1151-1152 (Preliminary)*, USITC Publication 4008, June 2008, pp. 11-12. In the Commission’s 2000 investigation, the scope of which included only citric acid and sodium citrate, the Commission defined a single domestic like product that included both, finding that “although specific end product formulations limit the actual interchangeability of citric acid and sodium citrate, the record indicates that they are physically and chemically similar, are sold through the same channels of distribution at similar prices and share the same manufacturing processes, as well as common production facilities and employees . . . even though there are a few end uses unique to each of them, citric acid and sodium citrate can be used for similar purposes in a wide variety of food, beverage and industrial products.” *Citric Acid and Sodium Citrate from China, Inv. No. 731-TA-863 (Preliminary)*, USITC Publication 3277, February 2000, p. 7. The scope of these investigations includes citric acid, sodium citrate, and additionally, potassium citrate.


76 Petitioners’ prehearing brief, p. 6.
PART II: CONDITIONS OF COMPETITION IN THE U.S. MARKET

U.S. MARKET SEGMENTS

Citric acid and certain citrate salts have three primary end-use markets: foods and beverages (especially carbonated beverages and health drinks), industrial (detergents and cleaners), and pharmaceuticals.\(^1\)

In the food and beverage segment, citric acid and certain citrate salts must meet the purity standards of the U.S. Food and Drug Administration’s (“FDA”) Food Chemical Codex (“FCC”) for sale in the U.S. market. Likewise, in the pharmaceutical segment, citric acid and certain citrate salts must meet the standards of the U.S. Pharmacopoeia (“USP”).\(^2\) Citric acid and certain citrate salts that meet FCC and USP standards are called “food grade,” a standard higher than that required for the industrial segment. However, U.S. producers typically manufacture citric acid and certain citrate salts to meet the same FCC/USP standards regardless of end use, and they sell “food grade” product to the industrial segment as well as to the food and drug segment.\(^3\) JBL Canada, the Canadian producer, reports that all of its product is food grade. Petitioners stated that there is no price premium for product sold into the food and beverage segment.\(^4\) ***. ***.\(^5\)

Petitioners stated that subject imports from both Canada and China compete with the U.S. product across all the market segments for citric acid and certain citrate salts.\(^6\) JBL Canada asserts that its product is mainly sold in the food and beverage segment of the market; it also sells to the pharmaceutical segment, but sells relatively limited amounts to the industrial segment.\(^7\) Although importer United Foods stated that the Chinese product does not compete in the soft drink segment\(^8\) ***. United Foods also reported that the Chinese product is more available in the smaller food product segment, where the smaller volumes make the market less interesting to U.S. producers accustomed to larger shipment volumes.\(^9\) JBL and the Chinese producers report that they do not know the ultimate market of much of the product they sell through distributors.\(^10\)

*** sell citric acid and/or certain citrate salts throughout the United States.\(^11\) Among other importers, 15 of the 26 responding sold to a national market, two sold to six regions, two sold to two regions, and seven sold to only one region. Sales to the Midwest and the Southeast regions were most common, reported by five or six importers.

---

\(^1\) See Part IV for data on the relative sizes of these markets.

\(^2\) Petition, p. 7.

\(^3\) Petition, p. 12, and conference transcript, p. 20 (Oakley).

\(^4\) Conference transcript, p. 54 (Staloch).

\(^5\) Petitioners’ posthearing brief exh. 1, p. 7. Staff notes that ***.

\(^6\) Conference transcript, pp. 8-9 (Ellis).

\(^7\) Hearing transcript, pp. 169-170 (Rainville).

\(^8\) *** also reported difficulty using Chinese product due to caking problems, and added that ***. See Part IV for more details.

\(^9\) Conference transcript, pp. 110-114 (Hsu).

\(^10\) Hearing transcript, pp. 215-216 (Rainville, Mendoza).

\(^11\) *** U.S. producers submitted both producers’ and importers’ questionnaires in these investigations. Their answers were the same for both questionnaires submitted by their firm, thus, in this chapter, their responses have been counted only among producers.
CHANNELS OF DISTRIBUTION

Petitioners stated that all major domestic and foreign producers compete for critical large volume accounts across the food, beverage, and detergent industries. The largest four end users that provided purchaser questionnaires accounted for 38.6 percent of U.S. citric acid and certain citrate salts consumption between 2006 and 2008, while the largest 12 end users accounted for 49.8 percent. Petitioners report that citric acid and certain citrate salts are not sold to end users or distributors based on what end use is intended for the product, but rather on volume, with smaller-volume purchasers buying from distributors and larger end users buying directly from producers and importers.  

Table II-1 presents information on channels of distribution for U.S. producers as well as for U.S. importers of subject product from Canada, China, and product from nonsubject countries. U.S. product and subject imports were consistently sold to end users more frequently than to distributors, although U.S. producers ship a higher share of their product to end users than importers do. Nonetheless, some of the largest distributors of domestic product are also importers of Chinese product; thus, an end user purchasing from a single distributor/importer may be reported as purchasing from a distributor for domestic product and directly from an importer for Chinese product.

Table II-1

<table>
<thead>
<tr>
<th>Product</th>
<th>Type of purchaser</th>
<th>U.S.</th>
<th>Canada</th>
<th>China</th>
</tr>
</thead>
<tbody>
<tr>
<td>Citric acid</td>
<td>End users</td>
<td>94.9</td>
<td>***</td>
<td>86.0</td>
</tr>
<tr>
<td></td>
<td>Distributors</td>
<td>5.0</td>
<td>***</td>
<td>14.0</td>
</tr>
<tr>
<td>Citrate salts</td>
<td>End users</td>
<td>***</td>
<td>--</td>
<td>76.9</td>
</tr>
<tr>
<td></td>
<td>Distributors</td>
<td>***</td>
<td>--</td>
<td>23.1</td>
</tr>
</tbody>
</table>

Purchasers

Sixty-nine purchasers responded to the Commission’s purchasers’ questionnaire, of which 41 were end users and 28 were distributors. While there are many end users for citric acid and related citrate salts, purchases tend to be relatively concentrated. The top purchasers in order of size are *** *** ***, each of which reported purchasing more than *** pounds of citric acid and related citrate salts over the three years 2006-2008. *** pounds of citric acid and related citrate salts (including its imports). All other purchasers each report purchasing less than *** pounds of citric acid and related citrate salts

12 Conference transcript, pp. 74-75 (Oakley).
products over the three years. Many purchasers reported more than one end use for their citric acid. Information on the top purchasers of citric acid is presented in table II-2. These 17 large purchasers reported purchasing a total of *** billion pounds of citric acid between 2006 and 2008.\textsuperscript{13} All 17 firms reported purchasing U.S. product (two purchased U.S. product only); 9 purchased Canadian product; 13 purchased Chinese product; and 10 purchased nonsubject product.\textsuperscript{14}

\textbf{Table II-2}
\begin{center}
Citric acid and certain citrate salts: Major reporting purchasers of citric acid and certain citrate salts, 2006-2008, by industry, total amount purchased, and country sources
\end{center}
\begin{center}
\begin{tabular}{cccccccc}
 &  &  &  &  &  &  &  \\
* & * & * & * & * & * & * & * \\
\end{tabular}
\end{center}

\textbf{SUPPLY AND DEMAND CONSIDERATIONS}

\textbf{U.S. Supply}

\textbf{Domestic Production}

Based on available information, U.S. citric acid and certain citrate salts producers have the ability to respond to changes in demand with moderate-to-small changes in the quantity of shipments of U.S.-produced citric acid and certain citrate salts to the U.S. market. Factors which constrain supply responsiveness include no production of alternate products using the same equipment used to produce citric acid and certain citrate salts, high capacity utilization, and overall capacity has not increased from the 2006 levels.\textsuperscript{15} However, the existence of alternative markets and inventories may increase the supply responsiveness.

\textit{Industry capacity}

U.S. producers use deep tank fermentation to produce citric acid and certain citrate salts. This method is reportedly more productive and has lower labor costs than the shallow pan process that may be used by some Chinese plants, but has higher energy costs.\textsuperscript{16} U.S. producers stated that because of the high fixed costs in the industry, reducing production has “substantial” costs.\textsuperscript{17}

Overall U.S. capacity is unchanged since 2006. Capacity utilization was relatively high and increased steadily from 85.8 percent in 2006 to 91.7 percent in 2008. According to ***.\textsuperscript{18} Petitioners assert that the domestic industry has not been able to make the “lumpy” types of capital investment needed to build additional capacity because of the recent poor financial returns.\textsuperscript{19}

\begin{flushleft}
\textsuperscript{13} These purchases include some imports and there may be some double-counting if any of these purchasers purchased from any of the listed distributors.
\textsuperscript{14} Purchasers who had purchased more than 20 million pounds of citric acid and salts in 2006, 2007, or 2008 were also requested to provide additional price data; details of their purchases and negotiations are in app. D.
\textsuperscript{15} ***.
\textsuperscript{16} Petition, p. 10.
\textsuperscript{17} Conference transcript, p. 35 (Poulos).
\textsuperscript{18} ***.
\textsuperscript{19} Petitioners’ prehearing brief, pp. 79-82.
\end{flushleft}
Among U.S. producers, *** stated that there had been no changes in the product range or marketing of citric acid and certain citrate salts since January 1, 2005. ***, however, stated that marketing had become more price-focused because of large volumes of available imported material.

**Alternative markets**

Between January 2006 and December 2008, U.S. producers exported between 20.7 percent of production (in 2006) and 22.2 percent of production (in 2007). U.S. producers reported that they could divert export shipments to the U.S. market if circumstances warrant and plan to shift almost *** of their 2008 exports to the U.S. market.20

Respondent P&G does not believe there is much ability for U.S. producers to increase production or willingness on their part to shift product to the U.S. market. It cited as evidence of unwillingness to shift product to the U.S. market the inability of the U.S. producers to provide all the product purchasers requested while the producers continued to export despite the AUVs for exports being lower than those for U.S. shipments throughout the period for which data were collected in this investigation.21 P&G also asserts that by 2008 the U.S. producers were “effectively operating at 100 percent of capacity.”

**Inventory levels**

U.S. producers’ inventories fell steadily from 16.6 percent of shipments in 2006 to 8.7 percent in 2008. However, at this level, U.S. producers have some ability to use inventories as a means to increase supply.

**Production alternatives**

U.S. producers reported that they did not produce any other products on the equipment used to produce citric acid and certain citrate salts. However, the main input in citric acid production, corn, is used in the production of other products, including ethanol; ***,

**Supply availability**

Petitioners report that the claims of shortages are overwhelmingly related to 2008 and are indicative of the petition’s effects.23 ADM and Tate & Lyle reported that they met all their contractual obligations in 2008.24 Cargill reported that for the year 2008, it was able to meet its contractual agreements with all but one major customer, in spite of a plant disruption that caused the loss of about one week of production.25

Respondent PepsiCo reports that the “domestic producers are unable (and apparently unwilling) to satisfy United States demand for citric acid,” ***.26 P&G reported that in 2008, its shipments from one producer declined by 30 percent at the producer’s request, one U.S. producer supplied under

---

21 P&G’s prehearing brief, p. 32. Petitioners report that their export AUVs were higher than AUVs of domestic shipments in 2008. Petitioners’ posthearing brief, exh. 3, p. 7.
22 P&G’s prehearing brief, p. 33.
23 Hearing transcript, p. 60 (Anderson).
24 Hearing transcript, pp. 140-141 (Oakley and Poulous).
25 Hearing transcript, pp. 51-52 (Satloch).
26 PepsiCo’s prehearing brief, pp. 4, 8.
half of its agreed volume, and the third producer had no material available to meet any of the shortfalls of the other U.S. producers.27 As a result, it reported, only one of the U.S. producers met its contractual requirement, and the other two did not meet contractual requirements both in terms of timing and volume.28 Reckitt Benckiser reported that in 2007 it began to purchase from JBL Canada “only after U.S. producers refused to offer sufficient quantities to us.” It reported that it was unable to contract for all the product it wanted from U.S. producers in 2009. U.S. producers, it reported, have little interest in meeting the needs of small to mid-sized purchasers, preferring “to focus on large food and beverage purchasers.”29 Vertellus reported that in 2008, Tate & Lyle’s delivery lead times grew from 1 week to 10 weeks; this forced it to purchase Chinese product on the spot market to maintain supply. According to Vertellus, Tate & Lyle refused to contract to supply it in 2009, in spite of a “20-year relationship with Tate & Lyle,” and the other U.S. producers also refused to supply it in 2009. Vertellus reported that U.S. producers refused to supply it in spite of having capacity to produce what Vertellus needed since the U.S. producers report that they are not producing at full capacity.30 FBC reported that although Tate & Lyle had supplied it in 2008, all three U.S. producers refused to contract to supply it in 2009.31 P&G also reported that world demand is at *** percent of world supply, indicating that the citric acid market is tight worldwide.32

Purchasers were asked a number of questions about the availability of citric acid and certain citrate salts. Forty-eight of 65 responding purchasers (including ****) reported that the spike in corn prices had not affected the availability of citric acid and certain citrate salts. Twenty-nine of 69 responding purchasers reported that they had been put on allocation or had limits put on the amount of citric acid and certain citrate salts that they could purchase since January 2006. All three U.S. producers, JBL, and some importers of Chinese product were reported to have limited supply. ***,.33 According to purchasers, reasons for limits on supply included: ***,; U.S. manufacturers and their distributors refusing to quote from the end of 2008 to the time questionnaires were filled out; Tate & Lyle, JBL, ADM, and Cargill were sold out from January 2007 to 2008, forcing purchasers to use spot purchases; ***,; Canadian product was redirected to the U.S. beverage market in 2007, causing the purchaser to use more Chinese product; and reduced supply of Chinese product due to the Olympics.

Twenty-four of 69 responding purchasers reported that some suppliers were unable to supply some or all of their requirements. Sources from which purchasers were not able to obtain sufficient supply included U.S. producers, JBL, importers of Chinese product, and importers of product from Israel. *** reported that individual U.S. producers had been unable to meet their requirements.

Subject Imports

Canada

Based on available information, JBL Canada, the Canadian producer, has the ability to respond to changes in demand with moderate changes in the quantity of shipments of citric acid and certain citrate salts to the U.S. market. It has *** inventories, *** exports but a *** share of exports going to countries other than the United States, and *** capacity utilization. JBL Canada increased its capacity from 2006

28 Hearing transcript, p. 220 (Smith).
29 Hearing transcript, pp. 193-195 (Hofmann).
30 Hearing transcript, pp. 199-201 (Pensak).
31 Hearing transcript, pp. 205-206 (Bloom).
32 P&G’s posthearing brief, p. 11.
33***. ***.
to 2008, and reported that it had not observed any changes in the *** of citric acid and certain citrate salts.

**Industry capacity**

JBL Canada is the only known Canadian producer of citric acid. Its capacity increased from *** pounds in 2006 to *** pounds in 2008. JBL Canada projects that its capacity ***. Capacity utilization increased from *** percent in 2006 to *** percent in 2008.

JBL Canada produces only citric acid, not certain citrate salts, in its Canadian plant. It reported that it chose its Canadian location because of the proximity to customers, its main raw material supplier (Corn Products International), and its water supply. It also said that it has replaced supplying the U.S. market citric acid from its Austrian plant with production from its Canadian plant. It added that all of its Canadian citric acid is food grade.

**Alternative markets**

JBL Canada’s exports to markets other than the United States accounted for *** percent of its total shipments in 2006, *** percent in 2007, and *** percent in 2008. Sales to the Canadian home market were ***, falling from *** percent in 2006 to *** percent of shipments in 2008.

**Inventory levels**

JBL Canada’s inventories were ***, accounting for *** in 2008.

**China**

Based on available information, Chinese producers have the ability to respond to changes in demand with moderate-to-large changes in the quantity of shipments of citric acid and certain citrate salts to the U.S. market. The main contributing factors to the high degree of responsiveness of supply are the increase in capacity, the existence of alternate markets, and the availability of inventories. The December 2008 decision by the EU to address Chinese dumping via the imposition of antidumping duties and/or the acceptance of price undertakings on product from China may also contribute to some degree to Chinese responsiveness.

**Industry capacity**

Petitioners stated their belief that large Chinese producers use the deep tank fermentation production process (also used by U.S. producers ***), but that some smaller and older Chinese producers

---

34 *** to produce citric acid and certain citrate salts. *** an ion-exchange method of refining (rather than the solvent extraction ***). Petition, pp. 10-11.

35 U.S. Census data on the landed duty paid value of U.S. imports for consumption show that, over the last ten years, U.S. imports of Austrian product fell from a high of $22.6 million in 2001 to $2.8 million in 2003, and rose slowly to $4.3 million in 2008. U.S. imports of Canadian product rose from $0.1 million in 2001 to $26.6 million in 2003 and then $68.9 million in 2008.

36 Conference transcript, pp. 117-119 (Waite).

may still use the shallow pan production process. Petitioners described the equipment used by the five largest Chinese producers as “world class.” Petitioners also stated that most Chinese product is anhydrous now (unlike during the previous investigation in 2000). Petitioners also described Chinese capacity as having undergone massive expansion (that they claim was subsidized by the Chinese government) in order to increase exports, as the Chinese market for citric acid is much smaller than Chinese capacity to produce citric acid.

Chinese producers representing the vast majority of Chinese production responded to the Commission’s foreign producer questionnaires. Reported overall capacity increased from 1.4 billion pounds in 2006 to 2.0 billion pounds in 2008.

Chinese respondents report that the Chinese citric acid industry has been consolidating since 2002, and by 2008, 15 Chinese producers were approved for exports. Chinese respondents report that Chinese producer ***. In addition, they report that DSM, a Chinese producer with a reported capacity of 110 million pounds, has discontinued production in China, has closed its factory, and does not plan to rebuild capacity in China.

**Alternative markets**

Exports of Chinese citric acid and certain citrate salts to the United States accounted for 11.2 percent of China’s reported shipments in 2006, 9.4 percent in 2007, and 10.0 percent in 2008. Shipments of Chinese citric acid and certain citrate salts to the Chinese home market (including internal consumption) were 26.2 percent of total shipments in 2006, 28.6 percent in 2007, and 28.9 percent in 2008. Most shipments between 2006 and 2008 were to non-U.S., non-Chinese markets; shipments to these alternative markets accounted for between 61.2 and 62.6 percent of total Chinese shipments.

Exports of citric acid to the EU are subject to a December 2008 price undertaking. The Chinese respondents report that the EU expected imports from China to “remain at a substantial level, appearing sufficient to guarantee the security of supply in the EU.” With this price undertaking in place, they contend that “the Chinese producers can maintain their traditional reliance on the EU as their primary export market.” In addition, demand within China is expected to grow. The petitioners contend that demand is at best stable and likely to decline; they noted that predictions of growth were made before the global recession began and are no longer relevant.

---

38 Petition, p. 10.
39 Conference transcript, p. 25 (Oakley).
40 Conference transcript, p. 43 (Anderson).
41 Petition, pp. 33-34.
42 Hearing transcript, pp. 163-164 (Shao).
43 Chinese respondents’ prehearing brief, p. 72. The petitioners report that **. Petitioners’ posthearing brief, exh. 1, p. 38.
44 Chinese respondents’ prehearing brief, p. 73.
45 Chinese respondents’ prehearing brief, p. 80.
46 Chinese respondents’ prehearing brief, p. 80.
47 Hearing transcript, p. 166 (Shao).
48 Petitioners’ posthearing brief, exh. 4, pp. 1-5.
Inventory levels

Inventories of Chinese citric acid and certain citrate salts accounted for 6.2 percent of their total shipments in 2006 and 2007, but then more than doubled to 13.1 percent in 2008.

Nonsubject Imports

Citric acid and certain citrate salts have been imported into the United States from Israel, Colombia, Germany, Thailand, Austria, and Belgium, listed in descending order of 2008 volume. Petitioners described Belgium as producing substantially less than Canada and China, and all other nonsubject countries produce less than Belgium.49

U.S. Demand

Based on the available information, it is likely that changes in the price level of citric acid and certain citrate salts will result in a small change in the quantity of citric acid and certain citrate salts demanded. The main contributing factor to the small degree of responsiveness of demand is the low cost share of citric acid and certain citrate salts in most of their end uses. Contributing to some extent is (1) increases in price and supply uncertainty are likely to inhibit demand growth as firms formulate new products so that they do not include citric acid and certain citrate salts and (2) experimental uses such as green cement become less competitive.50

End Uses

In the food and beverage industry, citric acid is used as an acidulate, a preservative, and a flavor enhancer, especially in beverages (including carbonated, non-carbonated, dry powdered, and wine), jams, desserts, frozen foods, and canned fruits and vegetables. Citric acid is also used in pharmaceuticals and cosmetics, as well as in household laundry detergents, metal finishers, cleaners, textile treatments, and other industrial applications.51

Sodium citrate is used in the same products (and for the same reasons) as citric acid, but has additional uses in cheese and other dairy products, household cleaner products, and pharmaceuticals. Potassium citrate is used in pharmaceutical products as an antacid, a diuretic, and an expectorant. It is also used in “electro polishing” and as a buffering agent, and can be used in place of sodium citrate in food and beverage products when it is important to reduce the sodium content.52

***, U.S. consumption of citric acid in 2005 was ***.53 JBL Canada estimated that, on a global basis, demand for citric acid was 40 percent for beverage end uses, 20 percent for food end uses, 25 percent for detergent end uses, and the remainder for pharmaceuticals.54

---

49 Conference transcript, pp. 73-74 (Ellis and Anderson).
50 P&G reported that it has contemplated replacing phosphates with citric acid in dishwasher detergent but lack of availability of domestic supply may force it to look to other formulations or technologies. Hearing transcript, pp. 185-186 (Smith). ***
51 Petition, p. 8.
52 Petition, p. 8.
53 *** and staff calculations.
54 Conference transcript, pp. 118-119 (Waite).
Demand Characteristics

*** reported that U.S. consumption of citric acid and salts was *** metric tons (*** pounds) in 2005 and that world consumption of citric acid and salts was *** metric tons (*** pounds). *** projected that U.S. consumption of citric acid and salts will rise to *** metric tons (*** pounds) in 2010. *** estimates place the United States market as smaller than that of *** but larger than that of ***. P&G reports that in 2008 demand was expected to increase by ***.55

Demand from beverage manufacturers is highest from April to August of each year.56 However, a large portion of contracting is performed near the end of each year (see Part V for details on length of contracts and timing of these agreements).

Fifty-three of the 68 responding purchasers reported that the quantity of their purchases varies over the year. Seasonality was reported to account for this variation by 25 of these purchasers; other factors noted include sourcing customer requirements, product demand, price, and availability. ***.

Demand Trends

Increasing U.S. demand since 2006 was reported by all three producers and by 21 of 26 responding importers. Four importers reported that demand was unchanged and one reported that demand had fallen with the economic downturn. Reasons for increased demand included economic growth; citric acid is a relatively inexpensive product; downstream products were reformulated to increase use of citric acid; increased use in detergents; sodium reduction initiatives; and new products.

Purchasers who were end users were asked if demand for their end products which incorporate citric acid and related citrate salts had changed since January 2006. Twenty of the 41 responding purchasers reported increased demand for their products; 16 of the 20 reported that this had increased their demand for citric acid and related citrate salts while 4 stated that it had not. Five firms reported that demand for end product had decreased; four of these firms reported that this had affected the demand for citric acid and related citrate salts. Nine purchasers reported that demand had fluctuated, with six reporting that it had affected demand for citric acid and related citrate salts. Seven purchasers reported that the demand for their end products was unchanged.

Petitioners ***57 reported that the use of citric acid in laundry detergents has increased as citric acid has replaced phosphate-based formulations and because of the growth in sales of ultra-concentrated liquid detergents, which contain more citric acid than powdered detergents.58 Petitioners also described demand for potassium citrate as increasing due to the increased demand for low-sodium food and beverages, but later characterized detergent manufacturers as not having yet switched their formulas to incorporate citric acid.59 Chinese respondents reported that demand for citric acid remains strong in spite of the economic downturn.60 Respondents predicted the increased use of citric acid because dishwashing detergent will be required to no longer use phosphates after July 1, 2001;61 plasticizers will attempt to

---

55 P&G’s posthearing brief, p. 11 and exh. 6.
56 Conference transcript, p. 122 (Waite).
57 ***.
58 Petition, p. 8.
59 Conference transcript, p. 61 (Staloch), and petitioners’ postconference brief, exh.1, p. 29.
60 Chinese respondents’ prehearing brief, pp. 7-8.
61 Hearing transcript, p. 211 (Smith).
Future demand

Petitioners predict that demand will fall with the current economic downturn. They stated that the decline was not felt in 2008 because the recession only began to have an impact late in 2008. Petitioners also predicted that, for developing markets, citric acid demand will stagnate or decline; although economic development in the developing markets would lead to increased per-capita consumption, developing countries have been worse hit by the economic downturn. According to the Petitioners, China’s consumption has already fallen and its inventories have increased, so petitioners expect product to flood the U.S. market if duties are not imposed. In addition, Petitioners reported that demand for products using citric acid is also declining in the EU. They report that in spite of P&G’s statements that it does not expect its demand for citric acid to decline, P&G reported substantial drops in volume; in addition, falling sales in other countries will increase the Chinese product available for sale to the United States. New uses are speculative. Moreover, structural overcapacity is expected to remain in the world market.

On the whole, respondents expected demand for citric acid to not decline significantly during the current recession. PepsiCo reported anticipating “flatter, slightly declining volume for its beverage products in the current economic environment,” but expects demand to rise in the longer run. P&G reported that its sales fell 4 percent in its fabric and household care business during October to December 2008, but that “this reduction was primarily caused by P&G’s customers reducing their inventories” and these inventory reductions are expected to be temporary, as orders are already increasing. P&G reported that it estimated “global demand to be between 92 and 95 percent of global producers’ effective capacity to produce citric acid,” and as a result is talking with producers to increase the supply dedicated to P&G’s use. Reckitt Benckiser reported estimating “global operating capacity rate at above 90 percent and market growth at 6 to 8 percent annually even in today’s adverse economy.” Reckitt Benckiser reported that it will be eliminating phosphates from dishwashing detergents after July 1, 2010, requiring a new formulation that increases use of trisodium citrate, thus increasing its volume of purchases “roughly
fourfold.\textsuperscript{77} It also reported that the EU is considering banning phosphates in dishwashing detergents, and that such a change in Europe would increase global demand by 10 percent.\textsuperscript{78} Vertellus reported that it expects demand to increase despite the recession because of health and safety restrictions on the use of some phthalates which could be replaced by citrate esters.\textsuperscript{79} \textsuperscript{80} Respondents characterize global supply as tight with world demand *** percent of world supply.\textsuperscript{81}

**Changing Purchase Patterns**

Twenty-three of the 69 responding purchasers reported that they had changed purchasing patterns of citric acid and certain citrate salts in the last 3 years. Most of these reported that increased sales had resulted in increased purchases, but three reported that shortages or lack of domestic supply had caused purchasing patterns to change, increasing imports. Thirty-seven of 68 responding purchasers reported changing suppliers; a number of these shifted purchases among importers. ***.

**Variation in Sources Used Within a Year**

Forty-three of the 68 responding purchasers reported that the source of their product varies within a year. Factors affecting sourcing were customer requirements, product specifications, product demand, price, availability, and required volume above that contracted. ***.

**Reasons Purchasers Use of Multiple Sources**

P&G reported that it diversifies its sources of supply among producers both inside and outside the United States in order to ensure reliability of supply and minimize the risk of plant disruptions.\textsuperscript{82} Similarly, PepsiCo reported diversifying its supply to ensure that quality product is available to maintain and increase production.\textsuperscript{83} In contrast, Reckitt Benckiser reported that it prefers to use only material from U.S. sources for security and planning reasons, but that in 2007 it purchased from JBL because U.S. producers refused to offer it sufficient quantities.\textsuperscript{84} Petitioners report that there were no problems with availability during 2006 and 2007, and any such problems in 2008 were caused by the filing of the petition.\textsuperscript{85}
**Substitute Products**

*** responding U.S. producers, 9 of the 28 responding importers, but only 10 of the 63 responding purchasers, reported substitutes for citric acid and certain citrate salts. Substitutes listed include acetic acid, azocarbonamide, EDTA (ethylenediaminetetraacetic acid), fumaric acid, HCA (hydroxycitric acid), lactic acid, malic acid, phosphoric acid, potassium chloride, potassium phosphate, sodium bicarbonate, sulfuric acid, and tartaric acid. *** reported no substitutes for citric acid. P&G reported that in replacing phosphates in dishwasher detergent it is considering both citric acid and “other formulations or technologies,” reflecting that these are potential substitutes for citric acid, at least at the time of formulation of new products.86 The Soap and Detergent Association reports that antidumping duties would force its members to reformulate their products where possible to reduce the use of citric acid, indicating that some substitutes (even if less effective) exist.87 Substitution depends on the customer’s applications. For example, HCA can be used a substitute to lower the pH of a solution, while lactic acid, acetic acid, fumaric acid, malic acid, phosphoric acid, and tartaric acid can be used as substitutes in food and beverage additives, and sulfuric acid can be used as an industrial acidulate. *** U.S. producers, nine of the 10 responding importers, and all 10 of the responding purchasers reported that the prices of these substitutes did not affect the price of citric acid and certain citrate salts. The other importer responded that the prices of substitutes did affect the price of citric acid.

**Cost Share**

Thirty-six purchasers reported the cost share of citric acid and certain citrate salts in one or more end products, with a total of 75 end-product responses. There were 47 instances where purchasers reported that cost shares were less than 6 percent; 15 instances in which cost shares ranged from 6 percent to less than 25 percent, 5 instances in which cost shares ranged from 25 to less than 50 percent; and 8 instances in which cost shares were 50 percent and above. ***. Eight importers estimated that citric acid and certain citrate salts’ share of the cost of downstream products ranged from 1 to 50 percent for ***, with 11 of the 16 products having cost shares under 6 percent. U.S. producers estimated that citric acid and certain citrate salts’ share of the cost of downstream products was relatively low, ranging from under 1 percent to ***.

**SUBSTITUTABILITY ISSUES**

Purchasers were asked how frequently they purchased citric acid and certain citrate salts at the lowest price. Four reported that they always purchase the lowest-priced product, 27 reported that they usually purchased the lowest-priced product, 34 sometimes purchased the lowest-priced product, and 4 never purchase the lowest-priced product. ***.

**Lead Times**

Among U.S. producers, *** stated that *** percent of sales were from inventory with a lead time of ***, while *** sold *** and *** percent respectively from inventory with a lead time of *** days.

---

86 Hearing transcript, pp. 185-186 (Smith).
87 The Soap and Detergent Association, letter to the Commission, March 25, 2009.
The remainder was produced to order with lead times of ***. For imports from Canada, JBL reported selling *** of its product from inventory with a *** lead time.

Thirteen importers reported selling Chinese product from inventory; nine of these sold 90 to 100 percent from inventory and the remaining four sold 30 to 50 percent from inventory. Twelve importers reported selling Chinese product on a produced-to-order basis, five of which sold all their citric acid and certain citrate salts produced to order. Lead times for produced-to-order products ranged from 4 to 63 days, with eleven of these firms reporting lead times of 40 days or more.

Response if Subject Imports were No Longer Available

Purchasers were asked if they had purchased product from the subject countries since January 2006, and those who had were asked what they would do if this product were not available. Responses are in the following tabulation.

<table>
<thead>
<tr>
<th>Source</th>
<th>Purchased product from this source since 2006</th>
<th>If product from this country were not available, firm would purchase--</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Less product overall</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td>Canada</td>
<td>27</td>
<td>3</td>
</tr>
<tr>
<td>China</td>
<td>52</td>
<td>12</td>
</tr>
</tbody>
</table>

Two firms which reported that they would reduce their purchases if the Canadian product were not available stated that some of their customers’ specifications allowed only JBL Canada’s product and that if JBL Canada reduced the amount of product available, these purchasers would buy less. Three of the firms reporting that they would not purchase more U.S. material if less Canadian product were available reported that there are limited supplies of U.S. material. *** reported that U.S. producers had limited their supply, forcing it to look overseas. Two firms reported that they would not reduce their purchases, would increase their purchases of U.S. product, and not purchase overseas. One of these firms, ***, reported that customer demand dictates need, and that domestic supply was likely to be available.

Of the 12 purchasers of Chinese product that reported that if Chinese product were not available they would purchase less product overall, seven gave explanations. *** reported that it relies heavily on Chinese producers because domestic supply lines have collapsed. *** stated that if Chinese material were not available, it would have to use other sources or exit the market completely because it did not have the same variety of U.S. and non-Chinese import options; if its purchases of Chinese material fell it would reduce purchases due to lack of supply. *** reported that it was not approved to buy from U.S. producers. *** firm reported that it would buy as long as it could sell to the market based on cost. *** reported that it would try to replace Chinese volume with product from another country. *** reported that U.S. producers will not sell to small distributors. *** reported that U.S. product is far too costly to use on a regular basis. Other firms that explained why they would not purchase more U.S. product if

---

88 Petitioners report that lead times normally vary over the year, increasing during periods of high demand. Petitioners’ posthearing brief, exh. 4, pp. 23-24.

89 One additional purchaser did not explain why it would purchase less.

90 One firm reported that if Canadian product were not available it would purchase more Chinese product. Two firms did not explain their answers.
Chinese supply were limited mainly reported problems with U.S. supply. *** reported that U.S. producers have limited how much it could buy, forcing it to look overseas. *** reported that the U.S. producers do not make enough product for U.S. needs, therefore it needs to source elsewhere. ***. ***.

### Factors Affecting Purchasing Decisions

Purchasers, importers, and producers were asked if the various forms of citric acid (anhydrous, monohydrate, dihydrate, and solution) were always, frequently, sometimes, or never interchangeable (table II-3).

#### Table II-3
**Citric acid: Perceived interchangeability between forms, as reported by producers, importers, and purchasers**

<table>
<thead>
<tr>
<th>Types of citric acid</th>
<th>Number of U.S. producers reporting</th>
<th>Number of U.S. importers reporting</th>
<th>Number of U.S. purchasers reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A</td>
<td>F</td>
<td>S</td>
</tr>
<tr>
<td>Anhydrous and monohydrate</td>
<td>***</td>
<td>***</td>
<td>0</td>
</tr>
<tr>
<td>Anhydrous and dihydrate</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Anhydrous and solution</td>
<td>***</td>
<td>***</td>
<td>0</td>
</tr>
<tr>
<td>Monohydrate and dihydrate</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Monohydrate and solution</td>
<td>***</td>
<td>***</td>
<td>0</td>
</tr>
<tr>
<td>Dihydrate and solution</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

1 All U.S. producers reported that citric acid did not occur in dihydrate form.

Note.—A = Always, F = Frequently, S = Sometimes, N = Never. Answers from firms that are both producers and importers are included only with producers. Answers from firms that are both importers and purchasers are included with purchasers if they do not sell citric acid in the form in which they purchase it, otherwise they are included with importers.

Source: Compiled from data submitted in response to Commission questionnaires.

### Major Factors in Purchasing

Purchasers were asked to identify the three major factors considered by their firm in deciding from whom to purchase citric acid and certain citrate salts (table II-4). Quality was reported by the largest number of purchasers as the most important factor. Availability was reported by the largest number of firms as the second most important factor. Price was reported by the largest number of firms as the third most important factor, but was also the factor most reported as being in the top three factors. Other factors reported by more than one purchaser were approved supplier/traditional supplier/contract, consistency, reliability of supply or supplier, product meets specifications, delivery terms, service/technical support, and packaging.  

---

91 Purchasers were asked to report other factors beyond the top three that they considered in deciding from whom to purchase. One purchaser reported that U.S. producers would not sell to it because it was too small, one reported that consolidating purchases with those of other ingredients was a factor, and one reported that its purchases are influenced by ***.
Table II-4
Citric acid and certain citrate salts: Most important factors in selecting a supplier, as reported by purchasers

<table>
<thead>
<tr>
<th>Factor</th>
<th>Number one factor</th>
<th>Number two factor</th>
<th>Number three factor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality/(quality meets or exceeds standards)</td>
<td>33</td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td>Price</td>
<td>13</td>
<td>20</td>
<td>29</td>
</tr>
<tr>
<td>Approved supplier/traditional supplier/contract</td>
<td>10</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Availability</td>
<td>8</td>
<td>25</td>
<td>8</td>
</tr>
<tr>
<td>Consistency</td>
<td>1</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Product meets specifications</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Service/technical support</td>
<td>0</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Reliability of supply or supplier</td>
<td>0</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Delivery terms</td>
<td>0</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Packaging</td>
<td>0</td>
<td>0</td>
<td>2</td>
</tr>
<tr>
<td>Other2</td>
<td>2</td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

1 One firm reported both quality and consistency as most important factor, one firm reported both quality and service, and one reported both service and delivery terms as the second most important factor; all these responses are recorded.

2 “Other” includes performance and lead time as the first factor; distributorship as the second factor; and genetically modified organisms (“GMO”) and country as third factors.

Source: Compiled from data submitted in response to Commission questionnaires.

Factors Determining Quality

Purchasers were asked to identify the factors that determine the quality of citric acid and certain citrate salts. Purchasers reported specific factors including: meeting specifications such as FCC, USP, and kosher, and the paperwork to go with these standards or certificates of analysis; granulation characteristics such as free flowing, not caking, and granulation size; having product assayed for purity (lack of contamination with arsenic, oxalic acid, sulfates, mercury, calcium, iron, or chloride, or no residuals); physical characteristics such as appearance (color), flavor, and aroma; and other factors such as anhydrous; packaging; shelf life; solubility; supplier support; percent active; genetically modified organism (“GMO”); and product consistency.

Qualification

Purchasers were asked if they require their suppliers to be FCC and USP qualified and if so, for what share of their purchases this is required. Forty-eight of 69 responding purchasers reported that they required FCC and USP qualification for all of their purchases; 5 purchasers reported requiring FCC and USP qualification for 3 to 90 percent of their purchases; and 16 did not require FCC and USP qualification. **

Purchasers were asked if they required other qualifications from their suppliers and for which share of their purchases they were required. Thirty-three of 68 responding purchasers reported that they
required other qualification for all of their purchases and one reported additional qualifications for 10 percent of its purchases.\textsuperscript{92} Other factors considered in the qualification of a supplier included kosher certification, lab reviews, certificates of analysis, testing of samples, product meets customers’ specifications, qualified by customers, trial manufacturing, certificate of analysis, MSDS (material safety data sheet), nutritional information, allergen informant, and GMO.

Sixty-seven of the 69 responding purchasers reported some qualification of new suppliers, although one of these only required “price” for qualification. Time required for qualification was reported by 67 purchasers as ranging from 1 to 365 days, with 28 purchasers reporting times of less than 30 days, 26 reporting 30 to 60 days, and 13 over 60 days.\textsuperscript{***}

Seven purchasers,\textsuperscript{***}, reported that one or more domestic or foreign producers failed in their attempts to certify or qualify their citric acid and certain citrate salts or had lost their approved status since 2006. One reported that a U.S. producer had been disqualified because of granulation;\textsuperscript{93} three of these purchasers reported that Chinese firms had been disqualified for particle size, granulation, off-color product, inconsistent quality, and failing a quality audit; and four reported that product from Thailand had been disqualified, all for caking.

### Caking

Purchasers and importers were asked to report on the importance of caking, its impact on firms, and sources that supplied material which was caked. Twenty of 64 responding purchasers and 6 of 27 importers reported that caking was very important, 12 purchasers and 7 importers reported that it was somewhat important, and 32 purchasers and 14 importers reported that it was either not important or not a problem. Reasons given for why caking was a problem included that customers would not accept caked material, caked material does not flow properly, caked material has caused equipment to break, caking affects the weight of product and requires that formulas be reworked, caked product cannot be used in blending material, cannot be used in dry blends, and caked material takes longer to melt. Some firms reported that caking was not a problem because citric acid needed to be converted into liquid citric acid before use or because these firms converted caked material into liquid form.\textsuperscript{***}

Importers and purchasers were asked to report the frequency of caking of citric acid and certain citrate salts from different country sources. Responses are presented in the following tabulation.

<table>
<thead>
<tr>
<th>Source</th>
<th>Importers</th>
<th></th>
<th>Purchasers</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Frequently</td>
<td>Sometimes</td>
<td>Rarely</td>
<td>Never</td>
</tr>
<tr>
<td>U.S.</td>
<td>0</td>
<td>0</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td>Canada</td>
<td>0</td>
<td>0</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>China</td>
<td>1</td>
<td>5</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>Nonsubject countries</td>
<td>1</td>
<td>0</td>
<td>6</td>
<td>11</td>
</tr>
</tbody>
</table>

Both purchasers and importers agreed that caking in the U.S. and Canadian products tended to be similar and relatively uncommon; in contrast, product from China had more importers and purchasers reporting that there were at least sometimes problems with caking.

\textsuperscript{92} ***

\textsuperscript{93} This firm, ***, also rejected product from some Chinese producers.
Twenty-four purchasers and 13 importers reported that they had purchased caked material. Fourteen purchasers and 10 importers had taken measures to address caking. Six purchasers and seven importers reported that the cost of these measures was less than 1 percent of the cost of the citric acid, three purchasers reported that costs were 1 to 2 percent, four purchasers and two importers reported 2 to 5 percent, and three purchasers reported that these steps would cost 5 percent or more of the costs of citric acid and certain citrate salts.

Six purchasers and seven importers reported purchasing equipment or implementing a practice to reduce caking or clumping. ***. Other responses included not buying more material from sources providing caked material, returning caked material, not buying product manufactured from July through September, “solutionizing” equipment, and the special handling of caked material.

**Importance of 24 Specified Purchase Factors**

Purchasers were asked to rate the importance of 24 factors in their purchasing decisions (table II-5). Factors that were reported as “very important” by half or more of the responding firms were availability and availability as citric acid (64 firms), product consistency (62 firms), reliability of supply (61 firms), price (57 firms), availability as anhydrous form (54 firms), quality meets FCC/USP standards (52 firms), delivery time (42 firms), size of granulation (41 firms), and delivery terms and availability as sodium citrate (34 firms).

**Purchases from Specific Producers and Countries**

Purchasers were asked how frequently they and their customers were aware that the citric acid and certain citrate salts they purchased were produced in the United States or imported, and how frequently they knew the manufacturer. The following tabulation summarizes the responses.

<table>
<thead>
<tr>
<th>Purchaser/customer decision</th>
<th>Always</th>
<th>Usually</th>
<th>Sometimes</th>
<th>Never</th>
</tr>
</thead>
<tbody>
<tr>
<td>Purchaser aware of country of origin</td>
<td>54</td>
<td>11</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Purchaser aware of manufacturer</td>
<td>47</td>
<td>16</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Purchaser’s customer aware of country of origin</td>
<td>26</td>
<td>14</td>
<td>17</td>
<td>10</td>
</tr>
</tbody>
</table>

**Blending Product from Different Countries**

Most purchasers report that they did not blend citric acid and certain citrate salts from different countries, with 50 of 69 responding purchasers reporting that they never blended material from different sources. ***. Of the 26 responding distributors, only three reported blending material from different countries. ***. Blending of material from different sources by distributors was limited because of the importance of tracing material used in food.
### Table II-5
**Citric acid and certain citrate salts: Importance of purchase factors, as reported by purchasers**

<table>
<thead>
<tr>
<th>Factor</th>
<th>Very important</th>
<th>Somewhat important</th>
<th>Not important</th>
</tr>
</thead>
<tbody>
<tr>
<td>Availability</td>
<td>64</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Availability in anhydrous form</td>
<td>54</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>Availability as citric acid</td>
<td>64</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>Availability as potassium citrate</td>
<td>23</td>
<td>7</td>
<td>36</td>
</tr>
<tr>
<td>Availability as sodium citrate</td>
<td>34</td>
<td>11</td>
<td>22</td>
</tr>
<tr>
<td>Availability in dihydrate form</td>
<td>13</td>
<td>6</td>
<td>46</td>
</tr>
<tr>
<td>Availability in monohydrate form</td>
<td>5</td>
<td>10</td>
<td>51</td>
</tr>
<tr>
<td>Availability in solution/liquid form</td>
<td>12</td>
<td>10</td>
<td>44</td>
</tr>
<tr>
<td>Delivery terms</td>
<td>34</td>
<td>28</td>
<td>5</td>
</tr>
<tr>
<td>Delivery time</td>
<td>42</td>
<td>22</td>
<td>3</td>
</tr>
<tr>
<td>Discounts offered</td>
<td>19</td>
<td>24</td>
<td>23</td>
</tr>
<tr>
<td>Extension of credit</td>
<td>20</td>
<td>23</td>
<td>23</td>
</tr>
<tr>
<td>Genetically modified inputs</td>
<td>13</td>
<td>22</td>
<td>31</td>
</tr>
<tr>
<td>Minimum quantity requirements</td>
<td>12</td>
<td>27</td>
<td>28</td>
</tr>
<tr>
<td>Packaging</td>
<td>23</td>
<td>37</td>
<td>8</td>
</tr>
<tr>
<td>Price</td>
<td>57</td>
<td>11</td>
<td>0</td>
</tr>
<tr>
<td>Product consistency</td>
<td>62</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Product range</td>
<td>9</td>
<td>35</td>
<td>20</td>
</tr>
<tr>
<td>Quality meets FCC/USP standards</td>
<td>52</td>
<td>6</td>
<td>10</td>
</tr>
<tr>
<td>Quality exceeds FCC/USP standards</td>
<td>20</td>
<td>19</td>
<td>27</td>
</tr>
<tr>
<td>Reliability of supply</td>
<td>61</td>
<td>4</td>
<td>3</td>
</tr>
<tr>
<td>Size of granulation</td>
<td>41</td>
<td>21</td>
<td>6</td>
</tr>
<tr>
<td>Technical support</td>
<td>15</td>
<td>37</td>
<td>15</td>
</tr>
<tr>
<td>U.S. transportation costs</td>
<td>26</td>
<td>33</td>
<td>8</td>
</tr>
</tbody>
</table>

Note.—Not all companies gave responses for all factors.

Source: Compiled from data submitted in response to Commission questionnaires.

### Comparisons of Domestic Products and Subject Imports

Producers, importers, and purchasers were requested to provide information regarding the interchangeability of domestic, subject, and nonsubject citric acid and certain citrate salts and to discuss reasons for any opinions that the products were not interchangeable (table II-6). *** U.S. producers reported that product from each of the country pairs was always interchangeable. Most importers responded that citric acid and certain citrate salts from each of the different country sources were either always interchangeable or frequently interchangeable. Most purchasers reported that product from each of the country pairs was either always or frequently interchangeable. Reasons why product was not always interchangeable included: interchangeability differs between customers or by end use; products may behave differently based on the manufacturer and country of origin; only qualified product is interchangeable; Chinese product is not consistent; some food ingredient customers require that no ingredients originate in China; sometimes Chinese product is not as free-flowing/or cakes; Chinese
Table II-6
Citric acid and certain citrate salts: Perceived interchangeability between citric acid and certain citrate salts produced in the United States and in other countries, by country pairs

<table>
<thead>
<tr>
<th>Country pair</th>
<th>Number of U.S. producers reporting</th>
<th>Number of U.S. importers reporting</th>
<th>Number of U.S. purchasers reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A</td>
<td>F</td>
<td>S</td>
</tr>
<tr>
<td>U.S. vs. Canada</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>U.S. vs. China</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Canada vs. China</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>U.S. vs. nonsubject</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Canada vs. nonsubject</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>China vs. nonsubject</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
</tbody>
</table>

Note.—A = Always, F = Frequently, S = Sometimes, N = Never. Answers from firms that are both producers and importers are included only with producers. Answers from firms that are both importers and purchasers are included with purchasers if they do not sell citric acid in the form in which they purchase it, otherwise they are included with importers.

Source: Compiled from data submitted in response to Commission questionnaires.

product is not as readily accepted; some customers will use Chinese product if it is at a lower price but some will not use Chinese product; one customer is only completely happy with a specific granulation from one (Chinese) producer; and GMO requirements.

Producers, importers, and purchasers were requested to provide information regarding the significance of differences other than price for domestic, subject, and nonsubject citric acid and certain citrate salts (table II-7). *** responding U.S. producers reported that there were never differences other than price for all country pairs. The majority of importers in each case reported that there were at least sometimes differences other than price for each pair, except for China vs. nonsubject countries, where half of the responding importers reported there were never differences. Similarly, most purchasers reported there were at least sometimes differences between products from every country pair. U.S. product was reported to have better perceived quality, more uniform crystal size, less clumping, better documentation specifications sheets, kosher certification, and certification of analysis. With regard to Chinese product compared with U.S. product, the U.S. product was less available, Cargill was “sold out;” the Chinese service small distributors; purchasers may be reluctant to use Chinese material; Chinese product may not have been approved for use by purchasers; Chinese product has longer lead times; for Chinese product availability is an issue; and Chinese product clumps more in the summer. Differences between U.S. and Canadian citric acid and certain citrate salts included no distribution agreement with Canada and different logistics. Differences between Canadian and Chinese product include: Canadian product is available to cover the supply gaps if product from China is delayed; for Chinese product availability is an issue; and the lack of availability from Canada. In addition, one purchaser reported that its suppliers must fit its global strategy and one reported that Thailand was the only other source other than China with product available.
Table II-7
Citric acid and certain citrate salts: Perceived importance of differences in factors other than price between citric acid and certain citrate salts produced in the United States and in other countries in purchases of citric acid and certain citrate salts in the U.S. market, by country pairs

<table>
<thead>
<tr>
<th>Country pair</th>
<th>Number of U.S. producers reporting</th>
<th>Number of U.S. importers reporting</th>
<th>Number of U.S. purchasers reporting</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>A</td>
<td>F</td>
<td>S</td>
</tr>
<tr>
<td>U.S. vs. Canada</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>U.S. vs. China</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Canada vs. China</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>U.S. vs. nonsubject</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Canada vs. nonsubject</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>China vs. nonsubject</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
</tbody>
</table>

Note.--A = Always, F = Frequently, S = Sometimes, N = Never. Answers from firms that are both producers and importers are included only with producers. Answers from firms that are both importers and purchasers are included with purchasers if they do not sell citric acid in the form in which they purchase it, otherwise they are included with importers.

Source: Compiled from data submitted in response to Commission questionnaires.

Purchasers were also asked to compare domestically produced citric acid and certain citrate salts and those produced in subject and nonsubject countries, with respect to 24 different attributes (table II-8). Thirty-eight firms compared U.S. and Canadian product, although not for all factors. The majority of responding purchasers reported that these products were comparable for all factors except for availability in solution form, for which only a plurality reported they were comparable.

The majority of purchasers reported that U.S. and Chinese product were comparable for all factors except availability in solution/liquid form (where most reported that the U.S. product was superior); price (for which the majority of responding firms reported that the U.S. product was inferior, i.e., higher in price); delivery time (for which more firms found U.S. product to be superior than found U.S. and Chinese products to be comparable); and technical support (for which a plurality reported that U.S. and Chinese product were comparable but almost as many firms reported that the U.S. product was superior). Four purchasers compared Canadian and Chinese product. The majority of responding firms agreed that the products from Canada and China were comparable on seven factors: availability as citric acid, availability as potassium citrate, availability as sodium citrate, discounts offered, extension of credit, packaging, and size of granulation. The Canadian product was reported to be superior in terms of 11 factors: availability in liquid form, delivery terms, delivery time, minimum quantity requirements, product consistency, product range, quality meets FCC/USP standards, quality exceeds FCC/USP standards, reliability of supply, technical support, and U.S. transportation cost. Most responding firms reported that Canadian product was inferior in terms of availability in monohydrate form. Half the responding firms reported that Canadian product was superior for availability. Half also reported that Chinese product was superior on availability in anhydrous form. One firm reported that Canadian product was inferior and one reported that Canadian product was comparable to Chinese product in terms of availability in dihydrate form and availability of GMO product. For pricing, one firm each reported that Canadian product was superior, comparable, and inferior to Chinese product.
Table II-8
Citric acid and certain citrate salts: Comparisons of imported and U.S. product, as reported by purchasers

<table>
<thead>
<tr>
<th>Factor</th>
<th>U.S. vs. Canada</th>
<th>U.S. vs. China</th>
<th>Canada vs. China</th>
<th>U.S. vs. nonsubject</th>
<th>Canada vs. nonsubject</th>
<th>China vs. nonsubject</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>S C I</td>
<td>S C I</td>
<td>S C I</td>
<td>S C I</td>
<td>S C I</td>
<td>S C I</td>
</tr>
<tr>
<td>Availability</td>
<td>5 26 7</td>
<td>10 25 14</td>
<td>2 1 1</td>
<td>1 5 2</td>
<td>0 0 1</td>
<td>1 2 0</td>
</tr>
<tr>
<td>Availability in anhydrous form</td>
<td>4 28 6</td>
<td>2 39 7</td>
<td>1 1 2</td>
<td>1 5 1</td>
<td>0 0 1</td>
<td>1 2 0</td>
</tr>
<tr>
<td>Availability as citric acid</td>
<td>4 28 5</td>
<td>6 34 7</td>
<td>0 3 1</td>
<td>0 6 1</td>
<td>0 0 1</td>
<td>1 2 0</td>
</tr>
<tr>
<td>Availability as potassium citrate</td>
<td>5 21 2</td>
<td>6 26 3</td>
<td>0 1 0</td>
<td>1 4 1</td>
<td>0 0 0</td>
<td>0 1 1</td>
</tr>
<tr>
<td>Availability as sodium citrate</td>
<td>5 23 3</td>
<td>7 28 6</td>
<td>0 2 1</td>
<td>1 4 3</td>
<td>0 0 1</td>
<td>1 2 0</td>
</tr>
<tr>
<td>Availability in dihydrate form</td>
<td>2 17 2</td>
<td>3 19 3</td>
<td>0 1 1</td>
<td>1 2 1</td>
<td>0 0 1</td>
<td>1 1 0</td>
</tr>
<tr>
<td>Availability in monohydrate form</td>
<td>3 15 3</td>
<td>3 18 7</td>
<td>0 1 2</td>
<td>0 4 1</td>
<td>0 0 1</td>
<td>1 2 0</td>
</tr>
<tr>
<td>Availability in solution/liquid form</td>
<td>9 12 3</td>
<td>15 10 4</td>
<td>2 1 0</td>
<td>4 0 0</td>
<td>1 0 0</td>
<td>0 1 1</td>
</tr>
<tr>
<td>Delivery terms</td>
<td>6 29 1</td>
<td>15 29 2</td>
<td>3 1 0</td>
<td>2 6 0</td>
<td>0 1 0</td>
<td>0 2 1</td>
</tr>
<tr>
<td>Delivery time</td>
<td>9 26 1</td>
<td>23 22 4</td>
<td>3 0 0</td>
<td>5 4 0</td>
<td>1 0 0</td>
<td>0 2 1</td>
</tr>
<tr>
<td>Discounts offered</td>
<td>3 26 2</td>
<td>4 31 7</td>
<td>0 3 0</td>
<td>0 7 0</td>
<td>0 1 0</td>
<td>0 3 0</td>
</tr>
<tr>
<td>Extension of credit</td>
<td>4 24 3</td>
<td>9 28 3</td>
<td>1 2 0</td>
<td>1 6 0</td>
<td>0 1 0</td>
<td>0 3 0</td>
</tr>
<tr>
<td>Genetically modified inputs</td>
<td>2 23 2</td>
<td>2 24 9</td>
<td>0 1 1</td>
<td>0 2 2</td>
<td>0 0 0</td>
<td>0 2 0</td>
</tr>
<tr>
<td>Minimum quantity requirements</td>
<td>2 34 1</td>
<td>5 39 4</td>
<td>2 1 0</td>
<td>0 9 0</td>
<td>0 1 0</td>
<td>0 3 0</td>
</tr>
<tr>
<td>Packaging</td>
<td>2 36 0</td>
<td>5 43 0</td>
<td>0 4 0</td>
<td>1 7 0</td>
<td>0 1 0</td>
<td>0 3 0</td>
</tr>
<tr>
<td>Price</td>
<td>6 19 9</td>
<td>8 13 24</td>
<td>1 1 1</td>
<td>1 3 4</td>
<td>1 0 0</td>
<td>1 2 0</td>
</tr>
<tr>
<td>Product consistency</td>
<td>4 34 0</td>
<td>13 35 1</td>
<td>3 1 0</td>
<td>1 7 0</td>
<td>0 1 0</td>
<td>0 2 1</td>
</tr>
<tr>
<td>Product range</td>
<td>3 29 1</td>
<td>12 29 1</td>
<td>3 0 0</td>
<td>3 4 0</td>
<td>0 1 0</td>
<td>0 2 1</td>
</tr>
<tr>
<td>Quality meets FCC/USP standards</td>
<td>2 36 0</td>
<td>5 41 1</td>
<td>3 1 0</td>
<td>1 8 0</td>
<td>0 1 0</td>
<td>0 2 1</td>
</tr>
<tr>
<td>Quality exceeds FCC/USP standards</td>
<td>2 29 0</td>
<td>7 33 0</td>
<td>2 1 0</td>
<td>1 6 0</td>
<td>0 1 0</td>
<td>0 2 1</td>
</tr>
<tr>
<td>Reliability of supply</td>
<td>4 29 4</td>
<td>10 32 7</td>
<td>3 0 0</td>
<td>1 6 1</td>
<td>0 1 0</td>
<td>0 2 1</td>
</tr>
<tr>
<td>Size of granulation</td>
<td>3 35 0</td>
<td>6 41 1</td>
<td>1 2 0</td>
<td>1 7 1</td>
<td>0 1 0</td>
<td>0 2 1</td>
</tr>
<tr>
<td>Technical support</td>
<td>3 31 2</td>
<td>20 21 4</td>
<td>3 0 0</td>
<td>2 6 0</td>
<td>0 1 0</td>
<td>0 2 1</td>
</tr>
<tr>
<td>U.S. transportation costs</td>
<td>9 24 0</td>
<td>15 29 1</td>
<td>2 1 0</td>
<td>4 4 0</td>
<td>0 1 0</td>
<td>0 3 0</td>
</tr>
</tbody>
</table>

1 Some firms reported answers for multiple nonsubject countries.

2 A rating of superior means that the price or cost is generally lower. For example, if a firm reported “U.S. superior,” it meant that the price of the U.S. product was generally lower than the price of the imported product.

Note.—S=first listed country’s product is superior; C=both countries’ products are comparable; I=first listed country’s product is inferior. Not all firms gave responses for all factors.

Source: Compiled from data submitted in response to Commission questionnaires.
Nine purchasers compared U.S. product to nonsubject-country product. The majority of responding purchasers reported that these products were comparable for 17 of the 24 specified factors. For availability in solution/liquid form and delivery time, most responding purchasers reported that the U.S. product was superior. For price, half of the responding firms reported that U.S. product was inferior (i.e., higher in price); for availability as sodium citrate, availability in dihydrate form, genetically modified inputs, and U.S. transportation costs, half the firms reported that U.S. and nonsubject-country product were comparable.

One firm compared Canadian and nonsubject product, reporting that the products were comparable for 13 factors; Canadian product was superior for availability in solution/liquid form, delivery time, and price, and the Canadian product was inferior for availability, availability in anhydrous form, availability as citric acid, availability as sodium citrate, availability in dihydrate form, and availability in monohydrate form.

Three purchasers compared Chinese product with that from nonsubject countries for the 24 factors. For 21 factors, the majority of responding purchasers reported that products from China and nonsubject countries were comparable. For availability in dihydrate form, one firm each reported that the Chinese product was superior and comparable, and for availability in solution/liquid form and availability as potassium citrate, one each reported that the Chinese product was comparable and inferior.

Petitioners report that citric acid and certain citrate salts is a true commodity product and as such price is a paramount factor in sales negotiations. “The only real issue to work out in our annual negotiations with our customers is price.” Petitioners also report that all major world producers, including the Chinese, produce the same quality of citric acid.

JBL reported that it uses non-price factors in its sales, including premium product, the shortest lead time, dependable delivery, and customer service. These factors reportedly allow it to sell at premium prices. P&G and PepsiCo reported they must diversify their supply base to reduce the risk of plant disruptions. P&G reported non-price differences between the Canadian and Chinese product, the availability in solution form and shorter lead times which reduced possibility of delays, and the requirement to hold costly inventories. In addition, P&G contended that its delivered price for domestic product was lower than the price for imported product from both Canada and China. Reckitt Benckiser reported that it preferred purchasing domestic product for security and planning.

ELASTICITY ESTIMATES

This section discusses elasticity estimates. Elasticity estimates were provided in the prehearing report. The petitioners disagreed with the estimate of the elasticity of substitution in their prehearing and posthearing briefs. No other party provided any comments in its briefs.
U.S. Supply Elasticity\textsuperscript{101}

The domestic supply elasticity for citric acid and certain citrate salts measures the sensitivity of the quantity supplied by U.S. producers to changes in the U.S. market price of citric acid and certain citrate salts. The elasticity of domestic supply depends on factors such as the availability of inputs, the level of excess capacity, the level of inventories, and the availability of alternate markets for domestically produced citric acid and certain citrate salts. Analysis of these factors indicates that the U.S. industry has somewhat limited excess capacity, relatively low levels of inventories, and a moderate level of export shipments which could be used to increase domestic shipments in response to price increases. A supply elasticity in the range of 1 to 3 is suggested.

U.S. Demand Elasticity

The U.S. demand elasticity for citric acid and certain citrate salts measures the sensitivity of the overall quantity demanded to a change in the U.S. market price of citric acid and certain citrate salts. This sensitivity depends on the availability and viability of substitute products as well as on the component share of citric acid and certain citrate salts in the production of downstream products. Demand is estimated to be inelastic and is likely to be in the -0.2 to -0.7 range.

Substitution Elasticity

The elasticity of substitution depends on the extent of product differentiation between the domestic and imported products. Product differentiation depends on factors such as the range of products produced, quality, availability, and reliability of supply. In the prehearing report, the elasticity of substitution for imports from the subject countries was estimated to be in the range of 2 to 6, with the Chinese product more likely to be at the lower end of this range and the Canadian product at the higher end.

The petitioners report that in view of the price sensitivity of citric acid and the increases in the market share of the Chinese industry in both the U.S. and world markets, a substitution elasticity of 2 is too low. They report that the minimum elasticity of substitution for Chinese product should be at least 4. Petitioners also did not believe that the elasticities of substitution differ much between Chinese and Canadian product.\textsuperscript{102}

The petitioners’ estimates of elasticity of substitution are within those proposed by staff. They, however, propose interpreting the worldwide growth in Chinese sales as resulting mainly from price rather than any other reason. Staff continues believe that an estimate for the elasticity of substitution ranging between 2 to 6 percent is reasonable.

\textsuperscript{101} A supply function is not defined in the case of a non-competitive market.

\textsuperscript{102} Petitioners’ prehearing brief, exh. 20, p. 10 and petitioners’ posthearing brief, exh. 1, pp. 27-28.
PART III: U.S. PRODUCERS’ PRODUCTION, SHIPMENTS, AND EMPLOYMENT

Information presented in this section of the report is based on (except as noted) the questionnaire responses of three firms which accounted for all U.S. production of citric acid and certain citrate salts in 2008.

U.S. PRODUCERS

The Commission sent producer’s questionnaires to three firms identified in the petition as U.S. producers of citric acid and certain citrate salts. All three firms submitted responses. Table III-1 presents the list of U.S. producers with each company’s U.S. production location, share of U.S. production in 2008, and position on the petition.

Table III-1
Citric acid and certain citrate salts: U.S. producers, U.S. production locations, shares of U.S. production in 2008, and positions on the petition

<table>
<thead>
<tr>
<th>Firm</th>
<th>Production location</th>
<th>Share of production (percent)</th>
<th>Position on the petition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADM¹</td>
<td>Southport, NC</td>
<td>***</td>
<td>Petitioner</td>
</tr>
<tr>
<td>Cargill²</td>
<td>Eddyville, IA</td>
<td>***</td>
<td>Petitioner</td>
</tr>
<tr>
<td>Tate &amp; Lyle³</td>
<td>Decatur, IL</td>
<td>***</td>
<td>Petitioner</td>
</tr>
</tbody>
</table>

¹ ***.
² ***.
³ ***.

Source: Compiled from data submitted in response to Commission questionnaires.

---

¹ In the 2000 investigation, the Commission determined that U.S. firms that purchased citric acid and converted it into sodium citrate solution did not engage in sufficient production-related activities to warrant inclusion in the domestic industry, finding that conversion costs and technical expertise required in the conversion process were minimal. Citric Acid and Sodium Citrate From China, Inv. No. 731-TA-863 (Preliminary), USITC Publication 3277, February 2000, p. 8. In the preliminary phase of these investigations, petitioners contended that the nature of these converters has not changed since 2000, and that they should again be excluded from the domestic industry. Petitioners’ postconference brief, p. 5. No respondent advocated including converters in the domestic industry. Chinese respondents’ postconference brief, p. 6. The Commission did not revisit this issue in the preliminary phase of these investigations. Citric Acid and Certain Citrate Salts from Canada and China, Inv. Nos. 701-TA-456 and 731-TA-1151-1152 (Preliminary), USITC Publication 4008, June 2008, p. 12, fn. 74. Commission staff did not collect data regarding converting operations.
U.S. CAPACITY, PRODUCTION, AND CAPACITY UTILIZATION

Data on U.S. producers’ capacity, production, and capacity utilization are presented in table III-2. Total U.S. capacity remained steady from 2006 to 2008. U.S. capacity was equivalent to *** percent of apparent U.S. consumption of citric acid and certain citrate salts in 2008.2 Total U.S. production of the subject product increased by 6.8 percent from 2006 to 2008.3 Capacity utilization ranged from 85.8 percent in 2006 to 91.7 percent in 2008.4 None of the three U.S. producers reported any events that occurred during the period of investigation that would have materially affected their production or capacity.5 None of the three U.S. producers reported that they produced other products using the same manufacturing equipment and/or production employees that were used to produce citric acid and certain citrate salts.

Table III-2
Citric acid and certain citrate salts: U.S. producers’ capacity, production, and capacity utilization, 2006-2008

<table>
<thead>
<tr>
<th>Item</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADM</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Cargill</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Tate &amp; Lyle</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Total</td>
<td>553,913</td>
<td>553,913</td>
<td>553,913</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Item</th>
<th>Capacity utilization (percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADM</td>
<td>***</td>
</tr>
<tr>
<td>Cargill</td>
<td>***</td>
</tr>
<tr>
<td>Tate &amp; Lyle</td>
<td>***</td>
</tr>
<tr>
<td>Average</td>
<td>85.8</td>
</tr>
</tbody>
</table>

Source: Compiled from data submitted in response to Commission questionnaires.

---

2 A number of U.S. importers reported that after the imposition of preliminary duties on U.S. imports from China, they could no longer afford to import citric acid or citrate salts from China, but were also unable to acquire necessary volumes of product from U.S. producers. ***; see also Chinese respondents’ prehearing brief, pp. 11-12.

3 Both ADM and Cargill produced citric acid, sodium citrate, and potassium citrate during the period of investigation. Tate & Lyle produced only citric acid. ***.

4 ***.

5 ***. The petitioners described the episode as follows: ***. Petitioners claim that respondents are exaggerating the impact of this event on the ability of the U.S. industry to supply the market. Petitioners’ prehearing brief, pp. 18-19.
U.S. PRODUCERS' U.S. SHIPMENTS AND EXPORT SHIPMENTS

As detailed in table III-3, the volume of U.S. producers’ U.S. shipments of citric acid and certain citrate salts increased by 9.0 percent from 2006 to 2008.6 The value of U.S. shipments also increased by 30.1 percent during the same time period. ***. *** volumes that were transfers to related firms during the period of investigation. ***. *** reported export shipments ***. Export shipments from U.S. producers increased by 16.8 percent, by quantity, and 40.2 percent, by value, from 2006 to 2008.7 ***. *** reported export shipments to ***. *** reported export shipments to ***.

---

6 ***.

7 Petitioners project a *** in exports in 2009, with a shift of almost *** of their 2008 exports to the U.S. market in 2009. Petitioners’ posthearing brief, Responses to Questions from Commissioner Lane, p. 17.
# Table III-3

**Citric acid and certain citrate salts: U.S. producers' shipments, by types, 2006-2008**

<table>
<thead>
<tr>
<th>Item</th>
<th>Quantity (1,000 dry pounds)</th>
<th>Value ($1,000)</th>
<th>Unit value (per dry pound)</th>
<th>Share of shipment quantity (percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Commercial shipments</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Internal consumption</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Transfers to related firms</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
</tbody>
</table>

1. F.o.b. U.S. point of shipment.

Source: Compiled from data submitted in response to Commission questionnaires.
U.S. PRODUCERS’ IMPORTS AND PURCHASES OF IMPORTS

*** U.S. producers, ***, reported that it directly imported or purchased from U.S. importers citric acid or certain citrate salts from Canada or China during the period of investigation. Table III-4 presents *** direct imports of subject product from ***, its U.S. production, and the ratio of its U.S. imports to its U.S. production.8

Table III-4
Citric acid and certain citrate salts: U.S. producers’ subject imports and purchases of subject imports, 2006-2008

<table>
<thead>
<tr>
<th>Item</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inventories (1,000 dry pounds)</td>
<td>77,606</td>
<td>52,316</td>
<td>44,638</td>
</tr>
<tr>
<td>Ratio to production (percent)</td>
<td>16.3</td>
<td>10.7</td>
<td>8.8</td>
</tr>
<tr>
<td>Ratio to U.S. shipments (percent)</td>
<td>21.0</td>
<td>13.1</td>
<td>11.1</td>
</tr>
<tr>
<td>Ratio to total shipments (percent)</td>
<td>16.6</td>
<td>10.2</td>
<td>8.7</td>
</tr>
</tbody>
</table>

Source: Compiled from data submitted in response to Commission questionnaires.

U.S. PRODUCERS’ INVENTORIES

Data on end-of-period inventories of citric acid and certain citrate salts for the period of investigation are presented in table III-5.

Table III-5
Citric acid and certain citrate salts: U.S. producers’ end-of-period inventories, 2006-2008

<table>
<thead>
<tr>
<th>Item</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inventories (1,000 dry pounds)</td>
<td>77,606</td>
<td>52,316</td>
<td>44,638</td>
</tr>
<tr>
<td>Ratio to production (percent)</td>
<td>16.3</td>
<td>10.7</td>
<td>8.8</td>
</tr>
<tr>
<td>Ratio to U.S. shipments (percent)</td>
<td>21.0</td>
<td>13.1</td>
<td>11.1</td>
</tr>
<tr>
<td>Ratio to total shipments (percent)</td>
<td>16.6</td>
<td>10.2</td>
<td>8.7</td>
</tr>
</tbody>
</table>

Source: Compiled from data submitted in response to Commission questionnaires.

U.S. EMPLOYMENT, WAGES, AND PRODUCTIVITY

Data provided by U.S. producers on the number of production and related workers (“PRWs”) engaged in the production of citric acid and certain citrate salts, the total hours worked by such workers, and wages paid to such PRWs during the period for which data were collected in these investigations are presented in table III-6. From 2006 to 2008, the number of PRWs decreased by 4.6 percent,9 hours worked decreased by 4.5 percent, wages paid decreased by 4.0 percent, hourly wages increased by 0.5 percent, productivity increased by 11.8 percent, and unit labor costs decreased by 10.1 percent.

---

8 ***.
9 ***.
Table III-6
Citric acid and certain citrate salts: Average number of production and related workers producing citric acid and certain citrate salts, hours worked, hours worked per worker, wages paid to such employees, and hourly wages, productivity, and unit labor costs, 2006-2008

<table>
<thead>
<tr>
<th>Item</th>
<th>Calendar year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2006</td>
</tr>
<tr>
<td>PRWs (number)</td>
<td>306</td>
</tr>
<tr>
<td>Hours worked (1,000)</td>
<td>701</td>
</tr>
<tr>
<td>Hours worked per worker</td>
<td>2,291</td>
</tr>
<tr>
<td>Wages paid ($1,000)</td>
<td>22,656</td>
</tr>
<tr>
<td>Hourly wages</td>
<td>$32.34</td>
</tr>
<tr>
<td>Productivity (pounds per hour)</td>
<td>678.6</td>
</tr>
<tr>
<td>Unit labor costs (per pound)</td>
<td>$0.05</td>
</tr>
</tbody>
</table>

Source: Compiled from data submitted in response to Commission questionnaires.
PART IV: U.S. IMPORTS, APPARENT CONSUMPTION, AND MARKET SHARES

U.S. IMPORTERS

The Commission sent importer questionnaires to 158 firms believed to be U.S. importers or U.S. purchasers of citric acid and certain citrate salts, as well as to all three U.S. producers.1 Usable questionnaire responses were received from 31 firms, which accounted for 100 percent of U.S. imports from Canada, 86.5 percent of U.S. imports from China, and 55.9 percent of U.S. imports from nonsubject countries in 2008.2 Data for U.S. imports from Canada are compiled using the reported U.S. imports of Jungbunzlauer Technology GmbH & Co. (“JBL”), the U.S. importer of Canadian product which accounted for *** U.S. imports from Canada, ***.3 Data for U.S. imports from China and nonsubject countries are compiled using official Commerce statistics.4

Table IV-1 lists all responding U.S. importers of citric acid and certain citrate salts from Canada and China, their U.S. locations, and their quantities of imports, by source, in 2008.

Table IV-1
Citric acid and certain citrate salts: Reported U.S. imports, by importers and by sources of imports, 2008

| U.S. IMPORTS |
| * | * | * | * | * | * | * | * |

1 The Commission sent questionnaires to those firms identified in the petition, along with firms that, based on a review of data provided by U.S. Customs and Border Protection (“Customs”), may have imported citric acid or certain citrate salts since 2006. The Commission also identified potential U.S. importers or purchasers from U.S. customer lists provided by questionnaire respondents in the preliminary phase of these investigations.

2 In addition to the 30 usable responses (those respondents are shown in Table IV-1), the Commission received responses from *** indicating that they did not import citric acid or certain citrate salts during the period of investigation. A number of the firms listed above are purchasers of the subject product and did submit U.S. purchasers’ questionnaires.

3 ***.

4 Data for U.S. imports from China and nonsubject imports are compiled using HTS subheadings 2918.14.00 (citric acid), 2918.15.10 (sodium citrate), and 2918.15.50 (potassium citrate). During the preliminary phase of these investigations, petitioners stated that they were unaware of any U.S. imports of blends of citric acid or crude calcium citrate during the period of investigation. See Citric Acid and Certain Citrate Salts from Canada and China, Inv. nos. 701-TA-456 and 731-TA-1151-1152 (Preliminary), USITC Publication 4008, June 2008, p. 13, fn. 79.

U.S. imports from China and nonsubject countries may be somewhat overstated on a dry-weight basis. A small volume (approximately 7 percent) of such imports consist of citric acid in the monohydrate form, which contains only approximately 92 percent of citric acid by weight.
Table IV-2  
Citric acid and certain citrate salts: U.S. imports, by sources, 2006-2008

<table>
<thead>
<tr>
<th>Source</th>
<th>Calendar year</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2006</td>
<td>2007</td>
<td>2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Quantity (1,000 dry pounds)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>China</td>
<td>158,906</td>
<td>180,108</td>
<td>193,727</td>
<td></td>
</tr>
<tr>
<td>Subtotal</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>All others</td>
<td>68,584</td>
<td>65,634</td>
<td>55,594</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td></td>
<td>Value ($1,000)(^1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>China</td>
<td>65,542</td>
<td>76,571</td>
<td>118,342</td>
<td></td>
</tr>
<tr>
<td>Subtotal</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>All others</td>
<td>39,174</td>
<td>38,802</td>
<td>41,058</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td></td>
<td>Unit value (per dry pound)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>$***</td>
<td>$***</td>
<td>$***</td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>0.41</td>
<td>0.43</td>
<td>0.61</td>
<td></td>
</tr>
<tr>
<td>Average</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>All others</td>
<td>0.57</td>
<td>0.59</td>
<td>0.74</td>
<td></td>
</tr>
<tr>
<td>Average</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>Share of quantity (percent)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>Subtotal</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>All others</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td></td>
</tr>
<tr>
<td>Share of value (percent)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>China</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>Subtotal</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>All others</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>100.0</td>
<td>100.0</td>
<td>100.0</td>
<td></td>
</tr>
</tbody>
</table>

\(^1\) Landed, duty-paid.

Source: U.S. imports from Canada are compiled from U.S. importer questionnaires. U.S. imports from China and nonsubject countries are compiled from official Commerce statistics.
CUMULATION CONSIDERATIONS

Petitioners argued that the Commission should cumulate U.S. imports from Canada and China. JBL Canada urged the Commission not to cumulate these imports. The Commission preliminarily determined that there was a reasonable overlap of competition among subject imports and the domestic like product, and therefore, cumulatively assessed the volume and price effects of Canada and China. In the final phase of these investigations, Chinese respondents state that they believe there is no grounds to reverse the Commission’s preliminary findings with regard to cumulation.

In assessing whether imports should be cumulated, the Commission determines whether U.S. imports from the subject countries compete with each other and with the domestic like product and has generally considered four factors: (1) fungibility, (2) presence of sales or offers to sell in the same geographical market, (3) common or similar channels of distribution, and (4) simultaneous presence in the market. Issues concerning channels of distribution are addressed in Part II of this report. The remaining factors are addressed below.

Fungibility

Petitioners argued that citric acid and certain citrate salts whether originating from Canada, China, or the United States are a very fungible, commodity product produced to the same grades and standards. JBL Canada argued that U.S. imports from Canada are not fungible with those from China because despite being a commodity product, certain characteristics prevented the two products from actually being interchangeable in various end use market segments in the United States. Among these characteristics, JBL Canada cited the fact that the proximity of its production facility to the United States allowed it to ship citric acid in solution form with short lead times to large customers such as P&G, which uses citric acid solution in its production of detergents. JBL reported that in 2008, *** percent of its U.S. imports were in solution form while *** percent were in anhydrous form. *** U.S. importer reported importing subject product in solution form from China. U.S. producers reported that in 2008, *** percent of their U.S. commercial shipments consisted of anhydrous and dihydrate citric acid or citrate salts while *** percent of 2008 commercial shipments consisted of citric acid in solution form.

---

5 Petitioners’ prehearing brief, pp. 6-10; Petitioners posthearing brief, exh. 1, p. 19.
6 JBL Canada’s prehearing brief, pp. 19-30; JBL Canada’s posthearing brief, p. 7 (addressing cumulation in the context of the Commission’s threat of material injury analysis).
8 Chinese respondents’ posthearing brief, app. A, pp. 24-25 (addressing cumulation in the context of the Commission’s threat of material injury analysis). In the preliminary phase of these investigations, Chinese respondents argued that the Commission should not cumulate U.S. imports from Canada and China. Chinese respondents’ postconference brief, p. 6.
9 Petitioners’ prehearing brief, pp. 6-10.
10 JBL Canada’s prehearing brief, pp. 19-30.
11 A direct rail line between JBL’s production facility and P&G’s production facilities in Lima, OH and Alexandria, LA, allows JBL to economically ship citric acid in solution form. P&G claims that shipping citric acid in solution form from China would be economically unfeasible due to high transportation costs. P&G’s prehearing brief, p. 70. P&G stated that it also purchases and uses citric acid in monohydrate and anhydrous forms in the production of its detergents; however, it must first convert them to solutions, requiring additional time and cost. Conference transcript, p. 103 (Smith).
12 ***.

IV-3
JBL Canada claimed that its product did not compete with U.S. imports from China because its products are perceived in the U.S. market as a “premium product” in terms of purity, color, grade, and customer and technical assistance relative to the Chinese product and, unlike product from China, Canadian product is currently *** in the U.S. food and beverage market, especially ***, as opposed to the U.S. industrial market where *** of the Chinese product is used.13

P&G argued that U.S. imports from Canada and China are not fungible because a number of end users prefer Chinese product as it is produced with non-genetically modified (“GMO”) corn whereas U.S. and Canadian product are made with GMO corn.14 Petitioner and Canadian respondent estimate that approximately *** percent of the U.S. citric acid market is non-GMO citric acid.15

Chinese respondents argued that U.S. imports from China, although not entirely excluded from the large U.S. food and beverage market, are effectively excluded from the large U.S. soft drink market because product shipped from China in anhydrous (dry powder) form will generally “cake” by the time it reaches the U.S. market as a result of the moisture it absorbs from its trans-Pacific shipping.16 PepsiCo stated that ***.17 A number of U.S. purchasers of citric acid and certain citrate salts have reported “caking” issues with Chinese products.18 There was no reported caking of U.S.-produced citric acid or citric acid imported from Canada (*** percent of which was shipped in solution form in 2008).

In the preliminary phase of these investigations, the Commission determined that there was sufficient fungibility among the products to cumulate, stating “although there are some differences in terms of chemical and physical forms and grades sold by domestic, Canadian, and Chinese producers in the U.S. market, there is also at least some overlap, particularly for anhydrous citric acid. Moreover, all three sources competed for sales of food, beverage, pharmaceutical, and industrial-grade products in the U.S. market during the period of investigation (including for soft drink applications).”19

### End-Use Market Segments

Table IV-3 shows estimated 2008 U.S. shipment data grouped by end-use market segment. The domestic industry reported that *** percent of its U.S. shipments in 2008 were estimated to be used in the food and beverage market segment (*** percent for the soft drink sub-segment), *** percent to the

---

13 JBL Canada’s prehearing brief, pp. 21-23. Both citric acid from Canada and China generally meet the FCC/USP standards; however, JBL argued that its consistency both in quality product and customer service make its “brand” a premium one. See also Conference transcript, p. 124 (Waite). Petitioners argue that reported pricing data and purchaser perceptions of Canadian product undermine Canadian respondent’s claim of a premium “brand” product. Petitioners’ prehearing brief, p. 16.

14 P&G’s prehearing brief, pp. 68-69.

15 Petitioners’ posthearing brief, exh. 1, p. 26; JBL’s posthearing brief, exh. 8, p. 1. JBL estimates that *** to *** percent of the global market for citric acid is for non-GMO citric acid. Ibid.

16 Chinese respondents’ postconference brief, pp. 9-10. See also Chinese respondents’ prehearing brief, pp. 28-29. Asked at the preliminary conference, a witness for Chinese respondents had no knowledge of any shipping methods that would prevent the caking of anhydrous citric acid. Conference transcript, p. 132 (Hsu). Petitioners argued that the caking issue was being greatly exaggerated by respondents and would not occur with proper packaging, such as packing at correct temperatures and moisture levels into bags with proper moisture barriers. Petitioners’ postconference brief, exh. 1, p. 23 & exh. 13 (statement of L. Martin Hurt, Senior Product Manager, Tate & Lyle); Petitioners’ prehearing brief, p. 9 (“caking is not a common occurrence”).

17 PepsiCo’s prehearing brief, pp. 12-13. PepsiCo reported that ***. Ibid.

18 For an extensive discussion of U.S. purchasers reported experiences with “caking,” please see the section entitled “Caking” in Part II of this report.

industrial segment, *** percent to the pharmaceutical segment, and *** percent were unknown or were
sold to general distributors. For U.S. shipments of imports from Canada, *** percent were estimated to
be used in the food and beverage segment (*** percent for the soft drink sub-segment), *** percent to the
industrial segment, *** percent to the pharmaceutical segment, and *** percent were unknown or were
sold to general distributors. For U.S. shipments of imports from China, *** percent were estimated to be
used in the food and beverage segment, (*** percent for the soft drink sub-segment), *** percent to the
industrial segment. *** percent to the pharmaceutical segment, and *** percent were unknown or were
sold to general distributors.

Table IV-3
Citric acid and certain citrate salts: Estimated 2008 U.S. commercial shipments, by end-use
market segment, and by firm

* * * * * * * *

Geographical Markets

With regard to geographical market overlap, U.S. imports of citric acid and certain citrate salts
from China entered multiple U.S. ports of entry, dispersed across the nation. The five U.S. ports of entry
with the most volume were: (1) Los Angeles, CA; (2) New Orleans, LA; (3) Chicago, IL; (4) San
Francisco, CA; and (5) New York, NY. Petitioners argue that the Chinese product is available
nationwide.20

U.S. imports of citric acid and certain citrate salts from Canada generally enter the United States
through one of two ports of entry, namely Buffalo, NY or Detroit, MI, because of their proximity to JBL
Canada’s manufacturing facility in Port Colborne, Ontario. During the preliminary phase of these
investigations, petitioners and respondent JBL Canada both observed that although product from Canada
enters through two U.S. ports of entry, when transported by freight or rail, it competes nationwide with
U.S. and Chinese product.21

Simultaneous Presence in the Market

With regard to simultaneous presence in the market, petitioners state that imported citric acid and
certain citrate salts from both Canada and China have been simultaneously present in the U.S. market
along with domestic product during the period of investigation.22 The Canadian respondent stated that
Canadian and Chinese product are not simultaneously present in the same markets because the use of each
product in different market segments (by end use and customer type) attenuates competition between
product from Canada and product from China.23 Commerce statistics and pricing data submitted to the
Commission show that imports from Canada and China entered the United States in every month of the
period of investigation.

---

20 Petitioners’ postconference brief, exh. 15 and p. 12.
21 Ibid.; Respondent JBL’s postconference brief, p. 11. There is a direct rail line between JBL Canada’s
production facility and P&G’s production facilities in Lima, OH and Alexandria, LA. Respondent P&G’s
postconference brief, p. 28.
22 Petitioners’ prehearing brief, p. 10.
23 JBL’s prehearing brief, p. 25; JBL’s posthearing brief, p. 9.
NEGLIGIBILITY

The Tariff Act of 1930 provides for the termination of an investigation if imports of the subject product from a country are less than 3 percent of total imports, or, if there is more than one such country, their combined share is less than or equal to 7 percent of total imports, during the most recent 12 months for which data are available preceding the filing of the petition.\textsuperscript{24} The shares (in percent) of the total quantity of U.S. imports from Canada and China for the period of January 2007 through December 2007 using U.S. import data compiled from the Commission’s questionnaire responses (in the case of U.S. imports from Canada) and data compiled from Commerce statistics (in the case of China and nonsubject countries) were *** percent and *** percent, for Canada and China, respectively, well above the 3 percent negligibility threshold.

APPARENT U.S. CONSUMPTION

Data on apparent U.S. consumption of citric acid and certain citrate salts are presented in table IV-4. The quantity of apparent U.S. consumption of the subject product increased by *** percent from 2006 to 2008. The value of apparent U.S. consumption increased by *** percent during the same period.

<table>
<thead>
<tr>
<th>Item</th>
<th>Calendar year</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2006</td>
<td>2007</td>
<td>2008</td>
</tr>
<tr>
<td><strong>Quantity (1,000 dry pounds)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. producers’ U.S. shipments</td>
<td></td>
<td>369,451</td>
<td>399,578</td>
<td>402,518</td>
</tr>
<tr>
<td>U.S. imports from--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>China</td>
<td></td>
<td>158,906</td>
<td>180,108</td>
<td>193,727</td>
</tr>
<tr>
<td>Subtotal</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>All other countries</td>
<td></td>
<td>68,584</td>
<td>65,634</td>
<td>55,594</td>
</tr>
<tr>
<td>Total imports</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apparent U.S. consumption</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td><strong>Value ($1,000)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>U.S. producers’ U.S. shipments</td>
<td></td>
<td>165,013</td>
<td>180,132</td>
<td>214,641</td>
</tr>
<tr>
<td>U.S. imports from--</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>China</td>
<td></td>
<td>65,542</td>
<td>76,571</td>
<td>118,342</td>
</tr>
<tr>
<td>Subtotal</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>All other countries</td>
<td></td>
<td>39,174</td>
<td>38,802</td>
<td>41,058</td>
</tr>
<tr>
<td>Total imports</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apparent U.S. consumption</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
</tbody>
</table>

Note.–U.S. import data are on a landed, duty-paid basis, whereas U.S. producers’ shipments consist of U.S. producers’ f.o.b. shipments to their customers. Accordingly, the two sets of data are for different levels of trade.

Source: Data regarding the U.S. industry are compiled from data submitted in response to Commission questionnaires. U.S. imports from Canada are compiled from U.S. importer questionnaires. U.S. imports from China and nonsubject countries are compiled from official Commerce statistics.
U.S. MARKET SHARES

Data on U.S. market shares for citric acid and certain citrate salts are presented in table IV-5. From 2006 to 2008, U.S. producers lost *** percentage points of market share based on quantity and *** percentage points based on value. U.S. imports from Canada gained *** percentage points of U.S. market share from 2006 to 2008, based on quantity, and *** percentage points based on value. U.S. imports from China gained *** percentage points of U.S. market share from 2006 to 2008, based on quantity, and *** percentage points based on value. From 2006 to 2008, U.S. imports from nonsubject countries lost *** percentage points of U.S. market share based on quantity and *** percentage points based on value.

Table IV-5
Citric acid and certain citrate salts: Apparent U.S. consumption and market shares, 2006-2008

<table>
<thead>
<tr>
<th>Item</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. production</td>
<td>475,428</td>
<td>488,403</td>
<td>507,917</td>
</tr>
<tr>
<td>U.S. imports from--</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>China</td>
<td>158,906</td>
<td>180,108</td>
<td>193,727</td>
</tr>
<tr>
<td>Subtotal</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>All other countries</td>
<td>68,584</td>
<td>65,634</td>
<td>55,594</td>
</tr>
<tr>
<td>Total imports</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
</tbody>
</table>

Data on the ratio of imports to U.S. production of citric acid and certain citrate salts are presented in table IV-6.

Table IV-6
Citric acid and certain citrate salts: U.S. production, U.S. imports, and ratios of imports to production, 2006-2008

<table>
<thead>
<tr>
<th>Item</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. imports from--</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>China</td>
<td>33.4</td>
<td>36.9</td>
<td>38.1</td>
</tr>
<tr>
<td>Subtotal</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>All other countries</td>
<td>14.4</td>
<td>13.4</td>
<td>10.9</td>
</tr>
<tr>
<td>Total imports</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
</tbody>
</table>

Ratio of imports to U.S. production (percent)

Source: Data regarding the U.S. industry are compiled from data submitted in response to Commission questionnaires. U.S. imports from Canada are compiled from U.S. importer questionnaires. U.S. imports from China and nonsubject countries are compiled from official Commerce statistics.
PART V: PRICING AND RELATED INFORMATION

FACTORs AFFECTING PRICES

Raw Material Costs

The principal raw materials used for producing citric acid and certain citrate salts are the “substrate” (a starch or sugary base that ferments into citric acid) and energy. The costs of both substrates and energy generally rose since January 2006 but declined since mid-2008. U.S. producers hedge corn prices to some degree.\(^1\) The prices of electric power generation, transmission, and distribution rose by 10.6 percent from January 2006 to December 2008.\(^2\)

U.S. and Canadian producers use corn (and sometimes other feedstocks such as molasses) as the substrate. Chinese producers, on the other hand, use a variety of bases including sweet potato powder, tapioca, wheat, and corn.\(^3\) U.S. corn prices are shown in figure V-1.

Figure V-1
U.S. corn prices: Monthly price of No. 2 yellow corn in Central Illinois, January 2006 through December 2008


Thirty-two of 64 responding purchasers, including ***, reported that the spike in the corn price had not affected the price of citric acid and certain citrate salts. ***.

---

\(^1\) *** U.S. producers reported that they had hedged against changes in the price of corn since 2006. ***. Only one of the 28 responding importers, ***, reported hedging.

\(^2\) See Bureau of Labor Statistics Producer Price Index PCU2211--2211--, “Electric power generation, transmission, and distribution.”

\(^3\) Petition, p. 10.
The only importer that reported using corn futures prices reported that the Chinese supplier will pass the corn price increase on to the importer. Sixteen of 62 responding purchasers reported that negotiations of contract prices are affected by the price of corn futures. The most common reason given by these purchasers was that higher corn future prices reflected higher future costs for the producers of citric acid and certain citrate salts.

Petitioners report that their contracts did not include price escalator clauses during the 2006 to 2008 period; however, ***. Petitioners assert that until 2007, when prices increased dramatically, the lack of escalators was not a problem.

Transportation Costs to the U.S. Market

Transportation costs for citric acid and certain citrate salts from Canada to the United States (excluding U.S. inland costs) are estimated to be approximately 4.0 percent of the total cost for citric acid and certain citrate salts. For China, transportation costs for citric acid and certain citrate salts are estimated to be approximately 13.0 percent of the total cost for citric acid and certain citrate salts. These estimates are derived from official import data and represent the transportation and other charges on imports valued on a c.i.f. basis, as compared with customs value.

U.S. Inland Transportation Costs

Among U.S. producers, U.S. inland transportation costs ranged from *** to *** percent. *** U.S. producers reported that they arrange transportation for their customers. U.S. producers reported that between *** and *** percent of their sales were to customers located between 100 and 1,000 miles of their production facilities; *** to *** percent were more than 1,000 miles from their production facilities, and *** to *** percent of their sales were within 100 miles of their production facilities.

Eighteen of the 20 responding importers indicated that U.S. inland transportation costs ranged between 1 to 10 percent. Twenty-three of the 26 responding importers reported that they arranged transportation for their customers, while three reported that their customers arrange transportation. Thirteen of the 24 responding importers reported selling half or more of their product between 0 and 100 miles from their U.S. points of shipment, 11 reported selling half or more of their product between 101 and 1,000 miles from their U.S. points of shipment, and one reported selling most of their product over 1,000 miles from its U.S. point of shipment.

Exchange Rates

The nominal and real values of the Canadian dollar and the nominal value of the Chinese yuan relative to the U.S. dollar are presented in figure V-2.

---

4 The only importer that reported using corn futures prices reported that the Chinese supplier will pass the corn price increase on to the importer.

5 Petitioners’ posthearing brief, exh. 2, pp. 18-19.

6 *** submitted both producers’ and importers’ questionnaires in these investigations. For purposes of this chapter, their answers (with the exception of pricing data and lost sales/lost revenues allegations) were the same for both questionnaires submitted by their firm. Thus, in this chapter, their responses have been counted only among producers.

7 The remaining two reporting shipping costs reported that transportation costs were 15 and 64 percent of total costs.
Figure V-2
Exchange rates: Indices of the nominal and real exchange rates, where available, between the currencies of Canada and China and the U.S. dollar, by quarters, January 2006-December 2008

PRICING PRACTICES

Pricing Methods

Citric acid is sold dry in powder, fine granulated, and granulated forms. ***(8 As a liquid, citric acid can be sold in an industrial grade that is 50 percent citric acid and 50 percent water, with the price usually being about 50 percent of the equivalent dry price. ***(9 Similarly, anhydrous material costs about 9 percent less than monohydrate due to the presence of 9 percent more water in the monohydrate version. ***(10

Price Determination

Among producers, *** reported using customer-by-customer negotiations to determine price, while *** reported determining price by “what the market will bear.” *** reported using price lists for their sales of citric acid and certain citrate salts. Similarly, importers reported using a variety of methods including transaction-by-transaction negotiations and contracts for multiple shipments. Six importers reported using a cost-plus method, adding profits of 3 to 10 percent to costs to determine the price. Three other importers reported basing prices on what competitors were charging or what the market would bear. Among importers, only *** reported using a price list. ***(11

Purchasers were asked if contract negotiations differed between suppliers of U.S. citric acid and certain citrate salts and suppliers of citric acid and certain citrate salts from other countries. No purchaser reported that negotiations differed between U.S. and Canadian suppliers, seven firms reported that negotiations differed between the U.S. and Chinese suppliers, and four firms reported that negotiations differed between the U.S. and nonsubject suppliers. Differences reported by the purchasers included: U.S. producers honor their obligations whereas Chinese suppliers are less likely to do so; U.S. producers tend to have a set price for distributors and usually give notice on price increases, while Chinese and nonsubject suppliers change prices order-to-order without notice; Chinese sales are volume and relationship driven while domestic prices are based on market conditions and return on investment; domestic suppliers typically give a general distribution price or a price determined by competitive activity at their customers’ level and agree to supply a certain volume, whereas Chinese and nonsubject suppliers just quote a price; U.S. producers prefer annual negotiations with “take it or leave it” prices, while Chinese firms’ prices are subject to re-negotiation; U.S. product is sold on contracts while Chinese product is sold in spot sales; Chinese and other suppliers are more apt than U.S. producers to negotiate spot sales; and the Canadian supplier “prefers annual bids but will not typically firm a price all year.” ***(12

Long-Term Contracts

Most contracts are annual and U.S. producers report that in this industry 12-month contracts are considered to be long-term. *** U.S. producers, all 10 responding importers, and all 39 responding

---

**(8 Conference transcript, pp. 103-104 (Smith). P&G reported that sales of liquid citric acid can reduce production costs by eliminating the need to fully dry the product and by making solution from output that does not meet industry standards for particle sizes. This enables producers to dry batches faster in spite of the increased amount of non-standard sized material this creates. Hearing transcript, pp. 178-179 (Smith).

**(9 Staff conversation with ***, and petition, p. 9.

**(10 Staff conversation with ***, and petition, p. 9.

**(11 JBL *** contends that it is not true for ***. JBL’s prehearing brief, p. 10.
purchasers reported that their typical long-term contracts were 12 months in duration. *** and four purchasers, including ***, reported contracts that were longer than one year in duration.13

Cargill reported selling *** percent of its citric acid and certain citrate salts on long-term contracts, Tate & Lyle *** percent, and ADM *** percent on long-term contracts. JBL reported selling *** percent of its Canadian product using long-term contracts. Seven importers of Chinese product reported using long-term contracts; five of these reported selling half or more of their product using long-term contracts. Most sales of the citric acid pricing products were contract sales. U.S. sales of these products were contract sales for over 99 percent of the quantity of these products sold, while Canadian spot sales of these products were *** percent of its sales, the Chinese products were almost 40 percent spot sales, and nonsubject product was all sold in spot sales, as shown in the following tabulation (in percent).14

<table>
<thead>
<tr>
<th>Type of purchaser</th>
<th>Type of sales</th>
<th>U.S.</th>
<th>Canada</th>
<th>China</th>
<th>Nonssubject</th>
</tr>
</thead>
<tbody>
<tr>
<td>End users</td>
<td>Contract</td>
<td>94.6</td>
<td>***</td>
<td>60.4</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>Spot</td>
<td>0.3</td>
<td>***</td>
<td>25.6</td>
<td>7.1</td>
</tr>
<tr>
<td>Distributors</td>
<td>Contract</td>
<td>4.4</td>
<td>***</td>
<td>1.6</td>
<td>0.0</td>
</tr>
<tr>
<td></td>
<td>Spot</td>
<td>0.6</td>
<td>***</td>
<td>12.4</td>
<td>92.9</td>
</tr>
</tbody>
</table>

For long-term contracts, ***, 9 of the 10 responding importers, and 26 of 37 responding purchasers reported that prices could not be renegotiated during the contract. ***. ***. Purchasers typically report that the terms for these contracts tended to be either set through negotiations or follow “industry standards.”

***, 8 importers, and 28 of the responding purchasers reported that long-term contracts fix both price and quantity. ***, two importers, and 10 purchasers reported that long-term contracts fix price but not quantity. Two purchasers, but no importers or producers, reported that long-term contracts only fix quantity. ***.

*** U.S. producers, 8 of 10 responding importers, and 24 of 40 responding purchasers reported that long-term contracts do not have meet-or-release provisions. ***. Only one purchaser, ***, reported using its meet-or-release provision.

*** responding U.S. producers and importers reported that the vast majority of their long-term contracts were with end users. For producer *** of sales. All nine responding importers reported that their long-term contracts accounted for between 85 and 100 percent of their sales. The most commonly reported industries purchasing citric acid and certain citrate salts via long-term contracts include: beverages (reported by *** producers and eight importers); food (*** producers and eight importers); and industrial (*** producers and three importers).

Producers and importers that sold on a contract basis were asked if the presence of product or bids from various sources of supply at the time of contract negotiations was a “very important,” “somewhat important,” or “not important” factor in price, and if this presence caused prices to increase, decrease, or not to change (table V-1).15

---

13 Some purchasers reported that long-term contracts ranged from 12 months to as long as 3 years. For example, Vertellus reported a two-year contract with Tate and Lyle. Hearing transcript, p. 199 (Pensak). Questionnaire responses show annual price negotiations in these multi-year contracts. ***.

14 Pricing data for citrate salts by spot and contract were not reported separately.
Table V-1  
Citric acid and certain citrate salts: Number of producers and importers reporting the impact of contract prices from different sources by the importance they place on the presence of product from these sources

<table>
<thead>
<tr>
<th>Importance on prices</th>
<th>U.S. producers</th>
<th>Importers</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Up</td>
<td>Neutral</td>
<td>Down</td>
</tr>
<tr>
<td>Presence of U.S. product</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not important</td>
<td>0</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Somewhat important</td>
<td>0</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Very important</td>
<td>0</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Presence of Canadian product</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not important</td>
<td>0</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Somewhat important</td>
<td>0</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Very important</td>
<td>0</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Presence of Chinese product</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not important</td>
<td>0</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Somewhat important</td>
<td>0</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Very important</td>
<td>0</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Presence of nonsubject product</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not important</td>
<td>0</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Somewhat important</td>
<td>0</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Very important</td>
<td>0</td>
<td>***</td>
<td>***</td>
</tr>
</tbody>
</table>

Source: Compiled from data submitted in response to Commission questionnaires.

Purchasers were asked their opinion of the impact on price that the existence of other sellers in the market has at the time of their contract negotiations (table V-2). Most purchasers reported that the availability of Chinese and nonsubject product tends to reduce prices, while most reported that the availability of Canadian product had no impact on price. Purchasers were more divided on the effect of the availability of U.S. product; the largest number reported that the presence of U.S. product reduces price. Purchasers who generally reported that multiple sources only reduced price or had no impact frequently reported that this was because more sources created greater supply or competition-reducing prices. A number of others reported that Chinese prices were lower than U.S. prices. P&G reported that U.S. producers offered it lower average delivered prices for citric acid than for product from Canada and China for every year between 2005 and 2008.15 ***.16 ***.17 ***.

---

15 Hearing transcript, pp. 181-182 (Smith).
16 *** reported that “***.”
17 *** stated that “***.”
Table V-2
Citric acid and certain citrate salts: Number of purchasers reporting the impact on price of the presence of other sellers in the market in contract negotiations

<table>
<thead>
<tr>
<th>Source</th>
<th>Increases prices</th>
<th>No impact on price</th>
<th>Reduces price</th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S.</td>
<td>12</td>
<td>19</td>
<td>23</td>
</tr>
<tr>
<td>Canada</td>
<td>4</td>
<td>22</td>
<td>16</td>
</tr>
<tr>
<td>Chinese</td>
<td>0</td>
<td>12</td>
<td>40</td>
</tr>
<tr>
<td>Nonsubject</td>
<td>0</td>
<td>18</td>
<td>17</td>
</tr>
</tbody>
</table>

Source: Compiled from data in response to Commission questionnaires.

Timing of Long-Term Contracting

Cargill described U.S. producers as contracting for approximately 80 percent of their output in November and December of each year. It added that “because we must sell our output to a few large customers within a very short window, the customers have tremendous negotiating leverage. It is almost like a reverse auction. At some point, Cargill and other U.S. producers must meet customers’ price requirements in order to book sufficient orders for the coming production year.”

When asked when long-term contracts were negotiated, 13 purchasers reported that negotiations were in the fourth quarter of the preceding year, 3 reported that negotiations were in the third quarter of the preceding year, 3 reported that negotiations were in the first quarter of the year, 6 reported annual negotiations, and 3 had other responses. The three main reasons purchasers reported for contract negotiations at the end of each year for the following year included: since the previous year’s corn crop was in, it was easier to predict the costs of producing citric acid and certain citrate salts for the following year at this time; this allowed firms to set their price/costs for the following year; and tradition.

P&G stated that the reason contracting is done at the end of each year is because U.S. producers decided to do so. P&G continued that it, like other large purchasers, would prefer to have staggered purchases throughout the year.

Short-Term Contracts

*** U.S. producers, 15 importers, and 20 purchasers reported using short-term contracts for citric acid and certain citrate salts. JBL reported selling *** percent of the Canadian product using short-term contracts. Eleven importers of Chinese product reported using short-term contracts, with three of these reporting that 60 to 100 percent of their sales were made using short-term contracts and eight firms reporting that 10 to 40 percent of their sales were made using short-term contracts. The duration for

---

18 Long-term contracts have been defined in this industry as contracts of one year or longer.

19 Cargill continued that losing one or two large contracts early in that season would dramatically increase pressure on the U.S. producers to make sure that they won subsequent sales. It also said that in such an environment, non-price factors were not important. Conference transcript, pp. 28-29 (Christiansen).

20 Some firms reported months that overlapped between quarters; those with months in both the third and fourth quarters were included in the third quarter, and those with months in both the fourth and first quarters were included in the first quarter. (This minimizes the number of contracts reported in the fourth quarter.)

21 Conference transcript, pp. 150-151 (Button and Smith).

22 Short-term contracts have been defined in this industry as contracts for less than one year.

23 Of the top four purchasers, only ***.
short-term contracts ranged from 1 to 9 months. Sixteen purchasers and 15 importers reported the duration of their short-term contracts. Twelve importers, including ***, and five purchasers reported contracts that were 3 months in duration. Thirteen importers and 16 purchasers reported that short-term contracts fix both price and quantity, one purchaser reported that these contracts fix only price, and one importer reported that these contracts fix neither price nor quantity. Nine importers and eight purchasers reported that these contracts did not contain meet-or-release provisions, while six importers and six purchasers reported that meet-or-release provisions were contained in short-term contracts. Two importers, ***, and one purchaser, ***, reported invoking meet-or-release provisions. Eight importers reported that all sales under short-term contracts were purchased by end users, one importer reported that its short-term contract sales were only to distributors, and the remaining four importers sold from 20 to 98 percent of their short-term contracts to distributors, with the rest to end users. The food and the beverage industries were the most commonly reported end users purchasing using short-term contracts, mentioned by five importers each. Purchasers typically reported that these contracts were entered into on an as-needed or quarterly basis.

**Spot Sales/Purchases**

*** reported selling some product using spot sales; between 2006 and 2008, the percentages of spot sales made by ADM, Cargill, and Tate & Lyle were ***, ***, and *** percent, respectively. JBL reported selling *** of the Canadian product on a spot basis. Six of the 16 importers of Chinese product reported selling all citric acid and certain citrate salts on a spot basis, four reported that spot sales accounted for 10 to 40 percent of sales, five reported these were 60 to 80 percent of sales, and one indicated that spot sales accounted for 85 percent of its total sales. While 47 of the 65 responding purchasers reported spot purchases between 2006 and 2008, the largest end users were less likely to purchase citric acid and certain citrate salts on a spot basis. ***. P&G reported using spot purchases only if an emergency arises.24 Purchasers reported that spot purchases tended to be on an as-needed basis, with prices reported to be set either by negotiation, the market, or quotes from suppliers.

United Foods stated that smaller customers buy on a spot basis only.25 It added that smaller customers will buy from distributors that sell citric acid and certain citrate salts along with a pallet of different products that may influence the price of the citric acid and certain citrate salts as well.26

Producers, importers, and purchasers were asked the importance of citric acid and certain citrate salts from different sources on their spot prices and if product from different sources tended to cause prices to increase, decrease, or have a neutral impact (table V-3).

**Other Sales/Purchase Conditions**

Most responding purchasers, 53 of the 69, did not purchase citric acid and certain citrate salts together with other products. Some purchasers reported buying mixed truckloads from U.S. producers, the Canadian producer, or distributors, and one reported buying hundreds of products from the same
Table V-3
Citric acid and certain citrate salts: Number of producers, importers, and purchasers reporting the impact on spot prices of product from different sources by the importance they place on the presence of product from these sources

<table>
<thead>
<tr>
<th>Importance on price</th>
<th>U.S. producers</th>
<th>Importers</th>
<th>Purchasers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Up</td>
<td>Neutral</td>
<td>Down</td>
</tr>
<tr>
<td>Presence of U.S. product</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not important</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Somewhat important</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Very important</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Presence of Canadian product</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not important</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Somewhat important</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Very important</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Presence of Chinese product</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not important</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Somewhat important</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Very important</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Presence of nonsubject product</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Not important</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Somewhat important</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Very important</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
</tbody>
</table>

Source: Compiled from data in response to Commission questionnaires.

Distributor. One purchaser, ***, reported that it would leverage citric acid and certain citrate salts against corn syrup for better cost. Others reported purchasing citric acid and certain citrate salts with other products, including: malic acid, ascorbic acid, tartaric acid, fumaric acid, sorbic acid, sodium citrate, sodium benzoate, sodium hex, sodium gluconate, potassium sorbate, zinc sulfate, manganese sulfate, and potassium barbate.

Four of 68 responding purchasers reporting using reverse auctions to purchase citric acid and certain citrate salts: ***. None of the top 17 purchasers reported purchasing citric acid and certain citrate salts with other products or using reverse auctions.

Importers who were also distributors and purchasers were asked from which sources they had received price bids for their spot purchases and which source gave the lowest bids in each of the three years covered by the investigation. Firms’ responses are in the following tabulation.
Producers and importers agreed that they learn about competitors’ pricing not through being shown competing offers directly, but rather from intelligence gathered during the negotiating process with purchasers.\textsuperscript{27} Petitioners report that since the price of citric acid is not determined by traders in an open market they do not know the price at any given time. Customers tell them the price that they want and “they may be telling us that our prices have to be lower than the prices they’ve actually been given by other competitors.”\textsuperscript{28} Pricing information also comes from distributors, particularly if price supports (i.e., discounts) are used in order to compete with spot sales.\textsuperscript{29} Petitioners also report that they are not treated differently than imports by purchasers.\textsuperscript{30} Respondents report that spot prices are an indicator of market trends. When spot prices are higher, as in the citric acid market during this period, this indicates that the market is tight, and contract negotiations should result in higher prices to reflect this.\textsuperscript{31} Respondents also state that spot and contract markets are separate markets and that spot sales do not take business away from contract sales.\textsuperscript{32}

### Sales Terms and Discounts

\[ *** \text{ and 22 importers stated that their typical sales terms were net 30 days delivered. Of those 22 importers, nine quoted prices on a delivered basis, nine quoted prices on an f.o.b. warehouse basis, and four used some combination of delivered and f.o.b. warehouse quotations. Two importers had sales terms of net 60 days delivered. One additional importer reported “no” sales terms, but stated that it quoted prices on a delivered basis.} \]

\[ *** \text{ reported that they did not have a discount policy, although ***.} \textsuperscript{33} \text{ Among importers, six reported offering discounts, with five of those basing discounts on volume and one basing discounts on} \]

---

\textsuperscript{27} Conference transcript, pp. 95 (Oakley) and 146 (Waite).

\textsuperscript{28} Hearing transcript, pp. 77-78 (Beroni).

\textsuperscript{29} Hearing transcript, pp. 79-80 (Lorusso).

\textsuperscript{30} Hearing transcript, p. 81 (Oakley, Anderson).

\textsuperscript{31} Hearing transcript, p. 246 (Button).

\textsuperscript{32} Hearing transcript, p. 247 (Cameron).

\textsuperscript{33} However, at the conference, petitioners clarified that while they do not offer volume-based discounts or rebates, volume does play a role in price negotiations. Conference transcript, p. 97 (Anderson).
competitive conditions. Nineteen importers reported that they do not offer discounts on their sales of citric acid and certain citrate salts.

**PRICE DATA**

The Commission requested U.S. producers and importers of citric acid and certain citrate salts to provide quarterly data for the total quantity and net f.o.b. value of citric acid and certain citrate salts that were shipped to unrelated customers in the U.S. market. Data were requested for the period January 2006-December 2008, and values and quantities were requested on an anhydrous-equivalent basis. The products for which pricing data were requested are as follows:

*Product 1.*—Citric acid, granular, in dry form in 25-kilogram and 50-pound bags. Excluding all product packaged and sold as fine granular product.34

*Product 2.*—Citric acid, granular, in dry form packed in bulk sacks (“supersacks”). Excluding all product packaged and sold as fine granular product.

*Product 3.*—Citric acid, in 48 to 52 percent solution form.

*Product 4.*—Sodium citrate, granular, in dry form in 25-kilogram and 50-pound bags.

*Product 5.*—Potassium citrate, granular, in dry form in 25-kilogram and 50-pound bags.

Pricing data were requested separately for sales to end users and distributors for all 5 pricing products; in addition, prices for citric acid products 1 through 3 were requested separately for spot sales and contract sales.

Three U.S. producers, *** of Canadian product,35 and 21 importers of Chinese product36 provided usable pricing data for sales of the requested products, although not all firms reported pricing for all products for all quarters. Pricing data reported by these firms accounted for approximately 56.3 percent of U.S. producers’ U.S. shipments of citric acid and certain citrate salts, *** percent of U.S. shipments of subject imports from Canada, and 60.0 percent of U.S. shipments of subject imports from China in 2008.

**Price Trends and Comparisons**

Producers’ and importers’ pricing data by sales to end users vs. distributors and by spot sales vs. contract sales are presented in tables V-4 to V-8 and figures V-3 to V-7. A summary of pricing data is

---

34 The questionnaire requested data for granular product, and some firms included fine granular which had been a separate product in the preliminary phase questionnaire. It was unclear how fine granular should be treated in the final phase questionnaire. Prices were reported to differ between normal granular and fine granular product; therefore, it was decided to limit products 1 and 2 to exclude fine granular. All firms were contacted and requested to make any necessary adjustments in their data. All importers that reported any price data for fine granular product in the preliminary phase of the investigations were checked; some had not included fine granular in their responses to the final phase questionnaires, and the others either removed fine granular data or reported that they charge the same price for fine granular as for regular granular. The U.S. producers excluded fine granular from their pricing data in their responses to the final phase questionnaire.

35 ***. *** of Canadian product reporting price data ***.

36 Importers of Chinese product reporting price data were: ***.
Table V-4
Citric acid and certain citrate salts: Weighted-average delivered prices and quantities of domestic and imported product 1, and margins of (overselling)/underselling by spot and contract sales, by type of purchaser and by quarters, January 2006-December 2008

<table>
<thead>
<tr>
<th>Period</th>
<th>United States</th>
<th>Canada</th>
<th>China</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Price (per pound)</td>
<td>Quantity (1,000 dry pounds)</td>
<td>Price (per pound)</td>
</tr>
<tr>
<td>Spot sales to end users</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>$***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>2007:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>2008:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Contract sales to end users</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>2007:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>2008:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>0.55</td>
<td>13,428</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>0.54</td>
<td>11,299</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>0.56</td>
<td>8,107</td>
<td>***</td>
</tr>
</tbody>
</table>

1 Citric acid, granular, in dry form in 25-kilogram and 50-pound bags sold.

Table continued on next page.
Table V-4—Continued
Citric acid and certain citrate salts: Weighted-average delivered prices and quantities of domestic and imported product \(^1\), and margins of (overselling)/underselling by spot and contract sales, by type of purchaser and by quarters, January 2006-December 2008

<table>
<thead>
<tr>
<th>Period</th>
<th>United States</th>
<th></th>
<th></th>
<th></th>
<th>China</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Price (per pound)</td>
<td>Quantity (1,000 dry pounds)</td>
<td>Price (per pound)</td>
<td>Quantity (1,000 dry pounds)</td>
<td>Margin (percent)</td>
<td>Price (per pound)</td>
<td>Quantity (1,000 dry pounds)</td>
<td>Margin (percent)</td>
</tr>
<tr>
<td><strong>Spot sales to distributors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>$***</td>
<td>***</td>
<td>$***</td>
<td>***</td>
<td>$0.48</td>
<td>1,544</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.48</td>
<td>1,820</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.48</td>
<td>2,086</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.48</td>
<td>1,963</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>2007:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.48</td>
<td>2,768</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.49</td>
<td>2,494</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.50</td>
<td>2,687</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.52</td>
<td>1,718</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>2008:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.57</td>
<td>2,469</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.65</td>
<td>4,850</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.76</td>
<td>3,934</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.80</td>
<td>2,452</td>
<td>***</td>
<td>***</td>
</tr>
</tbody>
</table>

| **Contract sales to distributors** | | | | | | | | |
| 2006:        |               |                     |                     |                     | September |                     |                     |                     |
| Jan.-Mar.    | ***           | ***                 | ***                | ***                 | 0.50    | 1,373               | ***                 | ***                 |
| Apr.-June    | ***           | ***                 | ***                | ***                 | 0.48    | 2,548               | ***                 | ***                 |
| July-Sept.   | ***           | ***                 | ***                | ***                 | 0.49    | 2,278               | ***                 | ***                 |
| Oct.-Dec.    | ***           | ***                 | ***                | ***                 | 0.60    | 2,338               | ***                 | ***                 |
| 2007:        |               |                     |                     |                     | September |                     |                     |                     |
| Jan.-Mar.    | 0.50         | 1,373               | ***                | ***                 | 0.50    | 1,373               | ***                 | ***                 |
| Apr.-June    | ***           | ***                 | ***                | ***                 | 0.48    | 2,548               | ***                 | ***                 |
| July-Sept.   | 0.49         | 2,278               | ***                | ***                 | 0.49    | 2,278               | ***                 | ***                 |
| Oct.-Dec.    | 0.60         | 2,338               | ***                | ***                 | 0.60    | 2,338               | ***                 | ***                 |
| 2008:        |               |                     |                     |                     | September |                     |                     |                     |
| Jan.-Mar.    | ***           | ***                 | ***                | ***                 | 0.59    | 2,882               | ***                 | ***                 |
| Apr.-June    | 0.59         | 2,882               | ***                | ***                 | 0.59    | 2,882               | ***                 | ***                 |
| July-Sept.   | 0.60         | 2,554               | ***                | ***                 | 0.60    | 2,554               | ***                 | ***                 |
| Oct.-Dec.    | 0.60         | 2,338               | ***                | ***                 | 0.60    | 2,338               | ***                 | ***                 |

\(^1\) Citric acid, granular, in dry form in 25-kilogram and 50-pound bags sold.

Source: Compiled from data submitted in response to Commission questionnaires.
Table V-5
Citric acid and certain citrate salts: Weighted-average delivered prices and quantities of domestic and imported product, and margins of (overselling)/underselling by spot and contract sales, by type of purchaser and by quarters, January 2006-December 2008

<table>
<thead>
<tr>
<th>Period</th>
<th>United States</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th>Canada</th>
<th></th>
<th></th>
<th></th>
<th>China</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Price (per pound)</td>
<td>Quantity (1,000 dry pounds)</td>
<td>Price (per pound)</td>
<td>Quantity (1,000 dry pounds)</td>
<td>Margin (percent)</td>
<td>Price (per pound)</td>
<td>Quantity (1,000 dry pounds)</td>
<td>Margin (percent)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spot sales to end users</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>$***</td>
<td>***</td>
<td>$***</td>
<td>***</td>
<td>***</td>
<td>$***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>-</td>
<td>0</td>
<td>-</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>-</td>
<td>0</td>
<td>-</td>
<td>0.56</td>
<td>499</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>-</td>
<td>0</td>
<td>-</td>
<td>0.61</td>
<td>429</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2008:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>0.47</td>
<td>6,468</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apr.-June</td>
<td>0.47</td>
<td>13,539</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>July-Sept.</td>
<td>0.47</td>
<td>14,961</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.39</td>
<td>9,280</td>
<td>16.1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>0.48</td>
<td>5,950</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.39</td>
<td>5,392</td>
<td>17.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contract sales to end users</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>0.47</td>
<td>10,010</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apr.-June</td>
<td>0.47</td>
<td>14,264</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>July-Sept.</td>
<td>0.47</td>
<td>11,213</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>0.47</td>
<td>11,015</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>0.47</td>
<td>9,218</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apr.-June</td>
<td>0.53</td>
<td>13,602</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>July-Sept.</td>
<td>0.54</td>
<td>12,679</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>0.71</td>
<td>22,659</td>
<td>(31.0)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>0.53</td>
<td>11,803</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1 Citric acid, granular, in dry form packed in bulk sacks ("supersacks").

Source: Compiled from data submitted in response to Commission questionnaires.
Table V-6
Citric acid and certain citrate salts: Weighted-average delivered prices and quantities of domestic and imported product \(^1\), and margins of (overselling)/underselling by spot and contract sales, by type of purchaser and by quarters, January 2006-December 2008

<table>
<thead>
<tr>
<th>Period</th>
<th>United States</th>
<th>Canada</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Price (per pound)</td>
<td>Quantity (dry 1,000 pounds)</td>
</tr>
<tr>
<td></td>
<td>$***</td>
<td>***</td>
</tr>
<tr>
<td><strong>Spot sales to end users</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>0.44</td>
<td>30,423</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>0.43</td>
<td>27,241</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>0.46</td>
<td>26,420</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>0.44</td>
<td>25,294</td>
</tr>
<tr>
<td>2007:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>0.44</td>
<td>29,794</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>0.45</td>
<td>30,318</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>0.44</td>
<td>31,704</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>0.44</td>
<td>29,358</td>
</tr>
<tr>
<td>2008:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>0.51</td>
<td>23,582</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>0.53</td>
<td>23,754</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>0.53</td>
<td>21,562</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>0.53</td>
<td>20,069</td>
</tr>
</tbody>
</table>

\(^1\) Citric acid, in 48 to 52 percent solution form.

Source: Compiled from data submitted in response to Commission questionnaires.
Table V-7
Citric acid and certain citrate salts: Weighted-average delivered prices and quantities of domestic and imported product 4, and margins of (overselling)/underselling by type of purchaser and by quarters, January 2006-December 2008

<table>
<thead>
<tr>
<th>Period</th>
<th>United States</th>
<th></th>
<th></th>
<th>China</th>
<th></th>
<th></th>
<th>Margin (percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Price (per pound)</td>
<td>Quantity (1,000 dry pounds)</td>
<td>Price (per pound)</td>
<td>Quantity (1,000 dry pounds)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sales to end users</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2006:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>$***</td>
<td>***</td>
<td>$0.50</td>
<td>1,238</td>
<td>***</td>
<td>1,238</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>0.50</td>
<td>1,545</td>
<td>***</td>
<td>1,545</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>0.51</td>
<td>1,482</td>
<td>***</td>
<td>1,482</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>0.50</td>
<td>1,145</td>
<td>***</td>
<td>1,145</td>
<td>***</td>
</tr>
<tr>
<td><strong>2007:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>0.50</td>
<td>1,508</td>
<td>***</td>
<td>1,508</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>0.50</td>
<td>1,804</td>
<td>***</td>
<td>1,804</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>0.51</td>
<td>1,547</td>
<td>***</td>
<td>1,547</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>0.50</td>
<td>1,263</td>
<td>***</td>
<td>1,263</td>
<td>***</td>
</tr>
<tr>
<td><strong>2008:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>0.56</td>
<td>1,470</td>
<td>***</td>
<td>1,470</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>0.62</td>
<td>1,956</td>
<td>***</td>
<td>1,956</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>0.75</td>
<td>1,707</td>
<td>***</td>
<td>1,707</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>0.80</td>
<td>1,839</td>
<td>***</td>
<td>1,839</td>
<td>***</td>
</tr>
<tr>
<td><strong>Sales to distributors</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>2006:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>0.42</td>
<td>149</td>
<td>***</td>
<td>149</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>0.45</td>
<td>110</td>
<td>***</td>
<td>110</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>0.41</td>
<td>249</td>
<td>***</td>
<td>249</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>0.42</td>
<td>563</td>
<td>***</td>
<td>563</td>
<td>***</td>
</tr>
<tr>
<td><strong>2007:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>0.46</td>
<td>168</td>
<td>***</td>
<td>168</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>0.41</td>
<td>249</td>
<td>***</td>
<td>249</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>0.42</td>
<td>563</td>
<td>***</td>
<td>563</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>0.42</td>
<td>309</td>
<td>***</td>
<td>309</td>
<td>***</td>
</tr>
<tr>
<td><strong>2008:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>0.51</td>
<td>480</td>
<td>***</td>
<td>480</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>0.60</td>
<td>1,085</td>
<td>***</td>
<td>1,085</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>0.78</td>
<td>292</td>
<td>***</td>
<td>292</td>
<td>***</td>
</tr>
</tbody>
</table>

1 Sodium citrate, granular, in dry form in 25-kilogram and 50-pound bags.

Source: Compiled from data submitted in response to Commission questionnaires.
Table V-8
Citric acid and certain citrate salts: Weighted-average delivered prices and quantities of domestic and imported product 5, and margins of (overselling)/underselling by type of purchaser and by quarters, January 2006-December 2008

Figure V-3
Citric acid: Weighted-average delivered selling prices to distributors and end users via spot and contract sales, as reported by U.S. producers and importers of product 1, by quarters, January 2006-December 2008

Figure V-4
Citric acid: Weighted-average delivered selling prices to distributors and end users via spot and contract sales, as reported by U.S. producers and importers of product 2, by quarters, January 2006-December 2008

Figure V-5
Citric acid: Weighted-average delivered selling prices to distributors and end users via spot and contract sales, as reported by U.S. producers and importers of product 3, by quarters, January 2006-December 2008

Figure V-6
Citric acid: Weighted-average delivered selling prices to distributors and end users, as reported by U.S. producers and importers of product 4, by quarters, January 2006-December 2008

Figure V-7
Citric acid: Weighted-average delivered selling prices to distributors and end users, as reported by U.S. producers and importers of product 5, by quarters, January 2006-December 2008
provided in table V-9, and information regarding underselling and overselling of citric acid products is presented in table V-10.

Table V-9
Citric acid and certain citrate salts: Summary of weighted-average delivered prices for products 1-5, by country, type of purchaser, and by spot vs. contract sales (for products 1-3), January 2006-December 2008

Table V-10
Citric acid and certain citrate salts: Instances of underselling/(overselling) and the range and average of margins for products 1-5, January 2006-December 2008

Products 1, 2, and 3 consist of citric acid. *** sold *** three products. 16 Chinese importers provided data for product 1, and nine for product 2. Product 3, citric acid in solution, was not imported from China, but importer *** reported making and selling citric acid in solution from Chinese granular citric acid. Product 4 is a sodium citrate product sold by ***. Eleven Chinese importers provided data for product 4. Product 5 is a potassium citrate product sold by ***. Five importers from China provided data for product 5. The price of product 5, potassium citrate, was reported to increase in 2008 because of shortages of potassium due to a strike at a potassium mine.

For product 1, Canadian product undersold the U.S. product for nearly all spot sales while overselling occurred for most contract sales, and Chinese product mainly undersold for all combinations except contract sales to end users, the category in which there was the largest volume of both U.S. and Chinese sales. For product 2, Chinese product mainly undersold for all combinations, and Canadian

---

37 ***.
38 Staff telephone interview with ***.
39 ***.
40 ***.
product undersold for nearly all spot sales to end users and distributors but oversold half the time for contract sales to end users. For product 3, Canadian product mainly undersold for spot sales to end users and distributors, and mainly oversold for contract sales to end users, the category for which there was the most U.S. data. *** Canadian data were reported for products 2 or 3, contract sales to distributors. For products 4 and 5, Chinese product oversold the domestic product in all sales to end users, which are the categories with the most U.S. and Chinese sales. Domestically produced product 4 sold to distributors was mainly undersold by the Chinese product and domestically produced product 5 sold to distributors was undersold half the time by the Chinese product.

In addition, purchasers that purchased over 20 million pounds of citric acid and certain citrate salts were requested to provide purchase price data for the five listed products. Pricing was requested for purchases pursuant to contracts and spot purchases for products 1-3; prices for products 4 and 5 combined contract and spot purchases. Eight purchasers provided pricing data for U.S. product, four for Canadian product, and one for nonsubject product. For product 1, both spot and contract purchase prices were available. Canadian prices were below U.S. prices in 22 of the 23 price comparisons and Chinese prices were below U.S. prices in 14 of the 15 price comparisons. For product 2 contract purchases, Canadian prices were below U.S. prices in 3 of the 12 price comparisons and Chinese prices were below U.S. prices in 10 of the 12 price comparisons. For product 3 contract purchases, Canadian prices were above U.S. prices for all 12 quarters. Chinese prices were below U.S. prices in 7 of the 10 price comparisons for product 4 and all price comparisons for product 5.

**LOST SALES AND LOST REVENUES**

The Commission requested U.S. producers of citric acid and certain citrate salts to report any instances of lost sales or revenues they experienced due to competition from imports of citric acid and certain citrate salts from Canada or China during January 2005 to March 2008. All three U.S. producers reported that they had to either reduce prices or roll back announced price increases. The 60 lost sales allegations totaled $*** and involved *** pounds of citric acid; the 27 lost revenue allegations totaled $*** and involved *** pounds of citric acid. Staff contacted the listed purchasers, and 36 purchasers, covering 51 allegations, responded. A summary of the information obtained follows in tables V-11 and V-12 and the text descriptions below.

---

**Table V-11**

Citric acid and certain citrate salts: U.S. producers’ lost sales allegations

* * * * * * *

---

41 Purchasers reporting U.S. product pricing information were: ***. Purchasers reporting Canadian product price data were: ***. Purchasers reporting Chinese product price data were: ***. The only purchaser reporting nonsubject product price data was ***. Pricing data reported by these firms accounted for approximately 36.3 percent of U.S. producers’ U.S. shipments of citric acid and certain citrate salts, 44.5 percent of U.S. shipments of subject imports from Canada, and 30.6 percent of U.S. shipments of subject imports from China in 2008.

42 No new allegations were reported in the final phase questionnaires. The allegations included in this report differ slightly from those included in the preliminary phase staff report, since allegations from 2004 are not included, nor are two lost sales allegations for purchasers located in Canada.
### Table V-12
Citric acid and certain citrate salts: U.S. producers' lost revenue allegations

<p>| | | | | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>**</td>
</tr>
<tr>
<td>*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>*</td>
</tr>
</tbody>
</table>

43 ***.

44 ***.
PART VI: FINANCIAL EXPERIENCE OF U.S. PRODUCERS

BACKGROUND

All three U.S. producers provided useable financial data. ADM’s fiscal year ends on June 30 and Cargill’s fiscal year ends on May 31, while Tate & Lyle’s fiscal year ends on March 31. However, the financial data of all three producers were submitted on a calendar-year basis. Consistent with the presentation in other parts of this report, the only data presented in this section are the producers’ combined operations on citric acid and certain citrate salts; separate data on citric acid, sodium citrate, and potassium citrate are presented in appendix C.

In addition to commercial sales, *** reported transfers to related parties, and *** reported internal consumption. These transfers and internal consumption1 accounted for approximately *** percent and *** percent, respectively, of the industry’s 2008 sales values. The unit sales values of ***2 were ***. The unit sales values of ***3 were ***.

The questionnaire data of ADM were verified with company records at its plant facilities.4 All verification adjustments were incorporated into this report. The financial data of ADM were revised for all periods to ***. The revisions resulted in ***. A part of non-recurring charges related to ***.

OPERATIONS ON CITRIC ACID AND CERTAIN CITRATE SALTS

Aggregate income-and-loss data for the producers on their total operations producing/selling citric acid and certain citrate salts are presented in table VI-1. Despite increases in net sales quantities and values from period to period, the domestic industry incurred much greater losses in 2007 than in 2006. From 2007 to 2008, net sales value and per-unit sales values increased by approximately 20 percent while sales quantities were relatively unchanged. Even though profitability at the gross and operating profit levels improved, the gross profit margin was 2.1 percent and there were still losses at the operating income level. The decrease in the operating loss between 2007 and 2008 resulted from the $0.085 per pound increase in unit sales values, which was $0.027 per pound higher than the $0.058 per pound increase in unit total costs – the unit cost of goods sold (“COGS”) increased by $0.058 per pound (led by the increase of raw material costs) while unit selling, general and administrative (“SG&A”) expenses decreased by $0.001 per pound, for a net total cost (COGS and SG&A expenses combined) increase of $0.058 per pound.5

---

1 These related party transfers are to *** foreign affiliates. Since the trade (shipment) section of the U.S. producer questionnaire instructs producers to report *** shipments, *** are properly classified as *** and not *** in Part III.
2 February 24, 2009 e-mail from ***.
3 February 25, 2009 e-mail from ***.
4 Commission staff conducted a verification of ADM’s questionnaire response on March 31-April 2, 2009.
5 Petitioners contended that the increase in profitability was the result of a decrease in imports from China which was in turn the result of a European Union antidumping investigation and the filing of the U.S. cases (hearing transcript, pp. 15 (Ellis) and 44-45 (Christiansen)).

VI-1
In addition, *** producers reported *** amounts of other expenses; ***6, ***7, and ***8. These expenses were reported below the operating income (loss) line as other expenses.

Selected company-by-company data are presented in table VI-2. ***, the ***, reported increased sales quantities and values and *** in every period. While ***. *** reported capacity utilization rates (approximately *** percent in 2006 and 2007 and *** percent in 2008) were ***9 and this may also contribute to ***. While *** also generally had the ***, the disparity between ***. ***'s quantity and value of net sales increased in both 2007 and 2008. ***, on the other hand, reported decreased sales quantities and values from 2006 to 2007, and then increased sales quantities and values from 2007 to 2008. Its unit revenues and unit costs were generally ***. The company reported ***. ***10 ***.

---

6 *** based on the Statement of Financial Accounting Standards (SFAS) No. 143, “Accounting for assets retirement obligations” (February 24, 2009 e-mail from ***). The statement applies to legal obligations associated with the retirement of long-lived assets that result from the acquisition, construction, development and (or) the normal operation of a long-lived asset. This statement requires that the fair value of a liability for an asset retirement obligation be recognized in the period in which it is incurred if a reasonable estimate of fair value can be made. Since financial data should be based on the U.S. domestic production and sales operations only, ***.

7 ***.

8 ***. Refer to the e-mail from ***. Restructuring charges and impairment losses on long-lived assets to be held and used shall be reported as components of income from continuing operations, according to GAAP (Statement of Financial Accounting Standards (SFAS) No. 144, “Accounting for the impairment or disposal of long-lived assets”), with appropriate footnote disclosure.

9 See table III-2.

10 See page II-1, ***.
Table VI-1
Citric acid and certain citrate salts: Results of U.S. producers\(^1\) on their operations, calendar years 2006-2008

<table>
<thead>
<tr>
<th>Item</th>
<th>Calendar year</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2006</td>
</tr>
<tr>
<td><strong>Quantity (1,000 pounds)</strong></td>
<td></td>
</tr>
<tr>
<td>Net sales quantities:</td>
<td></td>
</tr>
<tr>
<td>Commercial sales</td>
<td>***</td>
</tr>
<tr>
<td>Internal consumption</td>
<td>***</td>
</tr>
<tr>
<td>Transfers to related firms</td>
<td>***</td>
</tr>
<tr>
<td>Total net sales quantities</td>
<td>466,160</td>
</tr>
<tr>
<td><strong>Value (1,000 dollars)</strong></td>
<td></td>
</tr>
<tr>
<td>Net sales values:</td>
<td></td>
</tr>
<tr>
<td>Commercial sales</td>
<td>***</td>
</tr>
<tr>
<td>Internal consumption</td>
<td>***</td>
</tr>
<tr>
<td>Transfers to related firms</td>
<td>***</td>
</tr>
<tr>
<td>Total net sales values</td>
<td>205,773</td>
</tr>
<tr>
<td>Cost of goods sold (COGS)</td>
<td>202,849</td>
</tr>
<tr>
<td>Gross profit (loss)</td>
<td>2,924</td>
</tr>
<tr>
<td>SG&amp;A expenses</td>
<td>13,653</td>
</tr>
<tr>
<td>Operating income (loss)</td>
<td>(10,729)</td>
</tr>
<tr>
<td>Interest expense</td>
<td>6,981</td>
</tr>
<tr>
<td>All other expenses(^1)</td>
<td>2,599</td>
</tr>
<tr>
<td>All other income</td>
<td>1,745</td>
</tr>
<tr>
<td>Net income (loss)</td>
<td>(18,564)</td>
</tr>
<tr>
<td>Depreciation/amortization</td>
<td>15,468</td>
</tr>
<tr>
<td>Cash flow</td>
<td>(3,096)</td>
</tr>
<tr>
<td><strong>Unit value (per pound)</strong></td>
<td></td>
</tr>
<tr>
<td>Net sales values</td>
<td>$0.441</td>
</tr>
<tr>
<td>COGS</td>
<td>0.435</td>
</tr>
<tr>
<td>Gross profit (loss)</td>
<td>0.006</td>
</tr>
<tr>
<td>SG&amp;A expenses</td>
<td>0.029</td>
</tr>
<tr>
<td>Operating income (loss)</td>
<td>(0.023)</td>
</tr>
</tbody>
</table>

Table continued on next page.
Table VI-1—Continued  
Citric acid and certain citrate salts: Results of U.S. producers\(^1\) on their operations, calendar years 2006-2008

<table>
<thead>
<tr>
<th>Item</th>
<th>Calendar year</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2006</td>
<td>2007</td>
<td>2008</td>
</tr>
<tr>
<td>Ratio to net sales (percent)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COGS</td>
<td>98.6</td>
<td>103.6</td>
<td>97.9</td>
</tr>
<tr>
<td>Gross profit (loss)</td>
<td>1.4</td>
<td>(3.6)</td>
<td>2.1</td>
</tr>
<tr>
<td>SG&amp;A expenses</td>
<td>6.6</td>
<td>5.9</td>
<td>4.8</td>
</tr>
<tr>
<td>Operating income (loss)</td>
<td>(5.2)</td>
<td>(9.5)</td>
<td>(2.8)</td>
</tr>
<tr>
<td>Number of firms reporting</td>
<td></td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Operating losses</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Data</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>

\(^1\) The large other expenses in 2008 are attributable to ***.

Source: Compiled from data submitted in response to Commission questionnaires.

Table VI-2
Citric acid and certain citrate salts: Selected financial data of producers on their operations, calendar years 2006-2008

\* \* \* \* \* \* \* \*
11 February 24, 2009 e-mail from ***.

12 Statement of Financial Accounting Standards No. 161 (FAS-161, Disclosures about Derivative Instruments and Hedging Activities; an amendment of FASB No. 133) changes the disclosure requirements for derivative instruments and hedging activities. This Statement has the same scope as Statement 133. It requires that the location and fair value amounts of derivative instruments be reported in the statement of financial position and the location and amount of the gains and losses be reported in the statement of financial performance. Fair value amounts and the effective portion of gains and losses shall be presented separately by type of derivative contract and the disclosure shall identify the line item(s) in both statements. Financial Accounting Standard (FAS-133, Accounting for Derivative Instruments and Hedging Activities) states that if inventory has been the hedged item in a fair value hedge, the inventory’s cost basis used in determining the lower-of-cost-or-market shall include the effects of adjusting its carrying amount as a result of recording the gain or loss on the hedged item. According to ADM’s notes to consolidated financial statements, Note 1, summary of significant accounting policies, ADM will be required to adopt FAS-161 on January 1, 2009. It further states that the adoption of this standard will require expanded disclosure in the notes to the company’s consolidated financial statements but will not affect financial results.

13 Mark-to-market or fair value accounting refers to the accounting standards (FAS-157, Fair Value Measurements) of assigning a value to a position held in a financial instrument based on the current fair market price for the instrument or similar instruments.

14 ***. FASB No. 161 (Disclosures about Derivative Instruments and Hedging Activities; an amendment of FASB No. 133) requires that the location and fair value amounts of derivative instruments be reported in the statement of financial position and that the location and amount of the gains and losses be reported in the statement of financial performance. Fair value amounts and the effective portion of gains and losses shall be presented separately by type of derivative contract and the disclosure shall identify the line item(s) in both statements. The effective portion of gains or loss is recorded as part of cost of sales and the ineffective portion of gains or loss is recorded as part of other income or expenses.

15 Petitioners noted several times at the staff conference that theirs was a capital-intensive industry with high fixed costs. Conference transcript, pp. 22-23 (Oakley); pp. 34-35 and 37 (Poulos); and, p. 41 (Anderson). While there is no exact definition of a capital-intensive or a high fixed cost industry, staff notes that other factory costs (generally considered fixed costs) accounted for approximately 50 percent of the domestic industry’s total cost of goods sold from 2006 through 2007 while they decreased to 44 percent in 2008.

16 The U.S. producers incurred a net cost (the excess of disposal costs over revenues earned) of $*** in 2007 ($*** per pound) to dispose of the byproducts of their citric acid production. Petitioners’ postconference brief, exhibit 1, pp. 16-17. This cost was reported in other factory costs.
consists of many different costs, such as energy, depreciation, general maintenance, repairs, insurance, and property taxes. Petitioners noted that their energy costs in particular have increased.\textsuperscript{17} While the ratio of total COGS to net sales increased from 98.6 percent in 2006 to 103.6 percent in 2007, it decreased back to 97.9 percent in 2008.

\begin{table}[h]
\centering
\caption{Citric acid and certain citrate salts: Selected financial data of producers on their operations, calendar years 2006-2008}
\begin{tabular}{|l|c|c|c|}
\hline
\textbf{Item} & \multicolumn{3}{c|}{\textbf{Calendar year}} \\
 & 2006 & 2007 & 2008 \\
\hline
COGS: & & & \\
Raw materials & $0.182$ & $0.205$ & $0.263$ \\
Direct labor & 0.033 & 0.029 & 0.028 \\
Factory overhead & 0.221 & 0.223 & 0.225 \\
Total COGS & 0.435 & 0.458 & 0.516 \\
SG&A expenses & 0.029 & 0.026 & 0.025 \\
Total cost & 0.464 & 0.484 & 0.542 \\
\hline
\end{tabular}
\end{table}

The variance analysis showing the effects of prices and volume on the producers’ revenues, and of expenses, costs, and volume on their total cost, is shown in table VI-4. The analysis illustrates that from 2006 to 2008 the decrease in losses resulted from a positive price variance ($44.1$ million; unit revenues increased), in spite of a negative cost/expense variance (negative $39.8$ million; unit total costs increased).

\textsuperscript{17} February 24, 2009 e-mail from ***.
Table VI-4
Citric acid and certain citrate salts: Variance analysis of U.S. producers' operations, calendar years 2006-2008

<table>
<thead>
<tr>
<th>Item</th>
<th>Between calendar years</th>
<th>2006-07</th>
<th>2007-08</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Value ($1,000)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net sales:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Price variance</td>
<td>44,149</td>
<td>52</td>
<td>44,097</td>
</tr>
<tr>
<td>Volume variance</td>
<td>21,786</td>
<td>21,084</td>
<td>702</td>
</tr>
<tr>
<td>Total net sales variance</td>
<td>65,935</td>
<td>21,136</td>
<td>44,799</td>
</tr>
<tr>
<td>Cost of goods sold:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost variance</td>
<td>(41,795)</td>
<td>(11,490)</td>
<td>(30,270)</td>
</tr>
<tr>
<td>Volume variance</td>
<td>(21,476)</td>
<td>(20,784)</td>
<td>(727)</td>
</tr>
<tr>
<td>Total COGS variance</td>
<td>(63,271)</td>
<td>(32,274)</td>
<td>(30,997)</td>
</tr>
<tr>
<td>Gross profit variance</td>
<td>2,664</td>
<td>(11,138)</td>
<td>13,802</td>
</tr>
<tr>
<td>SG&amp;A expense:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expense variance</td>
<td>2,005</td>
<td>1,632</td>
<td>369</td>
</tr>
<tr>
<td>Volume variance</td>
<td>(1,445)</td>
<td>(1,399)</td>
<td>(42)</td>
</tr>
<tr>
<td>Total SG&amp;A variance</td>
<td>560</td>
<td>233</td>
<td>327</td>
</tr>
<tr>
<td>Operating income variance</td>
<td>3,224</td>
<td>(10,905)</td>
<td>14,129</td>
</tr>
<tr>
<td>Summarized as:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Price variance</td>
<td>44,149</td>
<td>52</td>
<td>44,097</td>
</tr>
<tr>
<td>Net cost/expense variance</td>
<td>(39,789)</td>
<td>(9,858)</td>
<td>(29,901)</td>
</tr>
<tr>
<td>Volume variance</td>
<td>(1,136)</td>
<td>(1,099)</td>
<td>(67)</td>
</tr>
</tbody>
</table>

Source: Compiled from data submitted in response to Commission questionnaires.
CAPITAL EXPENDITURES AND RESEARCH AND DEVELOPMENT EXPENSES

Domestic citric acid producers’ capital expenditures and research and development (R&D) expenses are presented in table VI-5. The overall level of expenditures was generally low, being less than depreciation expenses (table VI-1) in every period. This is an indication that the domestic industry is not expanding or improving its productive facilities, but is at best maintaining them.

R&D expenses, the overall level was low.

Table VI-5
Citric acid and certain citrate salts: U.S. producers’ capital expenditures and research and development (R&D) expenses, calendar years 2006-2008

<table>
<thead>
<tr>
<th>Item</th>
<th>Calendar year</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>2006</td>
<td>2007</td>
</tr>
<tr>
<td></td>
<td>Value (1,000 dollars)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capital expenditures:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADM</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Cargill</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Tate &amp; Lyle</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Total</td>
<td>6,534</td>
<td>7,746</td>
<td>5,537</td>
</tr>
<tr>
<td>R&amp;D expenses:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ADM</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Cargill</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Tate &amp; Lyle</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Total</td>
<td>1,701</td>
<td>1,473</td>
<td>1,919</td>
</tr>
</tbody>
</table>

1 ADM reported the following: ***.
2 Expenditures cover ***.
3 ***.

Source: Compiled from data submitted in response to Commission questionnaires.

ASSETS AND RETURN ON INVESTMENT

Data on the domestic citric acid and certain citrate salts producers’ assets and their return on investment (defined as operating income divided by total assets) are presented in table VI-6. The value of total assets decreased *** in 2008 as ***.18 The return on investment approximated the operating income margins in table VI-1.

---

18 ***.
### Table VI-6
Citric acid and certain citrate salts: U.S. producers’ assets and return on assets, calendar years 2006-2008

<table>
<thead>
<tr>
<th>Item</th>
<th>Calendar year</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2006</td>
<td>2007</td>
<td>2008</td>
<td></td>
</tr>
<tr>
<td><strong>Value of assets</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current assets:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cash</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Accounts receivable (net)</td>
<td>22,034</td>
<td>25,635</td>
<td>32,987</td>
<td></td>
</tr>
<tr>
<td>Inventories (total)</td>
<td>51,891</td>
<td>35,376</td>
<td>50,008</td>
<td></td>
</tr>
<tr>
<td>All other current assets</td>
<td>4,670</td>
<td>1,390</td>
<td>457</td>
<td></td>
</tr>
<tr>
<td>Total current assets</td>
<td>78,595</td>
<td>62,401</td>
<td>83,452</td>
<td></td>
</tr>
<tr>
<td>Non-current assets:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Property, plant, and equipment (PPE) at cost</td>
<td>547,426</td>
<td>554,625</td>
<td>553,394</td>
<td></td>
</tr>
<tr>
<td>Net book value of PPE</td>
<td>115,601</td>
<td>109,386</td>
<td>77,909</td>
<td></td>
</tr>
<tr>
<td>Other non-current assets</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Total non-current assets</td>
<td>115,601</td>
<td>109,386</td>
<td>77,909</td>
<td></td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td>194,196</td>
<td>171,787</td>
<td>161,361</td>
<td></td>
</tr>
<tr>
<td>Operating income</td>
<td>(10,729)</td>
<td>(21,634)</td>
<td>(7,505)</td>
<td></td>
</tr>
<tr>
<td>Return on investment</td>
<td>(5.5)</td>
<td>(12.6)</td>
<td>(4.7)</td>
<td></td>
</tr>
</tbody>
</table>

Source: Compiled from data submitted in response to Commission questionnaires.

### CAPITAL AND INVESTMENT

The Commission requested U.S. producers to describe any actual negative effects since January 1, 2006, on their return on investment, growth, investment, ability to raise capital, existing development and production efforts (including efforts to develop a derivative or more advanced version of the product), or the scale of capital investments as a result of imports of citric acid and certain citrate salts from Canada or China. Their responses are as follows:

ADM ***.

Cargill ***.

Tate & Lyle ***.

The Commission also requested U.S. producers to describe any anticipated negative impact of imports of citric acid and certain citrate salts from Canada or China. Their responses are as follows:

ADM ***.
Cargill ***.
Tate & Lyle ***.
PART VII: THREAT CONSIDERATIONS AND INFORMATION ON PRODUCERS IN NONSUBJECT COUNTRIES

Section 771(7)(F)(i) of the Act (19 U.S.C. § 1677(7)(F)(i)) provides that--

In determining whether an industry in the United States is threatened with material injury by reason of imports (or sales for importation) of the subject merchandise, the Commission shall consider, among other relevant economic factors--

(I) if a countervailable subsidy is involved, such information as may be presented to it by the administering authority as to the nature of the subsidy (particularly as to whether the countervailable subsidy is a subsidy described in Article 3 or 6.1 of the Subsidies Agreement), and whether imports of the subject merchandise are likely to increase,

(II) any existing unused production capacity or imminent, substantial increase in production capacity in the exporting country indicating the likelihood of substantially increased imports of the subject merchandise into the United States, taking into account the availability of other export markets to absorb any additional exports,

(III) a significant rate of increase of the volume or market penetration of imports of the subject merchandise indicating the likelihood of substantially increased imports,

(IV) whether imports of the subject merchandise are entering at prices that are likely to have a significant depressing or suppressing effect on domestic prices, and are likely to increase demand for further imports,

(V) inventories of the subject merchandise,

(VI) the potential for product-shifting if production facilities in the foreign country, which can be used to produce the subject merchandise, are currently being used to produce other products,

(VII) in any investigation under this title which involves imports of both a raw agricultural product (within the meaning of paragraph (4)(E)(iv)) and any product processed from such raw agricultural product, the likelihood that there will be increased imports, by reason of product shifting, if there is an affirmative determination by the Commission

1 Section 771(7)(F)(ii) of the Act (19 U.S.C. § 1677(7)(F)(ii)) provides that “The Commission shall consider these factors . . . as a whole in making a determination of whether further dumped or subsidized imports are imminent and whether material injury by reason of imports would occur unless an order is issued or a suspension agreement is accepted under this title. The presence or absence of any factor which the Commission is required to consider . . . shall not necessarily give decisive guidance with respect to the determination. Such a determination may not be made on the basis of mere conjecture or supposition.”
under section 705(b)(1) or 735(b)(1) with respect to either the raw agricultural product or the processed agricultural product (but not both),

(VIII) the actual and potential negative effects on the existing development and production efforts of the domestic industry, including efforts to develop a derivative or more advanced version of the domestic like product, and

(IX) any other demonstrable adverse trends that indicate the probability that there is likely to be material injury by reason of imports (or sale for importation) of the subject merchandise (whether or not it is actually being imported at the time).\(^2\)

Information on the nature of the countervailable subsidies was presented in Part I of this report; information on the volume and pricing of imports of the subject merchandise is presented in Parts IV and V; and information on the effects of imports of the subject merchandise on U.S. producers’ existing development and production efforts is presented in Part VI. Information on inventories of the subject merchandise; foreign producers’ operations, including the potential for “product-shifting;” any other threat indicators, if applicable; and any dumping in third-country markets, follows. Also presented in this section of the report is information obtained for consideration by the Commission on nonsubject-country producers.

**THE INDUSTRY IN CANADA**

The Commission requested and received data from one firm, Jungbunzlauer Technology GmbH & Co. KG (“JBL Canada”), which was listed in the petition and accounted for all citric acid production in Canada during the period of investigation. JBL Canada does not produce sodium citrate, potassium citrate, or crude calcium citrate at its production facility in Canada. JBL Canada is wholly owned by the Swiss firm, Jungbunzlauer AG.

During the 2000 investigation, U.S. imports from nonsubject countries included imports from Jungbunzlauer Austria AG’s citric acid production facility in Vienna, Austria. In 1999, JBL began planning to build a citric acid production facility in North America to better supply that geographical market. In 2002, JBL Canada’s production facility began production of food and beverage grade citric acid.

During the period for which data were collected in these investigations, JBL Canada reported that *** percent of its total sales in the most recent fiscal year were sales of citric acid. In 2008, *** percent of JBL Canada’s total shipments of citric acid were exported to the United States, *** percent of its shipments were to its home market, and *** percent of its shipments were exported to other countries, principally to ***. JBL Canada reported a ***-percent increase in capacity from 2007 to 2008 ***. It has stated that it ***.\(^3\) JBL Canada’s production increased by *** percent between 2006 and 2008, and is projected to *** in 2009 and 2010. JBL Canada reported that it acted as its exclusive U.S. importer of

---

\(^2\) Section 771(7)(F)(iii) of the Act (19 U.S.C. § 1677(7)(F)(iii)) further provides that, in antidumping investigations, “... the Commission shall consider whether dumping in the markets of foreign countries (as evidenced by dumping findings or antidumping remedies in other WTO member markets against the same class or kind of merchandise manufactured or exported by the same party as under investigation) suggests a threat of material injury to the domestic industry.”

\(^3\) JBL Canada’s foreign producer’s questionnaire, p. 6.
record of citric acid ***. Table VII-1 presents data for reported production and shipments of citric acid for JBL Canada.

Table VII-1
Citric acid and certain citrate salts: Canada’s reported production capacity, production, shipments, and inventories, 2006-2008 and projections for 2009 and 2010

| * | * | * | * | * | * |

THE INDUSTRY IN CHINA

The Commission received 16 responses from foreign producers or exporters of citric acid and certain citrate salts in China. Data regarding the Chinese industry are based on 14 foreign producer questionnaires, which are believed to account for approximately 90 percent of Chinese export shipments to the United States in 2008. The largest five reporting Chinese producers accounted for the vast majority of reported 2008 production. These companies are: ***. Table VII-2 presents separately the capacity, production, capacity utilization, export shipments to the United States, and shares of reported production and exports of the 14 responding Chinese producers in 2008.

Table VII-2
Citric acid and certain citrate salts: China’s reported production capacity, production, shipments, and inventories, 2008

| * | * | * | * | * | * |

Table VII-3 presents data for capacity, production, and shipments of citric acid and certain citrate salts from all reporting producers in China. Chinese producers’ capacity increased by 41.9 percent from 2006 to 2008. Capacity is projected to increase further by 7.1 percent from 2008 to 2009 and remain virtually steady in 2010. The production of Chinese producers increased by 45.0 percent from 2006 to...

---

4 Foreign producer questionnaires were sent to counsel for the Chinese respondents. Two firms in China (***)) reported that they did not export to the United States from China citric acid or certain citrate salts during the period of investigation. ***.

5 Export shipments to the United States reported by responding Chinese producers accounted for 88.2 percent of U.S. imports in 2008 (based on Commerce statistics). According to ***.

6 Chinese respondents stated that there has been rapid consolidation of Chinese citric acid producers; and since 2002, the number of major producers of citric acid in China has fallen from over 100 to below 20. They claim that the driving force behind this consolidation is the government of China’s new environmental protection policies, which forced the closure of many obsolete citric acid manufacturing facilities and may slow or prevent the addition of more capacity. In 2008, pursuant to these environmental regulations, the Chinese government approved 15 Chinese producers of citric acid to export the product. Chinese respondents’ prehearing brief, pp. 70-71; Chinese respondents’ posthearing brief, app. A, p. 39.

7 According to ***. See Petitioners’ postconference brief, exh. 32, p. 1.

8 *** of the 14 responding Chinese producers (and *** out of the largest 5 producers), *** reported increases in capacity during the period of investigation. *** accounted for *** percent of the increase in capacity from 2006 to 2008. Chinese respondents’ posthearing brief, p. 10 fn. 5 (observing that ***).

9 Chinese respondents stated that in November 2008, because of violations of Chinese environmental regulations, *** lost its right to export citric acid. *** reported in its questionnaire that its projected 2009 exports to the United States would *** dry pounds. Chinese respondents’ prehearing brief, pp. 74-75. *** observe that *** is currently (continued...)

VII-3
2008, and is projected to decrease by 1.5 percent from 2008 to 2009 before rebounding slightly in 2010. Chinese producers reported capacity utilization rates ranging from 86.4 percent in 2006 to 89.0 percent in 2007.

During the period of investigation, the volume of Chinese producers’ export shipments to the United States increased by 20.4 percent from 2006 to 2008, but decreased as a share of China’s total shipments from 11.2 percent in 2006 to 10.0 percent in 2008. Meanwhile, the volume of Chinese producers’ shipments to the Chinese home market (including internal consumption) increased by 47.6 percent from 2006 to 2008 and increased as a share of total shipments during the period from 26.2 percent of total shipments in 2006 to 28.9 percent in 2008. From 2006 to 2008, Chinese commercial shipments to other countries increased by 31.2 percent. Throughout the period of investigation, the majority of the Chinese producers’ shipments went to other markets, ranging from 61.2 percent of total shipments in 2008 to 62.6 percent of total shipments in 2006. The top five Chinese producers reported that *** are their principal export markets.

---

9 (continued) soliciting overseas sales via public websites. ***.

Chinese respondents also stated that DSM Citric Acid (Wuxi), Ltd. (“DSM”) discontinued citric acid production in the first quarter of 2009 after the Chinese government requested that the production facility be moved to accommodate future urban development. DSM’s capacity is approximately 50,000 metric tons (110.2 million dry pounds). Chinese respondents’ prehearing brief, p. 73. Counsel for Chinese respondents do not represent DSM. The Commission did not receive a questionnaire response from DSM.

10 *** of the responding Chinese producers reported that they produced products other than citric acid or certain citrate salts on the same manufacturing equipment.

11 Chinese respondents project that exports to the United States in 2009 and 2010 will decrease dramatically as Chinese firms ship product to other markets, especially the European Union. Chinese respondents’ posthearing brief, p. 36.
Table VII-3
Citric acid and certain citrate salts: China’s reported production capacity, production, shipments, and inventories, 2006-2008 and projections for 2009 and 2010

<table>
<thead>
<tr>
<th>Item</th>
<th>Actual experience</th>
<th>Projections</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2006</td>
<td>2007</td>
</tr>
<tr>
<td><strong>Quantity (1,000 dry pounds)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capacity</td>
<td>1,442,509</td>
<td>1,932,143</td>
</tr>
<tr>
<td>Production</td>
<td>1,246,571</td>
<td>1,719,444</td>
</tr>
<tr>
<td>End-of-period inventories</td>
<td>79,311</td>
<td>106,798</td>
</tr>
<tr>
<td><strong>Shipments:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Internal consumption</td>
<td>10,799</td>
<td>28,503</td>
</tr>
<tr>
<td>Home market</td>
<td>323,077</td>
<td>460,653</td>
</tr>
<tr>
<td>Exports to--</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The United States</td>
<td>142,004</td>
<td>161,090</td>
</tr>
<tr>
<td>All other markets</td>
<td>797,443</td>
<td>1,061,714</td>
</tr>
<tr>
<td>Total exports</td>
<td>939,446</td>
<td>1,222,804</td>
</tr>
<tr>
<td>Total shipments</td>
<td>1,273,322</td>
<td>1,711,960</td>
</tr>
<tr>
<td><strong>Ratios and shares (percent)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capacity utilization</td>
<td>86.4</td>
<td>89.0</td>
</tr>
<tr>
<td>Inventories to production</td>
<td>6.4</td>
<td>6.2</td>
</tr>
<tr>
<td>Inventories to total shipments</td>
<td>6.2</td>
<td>6.2</td>
</tr>
<tr>
<td>Shares of total quantity of shipments</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Internal consumption</td>
<td>0.8</td>
<td>1.7</td>
</tr>
<tr>
<td>Home market</td>
<td>25.4</td>
<td>26.9</td>
</tr>
<tr>
<td>Exports to--</td>
<td></td>
<td></td>
</tr>
<tr>
<td>The United States</td>
<td>11.2</td>
<td>9.4</td>
</tr>
<tr>
<td>All other markets</td>
<td>62.6</td>
<td>62.0</td>
</tr>
<tr>
<td>Total exports</td>
<td>73.8</td>
<td>71.4</td>
</tr>
</tbody>
</table>

Source: Compiled from data submitted in Commission questionnaire responses.
COMBINED INDUSTRY DATA FOR BOTH SUBJECT COUNTRIES

Table VII-4 presents data for capacity, production, and shipments of citric acid and certain citrate salts from all reporting producers in Canada and China combined.

Table VII-4
Citric acid and certain citrate salts: Canada and China’s reported production capacity, production, shipments, and inventories, 2006-2008 and projections for 2009 and 2010

* * * * * * * *

U.S. IMPORTERS’ INVENTORIES

Reported inventories held by U.S. importers of subject merchandise from Canada, China, and nonsubject countries are shown in table VII-5.
### Table VII-5
Citric acid and certain citrate salts: U.S. importers' end-of-period inventories of subject and nonsubject imports, by sources, 2006-2008

<table>
<thead>
<tr>
<th>Source</th>
<th>Calendar year</th>
<th>2006</th>
<th>2007</th>
<th>2008</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imports from Canada:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventories (1,000 dry pounds)</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Ratio to imports (percent)</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Ratio to U.S. shipments of imports (percent)</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td><strong>Imports from China:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventories (1,000 dry pounds)</td>
<td></td>
<td>17,701</td>
<td>28,685</td>
<td>24,376</td>
</tr>
<tr>
<td>Ratio to imports (percent)</td>
<td></td>
<td>12.8</td>
<td>19.2</td>
<td>14.5</td>
</tr>
<tr>
<td>Ratio to U.S. shipments of imports (percent)</td>
<td></td>
<td>14.7</td>
<td>23.8</td>
<td>16.0</td>
</tr>
<tr>
<td><strong>Imports from Canada and China:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventories (1,000 dry pounds)</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Ratio to imports (percent)</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Ratio to U.S. shipments of imports (percent)</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td><strong>Imports from nonsubject countries:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventories (1,000 dry pounds)</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Ratio to imports (percent)</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Ratio to U.S. shipments of imports (percent)</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td><strong>Imports from all sources:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inventories (1,000 dry pounds)</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Ratio to imports (percent)</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Ratio to U.S. shipments of imports (percent)</td>
<td></td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
</tbody>
</table>

Note.—All ratios are calculated using data from firms providing both numerator and denominator information.

Source: Compiled from data submitted in response to Commission questionnaires.
U.S. IMPORTERS’ CURRENT ORDERS

The Commission requested U.S. importers to indicate whether they imported or arranged for the importation of citric acid or certain citrate salts after December 31, 2008. Four of the 30 reporting U.S. importers stated that they had imported or arranged for importation since December 31, 2008. Table VII-6 presents the four U.S. importers which indicated that they had imported or arranged for the importation of the subject product from Canada or China and the quantity of those U.S. imports.

Table VII-6
Citric acid and certain citrate salts: U.S. importers’ orders of subject imports from Canada and China subsequent to December 31, 2008, by firm

| * | * | * | * | * | * | * | *

ANTIDUMPING AND COUNTERVAILING DUTY ORDERS IN THIRD-COUNTRY MARKETS

On December 1, 2008, the European Union announced the imposition of definitive antidumping duties on imports of citric acid (including sodium citrate) from China. The definitive duties announced ranged from 6.6 percent to 42.7 percent.12 However, on December 2, 2008, the EU accepted a “price undertaking” from six Chinese exporters13 which offered to sell product in the EU at price levels which would eliminate the injurious effects of dumping.14

In 2005, the government of India conducted an antidumping duty investigation on its imports of citric acid from China and Ukraine. On August 25, 2005, it determined that the Indian citric acid industry was not materially injured and did not impose antidumping duties.15 Petitioners reported that Mexico imposed antidumping duties on imports of citric acid from China from 2003 until October 2008 at which time the duties expired. There is no indication that citric acid and certain citrate salts from Canada or China have been the subject of any import relief investigations in any other countries.

INFORMATION ON PRODUCERS IN NONSUBJECT COUNTRIES

In assessing whether the domestic industry is materially injured or threatened with material injury “by reason of subject imports,” the legislative history states “that the Commission must examine all relevant evidence, including any known factors, other than the dumped or subsidized imports, that may be injuring the domestic industry, and that the Commission must examine those other factors (including non-subject imports) “to ensure that it is not attributing injury from other sources to the subject imports.”16

---

13 These firms are: (1) Anhui BBCA Biochemical, (2) RZBC, (3) TTCA, (4) Yixing-Union Biochemical, (5) Laiwu Taihe Biochemistry, and (6) Wiefang Ensign. Chinese producers not covered by the price undertaking agreement would be subject to the 42.7 percent antidumping duty imposed by the EC.
15 See the India’s Ministry of Commerce and Industry website retrieved on May 6, 2008 http://commerce.nic.in/traderemedies/ad_casesinindia.asp?id=2. In 2003, the government of India imposed antidumping duties on citric acid from Indonesia and Thailand. In 2007, the government of South Africa terminated an antidumping duty investigation on citric acid from China for reasons unrelated to its domestic industry’s material injury.
Based on U.S. Government official trade statistics, the following nonsubject countries exported substantial amounts of citric acid, sodium citrate, or other salts and esters of citric acid to the U.S. market during the period of investigation: Israel, Colombia, Germany, Thailand, Austria, and Belgium (listed in descending order of import volume in 2008).

Table VII-7 presents estimates from *** on citric acid and included in exhibit I-2 of the petition, which show January 2006 capacities and full-year 2005 production.

**Table VII-7: World capacity (January 2006) and production (2005) of citric acid, by country/region**

| * | * | * | * | * | * | * | *

In Western Europe, there have been three operating citric acid plants during the period for which data were collected in these investigations. JBL, the parent of the Canadian respondent, owns the largest plant with a capacity of *** in Austria. At the time of the last investigation, Austria and Israel were the two largest sources of nonsubject imports in the U.S. market. Citrique Belge operates the ***, which has a capacity of ***. Tate & Lyle had a plant in the United Kingdom that had a capacity of ***, but closed the facility permanently in 2007. JBL used to operate an additional citric acid plant in Germany but closed this plant in 1991 due to logistical issues and currently converts purchased citric acid into citrate salts at this facility. ADM used to operate a plant in Ireland but it permanently closed the facility in 2005. Both ADM and Tate & Lyle assert that imports from China were the reasons for the closures.

All of the capacity listed for Central and South America is controlled by the petitioners. *** own the plants in Brazil which have a combined capacity of ***. *** has *** in the lone plant in Colombia, which has a capacity of ***. An Israeli company, Gadot Biochemical Industries LTC ("GBI") with a capacity of ***, is the largest producer in the Middle East. Two Iranian companies have the balance of the capacity in the region.

*** capacity in Japan ***, Showa Kako, with a capacity of ***. ***. The three countries included in “Other Asia” are India, Indonesia, and Thailand. Their capacities as of January 2006 were ***, ***, and ***, respectively. According to ***, the price for citric acid imports was ***. The prices for citric acid imports in others were ***. The trade estimates provided in *** showed most of the regions/countries to be net importers. The three exceptions to this rule, Central and South America, China, and the Middle East, had net exports of approximately ***.

---

17 ***, Conference transcript, p. 74 (Poulos).
18 ***.
19 ***.
20 GBI and Jiangsu Nuobei Biochemical reportedly have partnered to build a new citric acid plant in Jiangsu, China. “Gadot-Best Biochemical’s 60,000 t/a citric acid project under construction,” *China Corn Products News*, December 2007.
21 ***.
22 ***.
23 ***.
24 ***.
APPENDIX A

FEDERAL REGISTER NOTICES
INTERNATIONAL TRADE COMMISSION

[Investigations Nos. 701–TA–456 and 731–TA–1151–1152 (Final)]

Citric Acid and Certain Citrate Salts From Canada and China


ACTION: Scheduling of the final phase of countervailing duty and antidumping investigations.

SUMMARY: The Commission hereby gives notice of the scheduling of the final phase of countervailing duty investigation No. 701–TA–456 (Final) under section 705(b) of the Tariff Act of 1930 (19 U.S.C. 1671d(b)) (the Act) and the final phase of antidumping investigation Nos. 731–TA–1151–1152 (Final) under section 735(b) of the Act (19 U.S.C. 1673d(b)) to determine whether an industry in the United States is materially injured or threatened with material injury, or the establishment of an industry in the United States is materially retarded, by reason of subsidized imports from China and less-than-fair-value imports from Canada and China of citric acid and certain citrate salts, provided for in subheadings 2918.15.00, 2918.15.10, 2918.15.50, and 3824.90.92 of the Harmonized Tariff Schedule of the United States.¹

¹For purposes of these investigations, the Department of Commerce has defined the subject merchandise as “all grades and granulation sizes of citric acid, sodium citrate, and potassium citrate in their unblended forms, whether dry or in solution, and regardless of packaging type. The scope also includes blends of citric acid, sodium citrate, and potassium citrate; as well as blends with other ingredients, such as sugar, where the unblended form(s) of citric acid, sodium citrate, and potassium citrate constitute 40 percent or more, by weight, of the blend. The scope of this investigation also includes all forms of crude calcium citrate.”
For further information concerning the conduct of this phase of the investigations, hearing procedures, and rules of general application, consult the Commission’s Rules of Practice and Procedure, part 201, subparts A through E (19 CFR part 201), and part 207, subparts A and C (19 CFR part 207).

DATES: Effective Date: November 20, 2008.


Hearing-impaired persons can obtain information on this matter by contacting the Commission’s TDD terminal on 202–205–1810. Persons with mobility impairments who will need special assistance to access the Commission should contact the Office of the Secretary at 202–205–2000.

General information concerning the Commission may also be obtained by accessing its internet server (http://www.usitc.gov). The public record for these investigations may be viewed on the Commission’s electronic docket (EDIS) at http://edis.usitc.gov.

SUPPLEMENTARY INFORMATION:

Background.—The final phase of these investigations is being scheduled as a result of affirmative preliminary determinations by the Department of Commerce that certain benefits which constitute subsidies within the meaning of section 703 of the Act (19 U.S.C. 1671b) are being provided to manufacturers, producers, or exporters in China of citric acid and certain citric salts, and that imports from Canada and China are being sold in the United States at less than fair value within the meaning of section 733 of the Act (19 U.S.C. 1673b). The investigations were requested in a petition filed on April 14, 2008, by Archer Daniels Midland Co., Decatur, IL; Cargill, Inc., Wayzata, MN; and Tate & Lyle Americas, Inc., Decatur, IL.

Participation in the investigations and public service list.—Persons, including industrial users of the subject merchandise and, if the merchandise is sold at the retail level, representative consumer organizations, wishing to participate in the final phase of these investigations as parties must file an entry of appearance with the Secretary to the Commission, as provided in section 201.11 of the Commission’s rules, no later than 21 days prior to the hearing date specified in this notice. A party that filed a notice of appearance during the preliminary phase of the investigations need not file an additional notice of appearance during this final phase. The Secretary will maintain a public service list containing the names and addresses of all persons, or their representatives, who are parties to the investigations.

Limited disclosure of business proprietary information (BPI) under an administrative protective order (APO) and BPI service list.—Pursuant to section 207.7(a) of the Commission’s rules, the Secretary will make BPI gathered in the final phase of these investigations available to authorized applicants under the APO issued in the investigations, provided that the application is made no later than 21 days prior to the hearing date specified in this notice. Authorized applicants must represent interested parties, as defined by 19 U.S.C. 1677(9), who are parties to the investigations. A party granted access to BPI in the preliminary phase of the investigations need not reapply for such access. A separate service list will be maintained by the Secretary for those parties authorized to receive BPI under the APO.

Staff report.—The prehearing staff report in the final phase of these investigations will be placed in the nonpublic record on March 24, 2009, and a public version will be issued thereafter, pursuant to section 207.22 of the Commission’s rules.

Hearing.—The Commission will hold a hearing in connection with the final phase of these investigations beginning at 9:30 a.m. on April 7, 2009, at the U.S. International Trade Commission Building. Requests to appear at the hearing should be filed in writing with the Secretary to the Commission on or before March 30, 2009. A nonparty who has testimony that may aid the Commission’s deliberations may request permission to present a short statement at the hearing. All parties and nonparties desiring to appear at the hearing and make oral presentations should attend a prehearing conference to be held at 9:30 a.m. on April 1, 2009, at the U.S. International Trade Commission Building. Oral testimony and written materials to be submitted at the public hearing are governed by sections 201.6(b)(2), 201.13(f), and 207.24 of the Commission’s rules. Parties must submit any request to present a portion of their hearing testimony in camera no later than 7 business days prior to the date of the hearing.

Written submissions.—Each party who is an interested party shall submit a prehearing brief to the Commission. Prehearing briefs must conform with the provisions of section 207.23 of the Commission’s rules; the deadline for filing is March 31, 2009. Parties may also file written testimony in connection with their presentation at the hearing, as provided in section 207.24 of the Commission’s rules, and posthearing briefs, which must conform with the provisions of section 207.25 of the Commission’s rules. The deadline for filing posthearing briefs is April 15, 2009; witness testimony must be filed no later than three days before the hearing. In addition, any person who has not entered an appearance as a party to the investigations may submit a written statement of information pertinent to the subject of the investigations, including statements of support or opposition to the petition, on or before April 15, 2009. On May 1, 2009, the Commission will make available to parties all information on which they have not had an opportunity to comment. Parties may submit final comments on this information on or before May 5, 2009, but such final comments must not contain new factual information and must otherwise comply with section 207.30 of the Commission’s rules. All written submissions must conform with the provisions of section 201.8 of the Commission’s rules; any submissions that contain BPI must also conform with the requirements of sections 201.6, 207.3, and 207.7 of the Commission’s rules. The Commission’s rules do not authorize filing of submissions with the Secretary by facsimile or electronic means, except to the extent permitted by section 201.8 of the Commission’s rules, as amended, 67 FR 68306 (November 8, 2002). Even where electronic filing of a document is permitted, certain documents must also be filed in paper form, as specified in...
II(C) of the Commission’s Handbook on Electronic Filing Procedures, 67 FR 68168, 68173 (November 8, 2002).

Additional written submissions to the Commission, including requests pursuant to section 201.12 of the Commission’s rules, shall not be accepted unless good cause is shown for accepting such submissions, or unless the submission is pursuant to a specific request by a Commissioner or Commission staff.

In accordance with sections 201.16(c) and 207.3 of the Commission’s rules, each document filed by a party to the investigations must be served on all other parties to the investigations (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service.

Authority: These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.21 of the Commission’s rules.

Issued: December 1, 2008.

By order of the Commission.

William R. Bishop,

Acting Secretary to the Commission.

[FR Doc. E8–28730 Filed 12–3–08; 8:45 am]

BILLING CODE 7020–02–P
DEPARTMENT OF COMMERCE
International Trade Administration
(C–570–938)

Citric Acid and Certain Citrate Salts From the People’s Republic of China: Final Affirmative Countervailing Duty Determination

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

SUMMARY: The Department of Commerce (“Department”) has determined that countervailable subsidies are being provided to producers and exporters of citric acid and certain citrate salts (“citric acid”) from the People’s Republic of China (“PRC”). For information on the estimated countervailing duty rates, please see the “Suspension of Liquidation” section, below.

EFFECTIVE DATE: April 13, 2009.

FOR FURTHER INFORMATION CONTACT: David Neubacher, Shelly Atkinson or Damian Felton, AD/CVD Operations, Office 1, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230; telephone: (202) 482–5823, (202) 482–0116 or (202) 482–0133, respectively.

SUPPLEMENTARY INFORMATION:

Petitioners
The petitioners in this investigation are Archer Daniels Midland Company, Cargill, Incorporated, and Tate & Lyle America, Inc. (collectively, “Petitioners”).

Period of Investigation
The period for which we are measuring subsidies, or period of investigation, is January 1, 2007, through December 31, 2007.

Case History
The following events have occurred since the announcement of the preliminary determination, which was published in the Federal Register on September 19, 2008. See Citric Acid and Certain Citrate Salts From the People’s Republic of China: Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Countervailing Duty Determination With Final Antidumping Duty Determination, 73 FR 54367 (September 19, 2008) (“Preliminary Determination”).

The Department issued several supplemental questionnaires to the Government of the People’s Republic of China (“GOC”), TTCA Co., Ltd. (formerly Shandong TTCA Biochemical Co., Ltd.) (“TTCA”) and Yixing Union Biochemical Co. Ltd. (“Yixing Union”) and its cross–owned affiliate Yixing Union Cogeneration Co., Ltd., and received responses in September and October 2008.

Public versions of the questionnaires and responses, as well as the various memoranda cited below are available at the Department’s Central Records Unit (Room 1117 in the HCHB Building) (hereafter referred to as “CRU”).

On September 12, 2008, the Department determined to investigate certain subsidies alleged by Petitioners in their submission of August 8, 2008. See Memorandum to Susan Kuhbach, Senior Director, Office 1, entitled “Analysis of Petitioners’ New Subsidy Allegations” (September 12, 2008). On October 1, 2008, the Department issued questionnaires to the GOC, TTCA and Yixing Union regarding these new subsidy allegations. We received responses to these questionnaires as well as to supplemental questionnaires regarding the newly alleged submissions in October 2008.

On October 20, 2008, the Department initiated an investigation of TTCA’s creditworthiness for the years 2004, 2006 and 2007, pursuant to 19 CFR 351.505(a)(6). See Memorandum to Susan H. Kuhbach, Senior Director, Office 1, entitled “Uncreditable Allegation for TTCA” (October 20, 2008). On February 25, 2009, we issued our preliminary determination that TTCA was uncreditworthy for the years investigated. See Memorandum to Susan H. Kuhbach, Senior Office Director, AD/CVD Operations, Office 1, entitled “Preliminary Creditworthiness Determination for TTCA Co., Ltd.” (February 25, 2009).

From November 1 through November 20, 2008, we conducted verification of the questionnaire responses submitted by the GOC, TTCA and Yixing Union.

On March 4, 2009, we issued our post–preliminary determination regarding the new subsidy allegations and certain other programs discovered in the course of the investigation. See Memorandum to Ronald K. Lorentzen, Acting Assistant Secretary for Import Administration, entitled “Post–Preliminary Findings for the New Subsidy Allegations” (March 4, 2009).

We received case briefs from the GOC and Yixing Union on March 12, 2009, and from Petitioners and TTCA on March 13, 2009. The same parties submitted rebuttal briefs on March 18 and 19, 2009, respectively.
Scope of the Investigation

The scope of this investigation includes all grades and granulation sizes of citric acid, sodium citrate, and potassium citrate in their unblended forms, whether dry or in solution, and regardless of packaging type. The scope also includes blends of citric acid, sodium citrate, and potassium citrate; as well as blends with other ingredients, such as sugar, where the unblended form(s) of citric acid, sodium citrate, and potassium citrate constitute 40 percent or more, by weight, of the blend. The scope of this investigation also includes all forms of crude calcium citrate, including dicalcium citrate monohydrate, and tricalcium citrate tetrahydrate, which are intermediate products in the production of citric acid, sodium citrate, and potassium citrate. The scope of this investigation does not include calcium citrate that satisfies the standards set forth in the United States Pharmacopeia and has been mixed with a functional excipient, such as dextrose or starch, where the excipient constitutes at least 2 percent, by weight, of the product. The scope of this investigation includes the hydrous and anhydrous forms of citric acid, the dihydrate and anhydrous forms of sodium citrate, otherwise known as citric acid sodium salt, and the monohydrate and monopotassium forms of potassium citrate. Sodium citrate also includes both trisodium citrate and monosodium citrate, which are also known as citric acid trisodium salt and citric acid monosodium salt, respectively. Citric acid and sodium citrate are classifiable under 2918.15.0000 and 3824.90.9290 of the Harmonized Tariff Schedule of the United States (HTSUS), respectively. Potassium citrate and crude calcium citrate are classifiable under 2918.15.5000 and 3824.90.9290 of the HTSUS, respectively. Blends that include citric acid, sodium citrate, and potassium citrate are classifiable under 3824.90.9290 of the HTSUS. Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the merchandise is dispositive.

Injury Test

Because the PRC is a “Subsidies Agreement Country” within the meaning of section 701(b) of the Tariff Act of 1930, as amended (“Act”), section 701(a)(2) of the Act applies to this investigation. Accordingly, the International Trade Commission (“ITC”) must determine whether imports of the subject merchandise from the PRC materially injure, or threaten material injury to a U.S. industry. On June 11, 2008, the ITC published its preliminary determination that there is a reasonable indication that an industry in the United States is materially injured or threatened with material injury by reason of imports from China of citric acid. See Citric Acid and Certain Citrate Salts From Canada and China; Determinations, 73 FR 33115 (June 11, 2008).

Analysis of Comments Received

All issues raised in the case and rebuttal briefs by parties to this investigation are addressed in the Memorandum from John M. Anderson, Acting Deputy Assistant Secretary for Antidumping and Countervailing Duty Operations, to Ronald K. Lorentzen, Acting Assistant Secretary for Import Administration, entitled “Issues and Decision Memorandum for the Final Determination in the Countervailing Duty Investigation of Citric Acid and Certain Citrate Salts from the People’s Republic of China” (April 6, 2009) (hereafter referred to as the “Decision Memorandum”), which is hereby adopted by this notice. Attached to this notice as an Appendix is a list of the issues that parties have raised and to which we have responded in the Decision Memorandum. Parties can find this public memorandum in the Department’s CRU. In addition, a complete version of the Decision Memorandum can be accessed directly on the Internet at http://ia.ita.doc.gov/frn/. The paper copy and electronic version of the Decision Memorandum are identical in content.

Use of Adverse Facts Available

For purposes of this final determination, we have continued to rely on facts available and have again used adverse inferences in accordance with sections 776(a) and (b) of the Act to determine the countervailable subsidy rates for Anhui BBCA Biochemical Co., Ltd. (“Anhui BBCA”), which is one of the three companies not investigated, we will determine an all-others rate equal to the weighted average countervailable subsidy rates established for exporters and producers individually investigated, excluding any zero and de minimis countervailable subsidy rates, and any rates determined entirely under section 776 of the Act. As Anhui BBCA’s rate was calculated under section 776 of the Act, it is not included in the all-others rate.

Suspension of Liquidation

In accordance with section 705(c)(1)(B)(i)(I) of the Act, we have calculated an individual rate for the companies under investigation, Anhui BBCA, TTCA and Yixing Union. Section 705(c)(5)(A)(i) of the Act states that for companies not investigated, we will determine an all-others rate equal to the weighted average countervailable subsidy rates established for exporters and producers individually investigated, excluding any zero and de minimis countervailable subsidy rates, and any rates determined entirely under section 776 of the Act. As Anhui BBCA’s rate was calculated under section 776 of the Act, it is not included in the all-others rate.

Notwithstanding the language of section 705(c)(5)(A)(i) of the Act, we have not calculated the all-others rate by weight averaging the rates of TTCA and Yixing Union because doing so risks disclosure of proprietary information. Therefore, we have calculated a simple average of the two responding firms’ rates. Finally, because TTCA’s rate includes export subsidies, the all-others rate also includes export subsidies.
In accordance with section 703(d) of the Act, we instructed U.S. Customs and Border Protection to discontinue the suspension of liquidation for countervailing duty purposes for subject merchandise entered on or after January 17, 2009, but to continue the suspension of liquidation of entries made from September 19, 2008, through January 16, 2009.

We will issue a countervailing duty order and reinstate the suspension of liquidation under section 706(a) of the Act if the ITC issues a final affirmative injury determination, and will require a cash deposit of estimated countervailing duties for such entries of merchandise in the amounts indicated above. If the ITC determines that material injury, or threat of material injury, does not exist, this proceeding will be terminated and all estimated duties deposited or securities posted as a result of the suspension of liquidation will be refunded or canceled.

ITC Notification

In accordance with section 705(d) of the Act, we will notify the ITC of our determination. In addition, we are making available to the ITC all non–privileged and non–proprietary information related to this investigation. We will allow the ITC access to all privileged and business proprietary information in our files, provided the ITC confirms that it will not disclose such information, either publicly or under an APO, without the written consent of the Assistant Secretary for Import Administration.

Return or Destruction of Proprietary Information

In the event that the ITC issues a final negative injury determination, this notice will serve as the only reminder to parties subject to an administrative protective order (“APO”) of their responsibility concerning the destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305(a)(3). Timely written notification of the return/destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and terms of an APO is a violation which is subject to sanction.

This determination is published pursuant to sections 705(d) and 777(i) of the Act.


Ronald K. Lorentzen,
Acting Assistant Secretary for Import Administration.

APPENDIX

List of Comments and Issues in the Decision Memorandum

General Issues
Comment 1 Application of CVD Law to a Country the Department treats as an NME in a Parallel AD Investigation
Comment 2 Double Counting/Overlapping Remedies
Comment 3 Requirement to Provide Evidence of Lower Prices
Comment 4 Proposed Cutoff Date for Identifying Subsidies

Program Specific Issues
Comment 5 Policy Lending Whether Policy Lending Program Exists
Comment 6 Policy Lending Whether CIB is a Government Authority
Comment 7 Benchmark - Whether the Department is Required to Use a Chinese Benchmark
Comment 8 Benchmark - Whether Department Should Make an Inflation Adjustment to Its Regression–Based Benchmark Rate
Comment 9 Benchmark - Whether the Department has a Basis for Treating “Medium–term” as Having Terms of Two Years or Less
Comment 10 Benchmark - Whether to Remove Certain Countries from the IMF Data
Comment 11 Benchmark - Whether Negative Inflation–adjusted Interest Rates Should be Excluded from the Regressions
Comment 12 Benchmark - Whether the Regression is Statistically Invalid
Comment 13 Benchmark - Whether the Difference Between Long- and Short–term Interest Rates Cannot be Based on BB–grade
Comment 14 Benchmark - Whether the Adjustment for Long–term Rates should be Additive or Multiplicative
Comment 15 Benchmark - Whether the Discount Rate Computation is Flawed
Comment 16 FIE Tax Programs - Whether FIE Tax Programs are Specific
Comment 17 FIE Tax Programs - Whether They Have Been Terminated

TTCA Specific Issues
Comment 18 Whether the Application of Total AFA is Warranted
Comment 19 Whether the Application of Partial AFA is Warranted

Comment 20 Provision of Plant and Equipment for LTAR Whether the Department is Required to Issue a Finding
Comment 21 Provision of Plant and Equipment for LTAR Proposed Methodology for Measuring the Benefit
Comment 22 Provision of Land for LTAR Whether Land is a Good or a Service
Comment 23 Provision of Land for LTAR Whether the Use of an External Benchmark is Appropriate
Comment 24 Provision of Land for LTAR Whether Benchmark is New
Comment 25 Whether the Appropriate Benchmark Interest Rate for Floating Loan
Comment 26 Whether To Correct a Clerical Error in TTCA’s Subsidy Calculation

Yixing Union Specific Issues
Comment 27 Attribution of Yixing Union and Cogeneration Based on Cross–Ownership
Comment 28 Whether to Apply AFA for Land in the YEDZ for LTAR Program
Comment 29 How to Treat the Transfer of Allocated to Granted Land–use Rights from HPP to Cogeneration
Comment 30 Whether the Department’s Finding Regarding Land–use Rights in Yixing City Violates Due Process
Comment 31 Whether the Department’s Finding Regarding the Torch Program Violates Due Process

[FR Doc. E9–8358 Filed 4–10–09; 8:45 am]
DEPARTMENT OF COMMERCE

International Trade Administration

[A–570–937]

Citric Acid and Certain Citrate Salts From the People’s Republic of China: Final Affirmative Determination of Sales at Less Than Fair Value

AGENCY: International Trade Administration, Department of Commerce.

DATES: Effective Date: April 13, 2009.

SUMMARY: We invited interested parties to comment on our preliminary determination of sales at LTFV. The Department of Commerce (“the Department”) has determined that citric acid and certain citrate salts (“citric acid”) from the People’s Republic of China (“PRC”) is being, or is likely to be, sold in the United States at LTFV as provided in section 735 of the Tariff Act of 1930, as amended (“the Act”). The estimated margins of sales at less than
fair value (“LTFV”) are shown in the “Final Determination Margins” section of this notice.

FOR FURTHER INFORMATION CONTACT: Lilit Astvatsatryan or Andrea Staehler-Berton, AD/CVD Operations, Office 8, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW., Washington, DC 20230; telephone: (202) 482–6412 or (202) 482–4037, respectively.

SUPPLEMENTARY INFORMATION:

Case History


Between January 7 and 20, 2009, the Department conducted verifications of TTCA Co., Ltd. (aka Shandong TTCA Biochemistry Co., Ltd.) (“TTCA”) and Yixing Union Biochemical Co., Ltd. (“Yixing Union”) (“respondents”). See the “Verification” section below for additional information.


Verification

As provided in section 782(i) of the Act, we verified the information submitted by TTCA and Yixing Union for use in our final determination. See the Department’s verification reports on the record of this investigation in the Central Records Unit (“CRU”), Room 1117 of the main Department building, with respect to these entities. For all verified companies, we used standard verification procedures, including examination of relevant accounting and production records, as well as original source documents provided by respondents.

Analysis of Comments Received

All issues raised in the case and rebuttal briefs, and at the hearing, by parties to this investigation are addressed in the “Issues and Decision Memorandum for the Investigation of Citric Acid and Certain Citrate Salts from the People’s Republic of China,” dated concurrently with this notice and which is hereby adopted by this notice (“Issues and Decision Memorandum”). A list of the issues which parties raised and to which we respond in the Issues and Decision Memorandum is attached to this notice as an Appendix. The Issues and Decision Memorandum is a public document and is on file in the CRU, and is accessible on the Web at http://ia.ita.doc.gov/frn. The paper copy and electronic version of the memorandum are identical in content.

Changes Since the Preliminary Determination

Based on our analysis of information on the record of this investigation, we have made changes to the margin calculations for the final determination for all mandatory respondents.

General Issues

• We have updated the Indonesian and Indian inflator information for the wholesale price index (“WPI”) as published in the International Financial Statistics of the International Monetary Fund. See Final Determination of the Antidumping Duty Investigation of Citric Acid and Certain Citrate Salts from the People’s Republic of China: Surrogate Value Memorandum, dated April 6, 2009 (“Final SV Memo”), at 2.

• For the final determination, we have adjusted TTCA’s indirect labor. See Issues and Decision Memorandum, at Comment 4.

• We have revised the surrogate value for sodium lignosulphonate. See Final SV Memo, at 3, and Issues and Decision Memorandum, at Comment 11B.

• We have revised the surrogate financial ratios by including interest expenses in the SG&A calculation. See Final SV Memo, at 3, and Issues and Decision Memorandum, at Comment 3.

• Consistent with our practice, we have excluded beginning and ending finished goods inventories from the calculation of surrogate financial ratios for the final determination. See Final SV Memo, at 3.

• Based on the surrogate financial company’s treatment of certain depreciation and warehouse expenses as selling expenses, and depreciation and repairs and maintenance as general and administrative expenses, we have reclassified these expenses from the surrogate factory overhead ratio to the surrogate selling, general, and administrative ratio calculation for the final determination. See Final SV Memo, at 3–4.

• We were unable to segregate and, therefore, were unable to exclude energy costs from the calculation of the surrogate financial ratios. Accordingly, we have disregarded the respondents’ energy inputs (coal and steam by-product offsets for TTCA, electricity and steam for Yixing Union) in the calculation of normal value for purposes of the final determination, in order to avoid double-counting energy costs which have necessarily been captured in the surrogate financial ratios. See Investigation of Citric Acid and Certain Citrate Salts from the People’s Republic of China: Analysis of the Final Determination Margin Calculation for TTCA Co., Ltd., (a.k.a. Shandong TTCA Biochemistry Co., Ltd.), dated April 6, 2009 (“TTCA Final Analysis Memo”), at 2; see also Investigation of Citric Acid and Certain Citrate Salts from the People’s Republic of China: Analysis of the Final Determination Margin Calculation for Yixing Union Biochemical Co., Ltd., dated April 6, 2009 (“Yixing Union Final Analysis Memo”), at 1–2; and Issues and Decision Memorandum at Comment 2.

Company-Specific Changes Since the Preliminary Determination

TTCA

• For the final determination, we have adjusted TTCA’s indirect labor. See TTCA Final Analysis Memo at 1–2 and Issues and Decision Memorandum, at Comment 10.

• For the final determination, we have added TTCA’s billing adjustment expense to the gross unit price. See TTCA Final Analysis Memo, at 2 and Issues and Decision Memorandum, at Comment 11A.

• We have included TTCA’s low protein scrap by-product in the calculation of the normal value. See TTCA Final Analysis Memo, at 2–3 and Issues and Decision Memorandum, at Comment 15.

• We have adjusted TTCA’s reported consumption of calcium carbonate to account for the under-reported usage


---

rate. See TTCA Final Analysis Memo, at 3.

Yixing Union
• We have valued Yixing Union’s ocean freight using the reported international freight. See Yixing Union Final Analysis Memo.

Scope of Investigation
The scope of this investigation includes all grades and granulation sizes of citric acid, sodium citrate, and potassium citrate in their unblended forms, whether dry or in solution, and regardless of packaging type. The scope also includes blends of citric acid, sodium citrate, and potassium citrate; as well as blends with other ingredients, such as sugar, where the unblended form(s) of citric acid, sodium citrate, and potassium citrate constitute 40 percent or more, by weight, of the blend. The scope of this investigation also includes all forms of crude calcium citrate, including dicalcium citrate monohydrate, and tricalcium citrate trihydrate, which are intermediate products in the production of citric acid, sodium citrate, and potassium citrate. The scope of this investigation does not include calcium citrate that satisfies the standards set forth in the United States Pharmacopeia and has been mixed with a functional excipient, such as dextrose or starch, where the excipient constitutes at least 2%, by weight, of the product. The scope of this investigation includes the hydrous and anhydrous forms of citric acid, the dihydrate and anhydrous forms of sodium citrate, otherwise known as citric acid sodium salt, and the monohydrate and monopotassium forms of potassium citrate. Sodium citrate also includes both trisodium citrate and monosodium citrate, which are also known as citric acid trisodium salt and citric acid monosodium salt, respectively. Citric acid and sodium citrate are classifiable under 2918.15.1000 and 2918.15.1000 of the Harmonized Tariff Schedule of the United States (HTSUS), respectively. Potassium citrate and crude calcium citrate are classifiable under 2918.15.5000 and 3824.90.9290 of the HTSUS, respectively. Blends that include citric acid, sodium citrate, and potassium citrate are classifiable under 3824.90.9290 of the HTSUS. Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the merchandise is dispositive.

Surrogate Country
In the Preliminary Determination, we stated that we had selected Indonesia as the appropriate surrogate country to use in this investigation for the following reasons: (1) it is a significant producer of comparable merchandise; (2) it is at a similar level of economic development comparable to that of the PRC; and (3) we have reliable data from Indonesia that we can use to value the factors of production. See Preliminary Determination. For the final determination, we continue to use Indonesia as the primary surrogate country. See Issues and Decision Memorandum, at Comment 1.

Separate Rates
In proceedings involving non-market-economy (“NME”) countries, the Department begins with a rebuttable presumption that all companies within the country are subject to government control and, thus, should be assigned a single antidumping duty deposit rate. It is the Department’s policy to assign all exporters of merchandise subject to an investigation in an NME country this single rate unless an exporter can demonstrate that it is sufficiently independent so as to be entitled to a separate rate. See Final Determination of Sales at Less Than Fair Value: Sparklers from the People’s Republic of China, 56 FR 20588 (May 6, 1991) (“Sparklers”), as amplified by Notice of Final Determination of Sales at Less Than Fair Value: Silicon Carbide from the People’s Republic of China, 59 FR 22585 (May 2, 1994) (“Silicon Carbide”), and 19 CFR 351.107(d).

In the Preliminary Determination, we found that TTCA, Yixing Union and 11 separate rate applicants demonstrated their eligibility for separate rate status. For the final determination, we continue to find that the evidence placed on the record of this investigation by TTCA, Yixing Union, and the separate rate applicants demonstrate both a de jure and de facto absence of government control, with respect to their respective exports of the merchandise under investigation, and, thus continue to find that they are eligible for separate rate status.

Use of Facts Available
Section 776(a)(2) of the Act provides that, if an interested party: (A) Withholds information that has been requested by the Department; (B) fails to provide such information in a timely manner or in the form or manner requested subject to sections 782(c)(1) and (e) of the Act; (C) significantly impedes a proceeding under the antidumping statute; or (D) provides such information to the information cannot be verified, the Department shall, subject to subsection 782(d) of the Act, use facts otherwise available in reaching the applicable determination.

Section 782(c)(1) of the Act provides that if an interested party “promptly after receiving a request from (the Department) for information, notifies (the Department) that such party is unable to submit the information requested in the requested form and manner, together with a full explanation and suggested alternative forms in which such party is able to submit the information.” The Department may modify the requirements to avoid imposing an unreasonable burden on that party.

Section 782(d) of the Act provides that, if the Department determines that a response to a request for information does not comply with the request, the Department will inform the person submitting the response of the nature of the deficiency and shall, to the extent practicable, provide that person the opportunity to remedy or explain the deficiency. If that person submits further information that continues to be unsatisfactory, or this information is not submitted within the applicable time limits, the Department may, subject to section 782(e), disregard all or part of the original and subsequent responses, as appropriate.

Section 782(e) of the Act states that the Department shall not decline to consider information deemed “deficient” under section 782(d) if: (1) The information is submitted by the established deadline; (2) the information can be verified; (3) the information is not so incomplete that it cannot serve as a reliable basis for reaching the applicable determination; (4) the interested party has demonstrated that it acted to the best of its ability; and (5) the information can be used without undue difficulties.

Furthermore, section 776(b) of the Act states that if the Department “finds that an interested party has failed to cooperate by not acting to the best of its ability to comply with a request for information from the administering authority or the Commission, the administering authority or the Commission * * *, in reaching the applicable determination under this title, may use an inference that is adverse to the interests of that party in selecting from among the facts otherwise available.” See also Statement of Administrative Action (SAA) accompanying the Uruguay Round Agreements Act (URAA), H.R. Rep. No. 103–316, Vol. 1 at 870 (1994).

For this final determination, in accordance with sections 776(a)(2)(A), (B) and (D) and 776(b) of the Act, we have determined that the use of adverse
facts available ("AFA") is warranted for the PRC-wide entity, as discussed below.

The PRC-Wide Rate

Because we begin with the presumption that all companies within an NME country are subject to government control and because only the companies listed under the "Final Determination Margins" section below have overcome that presumption, we are applying a single antidumping rate—the PRC-wide rate—to all other exporters of subject merchandise from the PRC. See, e.g., Synthetic Indigo from the People’s Republic of China: Notice of Final Determination of Sales at Less Than Fair Value, 65 FR 25706 (May 3, 2000). The PRC-wide rate applies to all entries of subject merchandise except for entries from the respondents identified as receiving a separate rate in the "Final Determination Margins" section below. In the Preliminary Determination, the Department found that the PRC-wide entity did not respond to our request for information because record evidence indicates there were more exporters of citric acid from the PRC during the POI than those that were found to be eligible for a separate rate and responded to the Q&V questionnaire or the full antidumping questionnaire. Therefore, in the Preliminary Determination we treated these PRC exporters as part of the PRC-wide entity because they did not demonstrate that they operate free of government control over their export activities. No additional information was placed on the record with respect to these entities after the Preliminary Determination.

In addition, because the PRC-wide entity has not provided the Department with the requested information, pursuant to section 776(a)(2)(A) and (C) of the Act, the Department continues to find that the use of facts available is appropriate to determine the PRC-wide rate. Section 776(b) of the Act provides that, in selecting from among the facts otherwise available, an adverse inference is warranted. In the Preliminary Determination, as facts available, we assigned to the PRC-wide entity the margin alleged in the petition, i.e., 156.87 percent. See Preliminary Determination, 73 FR at 70332. For the final determination, we have continued to assign to the PRC-wide entity the rate of 156.87 percent.

Corroboration

Section 776(c) of the Act provides that, when the Department relies on secondary information in using the facts otherwise available, it must, to the extent practicable, corrobore that information from independent sources that are reasonably at its disposal. We have interpreted “corrobore” to mean that we will, to the extent practicable, examine the reliability and relevance of the information submitted. See Notice of Final Determination of Sales at Less Than Fair Value: Certain Cold-Rolled Flat-Rolled Carbon-Quality Steel Products from the Russian Federation, 65 FR 5510, 5518 (February 4, 2000); see, e.g., Tapered Roller Bearings and Parts Thereof, Finished and Unfinished, from Japan, and Tapered Roller Bearings, Four Inches or Less in Outside Diameter, and Components Thereof, from Japan: Preliminary Results of Antidumping Duty Administrative Reviews and Partial Termination of Administrative Reviews, 61 FR 57391, 57392 (November 6, 1996), unchanged in Tapered Roller Bearings and Parts Thereof, Finished and Unfinished, from Japan, and Tapered Roller Bearings, Four Inches or Less in Outside Diameter, and Components Thereof, from Japan: Final Results of Antidumping Duty Corroboration

Section 776(c) of the Act provides that, when the Department relies on secondary information in using the facts otherwise available, it must, to the extent practicable, corrobore that information from independent sources that are reasonably at its disposal. We have interpreted “corrobore” to mean that we will, to the extent practicable, examine the reliability and relevance of the information submitted. See Notice of Final Determination of Sales at Less Than Fair Value: Certain Cold-Rolled Flat-Rolled Carbon-Quality Steel Products from the Russian Federation, 65 FR 5510, 5518 (February 4, 2000); see, e.g., Tapered Roller Bearings and Parts Thereof, Finished and Unfinished, from Japan, and Tapered Roller Bearings, Four Inches or Less in Outside Diameter, and Components Thereof, from Japan: Preliminary Results of Antidumping Duty Administrative Reviews and Partial Termination of Administrative Reviews, 61 FR 57391, 57392 (November 6, 1996), unchanged in Tapered Roller Bearings and Parts Thereof, Finished and Unfinished, from Japan, and Tapered Roller Bearings, Four Inches or Less in Outside Diameter, and Components Thereof, from Japan: Final Results of Antidumping Duty

Combination Rates

In the Preliminary Determination, the Department stated that it would calculate combination rates for the respondents that are eligible for a separate rate in this investigation. See Preliminary Determination, 73 FR at 62961. This practice is described in Policy Bulletin 05.1, “Separate Rates Practice and Application of Combination Rates in Antidumping Investigations Involving Non-Market Economy Countries” available at http://ia.ita.doc.gov/policy/index.html. Final Determination Margins

We determine that the following percentage weighted-average margins exist for the POI:

<table>
<thead>
<tr>
<th>Exporter</th>
<th>Producer</th>
<th>Margin</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTCA Co., Ltd. (a.k.a. Shandong TTCA Biochemistry Co., Ltd.)</td>
<td>TTCA Co., Ltd. (a.k.a. Shandong TTCA Biochemistry Co., Ltd.)</td>
<td>129.08</td>
</tr>
<tr>
<td>Yixing Union Biochemical Co., Ltd</td>
<td>Yixing Union Biochemical Co., Ltd</td>
<td>94.61</td>
</tr>
<tr>
<td>Anhui BBCA Biochemical Co., Ltd</td>
<td>Anhui BBCA Biochemical Co., Ltd</td>
<td>111.85</td>
</tr>
<tr>
<td>A.H.A. International Co., Ltd</td>
<td>China BBCA Maanshan Biochemical Corp</td>
<td>111.85</td>
</tr>
<tr>
<td>A.H.A. International Co., Ltd</td>
<td>Yixing Union Biochemical Co., Ltd</td>
<td>111.85</td>
</tr>
<tr>
<td>High Hope International Group Jiangsu Native Produce IMP &amp; EXP Co., Ltd</td>
<td>Nantong Feiyu Fine Chemical Co., Ltd</td>
<td>111.85</td>
</tr>
<tr>
<td>Huangshi Xinghua Biochemical Co., Ltd</td>
<td>Yixing Union Biochemical Co., Ltd</td>
<td>111.85</td>
</tr>
</tbody>
</table>

Determination
Final Affirmative Countervailing Duty
Citric Acid and Certain Citrate Salts

subsidy of 1.76 percent

publication of the November 20, 2008, the date of
merchandise entered or withdrawn from
liquidation of all imports of subject

U.S. Customs and Border Protection
735(c)(1)(B) of the Act, we are directing
this proceeding in accordance with 19
CFR 351.224(b).

Liquidation
Continuation of Suspension of

In accordance with section
735(c)(1)(B) of the Act, we are directing
U.S. Customs and Border Protection
(“CBP”) to continue to suspend
liquidation of all imports of subject
merchandise entered or withdrawn from
warehouse, for consumption on or after November 20, 2008, the date of
publication of the Preliminary
Determination in the Federal Register.
We will instruct CBP to continue to
require a cash deposit or the posting of a
bond for all companies based on the
estimated weighted-average dumping
margins shown above, adjusted for the
export subsidy rate determined in CVD
Citric Acid Final (i.e., countervailable
subsidy of 1.76 percent ad valorem). See
Citric Acid and Certain Citrate Salts
From the People’s Republic of China:
Final Affirmative Countervailing Duty
Determination (“CVD Citric Acid
Final”), to be published concurrently
with this notice. Furthermore, for all
separate-rate recipients that were not
selected as mandatory respondents, we
will instruct CBP to require an
antidumping cash deposit or the posting
of a bond for each entry equal to the
average of the margins calculated for the
mandatory respondents, adjusted for
their respective export subsidy rates, if
applicable, from CVD Citric Acid Final.
The suspension of liquidation
instructions will remain in effect until
further notice.

ITC Notification
In accordance with section 735(d) of
the Act, we have notified the
International Trade Commission (“ITC”) of our final determination of sales at
LTFV. As our final determination is
affirmative, in accordance with section
735(b)(2) of the Act, within 45 days the
ITC will determine whether the
domestic industry in the United States
is materially injured, or threatened with
material injury, by reason of imports or
sales (or the likelihood of sales) for
importation of the subject merchandise.
If the ITC determines that material
injury or threat of material injury does
not exist, the proceeding will be
terminated and all securities posted will
be refunded or canceled. If the ITC
determines that such injury does exist,
The Department will issue an
antidumping duty order directing CBP
to assess antidumping duties on all
imports of the subject merchandise
entered, or withdrawn from warehouse,
for consumption on or after the effective
date of the suspension of liquidation.

Notification Regarding APO
This notice also serves as a reminder
to the parties subject to administrative
protective order (“APO”) of their
responsibility concerning the
disposition of proprietary information
disclosed under APO in accordance
with 19 CFR 351.305. Timely
notification of return or destruction of
APO materials or conversion to judicial
protective order is hereby requested.
Failure to comply with the regulations
and the terms of an APO is a
sanctionable violation.
This determination and notice are
issued and published in accordance with sections 735(d) and 777(i)(1) of the Act.


Ronald K. Lorentzen,
Acting Assistant Secretary for Import
Administration.

Appendix

General Issues

Comment 1: Selection of Surrogate Country

Exporter
Lianyungang JF International Trade Co., Ltd
Laiwu Taihe Biochemistry Co., Ltd
Lianyungang Shuren Scientific Creation Import & Export Co., Ltd.
Penglai Marine Bio-Tech Co., Ltd
RZBC Imp & Exp. Co., Ltd./RZBC Co., Ltd./RZBC (Juxian) Co., Ltd.
RZBC Imp & Exp. Co., Ltd./RZBC Co., Ltd./RZBC (Juxian) Co., Ltd.
Shihezi City Changyun Biochemical Co., Ltd
Weifang Ensign Industry Co., Ltd
PRC-Wide Entity

Producer
TTCA Co., Ltd. (a.k.a. Shandong TTCA Biochemistry Co., Ltd.)
Laiwu Taihe Biochemistry Co., Ltd
Lianyungang Great Chemical Industry Co., Ltd
Penglai Marine Bio-Tech Co., Ltd
RZBC Co., Ltd
RZBC (Juxian) Co., Ltd
Lianyungang Great Chemical Industry Co., Ltd
Shihezi City Changyun Biochemical Co., Ltd
Weifang Ensign Industry Co., Ltd

Margin
111.85
111.85
111.85
111.85
111.85
111.85
111.85
111.85
111.85
156.87

Disclosure
We will disclose the calculations
performed within five days of the date
of publication of this notice to parties in
this proceeding in accordance with 19
CFR 351.224(b).

Comment 2: Treatment of Energy in the
Surrogate Financial Statements
Comment 3: Treatment of Interest Expense
and Income in Selling, General and
Administrative Expenses
Comment 4: Correct Calculation for the
Inflator of the Indian Trucking Value
Comment 5A: Surrogate Value for calcium
Carbonate
Comment 5C: Surrogate Value for Coal
Comment 5D: Surrogate Value for Water
Comment 5E: Surrogate Value for Brokerage
and Handling
Comment 6: Indonesian Inflator
Comment 7: Valuation of High Protein Corn
By-Product
Comment 8: Additional Expenses for Sales of
Corn Feed By-Product Offset

Issues Specific to TTCA
Comment 9: Date of Sale: Contract Date
Versus Invoice Date
Comment 10: Adjustment of TTCA’s Labor
Factors
Comment 11A: Correction of Clerical Error in
Application of Billing Adjustment
Comment 11B: Correction of Clerical Error in
the Surrogate Value of Sodium
Lignosulphonate
Comment 12: Offset for Steam By-Product
Comment 13: Use of TTCA’s Market-
Economy Freight Costs
Comment 14: Adjustment of the Surrogate
Value for Hydrochloric Acid/Hyrogen
Chloride
Comment 15: Low-Protein Scrap Offset

Issues Specific to Yixing Union
Comment 16: Yixing Union Corn Usage Rate
Comment 17: Yixing Union Mycelium By-
Product Offset

Issues Specific to Yixing Union
Comment 18: Inflation of the Surrogate Value
for Steam

[FR Doc. E9–8359 Filed 4–10–09; 8:45 am]

BILLING CODE 3510–DS–P
DEPARTMENT OF COMMERCE
International Trade Administration
A–122–853
Notice of Final Determination of Sales at Less Than Fair Value: Citric Acid and Certain Citrate Salts from Canada

AGENCY: Import Administration, International Trade Administration, Department of Commerce.

SUMMARY: We determine that imports of citric acid and certain citrate salts (citric acid) are being, or are likely to be, sold in the United States at less than fair value (LTFV), as provided in section 735 of the Tariff Act of 1930, as amended (the Act). The estimated margins of sales at LTFV are shown in the “Final Determination Margins” section of this notice.

EFFECTIVE DATE: April 13, 2009.

FOR FURTHER INFORMATION CONTACT: Terre Keaton Stefanova or Rebecca Trainor, AD/CVD Operations, Office 2, Import Administration, International Trade Administration, U.S. Department of Commerce, 14th Street and Constitution Avenue, NW, Washington, DC 20230; telephone: (202) 482–1290 or (202) 482–4007, respectively.

SUPPLEMENTARY INFORMATION:

Background
On November 20, 2008, the Department of Commerce (Department) published in the Federal Register the preliminary determination of sales at LTFV in the antidumping duty investigation of citric acid from Canada. See Citric Acid and Certain Citrate Salts from Canada: Notice of Preliminary Determination of Sales at Less Than Fair Value and Postponement of Final Determination, 73 FR 70324 (November 20, 2008) (Preliminary Determination).

In November and December 2008, the respondent, Jungbunzlauer Technology GMBH & Co KG (JBLT), submitted revised home market and U.S. sales listings and cost data. On December 1, 2008, we received pre–verification comments from the petitioners. On December 18, 2008, the petitioners requested a hearing to discuss issues addressed by the interested parties in their case and rebuttal briefs. From December 9 through December 16, 2008, we verified the respondent’s sales data.

On January 6, 2009, the respondent informed the Department that its Canadian operations had recently undergone a corporate restructuring which resulted in JBL Canada, Inc. becoming the producer, seller and exporter of citric acid from Canada, effective December 31, 2008. For further discussion, see “Corporate Restructuring” section below.

From January 12 through January 16, 2009, we verified the respondent’s cost data. On February 5, 2009, we issued the sales verification report, and requested that the respondent submit a revised home market and U.S. sales listing per verification findings. We received the revised sales listings on February 17, 2009. On February 24, 2009, we issued the cost verification report. We provided the interested parties an opportunity to comment on the Preliminary Determination and the Department’s verification findings.

On February 26, 2009, the petitioners withdrew their request for a hearing. On March 3 and March 9, 2009, respectively, the petitioners and respondent each submitted case and rebuttal briefs. Because the petitioners were the only interested party to request a hearing and subsequently withdrew its request, no hearing was held on issues raised in the case and rebuttal briefs.

Period of Investigation
The period of investigation (POI) is April 1, 2007, through March 31, 2008. This period corresponds to the four most recent fiscal quarters prior to the month of the filing of the petition.

Scope of Investigation
The scope of this investigation includes all grades and granulation sizes of citric acid, sodium citrate, and potassium citrate in their unblended forms, whether dry or in solution, and regardless of packaging type. The scope also includes blends of citric acid, sodium citrate, and potassium citrate; as well as blends with other ingredients, such as sugar, where the unblended form(s) of citric acid, sodium citrate, and potassium citrate constitute 40 percent or more by weight, of the blend. The scope of this investigation also includes all forms of crude calcium citrate, including dicalcium citrate monohydrate, and tricalcium citrate tetrahydrate, which are intermediate products in the production of citric acid, sodium citrate, and potassium citrate. The scope of this investigation does not include calcium citrate that satisfies the standards set forth in the United States Pharmacopeia and has been mixed with a functional excipient, such as dextrose or starch, where the excipient constitutes at least 2 percent, by weight, of the product. The scope of this investigation includes the hydrous and anhydrous forms of citric acid, the dihydrate and anhydrous forms of sodium citrate, otherwise known as citric acid sodium salt, and the monohydrate and monopotassium forms of potassium citrate. Sodium citrate also includes both trisodium citrate and monosodium citrate, which are also known as citric acid trisodium salt and citric acid monosodium salt, respectively. Citric acid and sodium citrate are classifiable under 2918.15.0000 and 3824.90.9290 of the Harmonized Tariff Schedule of the United States (HTSUS), respectively. Potassium citrate and crude calcium citrate are classifiable under 2918.15.5000 and 3824.90.9290 of the HTSUS, respectively. Blends that include citric acid, sodium citrate, and potassium citrate are classifiable under 3824.90.9290 of the HTSUS. Although the HTSUS subheadings are provided for convenience and customs purposes, the written description of the merchandise is dispositive.

Corporate Restructuring
The respondent reported, and the Department verified, that during the POI, three subsidiaries of the Jungbunzlauer Group (JBL Group) were involved in the production and sale of citric acid to the United States. The production of citric acid in Canada involved two separate legal entities, JBLT and JBL Canada, Inc. JBLT was responsible for citric acid production and JBL Canada Inc. was responsible for infrastructure and personnel in connection with JBLT’s operations. The third entity, JBL Inc., located in the United States was responsible for selling products from the JBL Group (including JBLT) to the United States, Canada and Mexico.

As noted above, during the course of this investigation JBLT informed the Department that it had undergone a corporate restructuring. We requested that JBLT submit a detailed explanation and supporting documentation of the corporate restructuring. We also provided the petitioners the opportunity to file comments. See January 23, 2009 Memorandum to the File, and the

---

1 The petitioners in this investigation are Archer Daniels Midland Company, Cargill, Incorporated, and Tate & Lyle Americas, Inc.

2 See Memorandum to the File through James Maeder, Director Office 2 from Rebecca Trainor and Kate Johnson International Trade Compliance Analysts Office 2, “Verification of the Sales Response of Jungbunzlauer Technology GMBH & Co. KG (JBLT) in the Antidumping Investigation of Citric Acid and Certain Citrate Salts from Canada,” dated February 5, 2009 (Sales Verification Report).

January 9 and 14, 2009, submissions from JBLT. We did not receive comments from the petitioners on this matter. At verification we examined the corporate restructuring information submitted by JBLT (see Cost Verification Report at 4).

Based on the corporate restructuring documentation, as verified, JBL Canada Inc., rather than JBLT, is the entity responsible for all the activities related to Canadian citric acid production and exportation, effective December 31, 2008. Therefore, we will assign the final determination margin to JBL Canada, Inc.

Verification

As provided in section 782(j) of the Act, we verified the sales and cost information submitted by the respondent for use in our final determination. We used standard verification procedures including an examination of relevant accounting and production records, and original source documents provided by the respondent. Our sales and cost verification results are outlined in separate verification reports. See Sales Verification Report and Cost Verification Report. The verification reports are on file and available in the Central Records Unit, Room 1117 of the Commerce Department.

Analysis of Comments Received

All issues raised in the case and rebuttal briefs submitted by the parties to this investigation are addressed in the “Issues and Decision Memorandum for the Final Determination in the Less–Than-Fair–Value Investigation of Citric Acid and Certain Citrate Salts from Canada” from John Anderson, Acting Deputy Assistant Secretary for Import Administration, to Ronald K. Lorentzen, Acting Assistant Secretary for Import Administration (Decision Memo), dated April 6, 2009, which is hereby adopted by this notice. A list of the issues that parties have raised and to which we have responded, all of which are in the Decision Memo, is attached to this notice as an appendix. Parties can find a complete discussion of all issues raised in this investigation and the corresponding recommendations in the Decision Memo, which is on file in the Central Records Unit, Room 1117 of the Commerce Department. In addition, a complete version of the Decision Memo can be accessed directly on the Web at http://ia.ita.doc.gov/frn. The paper copy and electronic version of the Decision Memo are identical in content.

Changes Since the Preliminary Determination

Based on our analysis of the comments received and our findings at verification, we have made certain changes to the margin calculations for JBL Canada Inc. For a discussion of these changes, see the “Margin Calculations” section of the Decision Memo.

Facts Available

Section 776(a) of the Act provides that the Department will apply “facts otherwise available” if necessary information is not available on the record or an interested party: 1) withholds information that has been requested by the Department; 2) fails to provide such information within the deadlines established, or in the form or manner requested by the Department, subject to subsections (c)(1) and (e) of section 782 of the Act; 3) significantly impedes a proceeding; or 4) provides such information, but the information cannot be verified. As stated in the Preliminary Determination, our antidumping questionnaire instructs respondents to report prices and expenses in the currency in which they were incurred. See Preliminary Determination at 73 FR 70327.

Nevertheless, in this case, the respondent reported data that had been converted from multiple currencies into Canadian dollars (CAD) in the home market, and into U.S. dollars (USD) in the U.S. market because its company–wide electronic data processing system (SAP) automatically converts all foreign currency transactions into the currency of the respective JBL Group entity at the moment of posting. According to the respondent, the entry of data and the currency conversion is a simultaneous process in its accounting system. As a result, SAP does not retain the original foreign currency amount in the sales database or in the general ledger. Based on the respondent’s representation that the currency conversion process is a company–wide procedure that is done in the normal course of business, we accepted the data as reported for the preliminary determination. However, we stated our intention to examine the reasonableness of the price and expense reporting based on this system at verification. See Preliminary Determination at 73 FR 70327.

At verification, we found that the SAP system does maintain a record of the original currency from which entries were converted and the exchange rate used. Therefore, the price and expense data could have been reported in the original foreign currency amount as incurred. See Sales Verification Report at 4 and 5. Based on our verification findings, we believe that it was possible for the respondent to have reported prices and expenses in the currency in which they were incurred, contrary to the representation in the respondent’s questionnaire responses. For these reasons, we find that it is appropriate to resort to facts otherwise available to account for the unreported information. See, e.g., Canned Pineapple Fruit from Thailand, 68 FR 65247 (November 19, 2003), and accompanying Issues and Decision Memorandum at Comment 20b where the Department applied facts otherwise available to a respondent that did not provide requested information. Therefore, we have determined that the gross unit prices for certain home market customers who were invoiced in USD during the POI (see the Sales Verification Report at Exhibit 4), and all U.S inland freight expenses should be based on facts available in accordance with sections 776(a)(2)(A), (B), and (D) of the Act.5

In selecting from among the facts otherwise available, section 776(b) of the Act authorizes the Department to use an adverse inference if the Department finds that an interested party failed to cooperate by not acting to the best of its ability to comply with a request for information. See, e.g., Notice of Final Results of Antidumping Duty Administrative Review: Stainless Steel Bar from India, 70 FR 54023, 54025–26 (September 13, 2005); see also Notice of Final Determination of Sales at Less Than Fair Value and Final Negative Critical Circumstances: Carbon and Certain Alloy Steel Wire Rod from Brazil, 67 FR 55792, 55794–96 (August 30, 2002). The Statement of Administrative Action provides guidance by explaining that adverse inferences are appropriate “to ensure that the party does not obtain a more favorable result by failing to cooperate than if it had cooperated fully.” See Statement of Administrative Action accompanying the Uruguay Round Agreements Act, H.R. Doc. No. 103–316, Vol. 1, at 870 (1994). Furthermore, “affirmative evidence of bad faith on the part of a respondent is not required before the Department may make an

---

5 Because we could not isolate the U.S. inland freight expenses that were affected by the inappropriate currency conversions, we are applying facts available to all reported U.S. inland freight expenses.
adverse inference.” See Antidumping Duties; Countervailing Duties, 62 FR 27296, 27340 (May 19, 1997); see also Nippon Steel Corp. v. United States, 337 F.3d 1373, 1383 (Fed. Cir. 2003) (Nippon). Because: 1) the respondent had the necessary information within its control and it did not report this information; and 2) it failed to put forth its maximum effort to provide the requested information, we find that the respondent failed to cooperate to the best of its ability. Therefore, for the final determination, we are using facts available with an adverse inference and applying it to the gross unit prices of certain home market sales, and to all U.S. inland freight expenses. Specifically, as adverse facts available, we increased both the affected home market sales prices and the U.S. freight expenses by 1.16 percent, i.e., the percentage difference between the Department’s weighted-average POI exchange rate (used to convert comparison–market values to USD in the margin program), and JBLT’s POI average exchange rate (used by JBLT’s SAP system for currency conversion purposes). For further discussion, see Decision Memo at Comment 4 and the April 6, 2009, Memorandum to The File from Case Analyst, entitled “Calculations Performed for Jungbunzlauer Technology GMBH & Co. KG for the Final Determination in the Antidumping Duty Investigation of Citric Acid and Certain Citrate Salts from Canada.”

Continuation of Suspension of Liquidation

In accordance with section 735(c)(1)(B) of the Act, we are directing U.S. Customs and Border Protection (CBP) to continue to suspend liquidation of all imports of subject merchandise that are entered or withdrawn from warehouse, for consumption on or after November 20, 2008, the date of publication of the preliminary determination in the Federal Register. We will instruct CBP to continue to require a cash deposit or the posting of a bond for all companies based on the estimated weighted-average dumping margins shown below. The suspension of liquidation instructions will remain in effect until further notice.

Final Determination Margins

We determine that the following weighted-average dumping margins exist for the period April 1, 2007, through March 31, 2008:

<table>
<thead>
<tr>
<th>Manufacturer/Exporter</th>
<th>Weighted Average Margin (percent)</th>
</tr>
</thead>
<tbody>
<tr>
<td>JBL Canada, Inc.</td>
<td>23.21</td>
</tr>
<tr>
<td>All Others</td>
<td>23.21</td>
</tr>
</tbody>
</table>

All–Others Rate

Section 735(c)(5)(A) of the Act provides that the estimated “All–Others” rate shall be an amount equal to the weighted average of the estimated weighted-average dumping margins established for exporters and producers individually investigated, excluding any zero or de minimis margins, and any margins determined entirely under section 776 of the Act. In this investigation the Department calculated a company–specific rate only for JBL Canada Inc. Therefore, for purposes of determining the all–others rate and pursuant to section 735(c)(5)(A) of the Act, we are using the weighted–average dumping margin calculated for JBL Canada Inc., as referenced above. See, e.g., Notice of Final Determination of Sales at Less Than Fair Value: Stainless Steel Sheet and Strip in Coils From Italy, 64 FR 30750, 30755 (June 8, 1999); and Coated Free Sheet Paper from Indonesia: Notice of Preliminary Determination of Sales at Less Than Fair Value and Postponement of Final Determination, 72 FR 30753, 30757 (June 4, 2007), unchanged in final determination, Notice of Final Determination of Sales at Less Than Fair Value: Coated Free Sheet Paper from Indonesia, 72 FR 60636 (October 25, 2007).

Disclosure

We will disclose the calculations performed within five days of the date of publication of this notice to parties in this proceeding in accordance with 19 CFR 351.224(b).

International Trade Commission Notification

In accordance with section 735(d) of the Act, we have notified the International Trade Commission (ITC) of our final determination. As our final determination is affirmative, the ITC will determine within 45 days whether imports of the subject merchandise are causing material injury, or threat of material injury, to an industry in the United States. If the ITC determines that material injury or threat of injury does not exist, the proceeding will be terminated and all securities posted will be refunded or canceled. If the ITC determines that such injury does exist, the Department will issue an antidumping duty order directing CBP to assess antidumping duties on all imports of the subject merchandise entered, or withdrawn from warehouse, for consumption on or after the effective date of the suspension of liquidation.

Return or Destruction of Proprietary Information

This notice will serve as the only reminder to parties subject to administrative protective order (APO) of their responsibility concerning the destruction of proprietary information disclosed under APO in accordance with 19 CFR 351.305(a)(3). Timely written notification of return/destruction of APO materials or conversion to judicial protective order is hereby requested. Failure to comply with the regulations and the terms of an APO is a sanctionable violation.

We are issuing and publishing this determination and notice in accordance with sections 735(d) and 777(i) of the Act.

Ronald K. Lorentzen,
Acting Assistant Secretary for Import Administration.

Appendix--Issues in Decision Memo

Comments

Comment 1: Date of Sale and Whether to Exclude U.S. Sales Made Pursuant to Multiyear Contracts
Comment 2: Indirect Selling Expenses
Comment 3: Home Market Billing Adjustments
Comment 4: Currency Conversions
Comment 5: Electricity Purchased from an Affiliate
Comment 6: General and Administrative (G&A) Expense Ratio

[FR Doc. E9–8357 Filed 4–10–09; 8:45 am]
BILLING CODE: 3510–DS–S
APPENDIX B

HEARING WITNESSES
CALENDAR OF PUBLIC HEARING

Those listed below appeared as witnesses at the United States International Trade Commission’s hearing:

**Subject:** Citric Acid and Certain Citrate Salts from Canada and China

**Inv. Nos.:** 701-TA-456 and 731-TA-1151-1152 (Final)

**Date and Time:** April 7, 2009 - 9:30 a.m.

Sessions were held in connection with these investigations in the Main Hearing Room (room 101), 500 E Street, SW, Washington, DC.

**OPENING REMARKS:**

Petitioners (Neil R. Ellis, Sidley Austin LLP)
Respondents (Donald B. Cameron, Troutman Sanders LLP)

**In Support of the Imposition of Antidumping and Countervailing Duty Orders:**

Sidley Austin LLP
Washington, DC
on behalf of

Archer Daniels Midland Co. (“ADM”)
Cargill, Inc.
Tate & Lyle Americas, Inc. (“Tate & Lyle”)

Michael R. Baroni, President, Specialty Food Ingredients Division, ADM,
John Oakley, Business Director - Food Additives, Specialty Food Ingredients, ADM
Eric S. Warner, Jr., Plant Manager, ADM
Brian Tschosik, Division Controller, ADM
Mark Christiansen, Acidulants Sales Manager, Corn Milling, Cargill, Inc.
Jack Staloch, Vice President, Acidulants Product Line Manager; R&D Director, Biotechnology Development Center, Cargill, Inc.
L. Martin Hurt, Manager, Food Ingredients, Americas, Tate & Lyle
Curtis A. Poulos, Commercial Director, Food Ingredients - Acidulants, Tate & Lyle
Peter G. Lorusso, Vice President, Sales and Marketing, TLC Ingredients
Larry Richardson, Staff Representative, United Steel Workers
Charles L. Anderson, Principal, Capital Trade, Inc.
Andrew A. Szamosszegi, Managing Consultant, Capital Trade, Inc.

Neil R. Ellis
Jill Caiazzo
Geoffrey D. Antell

) – OF COUNSEL
In Opposition to the Imposition of the Antidumping and Countervailing Duty Orders:

Troutman Sanders LLP
Washington, DC
on behalf of

The Chinese Citric Acid Producers Coalition

Wang Qi, Vice Manager of Asia-Pacific Sales Department, Anhui BBCA Biochemical Co., Ltd.
Kou Guangzhi, Chairman of the Board, RZBC Co., Ltd.
Eric Shao, General Manager, RZBC Import and Export Co., Ltd.
Robert W. Bloom, President and CEO, FBC Industries, Inc.

Julie C. Mendoza
Donald B. Cameron
R. Will Planert
Judy Z. Wang

OF COUNSEL

Vorys, Sater, Seymour and Pease LLP
Washington, DC
on behalf of

Jungbunzlauer Technology GmbH & Co. KG (“JBL”)

Dan Rainville, President, JBL Inc.
Dr. Patrick Magrath, Economist, Georgetown Economic Services

Frederick P. Waite
Kimberly R. Young

OF COUNSEL

Neville Peterson LLP
Washington, DC
on behalf of

PepsiCo, Inc.

Barry Taylor, Purchasing Director, Pepsi Worldwide Flavors, PepsiCo, Inc.

George Thompson

OF COUNSEL
In Opposition to the Imposition of the Antidumping and Countervailing Duty Orders (Continued):

Lafave Associates
Washington, DC
on behalf of

The Procter & Gamble Manufacturing Co. (“P&G”)

A. Matt Smith, Senior Purchasing Manager, P&G
James Hodges, Purchasing Group Manager, P&G
Dr. Kenneth Button, Senior Vice President, Economic Consulting Services LLC
Jennifer Lutz, Senior Economist, Economic Consulting Services LLC

Arthur J. Lafave III ) – OF COUNSEL

Arnold & Porter LLP
Washington, DC
on behalf of

Reckitt Benckiser Inc.

Klaus Hofmann, Senior Vice President, Global Procurement, Reckitt Benckiser Group plc

Michael T. Shor ) – OF COUNSEL

Kelley Drye & Warren LLP
Washington, DC
on behalf of

Vertellus Specialties, Inc.

Tom Pensak, Director, Sales and Marketing, Vertellus Performance Materials, Inc.

Michael J. Coursey ) – OF COUNSEL

CLOSING REMARKS:

Petitioners (Neil R. Ellis, Sidley Austin LLP)
Respondents (Frederick P. Waite, Vorys, Sater, Seymour and Pease LLP)
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>U.S. consumption quantity:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amount</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Producers' share (1)</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Importers' share (1):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>China</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Subtotal</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>All other sources</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Total imports</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td><strong>U.S. consumption value:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amount</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Producers' share (1)</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Importers' share (1):</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>China</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Subtotal</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>All other sources</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Total imports</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td><strong>U.S. imports from:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Canada:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantity</td>
<td>158,906</td>
<td>180,108</td>
<td>193,727</td>
<td>21.9</td>
<td>13.3</td>
<td>7.6</td>
</tr>
<tr>
<td>Value</td>
<td>65,542</td>
<td>76,571</td>
<td>118,342</td>
<td>80.6</td>
<td>16.8</td>
<td>54.6</td>
</tr>
<tr>
<td>Unit value</td>
<td>$0.41</td>
<td>$0.43</td>
<td>$0.61</td>
<td>48.1</td>
<td>3.1</td>
<td>43.7</td>
</tr>
<tr>
<td>Ending inventory quantity</td>
<td>17,701</td>
<td>28,685</td>
<td>24,376</td>
<td>37.7</td>
<td>62.0</td>
<td>-15.0</td>
</tr>
<tr>
<td>China:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantity</td>
<td>68,584</td>
<td>65,634</td>
<td>55,594</td>
<td>-18.9</td>
<td>-4.3</td>
<td>-15.3</td>
</tr>
<tr>
<td>Value</td>
<td>39,174</td>
<td>38,802</td>
<td>41,058</td>
<td>4.8</td>
<td>-0.9</td>
<td>5.8</td>
</tr>
<tr>
<td>Unit value</td>
<td>$0.57</td>
<td>$0.59</td>
<td>$0.74</td>
<td>29.3</td>
<td>3.5</td>
<td>24.9</td>
</tr>
<tr>
<td>Ending inventory quantity</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table continued on next page.
Table C-1--Continued
Citric acid and certain citrate salts: Summary data concerning the U.S. market, 2006-2008

(Quantity=1,000 dry pounds, value=1,000 dollars, unit values, unit labor costs, and unit expenses are per pound; period changes=percent, except where noted)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>U.S. producers'</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Average capacity quantity . . . . . . . .</td>
<td>553,913</td>
<td>553,913</td>
<td>553,913</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
</tr>
<tr>
<td>Production quantity . . . . . . . . . . .</td>
<td>475,428</td>
<td>488,403</td>
<td>507,917</td>
<td>6.8</td>
<td>2.7</td>
<td>4.0</td>
</tr>
<tr>
<td>Capacity utilization (1) . . . . . . . . .</td>
<td>85.8</td>
<td>88.2</td>
<td>91.7</td>
<td>5.9</td>
<td>2.3</td>
<td>3.5</td>
</tr>
<tr>
<td>U.S. shipments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantity . . . . . . . . . . . . . . . . .</td>
<td>369,451</td>
<td>399,578</td>
<td>402,518</td>
<td>9.0</td>
<td>8.2</td>
<td>0.7</td>
</tr>
<tr>
<td>Value . . . . . . . . . . . . . . . . . . .</td>
<td>165,013</td>
<td>180,132</td>
<td>214,641</td>
<td>30.1</td>
<td>9.2</td>
<td>19.2</td>
</tr>
<tr>
<td>Unit value . . . . . . . . . . . . . . . .</td>
<td>$0.45</td>
<td>$0.45</td>
<td>$0.53</td>
<td>19.4</td>
<td>0.9</td>
<td>18.3</td>
</tr>
<tr>
<td>Export shipments:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantity . . . . . . . . . . . . . . . . .</td>
<td>96,709</td>
<td>114,348</td>
<td>112,996</td>
<td>16.8</td>
<td>18.2</td>
<td>-1.2</td>
</tr>
<tr>
<td>Value . . . . . . . . . . . . . . . . . . .</td>
<td>41,042</td>
<td>47,381</td>
<td>57,541</td>
<td>40.2</td>
<td>15.4</td>
<td>21.4</td>
</tr>
<tr>
<td>Unit value . . . . . . . . . . . . . . . .</td>
<td>$0.42</td>
<td>$0.41</td>
<td>$0.51</td>
<td>20.0</td>
<td>-2.4</td>
<td>22.9</td>
</tr>
<tr>
<td>Ending inventory quantity . . . . . . . .</td>
<td>77,606</td>
<td>52,316</td>
<td>44,638</td>
<td>-42.5</td>
<td>-32.6</td>
<td>-14.7</td>
</tr>
<tr>
<td>Inventories/total shipments (1)</td>
<td>16.6</td>
<td>10.2</td>
<td>8.7</td>
<td>-8.0</td>
<td>-6.5</td>
<td>-1.5</td>
</tr>
<tr>
<td>Production workers . . . . . . . . . . .</td>
<td>306</td>
<td>300</td>
<td>292</td>
<td>-4.6</td>
<td>-2.0</td>
<td>-2.7</td>
</tr>
<tr>
<td>Hours worked (1,000s) . . . . . . . . . .</td>
<td>701</td>
<td>687</td>
<td>669</td>
<td>-4.5</td>
<td>-1.9</td>
<td>-2.6</td>
</tr>
<tr>
<td>Wages paid ($1,000) . . . . . . . . . . .</td>
<td>22,656</td>
<td>21,781</td>
<td>21,751</td>
<td>-4.0</td>
<td>-3.9</td>
<td>-0.1</td>
</tr>
<tr>
<td>Hourly wages . . . . . . . . . . . . . . .</td>
<td>$32.34</td>
<td>$31.70</td>
<td>$32.50</td>
<td>0.5</td>
<td>-2.0</td>
<td>2.5</td>
</tr>
<tr>
<td>Productivity (pounds per hour)</td>
<td>678.6</td>
<td>710.8</td>
<td>758.9</td>
<td>11.8</td>
<td>4.7</td>
<td>6.8</td>
</tr>
<tr>
<td>Unit labor costs . . . . . . . . . . . . .</td>
<td>$0.05</td>
<td>$0.04</td>
<td>$0.04</td>
<td>-10.1</td>
<td>-6.4</td>
<td>-4.0</td>
</tr>
<tr>
<td>Net sales:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantity . . . . . . . . . . . . . . . . .</td>
<td>466,160</td>
<td>513,924</td>
<td>515,514</td>
<td>10.6</td>
<td>10.2</td>
<td>0.3</td>
</tr>
<tr>
<td>Value . . . . . . . . . . . . . . . . . . .</td>
<td>205,773</td>
<td>226,909</td>
<td>271,708</td>
<td>32.0</td>
<td>10.3</td>
<td>19.7</td>
</tr>
<tr>
<td>Unit value . . . . . . . . . . . . . . . .</td>
<td>$0.44</td>
<td>$0.44</td>
<td>$0.53</td>
<td>19.4</td>
<td>0.0</td>
<td>19.4</td>
</tr>
<tr>
<td>Cost of goods sold (COGS) . . . . . . . .</td>
<td>202,849</td>
<td>235,123</td>
<td>266,120</td>
<td>31.2</td>
<td>15.9</td>
<td>13.2</td>
</tr>
<tr>
<td>Gross profit or (loss) . . . . . . . . .</td>
<td>2,924</td>
<td>(8,214)</td>
<td>5,588</td>
<td>91.1</td>
<td>(2)</td>
<td>(2)</td>
</tr>
<tr>
<td>SG&amp;A expenses . . . . . . . . . . . . . .</td>
<td>13,653</td>
<td>13,420</td>
<td>13,093</td>
<td>-4.1</td>
<td>-1.7</td>
<td>-2.4</td>
</tr>
<tr>
<td>Operating income or (loss) . . . . . . .</td>
<td>(10,729)</td>
<td>(21,634)</td>
<td>(7,505)</td>
<td>30.0</td>
<td>-101.6</td>
<td>65.3</td>
</tr>
<tr>
<td>Capital expenditures . . . . . . . . . .</td>
<td>6,534</td>
<td>7,746</td>
<td>5,537</td>
<td>-15.3</td>
<td>18.5</td>
<td>-28.5</td>
</tr>
<tr>
<td>Unit COGS . . . . . . . . . . . . . . . .</td>
<td>$0.44</td>
<td>$0.46</td>
<td>$0.52</td>
<td>18.6</td>
<td>5.1</td>
<td>12.8</td>
</tr>
<tr>
<td>Unit SG&amp;A expenses . . . . . . . . . . .</td>
<td>$0.03</td>
<td>$0.03</td>
<td>$0.03</td>
<td>-13.3</td>
<td>-10.8</td>
<td>-2.7</td>
</tr>
<tr>
<td>Unit operating income or (loss) . . . . .</td>
<td>($0.02)</td>
<td>($0.04)</td>
<td>($0.01)</td>
<td>36.7</td>
<td>-82.9</td>
<td>65.4</td>
</tr>
<tr>
<td>COGS/sales (1) . . . . . . . . . . . . . .</td>
<td>98.6</td>
<td>103.6</td>
<td>97.9</td>
<td>-0.6</td>
<td>5.0</td>
<td>-5.7</td>
</tr>
<tr>
<td>Operating income or (loss)/ sales (1) . .</td>
<td>(5.2)</td>
<td>(9.5)</td>
<td>(2.8)</td>
<td>2.5</td>
<td>-4.3</td>
<td>6.8</td>
</tr>
</tbody>
</table>

(1) "Reported data" are in percent and "period changes" are in percentage points.
(2) Undefined.

Note.--Financial data are reported on a fiscal year basis and may not necessarily be comparable to data reported on a calendar year basis. Because of rounding, figures may not add to the totals shown. Unit values and shares are calculated from the unrounded figures.

Source: Compiled from data submitted in response to Commission questionnaires and from official Commerce statistics.
Table C-2
Citric acid: Summary data concerning the U.S. market, 2006-2008

* * * * * * * *

Table C-3
Sodium citrate: Summary data concerning the U.S. market, 2006-2008

* * * * * * * *

Table C-4
Potassium citrate: Summary data concerning the U.S. market, 2006-2008

* * * * * * * *
APPENDIX D

LARGEST PURCHASERS’ DATA ON BIDS AND PRICES
Table D-1
Citric acid and certain citrate salts: Information on the three largest bids of U.S. purchasers of more than 20 million pounds in one year, 2006-2008

* * * * * * *

Reasons for choosing the supplier(s) of the winning bid(s):

* * * * * * *
Table D-2
Citric acid and certain citrate salts: Weighted-average delivered prices and quantities reported by purchasers of domestic and imported product 1, by spot and contract purchases, and by quarters, January 2006-December 2008

<table>
<thead>
<tr>
<th>Period</th>
<th>Price (per pound)</th>
<th>Price (per pound)</th>
<th>Price (per pound)</th>
<th>Price (per pound)</th>
<th>Quantity (1,000 dry pounds)</th>
<th>Quantity (1,000 dry pounds)</th>
<th>Quantity (1,000 dry pounds)</th>
<th>Quantity (1,000 dry pounds)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>United States</td>
<td>Canada</td>
<td>China</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Spot Purchases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>$***</td>
<td>***</td>
<td>$***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apr.-June</td>
<td>--</td>
<td>0</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2007:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2008:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td>***</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Contract Purchases |
|--------------------|------------------|------------------|------------------|------------------|----------------------------|----------------------------|----------------------------|----------------------------|
| 2006:              |                  |                  |                  |                  |                            |                            |                            |                            |
| Jan.-Mar.          | 0.53             | 10,160           | ***              | ***              | --                         | 0                          |                            |                            |
| Apr.-June          | 0.52             | 11,407           | ***              | ***              | --                         | 0                          |                            |                            |
| July-Sept.         | 0.53             | 11,842           | ***              | ***              | --                         | 0                          |                            |                            |
| Oct.-Dec.          | 0.54             | 9,503            | ***              | ***              | --                         | 0                          |                            |                            |
| 2007:              |                  |                  |                  |                  |                            |                            |                            |                            |
| Jan.-Mar.          | 0.57             | 11,440           | ***              | ***              | --                         | 0                          |                            |                            |
| Apr.-June          | 0.54             | 13,701           | ***              | ***              | --                         | 0                          |                            |                            |
| July-Sept.         | 0.57             | 12,085           | ***              | ***              | --                         | 0                          |                            |                            |
| Oct.-Dec.          | 0.57             | 12,081           | ***              | ***              | --                         | 0                          |                            |                            |
| 2008:              |                  |                  |                  |                  |                            |                            |                            |                            |
| Jan.-Mar.          | 0.53             | 13,535           | ***              | ***              | ***                        | ***                        | ***                        | ***                        |
| Apr.-June          | 0.52             | 14,933           | ***              | ***              | ***                        | ***                        | ***                        | ***                        |
| July-Sept.         | 0.52             | 13,842           | ***              | ***              | ***                        | ***                        | ***                        | ***                        |
| Oct.-Dec.          | 0.52             | 13,309           | ***              | ***              | ***                        | ***                        | ***                        | ***                        |

1 Citric acid, granular, in dry form in 25-kilogram and 50-pound bags.

Source: Compiled from responses to Commission questionnaires.
Table D-3
Citric acid and certain citrate salts: Weighted-average delivered contract prices and quantities reported by purchasers of domestic and imported products 2 and 3, by quarters, January 2006-December 2008

<p>| | | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>
Table D-4
Citric acid and certain citrate salts: Weighted-average delivered prices and quantities reported by purchasers of domestic and imported products 4 and 5,\(^1\) by quarters, January 2006-December 2008

<table>
<thead>
<tr>
<th>Period</th>
<th>United States</th>
<th>China</th>
<th>Nonsubject</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Price (per pound)</td>
<td>Quantity (1,000 dry pounds)</td>
<td>Price (per pound)</td>
</tr>
<tr>
<td><strong>Product 4</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>$0.47</td>
<td>1,371</td>
<td>$***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>0.47</td>
<td>1,696</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>0.47</td>
<td>1,706</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>0.47</td>
<td>1,226</td>
<td>***</td>
</tr>
<tr>
<td>2007:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>0.49</td>
<td>1,454</td>
<td>--</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>0.51</td>
<td>1,889</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>0.50</td>
<td>1,596</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>0.50</td>
<td>1,541</td>
<td>***</td>
</tr>
<tr>
<td>2008:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>0.54</td>
<td>1,527</td>
<td>--</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>0.55</td>
<td>1,772</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>0.55</td>
<td>1,615</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>0.54</td>
<td>1,460</td>
<td>***</td>
</tr>
<tr>
<td><strong>Product 5</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>2007:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>2008:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jan.-Mar.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Apr.-June</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>July-Sept.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
<tr>
<td>Oct.-Dec.</td>
<td>***</td>
<td>***</td>
<td>***</td>
</tr>
</tbody>
</table>

\(^1\) Product 4 is sodium citrate, granular, in dry form in 25-kilogram and 50-pound bags, and product 5 is potassium citrate, granular, in dry form in 25-kilogram and 50-pound bags.

Source: Compiled from responses to Commission questionnaires.